UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

 


 

FORM 10-Q

 


 

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the quarter ended March 31, 2023

 

OR

 

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the transition period from                         to                      

 

Commission File Number 000-53601

 

mitesco_logo1.jpg

 

MITESCO, INC.

(Exact Name of Registrant as Specified in its Charter)

 

Delaware

 

87-0496850

(State Other Jurisdiction of Incorporation or Organization)

 

(I.R.S. Employer Identification Number)

 

18202 Minnetonka Blvd., Suite 100

Deephaven, MN 55391

(Address of principal executive offices) (Zip code)

 

844-383-8689

(Registrant’s telephone number, including area code)

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class

Trading Symbol(s)

Name of each exchange on which registered

N/A

N/A

N/A

 

 

Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. YES ☐ No ☒

 

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ NO ☐

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large, accelerated filer”, “accelerated filer”, “smaller reporting company”, and “emerging growth company” in Rule 12b-2 of the Exchange Act.

 

Large accelerated filer ☐

Accelerated filer ☐

Non-accelerated filer

Smaller reporting company

 

Emerging growth company

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act. YES ☐ No ☒

 

As of September 25, 2023, the registrant had outstanding 5,310,761 shares of common stock issued and outstanding.

 

 

 

 

Table of Contents

 

PART I  FINANCIAL INFORMATION

 

 

 

 

 

 

Item 1.

Financial Statements (Unaudited)

 

4

 

Condensed Consolidated Balance Sheets as of March 31, 2023 and December 31, 2022

 

4

 

Condensed Consolidated Statements of Operations for the three months ended March 31, 2023 and 2022

 

5

 

Condensed Consolidated Stockholder’s Deficit for the three months ended March 31, 2023 and 2022

 

6

 

Condensed Consolidated Statements of Cash Flows for the three months ended March 31, 2023 and 2022

 

7

 

Notes to Condensed Consolidated Financial Statements

 

9

 

 

 

 

Item 2.

Management’s Discussion and Analysis of Financial Condition and Results of Operations.

 

39

 

 

 

 

Item 3.

Quantitative and Qualitative Disclosures About Market Risk.

 

43

 

 

 

 

Item 4.

Controls and Procedures.

 

43

 

 

 

 

PART II  OTHER INFORMATION

 

 

 

 

 

 

Item 1.

Legal Proceedings.

 

44

 

 

 

 

Item 1A.

Risk Factors.

 

44

 

 

 

 

Item 2.

Unregistered Sales of Equity Securities, Use of Proceeds, and Issuer Purchases of Equity Securities.

 

44

 

 

 

 

Item 3.

Defaults Upon Senior Securities.

 

45

 

 

 

 

Item 4.

Mine Safety Disclosures.

 

45

 

 

 

 

Item 5.

Other Information.

 

45

 

 

 

 

Item 6.

Exhibits.

 

45

 

 

 

 

Signatures

 

47

 

 

 

PART I. FINANCIAL INFORMATION

 

Item 1. Financial Statements

 

MITESCO, INC.

CONDENSED CONSOLIDATED BALANCE SHEETS

(UNAUDITED)

 

   

March 31,

   

December 31,

 

ASSETS

 

2023

   

2022

 
                 

Current assets

               

Cash and cash equivalents

  $ 299     $ 35,623  

Accounts Receivable

    6,602       30,943  

Inventory

    90       -  

Prepaid expenses

    59,830       113,722  

Total current assets

    66,821       180,288  
                 

Right to use assets, net

    -       544,063  

Fixed assets, net of accumulated depreciation of $45,000 and $.06 million

    47,016       1,877,629  
                 

Total Assets

  $ 113,837     $ 2,601,980  
                 

LIABILITIES AND (DEFICIENCY IN) STOCKHOLDERS' EQUITY

               

Current liabilities

               

Accounts payable and accrued liabilities

  $ 8,340,773     $ 7,353,215  

Accrued interest

    513,256       362,094  

Accrued interest - related parties

    313,691       198,753  

Derivative liabilities

    679,690       568,912  

Lease liability - operating leases, current

    512,895       442,866  

Notes payable, net of discounts of $0 and $0.4 million

    6,166,240       5,112,701  

Notes payable - related parties, net of discounts of $8,000 and $0.3 million

    2,791,176       2,776,962  

SBA Loan Payable

    460,406       460,406  

Other current liabilities

    121,136       96,136  

Preferred stock dividends payable

    444,864       395,407  

Preferred stock dividends payable - related parties

    30,052       35,019  

Total current liabilities

    20,374,179       17,802,471  
                 

Lease Liability- operating leases, non-current

    3,553,932       3,936,858  
                 

Total Liabilities

    23,928,111       21,739,329  
                 

Commitments and contingencies

   
-
     
-
 
                 

Stockholders' deficit

               
                 

Preferred stock, $0.01 par value, 100,000,000 shares authorized; 500,000 shares designated Series A; 3,000,000 shares designated Series C; 10,000,000 shares designated Series D; 27,324 shares designated Series X; 10,000 designated Series E; and 140,000 designated Series F.

    -       -  

Preferred stock, Series A, $0.01 par value, 0 shares issued and outstanding as of March 31, 2023 and December 31, 2022

    -       -  

Preferred stock, Series C, $0.01 par value, 1,047,619 shares issued and outstanding as of March 31, 2023 and December 31, 2022

    10,476       10,476  

Preferred stock, Series D, $0.01 par value, 3,100,000 shares issued and outstanding as of March 31, 2023 and December 31, 2022

    31,000       31,000  

Preferred stock, Series X, $0.01 par value, 24,227 shares issued and outstanding at March 31, 2023 and December 31, 2022

    242       242  

Common stock subscribed

    36,575       36,575  

Common stock, $0.01 par value, 500,000,000 shares authorized, 4,995,573 and 4,630,372 shares issued and outstanding as of March 31, 2023 and December 31 2022, respectively

    49,957       46,305  

Additional paid-in capital

    30,385,762       29,452,514  

Accumulated deficit

    (54,328,286 )     (48,714,461 )

Total stockholders' deficit

    (23,814,274 )     (19,137,349 )
                 

Total liabilities and stockholders' deficit

  $ 113,837     $ 2,601,980  

 

See accompanying notes to these unaudited condensed consolidated financial statements.

 

 

MITESCO, INC.

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

(UNAUDITED)

 

   

For the Three Months

 
   

Ended

 
   

March 31,

 
   

2023

   

2022

 
                 

Revenue-services

  $ -     $ 92,461  

Revenue-products

    -       27,915  

Total revenue

    -       120,376  
                 

Cost of goods sold-services

  $ 2,419     $ 577,556  

Cost of goods sold-products

    -       10,767  

Total cost of goods sold

    2,419       588,323  
                 

Gross (loss) profit

    (2,419 )     (467,947 )
                 

Operating expenses:

               

General and administrative

  $ 2,011,404     $ 2,563,829  

Impairment of fixed assets

    2,271,893       -  
                 

Total operating expenses

    4,283,297       2,563,829  
                 

Net Operating Loss

    (4,285,716 )     (3,031,776 )
                 

Other income (expense):

               

Interest expense

    (1,376,066 )     (828,325 )

Interest expense - related parties

    (129,162 )     -  

Gain on termination of operating lease

    287,897       -  

Gain on waiver and commitment fee shares

    -       198,273  

Gain on settlement of accrued salary

    -       15,032  

(Loss) Gain on settlement of accounts payable

    -       (78,235 )

(Loss) Gain on revaluation of derivative liabilities

    (110,778 )     79,837  

Total other expense

    (1,328,109 )     (613,418 )
                 

Loss before provision for income taxes

    (5,613,825 )     (3,645,194 )
                 

Provision for income taxes

    -       -  
                 

Net loss

  $ (5,613,825 )   $ (3,645,194 )
                 

Preferred stock dividends

    (61,823 )     (61,695 )

Preferred stock dividends - related parties

    (17,996 )     (17,997 )
                 

Net loss available to common shareholders

  $ (5,693,644 )   $ (3,724,886 )
                 

Net loss per share - basic and diluted

  $ (1.18 )   $ (0.87 )
                 

Weighted average shares outstanding - basic and diluted

    4,825,054       4,274,064  

 

See accompanying notes to these unaudited condensed consolidated financial statements.

 

 

MITESCO, INC.

CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERSDEFICIT

FOR THE THREE MONTHS ENDED MARCH 31, 2023 and 2022

(UNAUDITED)

 

   

Preferred Stock

Series A

   

Preferred Stock

Series C

   

Preferred Stock

Series D

   

Preferred Stock

Series X

   

Common

Stock

   

Additional

   

Common Stock

   

Accumulated

         
   

Shares

   

Amount

   

Shares

   

Amount

   

Shares

   

Amount

   

Shares

   

Amount

   

Shares

   

Amount

   

Paid-in capital

   

Subscribed

   

Deficit

   

Total

 
                                                                                                                 

Balance, December 31, 2021

    -     $ -       940,644     $ 9,406       3,100,000     $ 31,000       24,227     $ 242       4,266,669     $ 42,667     $ 26,385,728     $ 132,163     $ (25,478,332 )   $ 1,122,874  

Vesting of common stock issued to employees

    -       -       -       -       -       -       -       -       -       -       1,512       -       -       1,512  

Vesting of stock options issued to employees

    -       -       -       -       -       -       -       -       -       -       167,015       -       -       167,015  

Conversion of accounts payable to common stock

    -       -       -       -       -       -       -       -       63,593       636       577,599       -       -       578,235  

Commitment fee shares

    -       -       -       -       -       -       -       -       34,400       344       242,962       -       -       243,306  

Waiver fee shares

    -       -       -       -       -       -       -       -       30,835       308       275,410       91,440       -       367,158  

Warrants issued with note payable - Diamond 1

    -       -       -       -       -       -       -       -                       2,914       -       -       2,914  

Warrants issued with note payable - Diamond 2

    -       -       -       -       -       -       -       -                       2,213       -       -       2,213  

Gain on settlement of accrued payroll

    -       -       -       -       -       -       -       -       (8,000 )     (80 )     80       -       -       -  

Issuance of shares previously subscribed for conversion of accounts payable

    -       -       -       -       -       -       -       -       7,648       76       95,512       (95,588 )     -       -  

Preferred stock dividends

    -       -       -       -       -       -       -       -       -       -       (79,692 )     -       -       (79,692 )

Loss for the three months ended March 31, 2022

    -       -       -       -       -       -       -       -       -       -       -       -       (3,645,194 )     (3,645,194 )

Balance, March 31, 2022

    -       -       940,644     $ 9,406       3,100,000     $ 31,000       24,227     $ 242       4,395,145     $ 43,951     $ 27,671,253     $ 128,015     $ (29,123,526 )   $ (1,239,659 )
                                                                                                                 
                                                                                                                 

Balance, December 31, 2022

    -     $ -       1,047,619     $ 10,476       3,100,000     $ 31,000       24,227     $ 242       4,630,372     $ 46,305     $ 29,452,514     $ 36,575     $ (48,714,461 )   $ (19,137,349 )

Shares issued for conversion of note payable

    -       -       -       -       -       -       -       -       57,138       571       82,885       -       -       83,456  

Vesting of stock options issued to employees

    -       -       -       -       -       -       -       -       -       -       933       -       -       933  

Issuance of common stock to service providers

    -       -       -       -       -       -       -       -       300,000       3,000       894,000       -       -       897,000  

Preferred stock dividends

    -       -       -       -       -       -       -       -       -       -       (79,818 )     -       -       (79,818 )

Shares issued for Series X dividends

    -       -       -       -       -       -       -       -       8,063       81       35,248       -       -       35,329  

Loss for the three months ended March 31, 2023

    -       -       -       -       -       -       -       -       -       -       -       -       (5,613,825 )     (5,613,825 )

Balance, March 31, 2023

    -     $ -       1,047,619     $ 10,476       3,100,000     $ 31,000       24,227     $ 242       4,995,573     $ 49,957       30,385,762     $ 36,575     $ (54,328,286 )   $ (23,814,274 )

 

See accompanying notes to these unaudited condensed consolidated financial statements.

 

 

MITESCO, INC.

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(UNAUDITED)

 

   

For the Three Months

 
   

Ended

 
   

March 31,

 
   

2023

   

2022

 

CASH FLOWS FROM OPERATING ACTIVITIES

               

Net loss

  $ (5,613,825 )   $ (3,645,194 )

Adjustments to reconcile net loss to net cash used in operating activities:

               

Impairment of assets

    2,271,893       -  

Gain on lease termination

    (287,897 )     -  

Depreciation

    102,783       179,886  

Penalties on notes payable

    1,102,778       -  

Amortization of right-to-use asset

    -       267,463  

Financing cost - waiver fee shares

    -       565,431  

Gain on waiver fee shares

    -       (198,273 )

Gain on conversion of accrued salary

    -       (15,032 )

(Gain) loss on revaluation of derivative liabilities

    110,778       (79,837 )

Loss on settlement of accounts payable

    -       78,235  

Amortization of discount on notes payable

    23,538       231,180  

Amortization of discount on notes payable - related parties

    14,214       -  

Share-based compensation

    897,933       168,527  

Changes in assets and liabilities:

               

Accounts receivables

    24,341       (11,274 )

Prepaid expenses

    53,892       (19,699 )

Inventory

    (90 )     (5,279 )

Accounts payable and accrued liabilities

    989,559       534,132  

Operating lease liability, net

    -       12,158  

Accrued interest

    159,841       31,714  

Accrued interest - related parties

    114,938       -  

Net cash used in operating activities

    (35,324 )     (1,905,862 )
                 

CASH FLOWS FROM INVESTING ACTIVITIES

               

Cash paid for acquisition of fixed assets and construction in progress

    -       (19,223 )

Net cash used in investing activities

    -       (19,223 )
                 

CASH FLOWS FROM FINANCING ACTIVITIES

               

Proceeds from notes payable - related parties, net of discounts

    -       348,750  

Proceeds from notes payable, net of discounts

    -       675,000  

Net cash provided by financing activities

    -       1,023,750  

Net decrease in cash and cash equivalents

    (35,324 )     (901,335 )
                 

Cash and cash equivalents at beginning of period

    35,623       1,164,483  

Cash and cash equivalents at end of period

  $ 299     $ 263,148  

 

See accompanying notes to these unaudited condensed consolidated financial statements.

 

 

MITESCO, INC.

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(UNAUDITED)

 

   

For the Three Months

 
   

Ended

 
   

March 31,

 
   

2023

   

2022

 
                 

SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION:

               

Interest paid

  $ -     $ 2,680  
                 

NON-CASH INVESTING AND FINANCING ACTIVITIES:

               

Stock issued for common stock subscribed

  $ 83,456     $ -  

Preferred stock dividend

  $ 79,818     $ 79,692  

Conversion of accounts payable to common stock

  $ -     $ 500,000  

Increase in capital expenditures included in accounts payable

  $ 109,383

 

  $ 1,009,471  

 

 

 

See accompanying notes to these unaudited condensed consolidated financial statements.

 

 

MITESCO, INC.

NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

March 31, 2023 AND 2022

 

Note 1: Description of Business

 

Company Overview

 

Mitesco, Inc. (the “Company,” “we,” “us,” or “our”) was formed in the state of Delaware on January 18, 2012. On December 9, 2015, we restructured our operations and acquired Newco4pharmacy, LLC, a development stage company which sought to acquire compounding pharmacy businesses. As a part of the restructuring, we completed a “spin out” of our former business line. On April 24, 2020, we changed our name to Mitesco, Inc.

 

We are a holding company with current operating plans to participate in the healthcare industry through the development of healthcare services, and with a view toward additional services and technology that may find a ready market in the healthcare industry. During early 2022 we continued on our plan to open primary care clinics around the United States in select markets, utilizing the experience, expertise, and training of licensed, advanced degreed nurse practitioners (“Nurse Practitioners”). During 2022 our clinics provided complete primary care, as well as a limited set of offerings addressing more specific needs for the general public. The medical practice focuses on whole person health and prevention. During late 2022 we decided to close our clinics due to a lack of funding for their operations and growth plans.

 

We have always had a view toward additional healthcare technology and services offerings and are committing more time to that effort going forward. We have a number of near-term opportunities that we hope to pursue, assuming the capital markets make sufficient funding available at reasonable rates.

 

Our operations are subject to comprehensive federal, state, and local laws and regulations in the jurisdictions in which it does business. There also continues to be a heightened level of review and/or audit by federal and state regulators of the health and related benefits industry’s business and reporting practices. As of the date of this filing, we are not subject to any actual or anticipated regulatory reviews or audits relating to our operations.

 

The laws and rules governing our businesses and interpretations of those laws and rules continue to evolve each year and are subject to frequent change. The application of these complex legal and regulatory requirements to the detailed operation of our businesses creates areas of uncertainty. Further, there are numerous proposed health care, financial services and other laws and regulations at the federal and state level some of which could adversely affect our businesses if they are enacted. We cannot predict whether pending or future federal or state legislation will have an adverse effect on our business.

 

We can give no assurance that the businesses, financial condition, operating results and/or cash flows will not be materially adversely affected, or that we will not be required to materially change its business practices, based on: (i) future enactment of new health care or other laws or regulations; (ii) the interpretation or application of existing laws or regulations, including the laws and regulations described in this Government Regulation section, as they may relate to one or more of our businesses, one or more of the industries in which we compete and/or the health care industry generally; (iii) our pending or future federal or state governmental investigations.

 

Reverse Stock Split

 

On December 12, 2022, our board of directors approved the filing of a certificate of amendment to our amended and restated certificate of incorporation (the “Amendment”) with the Secretary of State of the State of Delaware to affect the one-for-fifty. The Amendment became effective at 5:00 p.m. Eastern Time on December 12, 2022.

 

Pursuant to the Amendment, at the effective time of the Amendment, every fifty (50) shares of our issued and outstanding common stock was automatically combined into one (1) issued and outstanding share of common stock The Reverse Stock Split affected all shares of our common stock outstanding immediately prior to the effective time of the Amendment. No fractional shares were issued as a result of the Reverse Stock Split. Stockholders of record who would otherwise be entitled to receive a fractional share received a full share thereof. As a result of the Reverse Stock Split, proportionate adjustments were made to the per share exercise price and/or the number of shares issuable upon the exercise or vesting of all stock options and warrants issued by us and outstanding immediately prior to the effective time of the Amendment, which resulted in a proportionate decrease in the number of shares of our common stock reserved for issuance upon exercise or vesting of such stock options and warrants and a proportionate increase in the exercise price of all such stock options and warrants. In addition, the number of shares reserved for issuance under our equity compensation plans immediately prior to the effective time of the Amendment were reduced proportionately. All share and per share amounts of common stock presented in this Quarterly Report on Form 10-Q have been retroactively adjusted to reflect the Reverse Stock Split.

 

 

Note 2: Financial Condition, Going Concern and Management Plans

 

As of March 31, 2023, the Company had cash and cash equivalents of approximately $300, current liabilities of $20.4 million, and has incurred significant losses from the previous clinic operations. Our strategy is to acquire healthcare technology and service businesses that have a unique positioning that gives them a differentiated competitive advantage in the market that  improves patients’ experience and outcomes and reduces healthcare costs as compared to other available treatments and solution. As previously noted, we made a strategic decision to reduce our capital needs by closing our clinic operations in the fourth quarter of 2022 and releasing a significant portion of our staff. As we redevelop our new strategy for lower cost operations, we expect to focus on acquisition of existing healthcare technology and services businesses. The Company’s activities are subject to significant risks and uncertainties, including failing to secure additional funding to execute its business plan.

 

Effective December 8, 2022, we closed all of our clinic locations due to a lack of funding. Subsequent to that date we have lost possession of all clinic locations. Due to difficulty in securing financing, we are uncertain of when or even if we will be able to resume operations at any clinic location.

 

As a result of these factors, there is substantial doubt about the ability of the Company to continue as a going concern for one year from the date the financial statements are issued. The Company’s continuance is dependent on raising capital and generating revenues sufficient to sustain operations. However, as of the date of these consolidated financial statements, no formal agreement exists.

 

The accompanying unaudited condensed consolidated financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts or amounts classified as liabilities that might be necessary should the Company be forced to take any such actions.

 

The COVID-19 pandemic, decades-high inflation and concerns about an economic recession in the United States or other major markets has resulted in, among other things, volatility in the capital markets that may have the effect of reducing the Company’s ability to access capital, which could in the future negatively affect the Company’s liquidity. In addition, a recession or market correction due to these factors could materially affect the Company’s business and the value of its common stock.

 

Note 3: Summary of Significant Accounting Policies

 

Principles of Consolidation The accompanying condensed consolidated financial statements include the accounts of Mitesco, Inc., and its wholly owned subsidiaries Mitesco NA, LLC and The Good Clinic, LLC. In addition, we anticipate that we will rely on the operating activities of certain legal entities in which we will not maintain a controlling ownership interest but over which we will have indirect influence and of which we will be considered the primary beneficiary. We expect that these entities will typically be subject to nominee ownership and transfer restriction agreements that effectively transfer the majority of the economic risks and rewards of their ownership to the Company. The Company’s management, restriction and other agreements concerning such nominee-owned entities typically includes both financial terms and protective and participating rights to the entities’ operating, strategic and non-clinical governance decisions which transfer substantial powers over and economic responsibility for these entities to the Company. As such, the Company applies the guidance of the Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) 810 – Consolidation (“ASC 810”), to determine when an entity that is insufficiently capitalized or not controlled through its voting interests, referred to as a variable interest entity should be consolidated. All intercompany balances and transactions have been eliminated.

 

Use of Estimates - The preparation of these financial statements requires our management to make estimates and assumptions about future events that affect the amounts reported in the financial statements and related notes. Future events and their effects cannot be determined with absolute certainty. Therefore, the determination of estimates requires the exercise of judgment.

 

Significant Accounting Policies

 

There have been no material changes in the Company’s significant accounting policies from those previously disclosed in the 2022 Annual Report.

 

New Accounting Standards

 

From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board (“FASB”) or other standard setting bodies that the Company adopts as of the specified effective date. Unless otherwise discussed, the Company does not believe that the impact of recently issued standards that are not yet effective will have a material impact on its financial position or results of operations upon adoption.

 

 

Note 4: Net Loss Per Share Applicable to Common Shareholders

 

Net Loss per Share Applicable to Common Stockholders

 

Basic loss per common share is computed by dividing net loss by the weighted average number of common shares outstanding during the reporting period. Diluted loss per common share is computed similarly to basic loss per common share except that it reflects the potential dilution that could occur if dilutive securities or other obligations to issue common stock were exercised or converted into common stock.

 

The following table sets forth the computation of loss per share for the three months ended March 31, 2023, and 2022, respectively:

 

   

For the Three Months Ended

 
   

March 31,

 
   

2023

   

2022

 

Numerator:

               

Net loss applicable to common shareholders

  $ (5,693,644

)

  $ (3,724,886

)

                 

Denominator:

               

Weighted average common shares outstanding

    4,825,054       4,274,064  
                 

Net loss per share:

               

Basic and diluted

  $ (1.18

)

  $ (0.87

)

 

The Company excluded all common equivalent shares outstanding for warrants, options, and convertible instruments to purchase common stock from the calculation of diluted net loss per share because all such securities are antidilutive for the periods presented. As of March 31, 2023, and 2022, the following shares were issuable and excluded from the calculation of diluted loss:

 

   

For the Years Ended

 
   

March 31,

 
   

2023

   

2022

 

Common stock options

    215,881       373,425  

Common stock purchase warrants

    672,334       628,100  

Convertible Preferred Stock

    347,652       347,652  

Accrued interest on Preferred Stock

    47,767       24,618  

Potentially dilutive securities

    1,283,634       1,373,795  

 

Note 5: Related Party Transactions

 

For the three months ended March 31, 2023:

 

During the three months ended March 31, 2023, the Company accrued dividends on its Series X Preferred Stock in the total amount of $15,141. Of this amount, a total of $2,000 was payable to officers and directors, $7,814 was payable to a related party shareholder, and $5,327 was payable to non-related parties.

 

On March 31, 2023, the Company issued a total of 8,063 shares of common stock for accrued dividends on its Series X Preferred Stock. Of this amount, a total of 1,066 shares were issued to officers and directors, 4,160 were issued to a related party shareholder, and 2,837 were issued to no-related parties.

 

 

For the three months ended March 31, 2022:

 

The Company issued a 10% Promissory Note due August 14, 2022 (the “Note”), dated February 14, 2022, to Lawrence Diamond (the “Lender”). Mr. Diamond is the Chief Executive Officer of the Company and a member of its Board of Directors. The principal amount of the Note is $175,000, carries a 10% interest rate per annum, payable in monthly installments, and has a maturity date that is the earlier of (i) six (6) months from the date of execution, or (ii) the date on which the Company successfully lists its shares of common stock on Nasdaq or NYSE. The purchase price of the Note payable to the Company for the Note was $148,750 and was funded on February 14, 2022. The amount payable at maturity will be $175,000 plus 10% of that amount plus accrued and unpaid interest. Following an event of default, as defined in the Note, the principal amount shall bear interest for each day until paid, at a rate per annum equal to the lesser of the maximum interest permitted by applicable law and 18%. The Note contains a “most favored nations” clause that provides that, so long as the Note is outstanding, if the Company issues any new security, which the Lender reasonably believes contains a term that is more favorable than those in the Note, the Company shall notify the Lender of such term, and such term, at the option of the Lender, shall become a part of the Note. In addition to the Note and Lender will be issued 7,350 5-year warrants that may be exercised at $25.00 per share and 7,350 5-year warrants that may be exercised at $37.50 per share. These warrants have all of the same terms as those previously issued in conjunction with the Company’s Series C Preferred shares and its Series D Preferred shares.

 

During the three months ended March 31, 2022, the Company accrued dividends on its Series X Preferred Stock in the total amount of approximately $15,000. Of this amount, a total of $2,000 was payable to officers and directors, $8,000 was payable to a related party shareholder, and $6,000 was payable to non-related parties.

 

Note 6: Accounts Payable and Accrued Liabilities

 

Accounts payable and accrued liabilities consisted of the following at March 31, 2023 and December 31, 2022:

 

   

March 31,

   

December 31,

 
   

2023

   

2022

 

Trade accounts payable

  $ 7,482,128     $ 6,761,793  

Accrued payroll and payroll taxes

    858,645       590,915  

Other

    -       507  

Total accounts payable and accrued liabilities

  $ 8,340,773     $ 7,353,215  

 

Note 7: Right to Use Assets and Lease Liabilities Operating Leases

 

During the year ended December 31, 2022, the Company recognized an impairment of Right-to-Use (RTU) assets in the amount of $3.2 million in connection with the closing of its clinics during the period. During the three months ended March 31, 2023, the Company recognized an additional impairment in the amount of $0.5 million in connection with its remaining leased properties.

 

As of March 31, 2023, the Company had total operating lease liabilities of approximately $4.1 million and right to use assets of $0, which were included in the condensed consolidated balance sheet.

 

Right to use assets – operating leases are summarized below:

 

   

March 31,

2023

   

December 31,

2022

 

Right to use assets, net

  $ -     $ 544,063  

 

Operating lease liabilities are summarized below:

   

March 31,

2023

   

December 31,

2022

 

Lease liability

  $ 4,066,827     $ 4,379,724  

Less: current portion

    (512,895

)

    (442,866

)

Lease liability, non-current

  $ 3,553,932     $ 3,936,858  

 

 

Maturity analysis under these lease agreements are as follows:

 

For the twelve months ended March 31, 2024

  $ 1,087,018  

For the twelve months ended March 31, 2025

    824,520  

For the twelve months ended March 31, 2026

    843,270  

For the twelve months ended March 31, 2027

    862,264  

For the twelve months ended March 31, 2028

    880,268  

Thereafter

    1,586,661  

Total

  $ 6,084,001  

Less: Present value discount

    (2,017,174

)

Lease liability

  $ 4,066,827  

 

Effective February 3, 2023, the Company entered into a termination agreement for the lease of its clinic located in Wayzata, Minnesota. The terms of the agreement call for a payment by the Company in the amount of $25,000 in full settlement of all amounts payable by the Company under this lease. The amount of operating lease liability recorded by the Company at the time of the settlement was $312,897. The Company accrued a liability in the amount of $25,000 and recorded a gain on settlement of lease liability in the amount of $287,897 during the three months ended March 31, 2023.

 

Effective March 3, 2023, the Company entered into a termination agreement for the lease of its clinic located in Eagen, Minnesota. The Company is currently involved in legal proceedings with the landlord of this clinic, and no gain or loss was recorded on this lease termination. An estimate of the potential liability resulting from these legal proceedings cannot be made at this time. At March 31, 2023, an operating lease liability in the amount of $474,074 is recorded on the Company’s balance sheet in connection with this lease.

 

Note 8: SBA Loan Payable

 

PPP Loan

 

During March 2020, in response to the COVID-19 crisis, the federal government announced plans to offer loans to small businesses in various forms, including the Payroll Protection Program, or “PPP”, established as part of the Corona Virus Aid, Relief and Economic Security Act (“CARES Act”) and administered by the U.S. Small Business Administration. On April 25, 2020, the Company entered an unsecured Promissory Note with Bank of America for a loan in the original principal amount of $460,400, and the Company received the full amount of the loan proceeds on May 4, 2020 (the “PPP Loan”). The PPP Loan bears interest at the rate of 1% per year. During the year ended December 31, 2022, the Company accrued interest in the amount of $4,632

 

During the three months ended March 31, 2023, the Company accrued interest in the amount of $1,135 on the PPP Loan; at March 31, 2023, the balance due on this loan was principal in the amount of $460,400 and accrued interest in the amount of $12,424. This loan is in default at March 31, 2023.

 

Note 9: Notes Payable

 

AJB Note

 

On March 18, 2022, the Company entered into a Securities Purchase Agreement (the “AJB Agreement”) with AJB Capital Investments, LLC (“AJB”) with respect to the sale and issuance to AJB of: (i) an initial commitment fee in the amount of $430,000 in the form of 34,400 shares (the “AJB Commitment Fee Shares”) of the Company’s Common Stock, (ii) a promissory note in the aggregate principal amount of $750,000 (the “AJB Note”), and (iii) Common Stock Purchase Warrants to purchase 15,000 shares of the Company’s Common Stock (the “AJB Warrants”). The AJB Note and AJB Warrants were issued on March 17, 2022 and were held in escrow pending effectiveness of the AJB Agreement. Should AJB receive net proceeds of less than $430,000 from the sale of the AJB Commitment Fee Shares, the Company will issue additional shares to AJB or pay the shortfall amount to AJB in cash (the “AJB True-up Obligation”. The terms of the AJB Agreement resulted in the Company recording a derivative liability in the initial amount of $106,608. On November 18, 2022, the Company issued 91,328 shares of common stock to AJB and recorded a loss in the amount of $9,007 in connection with the settlement of the AJB True-up Obligation. See notes 11 and 12.

 

 

The AJB Note was issued in the principal amount of $750,000 for a purchase price of $675,000, resulting in an original issue discount of $75,000, and has a due date, as extended, of March 17, 2023. The AJB Note bears interest at the rate of 10% per year for the first six months and 12% thereafter. In the event of default as defined in the AJB Note this rate will increase to 18% and the AJB Note will become convertible at a price per share equal to the lowest trading price during the previous twenty trading days prior to the conversion date. The AJB Note entered default status on October 6, 2022. The AJB Commitment Fee Shares and AJB Warrants resulted in a discount to the AJB Note in the amount of $349,914. The Company charged the amount of $62,000 to interest on the AJB Note during the year ended December 31, 2022. Discounts in the amount of $424,914 were amortized to interest expense during the year ended December 31, 2022, and total discounts in the amount of $0 remained outstanding at December 31, 2022. Principal and accrued interest in the amounts $750,000 and $22,833, respectively, were due on the AJB Note at December 31, 2022.

 

During the three months ended March 31, 2023, a default penalty in the amount of $375,000 and an additional fee in the amount of $15,000 were added to the principal amount of the AJB note, and interest in the amount of $62,897 was accrued. At March 31, 2023, principal and interest in the amount of $1,140,000 and $85,730, respectively, were due on the AJB Note. This note was in default at March 31, 2023.

 

Anson Investments Note

 

On April 6, 2022, the Company entered into a Securities Purchase Agreement (the “Anson Investments Agreement”) with Anson Investments Master Fund LP (“Anson Investments”) with respect to the sale and issuance to Anson Investments of: (i) an initial commitment fee in the amount of $322,500 in the form of 25,800 shares (the “Anson Investments Commitment Fee Shares”) of the Company’s Common Stock, (ii) a promissory note in the aggregate principal amount of $562,500 (the “Anson Investments Note”), and (iii) Common Stock Purchase Warrants to purchase 11,250 shares of the Common Stock (the “Anson Investments Warrants”). Should Anson Investments receive net proceeds of less than $322,500 from the sale of the Anson Investments Commitment Fee Shares, the Company will issue additional shares to Anson Investments or pay the shortfall amount to Anson Investments in cash. The terms of the Anson Investments Agreement resulted in the Company recording a derivative liability in the initial amount of $27,040.

 

The Anson Investments Note was issued in the principal amount of $562,500 for a purchase price of $506,250 resulting in an original issue discount of $56,250. The Anson Investments Note has a due date of October 6, 2022 and bears interest at the rate of 10% per year for the first six months and 12% thereafter. In the event of default as defined in the Anson Investments Note this rate will increase to 18% and the Anson Investment Note will become convertible at a price per share equal to the lowest trading price during the previous twenty trading days prior to the conversion date. The Anson Investments Note entered default status on October 6, 2022. The Anson Investments Commitment Fee Shares and Anson Investments Warrants resulted in a discount to the Anson Investments Note in the amount of $416,375. The Company charged the amount of $68,844 to interest on the Anson Investments note during the year ended December 31, 2022. Discounts in the amount of $472,625 were amortized to interest expense during the year ended December 31, 2022, and total discounts in the amount of $0 remained outstanding at December 31, 2022. Principal and accrued interest in the amounts $562,500 and $41,500, respectively, were due on the AJB Note at December 31, 2022.

 

During the three months ended March 31, 2023, a default penalty in the amount of $281,250 and an additional fee in the amount of $15,000 were added to the principal amount of the Anson Investments Note, and interest in the amount of $22,433 was accrued. At March 31, 2023, principal and interest in the amount of $858,750 and $63,933, respectively, were due on the Anson Investments Note. This note was in default at March 31, 2023.

 

Anson East Note

 

On April 6, 2022, the Company entered into a Securities Purchase Agreement (the “Anson East Agreement”) with Anson East Master Fund LP (“Anson East”) with respect to the sale and issuance to Anson East of: (i) an initial commitment fee in the amount of $107,500 in the form of 8,600 shares (the “Anson East Commitment Fee Shares”) of the Company’s Common Stock, (ii) a promissory note in the aggregate principal amount of $187,500 (the “Anson East Note”), and (iii) Common Stock Purchase Warrants to purchase 3,750 shares of the Company’s common stock (the “Anson East Warrants”). Should Anson East receive net proceeds of less than $107,500 from the sale of the Anson East Commitment Fee Shares, the Company will issue additional shares to Anson East or pay the shortfall amount to Anson East in cash. The terms of the Anson East Agreement resulted in the Company recording a derivative liability in the initial amount of $9,014.

 

 

The Anson East Note was issued in the principal amount of $187,500 for a purchase price of $168,750 resulting in an original issue discount of $18,750. The Anson East Note has a due date of October 6, 2022 and bears interest at the rate of 10% per year for the first six months and 12% thereafter. In the event of default as defined in the Anson East Note this rate will increase to 18%, and the Anson East Note will become convertible at a price per share equal to the lowest trading price during the previous twenty trading days prior to the conversion date. The Anson East Note entered default status on October 6, 2022. The Anson East Commitment Fee Shares and Anson East Warrants resulted in a discount to the Anson East Note in the amount of $147,290. The Company charged the amount of $22,948 to interest on the Anson Investments note during the year ended December 31, 2022. Discounts in the amount of $166,040 were amortized to interest expense during the year ended December 31, 2022, and total discounts in the amount of $0 remained outstanding at December 31, 2022. Principal and accrued interest in the amounts $187,500 and $13,833, respectively, were due on the Anson East Note at December 31, 2022.

 

During the three months ended March 31, 2023, a default penalty in the amount of $93,750 and an additional fee in the amount of $15,000 were added to the principal amount of the Anson East Note, and interest in the amount of $7,922 was accrued. At March 31, 2023, principal and interest in the amount of $296,250 and $21,755, respectively, were due on the Anson East Note. This note was in default at March 31, 2023.

 

GS Capital Note

 

On April 18, 2022, the Company entered into a Securities Purchase Agreement (the “GS Capital Agreement”) with GS Capital Investments, LLC (“GS Capital”) with respect to the sale and issuance to GS Capital of: (i) an initial commitment fee in the amount of $159,259 in the form of 12,741 shares (the “GS Capital Commitment Fee Shares”) of the Company’s Common Stock, (ii) a promissory note in the aggregate principal amount of $277,777 (the “GS Capital Note”), and (iii) Common Stock Purchase Warrants to purchase 5,556 shares of the Company’s common stock (the “GS Capital Warrants”). Should GS Capital receive net proceeds of less than $159,259 from the sale of the GS Capital Commitment Fee Shares, the Company will issue additional shares to GS Capital or pay the shortfall amount to GS Capital in cash. The terms of the GS Capital Agreement resulted in the Company recording a derivative liability in the initial amount of $21,920.

 

The GS Capital Note was issued in the principal amount of $277,777 for a purchase price of $250,000 resulting in an original issue discount of $27,777. The GS Capital Note has a due date of November 10, 2022 and bears interest at the rate of 10% per year for the first six months and 12% thereafter. In the event of default as defined in the GS Capital Note this rate will increase to 18%, and the GS Capital Note will become convertible at a price per share equal to the lowest trading price during the previous twenty trading days prior to the conversion date. The GS Capital Note entered default status on October 19, 2022. The GS Capital Commitment Fee Shares and GS Capital Warrants resulted in a discount to the GS Capital Note in the amount of $162,158. The Company charged the amount of $32,155 to interest on the GS Capital Note during the year ended December 31, 2022. Discounts in the amount of $212,435 were amortized to interest expense during the year ended December 31, 2022, and total discounts in the amount of $0 remained outstanding at December 31, 2022. Principal and accrued interest in the amounts $277,777 and $19,578, respectively, were due on the GS Capital Note at December 31, 2022.

 

During the three months ended March 31, 2023, GS Capital converted an aggregate amount of $72,777 of principal, $8,679 of accrued interest, and $2,000 of fees in the GL Capital Note into an aggregate of 57,138 shares of the Company’s common stock at an average price of $1.46 per share. These conversions were made pursuant to the terms of the GS Capital Note, and no gain or loss was recorded on these transactions. During the three months ended March 31, 2023, a default penalty in the amount of $138,889 and an additional fee in the amount of $15,000 were added to the principal amount of the GS Capital Note, and interest in the amount of $11,591 was accrued. At March 31, 2023, principal and interest in the amount of $358,889 and $22,490, respectively, were due on the GS Capital Note. This note was in default at March 31, 2023.

 

Kishon Note

 

On May 10, 2022, the Company entered into a Securities Purchase Agreement (the “Kishon Agreement”) with Kishon Investments, LLC (“Kishon”) with respect to the sale and issuance to Kishon of: (i) an initial commitment fee in the amount of $159,259 in the form of 12,741 shares (the “Kishon Commitment Fee Shares”) of the Company’s Common Stock, (ii) a promissory note in the aggregate principal amount of $277,777 (the “Kishon Note”), and (iii) Common Stock Purchase Warrants to purchase 5,556 shares of the Company’s common stock (the “Kishon Warrants”). Should Kishon receive net proceeds of less than $159,259 from the sale of the Kishon Commitment Fee Shares, the Company will issue additional shares to Kishon or pay the shortfall amount to Kishon in cash. The terms of the Kishon Agreement resulted in the Company recording a derivative liability in the initial amount of $27,793.

 

 

The Kishon Note was issued in the principal amount of $277,777 for a purchase price of $250,000 resulting in an original issue discount of $27,777. The Kishon Note has a due date of November 10, 2022 and bears interest at the rate of 10% per year for the first six months and 12% thereafter. In the event of default as defined in the Kishon Note this rate will increase to 18%, and the Kishon Note will become convertible at a price per share equal to the lowest trading price during the previous twenty trading days prior to the conversion date. The Kishon Note entered default status on November 11, 2022. The Kishon Commitment Fee Shares and Kishon Warrants resulted in a discount to the Kishon Note in the amount of $138,492. The Company charged the amount of $28,624 to interest on the Kishon Note during the year ended December 31, 2022. Discounts in the amount of $181,269 were amortized to interest expense during the year ended December 31, 2022, and total discounts in the amount of $0 remained outstanding at December 31, 2022. Principal and accrued interest in the amounts $277,777 and $17,822, respectively, were due on the Kishon Note at December 31, 2022. The Kishon Note was in default at December 31, 2022.

 

During the three months ended March 31, 2023, a default penalty in the amount of $138,889 and an additional fee in the amount of $15,000 were added to the principal amount of the Kishon Note, and interest in the amount of $12,004 was accrued. At March 31, 2023, principal and interest in the amount of $431,666 and $29,826, respectively, were due on the GS Capital Note. This note was in default at March 31, 2023.

 

Finnegan Note 1

 

On May 23, 2022, the Company issued a 10% Promissory Note in the principal amount of $47,059 to Jessica Finnegan (the “Finnegan Note 1”). The Finnegan Note 1 bears interest at the rate of 10% per annum accrued monthly and has a maturity date that is the earlier of (i) November 20, 2022, as extended, or (ii) five (5) business days after the date on which the Company successfully lists its shares of common stock on Nasdaq or NYSE. The purchase price of the Finnegan Note 1 was $40,000; the amount payable at maturity will be $47,059 plus 10% of that amount plus any accrued and unpaid interest. Following an event of default as defined in the Finnegan Note 1, the principal amount shall bear interest for each day until paid at a rate per annum equal to the lesser of the maximum interest permitted by applicable law and 18%. The Finnegan Note 1 entered default status on November 21, 2022, and the interest rate increased to 18%. The Finnegan Note 1 contains a “most favored nations” clause that provides that, so long as the note is outstanding, if the Company issues any new security which Ms. Finnegan reasonably believes contains a term that is more favorable than those in the Finnegan Note 1, the Company shall notify Ms. Finnegan of such term, and such term, at the option of Ms. Finnegan, shall become a part of the Finnegan Note 1. In addition, Ms. Finnegan received five-year warrants to purchase 386 shares of common stock at a price of $25.00 per share with a fair value of $2,000 at the date of issuance, and 1,930 shares of common stock with a value of $3,240; these amounts were recorded as discounts to the Finnegan Note 1. Interest in the amount of $3,285 was accrued on the Finnegan Note 1 during the year ended December 31, 2022. Discounts in the amount of $17,005 were amortized to interest expense during the year ended December 31, 2022, and total discounts in the amount of $0 remained outstanding at December 31, 2022. Principal and accrued interest in the amounts $51,765 and $3,285, respectively, were due on the Finnegan Note 1 at December 31, 2022.

 

During the three months ended March 31, 2023, interest in the amount of $2,163 was accrued on the Finnegan Note 1; principal and accrued interest in the amount of $51,765 and $5,448, respectively, were due on this note at March 31, 2023. This note was in default at March 31, 2023.

 

M Diamond Note

 

On May 26, 2022, the Company issued a 10% Promissory Note in the principal amount of $58,823 to Melissa Diamond (the “M Diamond Note”). The M Diamond Note bears interest at the rate of 10% per annum accrued monthly and has a maturity date that is the earlier of (i) November 30, 2022, or (ii) five business days after the date on which the Company successfully lists its shares of common stock on Nasdaq or NYSE. The purchase price of the M Diamond Note was $50,000; the amount payable at maturity will be $58,823 plus 10% of that amount plus any accrued and unpaid interest. Following an event of default as defined in the M Diamond Note, the principal amount shall bear interest for each day until paid at a rate per annum equal to the lesser of the maximum interest permitted by applicable law and 18%. The M Diamond Note entered default status on December 1, 2022, and the interest rate increased to 18%. The M Diamond Note contains a “most favored nations” clause that provides that, so long as the note is outstanding, if the Company issues any new security which Ms. Diamond reasonably believes contains a term that is more favorable than those in the M Diamond Note, the Company shall notify Ms. Diamond of such term, and such term, at the option of Ms. Diamond, shall become a part of the M Diamond Note. In addition, Ms. Diamond received five-year warrants to purchase 483 shares of common stock at a price of $25.00 per share with a fair value of $2,500 at the date of issuance, and 483 shares of common stock with a value of $4,050; these amounts were recorded as discounts to the M Diamond Note. Interest in the amount of $3,929 was accrued on the M Diamond Note during the year ended December 31, 2022. Discounts in the amount of $21,256 were amortized to interest expense during the year ended December 31, 2022, and total discounts in the amount of $0 remained outstanding at December 31, 2022. Principal and accrued interest in the amounts $64,705 and $3,929, respectively, were due on the M Diamond Note at December 31, 2022. During the three months ended March 31, 2023, interest in the amount of $2,702 was accrued on the M Diamond Note; principal and accrued interest in the amount of $64,705 and $6,631, respectively, were due on this note at March 31, 2023. This note was in default at March 31, 2023.

 

 

Finnegan Note 2

 

On May 26, 2022, the Company issued a 10% Promissory Note in the principal amount of $29,412 to Jessica Finnegan (the “Finnegan Note 2”). The Finnegan Note 2 bears interest at the rate of 10% per annum accrued monthly and has a maturity date that is the earlier of (i) November 30, 2022, or (ii) five business days after the date on which the Company successfully lists its shares of common stock on Nasdaq or NYSE. The purchase price of the Finnegan Note 2 was $25,000; the amount payable at maturity will be $29,412 plus 10% of that amount plus any accrued and unpaid interest. Following an event of default as defined in the Finnegan Note 2, the principal amount shall bear interest for each day until paid at a rate per annum equal to the lesser of the maximum interest permitted by applicable law and 18%. The Finnegan Note 2 entered default status on December 1, 2022, and the interest rate increased to 18%. The Finnegan Note 2 contains a “most favored nations” clause that provides that, so long as the note is outstanding, if the Company issues any new security which Ms. Finnegan reasonably believes contains a term that is more favorable than those in the Finnegan Note 2, the Company shall notify Ms. Finnegan of such term, and such term, at the option of Ms. Finnegan, shall become a part of the Finnegan Note 2. In addition, Ms. Finnegan received five-year warrants to purchase 242 shares of common stock at a price of $25.00 per share with a fair value of $1,250 at the date of issuance, and 242 shares of common stock with a value of $2,025; these amounts were recorded as discounts to the Finnegan Note 2. Interest in the amount of $1,965 was accrued on the Finnegan Note 2 during the year ended December 31, 2022. Discounts in the amount of $10,625 were amortized to interest expense during the year ended December 31, 2022, and total discounts in the amount of $0 remained outstanding at December 31, 2022. Principal and accrued interest in the amounts $32,353 and $1,965, respectively, were due on the Finnegan Note 2 at December 31, 2022. During the three months ended March 31, 2023, interest in the amount of $1,350 was accrued on the Finnegan Note 2; principal and accrued interest in the amount of $32,353 and $3,315, respectively, were due on this note at March 31, 2023. This note was in default at March 31, 2023.

 

Dragon Note

 

On June 9, 2022, the Company issued a 10% Promissory Note in the principal amount of $588,235 (the “Dragon Note”) to Dragon Dynamic Funds Platform Ltd (“Dragon Dynamic”). The Dragon Note bears interest at the rate of 10% per annum accrued monthly and has a maturity date that is the earlier of (i) December 9, 2022, or (ii) five business days after the date on which the Company successfully lists its shares of common stock on Nasdaq or NYSE. The purchase price of the Dragon Note was $500,000; the amount payable at maturity will be $588,235 plus 10% of that amount plus any accrued and unpaid interest. Costs in the amount of $47,500 were charged to discount on the Dragon Note. Following an event of default as defined in the Dragon Note, the principal amount shall bear interest for each day until paid at a rate per annum equal to the lesser of the maximum interest permitted by applicable law and 18%. The Dragon Note entered default status on December 10, 2022, and the interest rate increased to 18%. The Dragon Note contains a “most favored nations” clause that provides that, so long as the note is outstanding, if the Company issues any new security which Dragon Dynamic reasonably believes contains a term that is more favorable than those in the Dragon Note, the Company shall notify Dragon Dynamic of such term, and such term, at the option of Dragon Dynamic, shall become a part of the Dragon Note. In addition, Dragon Dynamic received five-year warrants to purchase 4,824 shares of common stock at a price of $25.00 per share with a fair value of $21,500 at the date of issuance, and 4,824 shares of common stock with a value of $44,000; these amounts were recorded as discounts to the Dragon Note. Interest in the amount of $35,874 was accrued on the Dragon Note during the year ended December 31, 2022. Discounts in the amount of $260,059 were amortized to interest expense during the year ended December 31, 2022, and total discounts in the amount of $0 remained outstanding at December 31, 2022. Principal and accrued interest in the amounts $647,059 and $35,874, respectively, were due on the Dragon Note at December 31, 2022. During the three months ended March 31, 2023, interest in the amount of $26,969 was accrued on the Dragon Note; principal and accrued interest in the amount of $647,059 and $62,843, respectively, were due on this note at March 31, 2023. This note was in default at March 31, 2023.

 

 

Mackay Note

 

On July 7, 2022, the Company issued a 10% Promissory Note in the principal amount of $294,118 to Mackay Investments, LLC (the “Mackay Note”). The Mackay Note bears interest at the rate of 10% per annum accrued monthly and has a maturity date that is the earlier of (i) August 10, 2022, or (ii) five business days after the date on which the Company successfully lists its shares of common stock on Nasdaq or NYSE. The purchase price of the Mackay Note was $250,000; the amount payable at maturity will be $294,118 plus 10% of that amount plus any accrued and unpaid interest. Following an event of default as defined in the Mackay Note, the principal amount shall bear interest for each day until paid at a rate per annum equal to the lesser of the maximum interest permitted by applicable law and 18%. The Mackay Note entered default status on August 11, 2022, and the interest rate increased to 18%. The Mackay Note contains a “most favored nations” clause that provides that, so long as the note is outstanding, if the Company issues any new security which Mackay Investments, LLC reasonably believes contains a term that is more favorable than those in the Mackay Note, the Company shall notify Mackay Investments, LLC of such term, and such term, at the option of Mackay Investments, LLC , shall become a part of the Mackay Note. In addition, Mackay Investments, LLC received five-year warrants to purchase 2,412 shares of common stock at a price of $25.00 per share with a fair value of $10,250 at the date of issuance, and 2,412 shares of common stock with a value of $44,118; these amounts were recorded as discounts to the Mackay Note. Interest in the amount of $20,193 was accrued on the Mackay Note during the year ended December 31, 2022. Discounts in the amount of $96,280 were amortized to interest expense during the year ended December 31, 2022, and total discounts in the amount of $0 remained outstanding at December 31, 2022. Principal and accrued interest in the amounts $323,530 and $20,193, respectively, were due on the Mackay Note at December 31, 2022.During the three months ended March 31, 2023, interest in the amount of $16,850 was accrued on the Mackay Note; principal and accrued interest in the amount of $323,530 and $37,043 respectively, were due on this note at March 31, 2023. This note was in default at March 31, 2023.

 

Schrier Note

 

On July 7, 2022, the Company issued a 10% Promissory Note in the principal amount of $23,259 to Charles Schrier (the “Schrier Note”). The Schrier Note bears interest at the rate of 10% per annum accrued monthly and has a maturity date that is the earlier of (i) January 8, 2023, or (ii) five business days after the date on which the Company successfully lists its shares of common stock on Nasdaq or NYSE. The purchase price of the Schrier Note was $20,000; the amount payable at maturity will be $23,529 plus 10% of that amount plus any accrued and unpaid interest. Following an event of default as defined in the Schrier Note, the principal amount shall bear interest for each day until paid at a rate per annum equal to the lesser of the maximum interest permitted by applicable law and 18%. The Schrier Note contains a “most favored nations” clause that provides that, so long as the note is outstanding, if the Company issues any new security which Mr. Schrier reasonably believes contains a term that is more favorable than those in the Schrier Note, the Company shall notify Mr. Schrier of such term, and such term, at the option of Mr. Schrier, shall become a part of the Schrier Note. In addition, Mr. Schrier received five-year warrants to purchase 193 shares of common stock at a price of $25.00 per share with a fair value of $820 at the date of issuance, and 193 shares of common stock with a value of $1,000; these amounts were recorded as discounts to the Schrier Note. Interest in the amount of $1,141 was accrued on the Schrier Note during the year ended December 31, 2022. Discounts in the amount of $7,367 were amortized to interest expense during the year ended December 31, 2022, and total discounts in the amount of $335 remained outstanding at December 31, 2022. Principal and accrued interest in the amounts $25,882 and $1,141, respectively, were due on the Schrier Note at December 31, 2022. During the three months ended March 31, 2023, interest in the amount of $1,033 was accrued on the Schrier Note; principal and accrued interest in the amount of $25,882 and $2,174, respectively, were due on this note at March 31, 2023. This note was in default at March 31, 2023.

 

Nommsen Note

 

On July 26, 2022, the Company issued a 10% Promissory Note in the principal amount of $58,823 to Eric S. Nommsen (the “Nommsen Note”). The Nommsen Note bears interest at the rate of 10% per annum accrued monthly and has a maturity date that is the earlier of (i) November 30, 2022, as extended, or (ii) five business days after the date on which the Company successfully lists its shares of common stock on Nasdaq or NYSE. The purchase price of the Nommsen Note was $50,000; the amount payable at maturity will be $58,823 plus 10% of that amount plus any accrued and unpaid interest. Following an event of default as defined in the Nommsen Note, the principal amount shall bear interest for each day until paid at a rate per annum equal to the lesser of the maximum interest permitted by applicable law and 18%. The Nommsen Note entered default status on December 1, 2022, and the interest rate increased to 18%. The Nommsen Note contains a “most favored nations” clause that provides that, so long as the note is outstanding, if the Company issues any new security which Mr. Nommsen reasonably believes contains a term that is more favorable than those in the Nommsen Note, the Company shall notify Mr. Nommsen of such term, and such term, at the option of Mr. Nommsen, shall become a part of the Nommsen Note. In addition, Mr. Nommsen received five-year warrants to purchase 483 shares of common stock at a price of $25.00 per share with a fair value of $1,850 at the date of issuance, and 483 shares of common stock with a value of $2,350; these amounts were recorded as discounts to the Nommsen Note. Interest in the amount of $2,946 was accrued on the Nommsen Note during the year ended December 31, 2022. Discounts in the amount of $18,905 were amortized to interest expense during the year ended December 31, 2022, and total discounts in the amount of $0 remained outstanding at December 31, 2022. Principal and accrued interest in the amounts $64,705 and $2,946, respectively, were due on the Nommsen Note at December 31, 2022. During the three months ended March 31, 2023, interest in the amount of $2,688 was accrued on the Nommsen Note; principal and accrued interest in the amount of $64,705 and $5,634, respectively, were due on this note at March 31, 2023. This note was in default at March 31, 2023.

 

 

Caplan Note

 

On July 27, 2022, the Company issued a 10% Promissory Note in the principal amount of $58,823 to James H. Caplan (the “Caplan Note”). The Caplan Note bears interest at the rate of 10% per annum accrued monthly and has a maturity date that is the earlier of (i) January 21, 2023, or (ii) five business days after the date on which the Company successfully lists its shares of common stock on Nasdaq or NYSE. The purchase price of the Caplan Note was $50,000; the amount payable at maturity will be $58,823 plus 10% of that amount plus any accrued and unpaid interest. Following an event of default as defined in the Caplan Note, the principal amount shall bear interest for each day until paid at a rate per annum equal to the lesser of the maximum interest permitted by applicable law and 18%. The Caplan Note contains a “most favored nations” clause that provides that, so long as the note is outstanding, if the Company issues any new security which Mr. Caplan reasonably believes contains a term that is more favorable than those in the Caplan Note, the Company shall notify Mr. Caplan of such term, and such term, at the option of Mr. Caplan, shall become a part of the Caplan Note. In addition, Mr. Caplan received five-year warrants to purchase 483 shares of common stock at a price of $25.00 per share with a fair value of $1,850 at the date of issuance, and 483 shares of common stock with a value of $2,350; these amounts were recorded as discounts to the Caplan Note. Interest in the amount of $2,531 was accrued on the Caplan Note during the year ended December 31, 2022. Discounts in the amount of $16,675 were amortized to interest expense during the year ended December 31, 2022, and total discounts in the amount of $2,230 remained outstanding at December 31, 2022. Principal and accrued interest in the amounts $64,705 and $2,531, respectively, were due on the Caplan Note at December 31, 2022. During the three months ended March 31, 2023, interest in the amount of $2,406 was accrued on the Caplan Note; principal and accrued interest in the amount of $64,705 and $4,937, respectively, were due on this note at March 31, 2023. This note was in default at March 31, 2023.

 

Finnegan Note 3

 

On August 4, 2022, the Company issued a 10% Promissory Note in the principal amount of $29,412 (the “Finnegan Note 3”) to Jessica, Kevin C., Brody, Isabella and Jack Finnegan (collectively, the “Finnegans”). The Finnegan Note 3 bears interest at the rate of 10% per annum accrued monthly and has a maturity date that is the earlier of (i) February 3, 2023, or (ii) five business days after the date on which the Company successfully lists its shares of common stock on Nasdaq or NYSE. The purchase price of the Finnegan Note 3 was $25,000; the amount payable at maturity will be $29,412 plus 10% of that amount plus any accrued and unpaid interest. Following an event of default as defined in the Finnegan Note 3, the principal amount shall bear interest for each day until paid at a rate per annum equal to the lesser of the maximum interest permitted by applicable law and 18%. The Finnegan Note 3 contains a “most favored nations” clause that provides that, so long as the note is outstanding, if the Company issues any new security which The Finnegans reasonably believes contains a term that is more favorable than those in the Finnegan Note 3, the Company shall notify The Finnegans of such term, and such term, at the option of The Finnegans, shall become a part of the Finnegan Note 3. In addition, The Finnegans received five-year warrants to purchase 242 shares of common stock at a price of $25.00 per share with a fair value of $850 at the date of issuance, and 242 shares of common stock with a value of $1,100; these amounts were recorded as discounts to the Finnegan Note 3. Interest in the amount of $1,200 was accrued on the Finnegan Note 3 during the year ended December 31, 2022. Discounts in the amount of $7,575 were amortized to interest expense during the year ended December 31, 2022, and total discounts in the amount of $1,728 remained outstanding at December 31, 2022. Principal and accrued interest in the amounts $32,353 and $1,200, respectively, were due on the Finnegan Note 3 at December 31, 2022. During the three months ended March 31, 2023, interest in the amount of $1,125 was accrued on the Finnegan Note 3; principal and accrued interest in the amount of $32,353 and $2,325, respectively, were due on this note at March 31, 2023. This note was in default at March 31, 2023.

 

Enright Note

 

On August 4, 2022, the Company issued a 10% Promissory Note in the principal amount of $120,000 to Jack Enright (the “Enright Note”). The Enright Note bears interest at the rate of 10% per annum accrued monthly and has a maturity date that is the earlier of (i) February 3, 2023, or (ii) five business days after the date on which the Company successfully lists its shares of common stock on Nasdaq or NYSE. The purchase price of the Enright Note was $102,000; the amount payable at maturity will be $120,000 plus 10% of that amount plus any accrued and unpaid interest. Following an event of default as defined in the Enright Note, the principal amount shall bear interest for each day until paid at a rate per annum equal to the lesser of the maximum interest permitted by applicable law and 18%. The Enright Note contains a “most favored nations” clause that provides that, so long as the note is outstanding, if the Company issues any new security which Mr. Enright reasonably believes contains a term that is more favorable than those in the Enright Note, the Company shall notify Mr. Enright of such term, and such term, at the option of Mr. Enright, shall become a part of the Enright Note. In addition, Mr. Enright received 984 shares of common stock with a value of $6,317; this amount was recorded as a discount to the Enright Note. Interest in the amount of $4,899 was accrued on the Enright Note during the year ended December 31, 2022. Discounts in the amount of $29,571 were amortized to interest expense during the year ended December 31, 2022, and total discounts in the amount of $6,746 remained outstanding at December 31, 2022. Principal and accrued interest in the amounts $132,000 and $4,899, respectively, were due on the Enright Note at December 31, 2022. During the three months ended March 31, 2023, interest in the amount of $4,561 was accrued on the Enright Note; principal and accrued interest in the amount of $132,000 and $9,460, respectively, were due on this note at March 31, 2023. This note was in default at March 31, 2023.

 

 

Mitchell Note

 

On September 2, 2022, the Company issued a 10% Promissory Note in the principal amount of $71,000 to John Mitchell (the “Mitchell Note”). The Mitchell Note bears interest at the rate of 10% per annum accrued monthly and has a maturity date that is the earlier of (i) November 30, 2022, or (ii) five business days after the date on which the Company successfully lists its shares of common stock on Nasdaq or NYSE. The purchase price of the Mitchell Note was $60,350; the amount payable at maturity will be $71,000 plus 10% of that amount plus any accrued and unpaid interest. Following an event of default as defined in the Mitchell Note, the principal amount shall bear interest for each day until paid at a rate per annum equal to the lesser of the maximum interest permitted by applicable law and 18%. The Mitchell Note entered default status on December 1, 2022, and the interest rate increased to 18%. The Mitchell Note contains a “most favored nations” clause that provides that, so long as the note is outstanding, if the Company issues any new security which Mr. Mitchell reasonably believes contains a term that is more favorable than those in the Mitchell Note, the Company shall notify Mr. Mitchell of such term, and such term, at the option of Mr. Mitchell, shall become a part of the Mitchell Note. In addition, Mr. Mitchell received 582 shares of common stock with a value of $3,124; this amount was recorded as a discount to the Mitchell Note. Interest in the amount of $2,817 was accrued on the Mitchell Note during the year ended December 31, 2022. Discounts in the amount of $20,874 were amortized to interest expense during the year ended December 31, 2022, and total discounts in the amount of $0 remained outstanding at December 31, 2022. Principal and accrued interest in the amounts $78,100 and $2,817, respectively, were due on the Mitchell Note at December 31, 2022. The Mitchell Note was in default at December 31, 2022. During the three months ended March 31, 2023, interest in the amount of $3,234 was accrued on the Mitchell Note; principal and accrued interest in the amount of $78,100 and $6,051, respectively, were due on this note at March 31, 2023. This note was in default at March 31, 2023.

 

Lightmas Note

 

On September 2, 2022, the Company issued a 10% Promissory Note in the principal amount of $60,000 to Frank Lightmas (the “Lightmas Note”). The Lightmas Note bears interest at the rate of 10% per annum accrued monthly and has a maturity date that is the earlier of (i) November 30, 2022, or (ii) five business days after the date on which the Company successfully lists its shares of common stock on Nasdaq or NYSE. The purchase price of the Lightmas Note was $51,000; the amount payable at maturity will be $60,000 plus 10% of that amount plus any accrued and unpaid interest. Following an event of default as defined in the Lightmas Note, the principal amount shall bear interest for each day until paid at a rate per annum equal to the lesser of the maximum interest permitted by applicable law and 18%. The Lightmas Note entered default status on December 1, 2022, and the interest rate increased to 18%. The Lightmas Note contains a “most favored nations” clause that provides that, so long as the note is outstanding, if the Company issues any new security which Mr. Lightmas reasonably believes contains a term that is more favorable than those in the Lightmas Note, the Company shall notify Mr. Lightmas of such term, and such term, at the option of Mr. Lightmas, shall become a part of the Lightmas Note. In addition, Mr. Lightmas received 492 shares of common stock with a value of $2,640; this amount was recorded as a discount to the Lightmas Note. Interest in the amount of $2,380 was accrued on the Lightmas Note during the year ended December 31, 2022. Discounts in the amount of $17,640 were amortized to interest expense during the year ended December 31, 2022, and total discounts in the amount of $0 remained outstanding at December 31, 2022. Principal and accrued interest in the amounts $66,000 and $2,380, respectively, were due on the Lightmas Note at December 31, 2022. The Lightmas Note was in default at December 31, 2022. During the three months ended March 31, 2023, interest in the amount of $2,733 was accrued on the Lightmas Note; principal and accrued interest in the amount of $66,000 and $5,113, respectively, were due on this note at March 31, 2023. This note was in default at March 31, 2023.

 

Lewis Note

 

On September 2, 2022, the Company issued a 10% Promissory Note in the principal amount of $30,000 to Lisa Lewis (the “Lewis Note”). The Lewis Note bears interest at the rate of 10% per annum accrued monthly and has a maturity date that is the earlier of (i) November 30, 2022, or (ii) five business days after the date on which the Company successfully lists its shares of common stock on Nasdaq or NYSE. The purchase price of the Lewis Note was $25,500; the amount payable at maturity will be $30,000 plus 10% of that amount plus any accrued and unpaid interest. Following an event of default as defined in the Lewis Note, the principal amount shall bear interest for each day until paid at a rate per annum equal to the lesser of the maximum interest permitted by applicable law and 18%. The Lewis Note entered default status on December 1, 2022, and the interest rate increased to 18%. The Lewis Note contains a “most favored nations” clause that provides that, so long as the note is outstanding, if the Company issues any new security which Ms. Lewis reasonably believes contains a term that is more favorable than those in the Lewis Note, the Company shall notify Ms. Lewis of such term, and such term, at the option of Ms. Lewis, shall become a part of the Lewis Note. In addition, Ms. Lewis received 246 shares of common stock with a value of $1,320; this amount was recorded as a discount to the Lewis Note. Interest in the amount of $1,190 was accrued on the Lewis Note during the year ended December 31, 2022. Discounts in the amount of $8,820 were amortized to interest expense during the year ended December 31, 2022, and total discounts in the amount of $0 remained outstanding at December 31, 2022. Principal and accrued interest in the amounts $33,000 and $1,190, respectively, were due on the Lewis Note at December 31, 2022. The Lewis Note was in default at December 31, 2022. During the three months ended March 31, 2023, interest in the amount of $1,367 was accrued on the Lewis Note; principal and accrued interest in the amount of $33,000 and $2,557, respectively, were due on this note at March 31, 2023. This note was in default at March 31, 2023.

 

 

Goff Note

 

On September 2, 2022, the Company issued a 10% Promissory Note in the principal amount of $30,000 to Sharon Goff (the “Goff Note”). The Goff Note bears interest at the rate of 10% per annum accrued monthly and has a maturity date that is the earlier of (i) November 30, 2022, or (ii) five business days after the date on which the Company successfully lists its shares of common stock on Nasdaq or NYSE. The purchase price of the Goff Note was $25,500; the amount payable at maturity will be $30,000 plus 10% of that amount plus any accrued and unpaid interest. Following an event of default as defined in the Goff Note, the principal amount shall bear interest for each day until paid at a rate per annum equal to the lesser of the maximum interest permitted by applicable law and 18%. The Goff Note entered default status on December 1, 2022, and the interest rate increased to 18%. The Goff Note contains a “most favored nations” clause that provides that, so long as the note is outstanding, if the Company issues any new security which Ms. Goff reasonably believes contains a term that is more favorable than those in the Goff Note, the Company shall notify Ms. Goff of such term, and such term, at the option of Ms. Goff, shall become a part of the Goff Note. In addition, Ms. Goff received 246 shares of common stock with a value of $1,320; this amount was recorded as a discount to the Goff Note. Interest in the amount of $1,190 was accrued on the Goff Note during the year ended December 31, 2022. Discounts in the amount of $8,820 were amortized to interest expense during the year ended December 31, 2022, and total discounts in the amount of $0 remained outstanding at December 31, 2022. Principal and accrued interest in the amounts $33,000 and $1,190, respectively, were due on the Goff Note at December 31, 2022. The Goff Note was in default at December 31, 2022. During the three months ended March 31, 2023, interest in the amount of $1,367 was accrued on the Goff Note; principal and accrued interest in the amount of $33,000 and $2,557, respectively, were due on this note at March 31, 2023. This note was in default at March 31, 2023.

 

Hagan Note

 

On September 2, 2022, the Company issued a 10% Promissory Note in the principal amount of $100,000 to Cliff Hagan (the “Hagan Note”). The Hagan Note bears interest at the rate of 10% per annum accrued monthly and has a maturity date that is the earlier of (i) December 10, 2022, or (ii) five business days after the date on which the Company successfully lists its shares of common stock on Nasdaq or NYSE. The purchase price of the Hagan Note was $85,000; the amount payable at maturity will be $100,000 plus 10% of that amount plus any accrued and unpaid interest. Following an event of default as defined in the Hagan Note, the principal amount shall bear interest for each day until paid at a rate per annum equal to the lesser of the maximum interest permitted by applicable law and 18%. The Hagan Note entered default status on December 11, 2022, and the interest rate increased to 18%. The Hagan Note contains a “most favored nations” clause that provides that, so long as the note is outstanding, if the Company issues any new security which Mr. Hagan reasonably believes contains a term that is more favorable than those in the Hagan Note, the Company shall notify Mr. Hagan of such term, and such term, at the option of Mr. Hagan, shall become a part of the Hagan Note. In addition, Mr. Hagan received 820 shares of common stock with a value of $4,715; this amount was recorded as a discount to the Hagan Note. Interest in the amount of $3,556 was accrued on the Hagan Note during the year ended December 31, 2022. Discounts in the amount of $29,715 were amortized to interest expense during the year ended December 31, 2022, and total discounts in the amount of $0 remained outstanding at December 31, 2022. Principal and accrued interest in the amounts $110,000 and $3,556, respectively, were due on the Hagan Note at December 31, 2022. During the three months ended March 31, 2023, interest in the amount of $4,550 was accrued on the Hagan Note; principal and accrued interest in the amount of $110,000 and $8,106, respectively, were due on this note at March 31, 2023. This note was in default at March 31, 2023.

 

Darling Note

 

On September 14, 2022, the Company issued a 10% Promissory Note in the principal amount of $200,000 to Darling Capital, LLC (“Darling”), (the “Darling Note”). The Darling Note bears interest at the rate of 10% per annum accrued monthly and has a maturity date that is the earlier of (i) December 15, 2022, or (ii) five business days after the date on which the Company successfully lists its shares of common stock on Nasdaq or NYSE. The purchase price of the Darling Note was $170,000; the amount payable at maturity will be $200,000 plus 10% of that amount plus any accrued and unpaid interest. Following an event of default as defined in the Darling Note, the principal amount shall bear interest for each day until paid at a rate per annum equal to the lesser of the maximum interest permitted by applicable law and 18%. The Darling Note entered default status on December 15, 2022, and the interest rate increased to 18%. The Darling Note contains a “most favored nations” clause that provides that, so long as the note is outstanding, if the Company issues any new security which Darling reasonably believes contains a term that is more favorable than those in the Darling Note, the Company shall notify Darling of such term, and such term, at the option of Darling shall become a part of the Darling Note. In addition, Darling received 1,640 shares of common stock with a value of $10,824; this amount was recorded as a discount to the Darling Note. Interest in the amount of $6,619 was accrued on the Darling Note during the year ended December 31, 2022. Discounts in the amount of $60,824 were amortized to interest expense during the year ended December 31, 2022, and total discounts in the amount of $0 remained outstanding at December 31, 2022. Principal and accrued interest in the amounts $220,000 and $6,619, respectively, were due on the Darling Note at December 31, 2022. During the three months ended March 31, 2023, interest in the amount of $9,092 was accrued on the Darling Note; principal and accrued interest in the amount of $220,000 and $15,711, respectively, were due on this note at March 31, 2023. This note was in default at March 31, 2023.

 

 

Leath Note

 

On September 15, 2022, the Company issued a 10% Promissory Note in the principal amount of $50,000 to Mack Leath (the “Leath Note”). The Leath Note bears interest at the rate of 10% per annum accrued monthly and has a maturity date that is the earlier of (i) December 15, 2022, or (ii) five business days after the date on which the Company successfully lists its shares of common stock on Nasdaq or NYSE. The purchase price of the Leath Note was $42,500; the amount payable at maturity will be $55,000 plus 10% of that amount plus any accrued and unpaid interest. Following an event of default as defined in the Leath Note, the principal amount shall bear interest for each day until paid at a rate per annum equal to the lesser of the maximum interest permitted by applicable law and 18%. The Leath Note entered default status on December 16, 2022, and the interest rate increased to 18%. The Leath Note contains a “most favored nations” clause that provides that, so long as the note is outstanding, if the Company issues any new security which Mr. Leath reasonably believes contains a term that is more favorable than those in the Leath Note, the Company shall notify Mr. Leath of such term, and such term, at the option of Mr. Leath, shall become a part of the Leath Note. In addition, Mr. Leath received 410 shares of common stock with a value of $2,868; this amount was recorded as a discount to the Leath Note. Interest in the amount of $1,641 was accrued on the Leath Note during the year ended December 31, 2022. Discounts in the amount of $15,368 were amortized to interest expense during the year ended December 31, 2022, and total discounts in the amount of $0 remained outstanding at December 31, 2022. Principal and accrued interest in the amounts $55,000 and $1,641, respectively, were due on the Leath Note at December 31, 2022. During the three months ended March 31, 2023, interest in the amount of $2,273 was accrued on the Leath Note; principal and accrued interest in the amount of $55,000 and $3,914, respectively, were due on this note at March 31, 2023. This note was in default at March 31, 2023.

 

Cavalry Note

 

On October 5, 2022, the Company issued a 10% Promissory Note in the principal amount of $500,000 to the Cavalry Fund LLP (“Cavalry”), (the “Cavalry Note”) with a due date of December 31, 2022. The Cavalry Note is subject to an exchange agreement (the “Series E Exchange Agreement”) whereby Cavalry will exchange (a) amounts due under the Cavalry Note, (b) 1,000,000 shares of the Company’s Series C Convertible Preferred Stock, and (c) 750,000 shares of the Company’s Series D Convertible Preferred Stock for a number of shares of the Company’s Series E Convertible Preferred Stock equal to 150% of the principal amount of the Cavalry Note plus 150% of the stated value of the Series C and Series D convertible Preferred Stock. See note 12. The Cavalry Note bears interest at the rate of 10% per annum which will accrue from the date of the note only if the Cavalry Note is not converted pursuant to the Series E Exchange Agreement by December 10, 2022. Following an event of default as defined in the Cavalry Note, the principal amount shall bear interest for each day until paid at a rate per annum equal to the lesser of the maximum interest permitted by applicable law and 18%. The Cavalry Note contains a “most favored nations” clause that provides that, so long as the note is outstanding, if the Company issues any new security which Cavalry reasonably believes contains a term that is more favorable than those in the Cavalry Note, the Company shall notify the Cavalry of such term, and such term, at the option of Cavalry, shall become a part of the Cavalry Note. In addition, Cavalry received five-year warrants to purchase 750 shares of common stock at a price equal to the price of any warrant included in an offering in connection with listing at the Nasdaq Global Market. These warrants are not deemed issued at December 31, 2022 because the exercise price was not yet determined. Costs in the amount of $7,500 were also charged to discount on the Cavalry Note. Discounts in the amount of $10,500 were amortized to interest expense during the year ended December 31, 2022, and total discounts in the amount of $0 remained outstanding at December 31, 2022. Principal and accrued interest in the amounts $500,000 and $11,918, respectively, were due on the Cavalry Note at December 31, 2022.

 

Concurrent with the Cavalry Note, the Company entered into an exchange agreement (the “Cavalry Exchange Agreement”). Pursuant to the Calvary Exchange Agreement, Cavalry shall exchange (a) 1,000,000 shares of the Company’s Series C Convertible Preferred Stock (b) 750,000 shares of the Company’s Series D Convertible Preferred Stock and (c) amounts owing under the Cavalry Note, for a number of Series E Convertible Preferred Stock (the “Series E Shares”) equal to 150% of the principal amount of the Cavalry Note, plus 150% of the stated value of the Series C Shares and Series D Shares (the “Series E Exchange Value”). No transactions occurred pursuant to the Cavalry Exchange Agreement during the year ended December 31, 2022. See notes 12 and 16.

 

During the three months ended March 31, 2023, interest in the amount of $22,655 was accrued on the Cavalry Note; principal and accrued interest in the amount of $500,000 and $34,583, respectively, were due on this note at March 31, 2023. This note was in default at March 31, 2023.

 

 

Mercer Note 1

 

On October 7, 2022, the Company issued a 10% Promissory Note in the principal amount of $300,000 to the Mercer Street Global Opportunity Fund (“Mercer”), (the “Mercer Note 1”) with a due date of December 31, 2022. The Mercer Note 1 is subject to the Series E Exchange Agreement whereby Mercer will exchange (a) amounts due under the Mercer Note 1, (b) 47,619 shares of the Company’s Series C Convertible Preferred Stock, and (c) 750,000 shares of the Company’s Series D Convertible Preferred Stock for a number of shares of the Company’s Series E Convertible Preferred Stock equal to 150% of the principal amount of the Mercer Note 1 plus 150% of the stated value of the Series C and Series D convertible Preferred Stock. See note 12. The Mercer Note 1 bears interest at the rate of 10% per annum which will accrue from the date of the note only if the Mercer Note 1 is not converted pursuant to the Series E Exchange Agreement by December 10, 2022. Following an event of default as defined in the Mercer Note 1, the principal amount shall bear interest for each day until paid at a rate per annum equal to the lesser of the maximum interest permitted by applicable law and 18%. The Mercer Note 1 contains a “most favored nations” clause that provides that, so long as the note is outstanding, if the Company issues any new security which Mercer reasonably believes contains a term that is more favorable than those in the Mercer Note 1, the Company shall notify Mercer of such term, and such term, at the option of Mercer, shall become a part of the Mercer Note 1. In addition, Mercer received five-year warrants to purchase 750 shares of common stock at a price equal to the price of any warrant included in an offering in connection with listing at the Nasdaq Global Market. These warrants are not deemed issued at December 31, 2022 because the exercise price was not yet determined. Interest in the amount of $6,986 was accrued on the Mercer Note 1 during the year ended December 31, 2022. Discounts in the amount of $10,500 were amortized to interest expense during the year ended December 31, 2022, and total discounts in the amount of $0 remained outstanding at December 31, 2022. Principal and accrued interest in the amounts $300,000 and $6,986, respectively, were due on the Mercer Note 1 at December 31, 2022.

 

Concurrent with the Mercer Note 1, the Company entered into an exchange agreement (the “Mercer Exchange Agreement”). Pursuant to the Mercer Exchange Agreement, Mercer shall exchange (a) 47,619 shares of the Company’s Series C Convertible Preferred Stock, (b) 750,000 shares of the Company’s Series D Convertible Preferred Stock, and (c) amounts owing under the Mercer Note, for a number of Series E Convertible Preferred Stock (the “Series E Shares”) equal to 150% of the principal amount of the Mercer Note, plus 150% of the stated value of the Series C Shares and Series D Shares (the “Series E Exchange Value”). No transactions occurred pursuant to the Cavalry Exchange Agreement during the year ended December 31, 2022. See note 12 and 16.

 

During the three months ended March 31, 2023, interest in the amount of $13,597 was accrued on the Mercer Note 1; principal and accrued interest in the amount of $300,000 and $20,583, respectively, were due on this note at March 31, 2023. This note was in default at March 31, 2023.

 

Pinz Note

 

On October 10, 2022, the Company issued a 10% Promissory Note in the principal amount of $30,000 to the Pinz Capital Special Opportunities Fund (“Pinz”), (the “Pinz Note”) with a due date of December 31, 2022. The Pinz Note is subject to the Series E Exchange Agreement whereby Pinz will exchange (a) amounts due under the Pinz Note, (b) 100,000 shares of the Company’s Series D Convertible Preferred Stock for a number of shares of the Company’s Series E Convertible Preferred Stock equal to 150% of the principal amount of the Pinz Note plus 150% of the stated value of the Series D convertible Preferred Stock. See note 12. The Pinz Note bears interest at the rate of 10% per annum which will accrue from the date of the note only if the Pinz Note is not converted pursuant to the Series E Exchange Agreement by December 10, 2022. Following an event of default as defined in the Pinz Note, the principal amount shall bear interest for each day until paid at a rate per annum equal to the lesser of the maximum interest permitted by applicable law and 18%. The Pinz Note contains a “most favored nations” clause that provides that, so long as the note is outstanding, if the Company issues any new security which the Pinz Fund LLP reasonably believes contains a term that is more favorable than those in the Pinz Note, the Company shall notify the Pinz Fund LLP of such term, and such term, at the option of the Pinz Fund, LLP, shall become a part of the Pinz Note. In Interest in the amount of $6,986 was accrued on the Pinz Note during the year ended December 31, 2022. Discounts in the amount of $2,100 were amortized to interest expense during the year ended December 31, 2022, and total discounts in the amount of $0 remained outstanding at December 31, 2022. Principal and accrued interest in the amounts $30,000 and $674, respectively, were due on the Pinz Note at December 31, 2022.

 

Concurrent with the Pinz Note, the Company entered into an exchange agreement (the “Pinz Exchange Agreement”). Pursuant to the Pinz Exchange Agreement, Pinz shall exchange (a) 100,000 shares of the Company’s Series D Convertible Preferred Stock, and (b) amounts owing under the Pinz Note, for a number of Series E Convertible Preferred Stock equal to 150% of the principal amount of the Pinz Note, plus 150% of the stated value of the Series D Shares. No transactions occurred pursuant to the Pinz Exchange Agreement during the year ended December 31, 2022. See note 12 and 16.

 

During the three months ended March 31, 2023, interest in the amount of $1,359 was accrued on the Pinz Note; principal and accrued interest in the amount of $30,000 and $2,033, respectively, were due on this note at March 31, 2023. This note was in default at March 31, 2023.

 

 

Mercer Note 2

 

On October 24, 2022, the Company issued a 10% Promissory Note in the principal amount of $100,000 to Mercer (the “Mercer Note 2”) with a due date of December 31, 2022. The Mercer Note 2 is subject to the Series E Exchange Agreement whereby Mercer will exchange (a) amounts due under the Mercer Note 2 for a number of shares of the Company’s Series E Convertible Preferred Stock equal to 150% of the principal amount of the Mercer Note 2. See note 122. The Mercer Note 2 bears interest at the rate of 10% per annum which will accrue from the date of the note only if the Mercer Note 2 is not converted pursuant to the Series E Exchange Agreement by December 10, 2022. Following an event of default as defined in the Mercer Note 2, the principal amount shall bear interest for each day until paid at a rate per annum equal to the lesser of the maximum interest permitted by applicable law and 18%. The Mercer Note 2 contains a “most favored nations” clause that provides that, so long as the note is outstanding, if the Company issues any new security which Mercer reasonably believes contains a term that is more favorable than those in the Mercer Note 2, the Company shall notify Mercer of such term, and such term, at the option of Mercer, shall become a part of the Mercer Note 2. In addition, Mercer received five-year warrants to purchase 750 shares of common stock at a price equal to the price of any warrant included in an offering in connection with listing at the Nasdaq Global Market. These warrants are not deemed issued at December 31, 2022 because the exercise price was not yet determined. Interest in the amount of $1,863 was accrued on the Mercer Note 2 during the year ended December 31, 2022. Discounts in the amount of $1,900 were amortized to interest expense during the year ended December 31, 2022, and total discounts in the amount of $0 remained outstanding at December 31, 2022. Principal and accrued interest in the amounts $100,000 and $1,863, respectively, were due on the Mercer Note 2 at December 31, 2022.

 

Amounts due under the Mercer Note 2 will convert pursuant to the terms of the Mercer Exchange Agreement into shares of the Company’s series E Preferred Stock. See note 12 and 16.

 

During the three months ended March 31, 2023, interest in the amount of $4,526 was accrued on the Mercer Note 2; principal and accrued interest in the amount of $100,000 and $6,389, respectively, were due on this note at March 31, 2023. This note was in default at March 31, 2023.

 

Mercer Note 3

 

On December 2, 2022, the Company issued a 10% Promissory Note in the principal amount of $125,000 to Mercer (the “Mercer Note 3”) with a due date of May 21, 2023. The Mercer Note 3 is subject to the Series E Exchange Agreement whereby Mercer will exchange amounts due under the Mercer Note 3 for a number of shares of the Company’s Series E Convertible Preferred Stock equal to 150% of the principal amount of the Mercer Note 3. See note 12. The Mercer Note 3 bears interest at the rate of 10% per annum which will accrue from the date of the note only if the Mercer Note 3 is not converted pursuant to the Series E Exchange Agreement by May 10, 2023. Following an event of default as defined in the Mercer Note 3, the principal amount shall bear interest for each day until paid at a rate per annum equal to the lesser of the maximum interest permitted by applicable law and 18%. The Mercer Note 3 contains a “most favored nations” clause that provides that, so long as the note is outstanding, if the Company issues any new security which Mercer reasonably believes contains a term that is more favorable than those in the Mercer Note 3, the Company shall notify Mercer of such term, and such term, at the option of Mercer, shall become a part of the Mercer Note 3. In addition, Mercer received five-year warrants to purchase 750 shares of common stock at a price equal to the price of any warrant included in an offering in connection with listing at the Nasdaq Global Market. These warrants are not deemed issued at December 31, 2022 because the exercise price was not yet. determined. Discounts in the amount of $4,028 were amortized to interest expense during the year ended December 31, 2022, and total discounts in the amount of $20,972 remained outstanding at December 31, 2022. Principal and accrued interest in the amounts $125,000 and $993, respectively, were due on the Mercer Note 3 at December 31, 2022.

 

During the three months ended March 31, 2023, interest in the amount of $3,139 was accrued on the Mercer Note 3; principal and accrued interest in the amount of $125,000 and $4,132, respectively, were due on this note at March 31, 2023. This note was in default at March 31, 2023.

 

 

These amounts are reflected in the table below:

 

   

March 31,

2023

   

December 31,

2022

 

Notes Payable

  $ 6,174,712     $ 5,144,742  

Less: Discount

    (8,472

)

    (32,041

)

Notes payable - net of discount

  $ 6,166,240     $ 5,112,701  
                 

Current Portion, net of discount

  $ 6,166,240     $ 5,112,701  

Long-term portion, net of discount

  $ -     $ -  

 

Interest expense on notes payable was $248,596 and $0 for the three months ended March 31, 2023 and 2022, respectively. Accrued interest on notes payable was $475,276 and $362,094 at March 31, 2023 and December 31, 2022, respectively.

 

Note 10: Notes Payable Related Parties

 

Howe Note 1

 

On December 30, 2021, we issued a 10% Promissory Note in the principal amount of $1,000,000 in a related party transaction to the Michael C. Howe Living Trust (the “Howe Note 1”). Michael C. Howe is the Chief Executive Officer of the Good Clinic LLC, one of our subsidiaries. The Howe Note 1 bears interest at the rate of 10% interest rate per annum and has a maturity date that is the earlier of (i) November 30, 2022, as extended, or (ii) five (5) business days after the date on which the Company successfully lists its shares of common stock on Nasdaq or NYSE. The purchase price of the Howe Note 1 was $850,000; the amount payable at maturity will be $1,000,000 plus 10% of that amount plus any accrued and unpaid interest. Following an event of default, as defined in the Howe Note 1, the principal amount shall bear interest for each day until paid at a rate per annum equal to the lesser of the maximum interest permitted by applicable law and 18%. The Howe Note 1 entered delinquent status on December 1, 2022, and the interest rate increased to 18%. The Howe Note 1 contains a “most favored nations” clause that provides that, so long as the note is outstanding, if the Company issues any new security, which Mr. Howe reasonably believes contains a term that is more favorable than those in the Howe Note 1, we shall notify Mr. Howe of such term, and such term, at the option of Mr. Howe, shall become a part of the Howe Note 1. In addition, Mr. Howe five-year warrants to purchase 42,000 shares of common stock at a price of $25.00 per share, and five-year warrants to purchase 42,000 shares of common stock at $37.50 per share with an aggregate fair value of $261,568 at the date of issuance, which was recorded as a discount to this note. Interest in the amount of $106,795 was accrued on the Howe Note 1 during the year ended December 31, 2022. Discounts in the amount of $511,568 were amortized to interest expense during the year ended December 31, 2022, and total discounts in the amount of $0 remained outstanding at December 31, 2022. Principal and accrued interest in the amounts $1,100,000 and $106,795, respectively, were due on the Howe Note 1 at December 31, 2022.

 

During the three months ended March 31, 2023, interest in the amount of $46,761 was accrued on the Howe Note 1; principal and accrued interest in the amount of $1,100,000 and $153,556, respectively, were due on this note at March 31, 2023. This note was in default at March 31, 2023.

 

Diamond Note 1

 

On February 24, 2022, the Company issued a 10% Promissory Note in the principal amount of $175,000 in a related party transaction to Lawrence Diamond, our Chief Executive Officer and a member of our Board of Directors (the “Diamond Note 1”). The Diamond Note 1 bears interest at the rate of 10% per annum accrued monthly and has a maturity date that is the earlier of (i) November 30, 2022, as extended, or (ii) five business days after the date on which the Company successfully lists its shares of common stock on Nasdaq or NYSE. The purchase price of the Diamond Note 1 was $148,750; the amount payable at maturity will be $175,000 plus 10% of that amount plus any accrued and unpaid interest. Following an event of default as defined in the Diamond Note 1, the principal amount shall bear interest for each day until paid at a rate per annum equal to the lesser of the maximum interest permitted by applicable law and 18%. The Diamond Note 1 entered default status on December 1, 2022, and the interest rate increased to 18%. The Diamond Note 1 contains a “most favored nations” clause that provides that, so long as the note is outstanding, if the Company issues any new security which Mr. Diamond reasonably believes contains a term that is more favorable than those in the Diamond Note 1, the Company shall notify Mr. Diamond of such term, and such term, at the option of Mr. Diamond, shall become a part of the Diamond Note 2. In addition, Mr. Diamond received five-year warrants to purchase 7,350 shares of common stock at a price of $25.00 per share, and five-year warrants to purchase 7,350 shares of common stock at $37.50 per share with an aggregate fair value of $2,914 at the date of issuance, which was recorded as a discount to this note. Interest in the amount of $16,052 was accrued on the Diamond Note 1 during the year ended December 31, 2022. Discounts in the amount of $46,664 were amortized to interest expense during the year ended December 31, 2022, and total discounts in the amount of $0 remained outstanding at December 31, 2022. Principal and accrued interest in the amounts $192,500 and $16,052, respectively, were due on the Diamond Note 1 at December 31, 2022.

 

 

During the three months ended March 31, 2023, interest in the amount of $8,099 was accrued on the Diamond Note 1; principal and accrued interest in the amount of $192,500 and $24,151, respectively, were due on this note at March 31, 2023. This note was in default at March 31, 2023.

 

Diamond Note 2

 

On March 18, 2022, the Company issued a 10% Promissory Note in the principal amount of $235,294 in a related party transaction to Lawrence Diamond, our Chief Executive Officer and a member of our Board of Directors (the “Diamond Note 2). The Diamond Note 2 bears interest at the rate of 10% per annum accrued monthly and has a maturity date that is the earlier of (i) November 30, 2022, as extended, or (ii) five business days after the date on which the Company successfully lists its shares of common stock on Nasdaq or NYSE. The purchase price of the Diamond Note 2 was $200,000; the amount payable at maturity will be $235,294 plus 10% of that amount plus any accrued and unpaid interest. Following an event of default as defined in the Diamond Note 2, the principal amount shall bear interest for each day until paid at a rate per annum equal to the lesser of the maximum interest permitted by applicable law and 18%. The Diamond Note 2 entered default status on December 1, 2022, and the interest rate increased to 18%. The Diamond Note 2 contains a “most favored nations” clause that provides that, so long as the note is outstanding, if the Company issues any new security which Mr. Diamond reasonably believes contains a term that is more favorable than those in the Diamond Note 2, the Company shall notify Mr. Diamond of such term, and such term, at the option of Mr. Diamond, shall become a part of the Diamond Note 2. In addition, Mr. Diamond received five-year warrants to purchase 1,930 shares of common stock at a price of $25.00 per share a fair value of $2,213 at the date of issuance, which was recorded as a discount to this note. Interest in the amount of $1,676 was accrued on the Diamond Note 2 during the year ended December 31, 2022. Principal in the amount of $235,294 was paid on the Diamond Note 2 during the year ended December 31, 2022. Discounts in the amount of $61,036 were amortized to interest expense during the year ended December 31, 2022, and total discounts in the amount of $0 remained outstanding at December 31, 2022. Principal and accrued interest in the amounts $23,529 and $1,699, respectively, were due on the Diamond Note 2 at December 31, 2022.

 

During the three months ended March 31, 2023, interest in the amount of $0 was accrued on the Diamond Note 2; principal and accrued interest in the amount of $23,529 and $1,676, respectively, were due on this note at March 31, 2023. This note was in default at March 31, 2023.

 

Diamond Note 3

 

On April 27, 2022, the Company issued a 10% Promissory Note in the principal amount of $235,294 in a related party transaction to Lawrence Diamond, our Chief Executive Officer and a member of our Board of Directors (the “Diamond Note 3”). The Diamond Note 3 bears interest at the rate of 10% per annum accrued monthly and has a maturity date that is the earlier of (i) November 30, 2022, as extended, or (ii) five business days after the date on which the Company successfully lists its shares of common stock on Nasdaq or NYSE. The purchase price of the Diamond Note 3 was $200,000; the amount payable at maturity will be $235,294 plus 10% of that amount plus any accrued and unpaid interest. Following an event of default as defined in the Diamond Note 3, the principal amount shall bear interest for each day until paid at a rate per annum equal to the lesser of the maximum interest permitted by applicable law and 18%. The Diamond Note 3 entered default status on December 1, 2022, and the interest rate increased to 18%. The Diamond Note 3 contains a “most favored nations” clause that provides that, so long as the note is outstanding, if the Company issues any new security which Mr. Diamond reasonably believes contains a term that is more favorable than those in the Diamond Note 3, the Company shall notify Mr. Diamond of such term, and such term, at the option of Mr. Diamond, shall become a part of the Diamond Note 3. In addition, Mr. Diamond received five-year warrants to purchase 1,930 shares of common stock at a price of $25.00 per share with a fair value of $8,800 at the date of issuance, and 1,930 shares of common stock with a value of $16,200; these amounts were recorded as discounts on the Diamond Note 3. Interest in the amount of $17,586 was accrued on the Diamond Note 3 during the year ended December 31, 2022. Discounts in the amount of $83,823 were amortized to interest expense during the year ended December 31, 2022, and total discounts in the amount of $0 remained outstanding at December 31, 2022. Principal and accrued interest in the amounts $258,823 and $17,586, respectively, were due on the Diamond Note 3 at December 31, 2022.

 

During the three months ended March 31, 2023, interest in the amount of $10,832 was accrued on the Diamond Note 3; principal and accrued interest in the amount of $258,823 and $28,418, respectively, were due on this note at March 31, 2023. This note was in default at March 31, 2023.

 

 

Diamond Note 4

 

On May 18, 2022, the Company issued a 10% Promissory Note in the principal amount of $47,059 in a related party transaction to Lawrence Diamond, our Chief Executive Officer and a member of our Board of Directors (the “Diamond Note 4”). The Diamond Note 4 bears interest at the rate of 10% per annum accrued monthly and has a maturity date that is the earlier of (i) November 30, 2022, as extended, or (ii) five business days after the date on which the Company successfully lists its shares of common stock on Nasdaq or NYSE. The purchase price of the Diamond Note 4 was $40,000; the amount payable at maturity will be $47,059 plus 10% of that amount plus any accrued and unpaid interest. Following an event of default as defined in the Diamond Note 4, the principal amount shall bear interest for each day until paid at a rate per annum equal to the lesser of the maximum interest permitted by applicable law and 18%. The Diamond Note 4 entered default status on December 1, 2022, and the interest rate increased to 18%. The Diamond Note 4 contains a “most favored nations” clause that provides that, so long as the note is outstanding, if the Company issues any new security which Mr. Diamond reasonably believes contains a term that is more favorable than those in the Diamond Note 4, the Company shall notify Mr. Diamond of such term, and such term, at the option of Mr. Diamond, shall become a part of the Diamond Note 4. In addition, Mr. Diamond received five-year warrants to purchase 386 shares of common stock at a price of $25.00 per share with a fair value of $2,960 at the date of issuance, and 1,930 shares of common stock with a value of $3,160; these amounts were recorded as discounts on the Diamond Note 4. Interest in the amount of $3,245 was accrued on the Diamond Note 4 during the year ended December 31, 2022. Discounts in the amount of $17,885 were amortized to interest expense during the year ended December 31, 2022, and total discounts in the amount of $0 remained outstanding at December 31, 2022. Principal and accrued interest in the amounts $51,765 and $3,245, respectively, were due on the Diamond Note 4 at December 31, 2022.

 

During the three months ended March 31, 2023, interest in the amount of $2,164 was accrued on the Diamond Note 4; principal and accrued interest in the amount of $51,765 and $5,409, respectively, were due on this note at March 31, 2023. This note was in default at March 31, 2023.

 

Diamond Note 5

 

On May 26, 2022, the Company issued a 10% Promissory Note in the principal amount of $58,823 in a related party transaction to Lawrence Diamond, our Chief Executive Officer and a member of our Board of Directors (the “Diamond Note 5”). The Diamond Note 5 bears interest at the rate of 10% per annum accrued monthly and has a maturity date that is the earlier of (i) November 30, 2022, or (ii) five business days after the date on which the Company successfully lists its shares of common stock on Nasdaq or NYSE. The purchase price of the Diamond Note 5 was $50,000; the amount payable at maturity will be $58,823 plus 10% of that amount plus any accrued and unpaid interest. Following an event of default as defined in the Diamond Note 5, the principal amount shall bear interest for each day until paid at a rate per annum equal to the lesser of the maximum interest permitted by applicable law and 18%. The Diamond Note 5 entered default status on December 1, 2022, and the interest rate increased to 18%. The Diamond Note 5 contains a “most favored nations” clause that provides that, so long as the note is outstanding, if the Company issues any new security which Mr. Diamond reasonably believes contains a term that is more favorable than those in the Diamond Note 5, the Company shall notify Mr. Diamond of such term, and such term, at the option of Mr. Diamond, shall become a part of the Diamond Note 5. In addition, Mr. Diamond received five-year warrants to purchase 483 shares of common stock at a price of $25.00 per share with a fair value of $2,500 at the date of issuance, and 483 shares of common stock with a value of $4,050; these amounts were recorded as discounts to the Diamond Note 5. Interest in the amount of $3,929 was accrued on the Diamond Note 5 during the year ended December 31, 2022. Discounts in the amount of $21,256 were amortized to interest expense during the year ended December 31, 2022, and total discounts in the amount of $0 remained outstanding at December 31, 2022. Principal and accrued interest in the amounts $64,705 and $3,929, respectively, were due on the Diamond Note 5 at December 31, 2022.

 

During the three months ended March 31, 2023, interest in the amount of $2,702 was accrued on the Diamond Note 5; principal and accrued interest in the amount of $64,705 and $6,631, respectively, were due on this note at March 31, 2023. This note was in default at March 31, 2023.

 

 

Lindstrom Note 1

 

On May 26, 2022, the Company issued a 10% Promissory Note in the principal amount of $41,176 in a related party transaction to Jenny Lindstrom, the Company’s Chief Legal Officer (the “Lindstrom Note 1”). The Lindstrom Note 1 bears interest at the rate of 10% per annum accrued monthly and has a maturity date that is the earlier of (i) November 30, 2022, or (ii) five business days after the date on which the Company successfully lists its shares of common stock on Nasdaq or NYSE. The purchase price of the Lindstrom Note 1 was $35,000; the amount payable at maturity will be $41,176 plus 10% of that amount plus any accrued and unpaid interest. Following an event of default as defined in the Lindstrom Note 1, the principal amount shall bear interest for each day until paid at a rate per annum equal to the lesser of the maximum interest permitted by applicable law and 18%. The Lindstrom Note 1 entered default status on December 1, 2022, and the interest rate increased to 18%. The Lindstrom Note 1 contains a “most favored nations” clause that provides that, so long as the note is outstanding, if the Company issues any new security which Ms. Lindstrom reasonably believes contains a term that is more favorable than those in the Lindstrom Note 1, the Company shall notify Ms. Lindstrom of such term, and such term, at the option of Ms. Lindstrom, shall become a part of the Lindstrom Note 1. In addition, Ms. Lindstrom received five-year warrants to purchase 338 shares of common stock at a price of $25.00 per share with a fair value of $1,750 at the date of issuance, and 338 shares of common stock with a value of $2,835; these amounts were recorded as discounts to the Lindstrom Note 1. Interest in the amount of $2,750 was accrued on the Lindstrom Note 1 during the year ended December 31, 2022. Discounts in the amount of $14,879 were amortized to interest expense during the year ended December 31, 2022, and total discounts in the amount of $0 remained outstanding at December 31, 2022. Principal and accrued interest in the amounts $45,294 and $2,750, respectively, were due on the Lindstrom Note 1 at December 31, 2022.

 

During the three months ended March 31, 2023, interest in the amount of $1,891 was accrued on the Lindstrom Note; principal and accrued interest in the amount of $45,294 and $4,641, respectively, were due on this note at March 31, 2023. This note was in default at March 31, 2023.

 

Dobbertin Note

 

On May 26, 2022, the Company issued a 10% Promissory Note in the principal amount of $17,647 in a related party transaction to Alexander Dobbertin (the “Dobbertin Note”). Mr. Dobbertin is the spouse of Jenny Lindstrom, the Company’s Chief Legal Officer. The Dobbertin Note bears interest at the rate of 10% per annum accrued monthly and has a maturity date that is the earlier of (i) November 30, 2022, or (ii) five business days after the date on which the Company successfully lists its shares of common stock on Nasdaq or NYSE. The purchase price of the Dobbertin Note was $15,000; the amount payable at maturity will be $17,647 plus 10% of that amount plus any accrued and unpaid interest. Following an event of default as defined in the Dobbertin Note, the principal amount shall bear interest for each day until paid at a rate per annum equal to the lesser of the maximum interest permitted by applicable law and 18%. The Dobbertin Note entered default status on December 1, 2022, and the interest rate increased to 18%. The Dobbertin Note contains a “most favored nations” clause that provides that, so long as the note is outstanding, if the Company issues any new security which Mr. Dobbertin reasonably believes contains a term that is more favorable than those in the Dobbertin Note, the Company shall notify Mr. Dobbertin of such term, and such term, at the option of Mr. Dobbertin, shall become a part of the Dobbertin Note. In addition, Mr. Dobbertin received five-year warrants to purchase 145 shares of common stock at a price of $25.00 per share with a fair value of $750 at the date of issuance, and 145 shares of common stock with a value of $1,215; these amounts were recorded as discounts to the Dobbertin Note. Interest in the amount of $1,179 was accrued on the Dobbertin Note during the year ended December 31, 2022. Discounts in the amount of $6,377 were amortized to interest expense during the year ended December 31, 2022, and total discounts in the amount of $0 remained outstanding at December 31, 2022. Principal and accrued interest in the amounts $19,412 and $1,179, respectively, were due on the Dobbertin Note at December 31, 2022.

 

During the three months ended March 31, 2023, interest in the amount of $811 was accrued on the Dobbertin Note; principal and accrued interest in the amount of $19,412 and $1,990, respectively, were due on this note at March 31, 2023. This note was in default at March 31, 2023.

 

 

Howe Note 2

 

On June 9, 2022, the Company issued a 10% Promissory Note in the principal amount of $300,000 in a related party transaction to the Michael C. Howe Living Trust (the “Howe Note 2”). Michael C. Howe is the Chief Executive Officer of the Good Clinic LLC, one of our subsidiaries. The Howe Note 2 bears interest at the rate of 10% per annum accrued monthly and has a maturity date that is the earlier of (i) November 30, 2022, or (ii) five business days after the date on which the Company successfully lists its shares of common stock on Nasdaq or NYSE. The purchase price of the Howe Note 2 was $255,000; the amount payable at maturity will be $300,000 plus 10% of that amount plus any accrued and unpaid interest. Following an event of default as defined in the Howe Note 2, the principal amount shall bear interest for each day until paid at a rate per annum equal to the lesser of the maximum interest permitted by applicable law and 18%. The Howe Note 2 entered default status on December 1, 2022, and the interest rate increased to 18%. The Howe Note 2 contains a “most favored nations” clause that provides that, so long as the note is outstanding, if the Company issues any new security which Mr. Howe reasonably believes contains a term that is more favorable than those in the Howe Note 2, the Company shall notify Mr. Howe of such term, and such term, at the option of Mr. Howe, shall become a part of the Howe Note 2. In addition, Mr. Howe received five-year warrants to purchase 2,460 shares of common stock at a price of $25.00 per share with a fair value of $10,965 at the date of issuance, and 2,460 shares of common stock with a value of $22,440; these amounts were recorded as discounts to the Howe Note 2. Interest in the amount of $18,888 was accrued on the Howe Note 2 during the year ended December 31, 2022. Discounts in the amount of $108,405 were amortized to interest expense during the year ended December 31, 2022, and total discounts in the amount of $0 remained outstanding at December 31, 2022. Principal and accrued interest in the amounts $330,000 and $18,888, respectively, were due on the Howe Note 2 at December 31, 2022.

 

During the three months ended March 31, 2023, interest in the amount of $8,099 was accrued on the Howe Note 2; principal and accrued interest in the amount of $330,000 and $32,650, respectively, were due on this note at March 31, 2023. This note was in default at March 31, 2023.

 

Howe Note 3

 

On July 21, 2022, the Company issued a 10% Promissory Note in the principal amount of $300,000 in a related party transaction to the Michael C. Howe Living Trust (the “Howe Note 3”). Michael C. Howe is the Chief Executive Officer of the Good Clinic LLC, one of our subsidiaries. The Howe Note 3 bears interest at the rate of 10% per annum accrued monthly and has a maturity date that is the earlier of (i) November 30, 2022, as extended, or (ii) five business days after the date on which the Company successfully lists its shares of common stock on Nasdaq or NYSE. The purchase price of the Howe Note 3 was $255,000; the amount payable at maturity will be $300,000 plus 10% of that amount plus any accrued and unpaid interest. Following an event of default as defined in the Howe Note 3, the principal amount shall bear interest for each day until paid at a rate per annum equal to the lesser of the maximum interest permitted by applicable law and 18%. The Howe Note 3 entered default status on December 1, 2022, and the interest rate increased to 18%. The Howe Note 3 contains a “most favored nations” clause that provides that, so long as the note is outstanding, if the Company issues any new security which Mr. Howe reasonably believes contains a term that is more favorable than those in the Howe Note 3, the Company shall notify Mr. Howe of such term, and such term, at the option of Mr. Howe, shall become a part of the Howe Note 3. In addition, Mr. Howe received five-year warrants to purchase 2,460 shares of common stock at a price of $25.00 per share with a fair value of $9,945 at the date of issuance, and 2,460 shares of common stock with a value of $12,495; these amounts were recorded as discounts to the Howe Note 3. Interest in the amount of $15,436 was accrued on the Howe Note 3 during the year ended December 31, 2022. Discounts in the amount of $97,440 were amortized to interest expense during the year ended December 31, 2022, and total discounts in the amount of $0 remained outstanding at December 31, 2022. Principal and accrued interest in the amounts $330,000 and $15,436, respectively, were due on the Howe Note 3 at December 31, 2022.

 

During the three months ended March 31, 2023, interest in the amount of $13,714 was accrued on the Howe Note 3; principal and accrued interest in the amount of $330,000 and $29,150, respectively, were due on this note at March 31, 2023. This note was in default at March 31, 2023.

 

 

Iturregui Note 1

 

On July 21, 2022, the Company issued a 10% Promissory Note in the principal amount of $29,412 in a related party transaction to Juan Carlos Iturregui, a member of the Company’s Board of Directors (the “Iturregui Note 1”). The Iturregui Note 1 bears interest at the rate of 10% per annum accrued monthly and has a maturity date that is the earlier of (i) January 21, 2023, or (ii) five business days after the date on which the Company successfully lists its shares of common stock on Nasdaq or NYSE. The purchase price of the Iturregui Note 1 was $25,000; the amount payable at maturity will be $29,412 plus 10% of that amount plus any accrued and unpaid interest. Following an event of default as defined in the Iturregui Note 1, the principal amount shall bear interest for each day until paid at a rate per annum equal to the lesser of the maximum interest permitted by applicable law and 18%. The Iturregui Note 1 contains a “most favored nations” clause that provides that, so long as the note is outstanding, if the Company issues any new security which Mr. Iturregui reasonably believes contains a term that is more favorable than those in the Iturregui Note 1, the Company shall notify Mr. Iturregui of such term, and such term, at the option of Mr. Iturregui, shall become a part of the Iturregui Note 1. In addition, Mr. Iturregui received five-year warrants to purchase 242 shares of common stock at a price of $25.00 per share with a fair value of $975 at the date of issuance, and 242 shares of common stock with a value of $1,225; these amounts were recorded as discounts to the Iturregui Note 1. Interest in the amount of $1,313 was accrued on the Iturregui Note 1 during the year ended December 31, 2022. Discounts in the amount of $8,464 were amortized to interest expense during the year ended December 31, 2022, and total discounts in the amount of $1,089 remained outstanding at December 31, 2022. Principal and accrued interest in the amounts $32,353 and $1,313, respectively, were due on the Iturregui Note 1 at December 31, 2022.

 

During the three months ended March 31, 2023, interest in the amount of $1,205 was accrued on the Iturregui Note 1; principal and accrued interest in the amount of $32,353 and $2,518, respectively, were due on this note at March 31, 2023. This note was in default at March 31, 2023.

 

Howe Note 4

 

On August 18, 2022, the Company issued a 10% Promissory Note in the principal amount of $200,000 in a related party transaction to the Michael C. Howe Living Trust (the “Howe Note 4”). Michael C. Howe is the Chief Executive Officer of the Good Clinic LLC, one of our subsidiaries. The Howe Note 4 bears interest at the rate of 10% per annum accrued monthly and has a maturity date that is the earlier of (i) November 30, 2022, or (ii) five business days after the date on which the Company successfully lists its shares of common stock on Nasdaq or NYSE. The purchase price of the Howe Note 4 was $170,000; the amount payable at maturity will be $200,000 plus 10% of that amount plus any accrued and unpaid interest. Following an event of default as defined in the Howe Note 4, the principal amount shall bear interest for each day until paid at a rate per annum equal to the lesser of the maximum interest permitted by applicable law and 18%. The Howe Note 4 entered default status on December 1, 2022, and the interest rate increased to 18%. The Howe Note 4 contains a “most favored nations” clause that provides that, so long as the note is outstanding, if the Company issues any new security which Mr. Howe reasonably believes contains a term that is more favorable than those in the Howe Note 4, the Company shall notify Mr. Howe of such term, and such term, at the option of Mr. Howe, shall become a part of the Howe Note 4. In addition, Mr. Howe received 1,640 shares of common stock with a value of $10,775; this amount was recorded as a discount to the Howe Note 4. Interest in the amount of $8,756 was accrued on the Howe Note 4 during the year ended December 31, 2022. Discounts in the amount of $60,775 were amortized to interest expense during the year ended December 31, 2022, and total discounts in the amount of $0 remained outstanding at December 31, 2022. Principal and accrued interest in the amounts $220,000 and $8,756, respectively, were due on the Howe Note 4 at December 31, 2022.

 

During the three months ended March 31, 2023, interest in the amount of $9,677 was accrued on the Howe Note 4; principal and accrued interest in the amount of $220,000 and $18,433, respectively, were due on this note at March 31, 2023. This note was in default at March 31, 2023.

 

November 29, 2022 Notes

 

On November 29, 2022, the Company issued seven identical promissory notes (the “November 29 Notes”) in related party transactions to the following individuals: (1) Thomas Brodmerkel, the Company’s CFO and Board Member; (2) Lawrence Diamond, the Company’s Chief Executive Officer and Board Member; (3) Sheila Schweitzer, Board Member; (4) Faraz Naqvi, a former Board Member; (5) Juan Carlos Iturregui, Board Member; (6) Jenny Lindstrom, the Company’s former Vice President and Chief Legal Officer; and (7) Michael C. Howe, Chief Executive Officer of The Good Clinic, one of our subsidiaries (collectively, the “November 29 Lenders”).

 

 

The November 29 notes have due dates of May 28, 2023. The November 29 Notes are subject to the Series E Exchange Agreement whereby each of the November 29 Lenders will exchange (a) amounts due under the November 29 Notes for a number of shares of the Company’s Series E Convertible Preferred Stock equal to 150% of the principal amount of each November 29 Note. See note 12. The November 29 Notes bear interest at the rate of 10% per annum which will accrue from the date of the note only if the November 29 Notes are not converted pursuant to the Series E Exchange Agreement by May 10, 2023. Following an event of default as defined in the November 29 Notes, the principal amount shall bear interest for each day until paid at a rate per annum equal to the lesser of the maximum interest permitted by applicable law and 18%. The November 29 Notes contain a “most favored nations” clause that provides that, so long as the note is outstanding, if the Company issues any new security which November 29 Lender reasonably believes contains a term that is more favorable than those in the November 29 Note, the Company shall notify the November 29 Lenders of such term, and such term, at the option of the November 29 Lenders, shall become a part of the November 29 Note. In addition, each of the November 29 Lenders will receive five-year warrants to purchase 750 shares of the Company’s common stock at a price equal to the price of any warrant included in an offering in connection with listing at the Nasdaq Global Market. These warrants are not deemed issued at December 31, 2022 because the exercise price was not yet determined. Discounts in the amount of $667 were amortized to interest expense for each of the November 29 Notes during the year ended December 31, 2022, and discounts in the amount of $3,083 remained outstanding for each of the November 29 Notes at December 31, 2022. Principal and accrued interest in the amounts $18,750 and $164, respectively, were due on each of the seven November 29 Note at December 31, 2022.

 

Concurrent with the November 29 Notes, the Company entered into separate exchange agreements (the “November 29 Notes Exchange Agreements”). Pursuant to the November 29 Notes Exchange Agreements, amounts due under the November 29 Notes will be exchanged for a number Series E Convertible Preferred Stock equal to 150% of the principal amount of the Notes. No transactions occurred pursuant to the November 29 Notes Exchange Agreements during the year ended December 31, 2022.

 

During the three months ended March 31, 2023, interest in the amount of $471 was accrued on each of the November 29 Notes; principal and accrued interest in the amount of $18,750 and $635, respectively, were due on each of these notes at March 31, 2023. These notes were in default at March 31, 2023.

 

These amounts are reflected in the table below:

 

   

March 31,

2023

   

December 31,

2022

 

Notes Payable

  $ 2,799,632     $ 2,799,632  

Less: Discount

  $ (8,456

)

  $ (22,670

)

Notes payable – net of discounts

  $ 2,791,176     $ 2,776,962  
                 

Current Portion, net of discount

  $ 2,791,176     $ 2,776,962  

Long-term portion, net of discount

  $ -     $ -  

 

Interest expense on notes payable – related parties was $114,938 and $27,174 for the three months ended March 31, 2023 and 2022, respectively Accrued interest on notes payable – related parties was $313,691 and $198,753 at March 31, 2023 and December 31, 2022, respectively.

 

Note 11: Derivative Liabilities

 

Certain of the Company’s convertible notes and warrants contain features that create derivative liabilities. The pricing model the Company uses for determining fair value of its derivatives is the Lattice Model. Valuations derived from this model are subject to ongoing internal and external verification and review. The model uses market-sourced inputs such as interest rates and stock price volatilities. Selection of these inputs involves management’s judgment and may impact net income. The derivative components of these notes are valued at issuance, at conversion, at restructuring, and at each period end.

 

Derivative liability activity for the for the period ended March 31, 2023 is summarized in the table below:

 

December 31, 2022

  $ 568,912  

Loss on revaluation

    110,778  

March 31, 2023

  $ 679,690  

 

 

The Company uses a Monte Carlo model to value certain features of its notes payable that create derivative liabilities. The following table summarizes the assumptions for the valuations:

 

   

December 31,

 
   

2022

 

Volatility

    95.1% to 123.2

%

Stock Price

  $ 1.06 to 3.50  

Risk-free interest rates

    4.35% to 4.37

%

Term (years)

    0.73 to 0.86  

 

   

March 31,

 
   

2023

 

Volatility

    159.6% to 169.9

%

Stock Price

  $ 1.24  

Risk-free interest rates

    4.40

%

Term (years)

    0.52 to 0.61  

 

Certain of our notes payable contain a commitment fee obligation with a true-up feature. The following assumptions were used for the valuation of the derivative liability associated with this obligation:

 

 

The stock price would fluctuate with the Company projected volatility.

 

The projected volatility curve from an annualized analysis for each valuation date was based on the historical volatility of the Company and the term remaining for the True-Up obligation.

 

The Company expected the note would be repaid 90% of the time by the maturity date, at which point the Company would redeem the 1,000,000 redeemable commitment fee shares for $1.

 

In the event the Company did not repay the note in time, the shareholders would sell their shares subject to volume restrictions.

 

Discount rates were based on risk-free rates in effect based on the remaining term. 50,000 simulations were run for each Monte Carlo simulation.

 

Note 12: Stockholders Equity (Deficit)

 

Common Stock

 

The Company has authorized 500,000,000 shares of common stock, par value $0.01; 4,995,573 shares were issued and outstanding on March 31, 2023.

 

Common Stock Transactions During the Three Months Ended March 31, 2023

 

On January 23, 2023, the Company issued 150,000 shares of common stock at the market price of $3.45 per share to a service provider. The aggregate value of $517,500 was charged to non-cash compensation during the three months ended March 31, 2023.

 

On February 21, 2023, the Company issued 150,000 shares of common stock at the market price of $2.53 per share to a service provider. The aggregate value of $379,500 was charged to non-cash compensation during the three months ended March 31, 2023.

 

During the three months ended March 31, 2023, GS Capital converted principal and accrued interest in a convertible note payable into shares of common stock as follows: On February 14, 2023, principal of $15,000, accrued interest of $1,632, and fees of $500 were converted at a price of $1.74 per share into 9,846 shares of common stock; on February 28, 2023, principal of $17,777, accrued interest of $2,057, and fees of $500 were converted at a price of $1.50 per share into 13,555 shares of common stock; on March 9, 2023, principal of $20,000, accrued interest of $2,399, and fees of $500 were converted at a price of $1.50 per share into 15,265 shares of common stock; and on March 28, 2023, principal of $20,000, accrued interest of $2,581, and fees of $500 were converted at a price of $1.25 per share into 18,472 shares of common stock. These conversions were made pursuant to the terms of the convertible note agreement and no gain or loss was recognized on these transactions.

 

On March 31, 2023, the Company issued a total of 8,063 shares of common stock for accrued dividends on its Series X Preferred Stock. Of this amount, a total of 1,066 shares were issued to officers and directors, 4,160 were issued to a related party shareholder, and 2,837 were issued to no-related parties.

 

 

Common Stock Transactions During the Three Months Ended March 31, 2022

 

On January 12, 2022, the Company entered into a settlement agreement with an ex-employee. Pursuant to the terms of this agreement, the Company agreed to pay the amount of $19,032 for accrued salary, and the employee returned to the Company for cancellation 8,000 shares of common stock previously issued as compensation. These shares were valued at par value of $0.01 or a total value of $4,000; the Company recorded a gain on cancellation of these shares in the amount of $15,032.

 

The Company entered into a debt-for-equity exchange agreement with Gardner Builders Holdings, LLC (“Gardner”) on January 7, 2022 (the “Debt for Equity Agreement”). Pursuant to the Debt for Equity Agreement, the Company issued shares of restricted common stock to Gardner in exchange for the Company Debt Obligations, as defined below.

 

The Agreement settled for certain accounts payable amounts owed by the Company to the Creditor (the “Accounts Payable Amount”) as well as upcoming amounts that will become due between the date of the Agreement and April 1, 2022. The Agreement also settled accrued interest and penalties on the amounts due through January 5, 2022, as well as future interest payments on amounts to be accrued in the first quarter of 2022 (collectively, the “Additional Costs”, and combined with the Accounts Payable Amount, the “Company Debt Obligations”). The Accounts Payable Amount was $500,000, the Additional Costs were $294,912 and the conversion price was $12.50. As a result, 63,593 Restricted Shares were authorized to be issued. The Company’s Board of Directors approved the Agreement on January 5, 2022.

 

On March 22, 2022 and March 31, 2022, the Company issued an aggregate 30,834 shares of common stock as waiver fees to holders of the Series C and Series D Preferred Stock for their waivers of certain covenants as set forth and defined in the Series C and Series C Certificates of Designations. The Company valued these shares at their contractual price of $12.50 per share and recorded the amount of $385,431 as waiver fees during the three months ended March 31, 2022. The Company recorded an aggregate gain upon issuance of these shares in the amount of $198,273 based on the market price of the Company’s common stock on the date of issuance.

 

On March 31, 2022, the Company issued 34,400 Commitment Fee Shares to AJB Capital Investors, LLC; see note 8. The Company utilized an outside valuation consultant to value the commitment fee shares, the True-Up Provision, and warrants. A Monte Carlo model was used to value the warrants and call features, and a probability weighted expected return model was used to value the True-Up Provision. The contractual price of the common stock $12.50 per share; valuation purposes, the common stock was valued at the market price on the date of the transaction of $6.14 per share. The derivative liability was valued at $106,608 on the date of the transaction. The discount on the notes due to the Commitment Fee Shares and warrants was valued at $349,914. The Company recorded the amount of $226,106 to additional paid-in capital pursuant to this transaction.

 

On March 31, 2022, the Company issued 7,647 shares of common stock at a price of $12.50 per share which were previously subscribed for the conversion of accounts payable in the amount of $95,558.

 

Preferred Stock

 

We have authorized to issue 100,000,000 shares of Preferred Stock with such rights designations and preferences as determined by our Board of Directors. We have designated 500,000 shares of Series A Preferred, 3,000,000 shares of Series C Preferred, 10,000,000 shares of Series D Preferred, 10,000 shares of Series E Preferred,  140,000 shares of Series F Preferred, and  27,324 shares of Series X Preferred.

 

Series A Preferred Stock Transactions During the Three Months Ended March 31, 2023

 

None.

 

Series A Preferred Stock Transactions During the Three Months Ended March 31, 2022

 

None.

 

Series C Preferred Stock

 

Series C Preferred Stock Transactions During the Three Months Ended March 31, 2023

 

The Company accrued dividends in the amount of $16,521 on the Series C Preferred Stock.

 

 

Series C Preferred Stock Transactions During the Three Months Ended March 31, 2022

 

The Company accrued dividends in the amount of $16,395 on the Series C Preferred Stock.

 

Series D Preferred Stock

 

Series D Preferred Stock Transactions During the Three Months Ended March 31, 2023

 

The Company accrued dividends in the amount of $48,156 on the Series D Preferred Stock.

 

Series D Preferred Stock Transactions During the Three Months Ended March 31, 2022

 

The Company accrued dividends in the amount of $48,156 on the Series D Preferred Stock.

 

Series E Preferred Stock

 

On November 7, 2022, the Company filed a Certificate of Designations, Preferences and Rights of Series E Convertible Perpetual Preferred Stock (the “Series E”) with the Delaware Secretary of State. The number of shares of Series E designated is 10,000 and each share of Series E has a stated value equal to $1,000. Each share of Series E Preferred Stock shall have a par value of $0.01.

 

Each share of Series E shall become convertible, at the option of the holder, commencing on the date of issuance, into such number of fully paid and non-assessable shares of Common Stock. The conversion price shall be, as of the conversion date, (a) prior to the date of the qualified offering the average VWAP per share of the Common Stock for the five (5) trading days prior to the date of conversion and (b) on or following the date of the qualified offering, the qualified offering price (the “Conversion Price”). Immediately following the 120th day following the qualified offering, the Conversion Price shall be adjusted to the lesser of (a) the average VWAP per share of the Common Stock for the five (5) trading days immediately following the 120th day following the qualified offering and (b) the Conversion Price on such date, which shall in no event be less than $0.05.

 

Series E Preferred Stock Transactions During the Three Months Ended March 31, 2023

 

None.

 

Series F Preferred Stock

 

On March 23, 2023, the Company filed a Certificate of Designation, Preferences and Rights of Series F 12% PIK Convertible Perpetual Preferred Stock (the "Series F”) with the Delaware Secretary of State. The number of shares of Series F designated is 140,000 and each share of Series F has a stated value equal to $1,000. Each share of Series F Preferred Stock shall have a par value of $0.01. Holders of the Series F are entitled to receive payment in kind dividends ("PIK Dividends”) at the quarterly rate of three-hundredths of one share outstanding per Series F Share. The Series F can be converted, at the option of the Series F shareholder into shares of the Company’s common stock at a price equal to 65% of the Volume Weighted Average Price ("VWAP”) on the conversion date. No conversions can occur until the Company has successfully completed an uplist to NASDAQ.

 

Series F Preferred Stock Transactions During the Three Months Ended March 31, 2023

 

None.

 

Series X Preferred Stock

 

The Company has 24,227 shares of its 10% Series X Cumulative Redeemable Perpetual Preferred Stock (the “Series X Preferred Stock”) outstanding as of March 31, 2023 and December 31, 2022. The Series X Preferred Stock has a par value of $0.01 per share, no stated maturity, a liquidation preference of $25.00 per share, and will not be subject to any sinking fund or mandatory redemption and will remain outstanding indefinitely unless the Company decides to redeem or otherwise repurchase the Series X Preferred Stock; the Series X Preferred Stock is not redeemable prior to November 4, 2020. The Series X Preferred Stock will rank senior to all classes of the Company’s common and preferred stock and accrues dividends at the rate of 10% on $25.00 per share. The Company reserves the right to pay the dividends in shares of the Company’s common stock at a price equal to the average closing price over the five days prior to the date of the dividend declaration. Each one share of the Series X Preferred Stock is entitled to 20,000 votes on all matters submitted to a vote of our shareholders.

 

 

Series X Preferred Stock Transactions During the Three Month Ended March 31, 2023

 

The Company accrued dividends in the amount of $15,141 on the Series X Preferred Stock.

 

On March 31, 2023, the Company issued 8,063 shares of common stock at an average price of $4.38 per share for accrued dividends on the Series X Preferred Stock.

 

Series X Preferred Stock Transactions During the Three Months Ended March 31, 2022

 

The Company accrued dividends in the amount of $15,141 on the Series X Preferred Stock.

 

Stock Options

 

The following table summarizes the options outstanding at March 31, 2023 and the related prices for the options to purchase shares of the Company’s common stock:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Weighted

 

 

 

 

 

 

Weighted

 

 

 

 

 

 

 

 

 

 

Weighted

 

 

average

 

 

 

 

 

 

average

 

 

 

 

 

 

 

 

 

 

average

 

 

exercise

 

 

 

 

 

 

exercise

 

 

Range of

 

 

Number of

 

 

remaining

 

 

price of

 

 

Number of

 

 

price of

 

 

exercise

 

 

options

 

 

contractual

 

 

outstanding

 

 

options

 

 

exercisable

 

 

prices

 

 

outstanding

 

 

life (years)

 

 

options

 

 

exercisable

 

 

options

 

 

$

1.50- 16.00

     

215,881

     

7.94

   

$

9.39

     

129,148

   

$

7.73

 
           

215,881

     

7.94

   

$

9.39

     

129,148

   

$

7.73

 

 

Transactions involving stock options are summarized as follows:

 

   

Shares

   

Weighted- Average

Exercise Price ($) (A)

 

Outstanding at December 31, 2022

    310,692     $ 10.01  

Granted

    -     $ -  

Expired

    (94,811

)

  $ 11.44  

Outstanding at March 31, 2023

    215,881     $ 9.39  

Options vested and exercisable

    129,148     $ 7.73  

 

At March 31, 2023, the total stock-based compensation cost related to unvested awards not yet recognized was $2.1 million.

 

Warrants

 

The following table summarizes the warrants outstanding on March 31, 2023, and the related prices for the warrants to purchase shares of the Company’s common stock:

 

   

Shares

   

Weighted- Average

Exercise Price ($)

 
                 

Outstanding on December 31, 2022

    672,334     $ 30.68  

Granted

    -     $ -  

Exercised

    -     $ -  

Outstanding on March 31, 2023

    672,334     $ 30.68  

 

 

Note 13: Fair Value Measurements

 

The following summarizes the Company’s derivative financial liabilities that are recorded at fair value on a recurring basis at March 31, 2023 and 2022.

 

   

March 31, 2023

 
   

Level 1

   

Level 2

   

Level 3

   

Total

 

Liabilities

                               

Derivative liabilities

  $ -     $ -     $ 679,690     $ 679,690  

 

   

March 31, 2022

 
   

Level 1

   

Level 2

   

Level 3

   

Total

 

Liabilities

                               

Derivative liabilities

  $ -     $ -     $ 568,912     $ 568,912  

 

Note 14: Commitments and Contingencies

 

Legal

 

From time to time, we may become involved in legal proceedings or be subject to claims arising in the ordinary course of our business.

 

On June 23, 2022, The Good Clinic LLC was notified that a former employee had filed a lawsuit for wrongful termination. The Good Clinic believes the lawsuit is without merit. The Company was not named in the suit. The Company expects to resolve it for nominal consideration. No change has been noted related to this lawsuit.

 

On October 25, 2022, the Company was notified that a vendor filed suit related to a contract dispute naming both The Good Clinic and The CEO of the Good Clinic. This suit was settled on May 5, 2023, and dismissed with prejudice on May 12, 2023. The settlement included the issuance of the Company’s restricted common stock. As a part of the settlement the Company issued 2,552 shares of its restricted common stock to the plaintiff and it issued to the CEO of The Good Clinic 19,622 of its restricted common stock, plus $3,000 in cash for reimbursement of expenses related to settling the suit with the vendor.

 

The Company has a number of legal situations involved with the winding down of its clinic business activities including claims regarding certain construction contracts and as a part of the process of cancellation of leases. The following is a summary as of the date of this filing:

 

 

The Wayzata, MN clinic leases was terminated for a commitment to pay $25,000.

 

Possession of the two Denver, Colorado clinic leases, known as Quincy and Radiant, has been relinquished to the landlords. The lease obligations remain in negotiations as does the handling of the mechanics liens placed on the properties.

 

The Eagan clinic, aka Vikings clinic, gave up possession in January of 2023. The mechanics lien has been placed on the property and was settled by the landlord in a confidential settlement with the lien holder. The Landlord terminated the lease as of March 3, 2023. Mitesco is now in settlement negotiations with the landlord for the handling of lease obligations. The Landlord filed suit against the Company on July 21, 2023 for unpaid rent, expenses related unpaid lease obligations and the settled construction lien.

 

The St. Paul clinic possession was relinquished in March 2023. The handling of lease obligations remain in negotiations, as does the handling of the mechanics liens placed on the properties.

 

The St. Louis Park clinic possession was relinquished in April 2023. The handling of lease obligations remain in negotiations as does the handling of the mechanics liens placed on the properties.

 

The Maple Grove clinic eviction occurred in April 2023. The handling of lease obligations remain in negotiations, as does the handling of the mechanics liens placed on the properties. On August 22, 2023 the landlord filed a lawsuit related to alleged unmet lease obligations and related to a construction lien on the property by the general contractor related to alleged non-payment of construction expenses.

 

The Northeast Minneapolis clinic, aka Nordhaus clinic, possession was relinquished in May 2023. There is no lien on the property. The handling of lease obligations remains in negotiations with the landlord.

 

 

Note 15: Subsequent Events

 

Issuance of Common Stock

 

On April 4, 2023, the Company issued 2,952 shares of common stock at a price of $1.05 per share to a service provider.

 

On April 5, 2023, the Company issued 94,738 shares of common stock to an investor at a price of $1.32 per share pursuant to a true-up agreement.

 

On May 5, 2023, the Company issued 2,552 shares of common stock to an investor at a price of $1.05 per share for satisfaction of accounts payable.

 

On May 9, 2023, the Company issued 19,622 shares of common stock to Michael C. Howe, a related party, at a price of $0.94 per share to reimburse Mr. Howe for costs incurred in connection with a settlement agreement with a vendor.

 

On June 9, 2023, the Company issued 20,212 shares of common stock as dividends on its Series X Preferred Stock at a price of $1.25 per share, including 1,670 to an officer, 1,003 to an ex-director, and 10,426 to a related party shareholder.

 

On June 29, 2023, the Company issued 131,362 shares of common stock at a price of $0.80 per share to a vendor in satisfaction of accounts payable in the amount of $105,089.

 

On August 29, 2023, the Company issued 43,750 shares of common stock at a price of $0.80 per share to a vendor in satisfaction of accounts payable in the amount of $35,000.

 

PPP Loan Payment Plan

 

On July 12, 2023, the Company entered into a payment plan arrangement with the U.S. Small Business Administration regarding PPP Loan. The terms of the payment plan call for monthly payments of approximately $2,595 for 180 months beginning July 1, 2023 resulting in total payments in the amount of $467,116.

 

Issuance of Series F Preferred Stock

 

Sale of Series F Preferred Stock Sold for Cash

 

On April 11, 2023, the Company entered into securities purchase agreements (each a “Purchase Agreement”) with investors providing for the sale and issuance of (i) Series F 12% PIK Convertible Perpetual Preferred Stock, par value $0.01 per share (the “Series F Shares”) and (ii) warrants to purchase shares of Common Stock (the “Warrants,” and together with the Series F Shares, the “Securities”). The Warrants have an initial exercise price of $2.50 per share and the final number of shares of Common Stock the warrant is exercisable for will equal the number of shares of Common Stock into which the Series F Shares convert divided by 2.

 

On April 11, 2023, the Company entered into a Purchase Agreement for the sale of 863 Securities at a price of $1,000 per Security for cash in the amount of $375,000 plus incentives in the amount of $487,500.

 

On April 11, 2023, the Company entered into a Purchase Agreement for the sale of 288 Securities at a price of $1,000 per Security for cash in the amount of $125,000 plus incentives in the amount of $162,500.

 

On April 11, 2023, the Company entered into a Purchase Agreement for the sale of 345 Securities at a price of $1,000 per Security for cash in the amount of $150,000 plus incentives in the amount of $195,000.

 

On June 30, 2023, the Company entered into a Purchase Agreement for the sale of 250 Securities at a price of $1,000 per Security for cash in the amount of $250,000.

 

 

Series F Preferred Stock Issued for Conversion of Debt

 

Also in connection with the Purchase Agreements, the Company entered into separate exchange agreements pursuant to which the investors in the Series F Preferred Stock exchanged certain securities, as defined in each individual Exchange Agreement, for a number Series F Shares (based on their liquidation preference of $1,000) equal to 120%, 165% or 230%, depending on whether the investor invested additional funds into the bridge financing, of the “Principal Amount,” “Stated Value” and/or liquidation preference of the Exchange Securities (including any payoff bonus, accrued dividends or interest).

 

On April 11, 2023, in transactions with nine investors, the Company issued an aggregate 8,023 shares of Series F Preferred Stock at a price of $1,000 per share in exchange for debt and accrued interest, including payoff bonuses, in the aggregate amount of $8,018,293.

 

Series F Preferred Stock Issued for Conversion of Series C and Series D Preferred Stock

 

On April 11, 2023, in transactions with two investors, the Company issued an aggregate 2,051 shares of Series F Preferred Stock at a price of $1,000 per share in exchange for Series C Preferred Stock and accrued dividends and payoff bonuses in the aggregate amount of $2,050,165.

 

On April 11, 2023, in transactions with five investors, the Company issued an aggregate 3,884 shares of Series F Preferred Stock at a price of $1,000 per share in exchange for Series D Preferred Stock and accrued dividends and payoff bonuses in the aggregate amount of $3,883,524.

 

Series F Preferred Stock Issued for Conversion of Accounts Payable

 

On June 29, 2023, the Company issued an aggregate 147 shares of Series F Preferred Stock to two creditors in satisfaction of accounts payable in the aggregate amount of $146,214.

 

Appointment of Ms. Sheila Schweitzer as Chairperson of the Board of Directors and President, Chief Operating Officer

 

Effective June 1, 2023, the Board of Directors appointed Ms. Sheila Schweitzer to the position of Chief Operating Officer. Ms. Schweitzer will receive a salary in the amount of $200,000 per year. Her employment agreement is for a period of one year.

 

Effective June 6, 2023, the Board of Directors of the Company appointed Ms. Schweitzer, who has been a member of the Board of Directors since 2021, to the position of Chairperson, replacing Mr. Tom Brodmerkel, who has completed his term as Chair. Mr. Brodmerkel will remain as Chief Financial Officer and continue to serve as a member of the Company’s Board of Directors.

 

Appointment of Mr. Allen Plunk to the Board of Directors

 

On July 18, 2023 the Company appointed Mr. Allen Plunk to its Board of Directors. This follows a recent assessment of its healthcare operations and coincides with its decision to place new emphasis on building out its acquisition of healthcare technology and services entities. Mr. Plunk will receive compensation commensurate with that of all other members of the Board of Directors.

 

 

ITEM 2. MANAGEMENTS DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

 

References to the Company, Mitesco, Inc., our, us or we refer to Mitesco, Inc. The following discussion and analysis of the Companys financial condition and results of operations should be read in conjunction with the unaudited interim financial statements and the notes thereto contained elsewhere in this report. Certain information contained in the discussion and analysis set forth below includes forward-looking statements that involve risks and uncertainties.

 

Cautionary Note Regarding Forward-Looking Statements

 

This Quarterly Report on Form 10-Q includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Exchange Act. We have based these forward-looking statements on our current expectations and projections about future events. These forward-looking statements are subject to known and unknown risks, uncertainties and assumptions about us that may cause our actual results, levels of activity, performance or achievements to be materially different from any future results, levels of activity, performance or achievements expressed or implied by such forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as may, should, could, would, expect, plan, anticipate, believe, estimate, continue, or the negative of such terms or other similar expressions. Factors that might cause or contribute to such a discrepancy include, but are not limited to, those described in our other SEC filings.

 

History and Outlook

 

Mitesco Inc. is a holding company with plans to participate in the healthcare technology, services and/or delivery industries. From 2020 through 2022, the Company was executing against a strategic plan to open primary care clinics utilizing advanced degreed nurse practitioners in select markets. The clinics operated under the name The Good Clinic. The Company performed on the strategy and began implementing growth plans for The Good Clinic with limited funding. The Company believed that upon execution of the business plan additional capital would be available on acceptable terms. However, the markets were not favorable to funding and as the Covid-19 pandemic lingered on, the Company was unsuccessful accessing adequate capital when needed, therefore in late 2022 the decision was made to close the clinics. As a result, Mitesco currently has no operating business.

 

Since the beginning of 2023, the Company has focused on winding down operations of The Good Clinic along with reducing other costs. To that purpose the Company has terminated all but 4 employees; management and the Board members are not taking cash compensation, and there are ongoing discussions to convert amounts owed to equity. We are also selling the remaining assets consisting of furniture, equipment, and supplies; the funds generated from the sale of assets will be used primarily to cover the costs of our SEC filings. We have also begun the process of redomiciling from Delaware to Nevada.

 

Results of Operations

 

The following period-to-period comparisons of our financial results are not necessarily indicative of results for the current period of any future periods. Further, as a result of any acquisitions of other businesses, and any additional pharmacy acquisitions or other such transactions we may pursue, we may experience large expenditures specific to the transactions that are not incident to our operations.

 

Comparison of the Three Months Ended March 31, 2023 and 2022

 

Revenue

 

The Company recognized revenue of $0 for the three months ended March 31, 2023, compared to approximately $0.1 million for the three months ended March 31, 2022. The decrease is the result of the halting of the Company’s clinic operations.

 

Cost of Sales

 

The Company incurred approximately $2,419 of cost of goods sold for the three months ended March 31, 2023, compared to $0.6 million for the three months ended March 31, 2022. The decrease is the result of the halting of the Company’s clinic operations.

 

Gross Profit/(Loss)

 

Our gross loss was approximately $2,419 for the three months ended March 31, 2023, compared to gross loss of $0.5 million for the three months ended March 31, 2022. The decrease is the result of the halting of the Company’s clinic operations.

 

 

Operating Expenses

 

Our total operating expenses for the three months ended March 31, 2023, were approximately $4.3 million. For the comparable period in 2022, the operating expenses were approximately $2.6 million. The increase is the result of the halting of the Company’s clinic operations.

 

During the current period we fully impaired our remaining operating assets in the amount of approximately $2.3 million.

 

General and administrative expenses for the three months ended March 31, 2023 were comprised primarily of payroll and related costs of approximately $0.3 million, building and facility costs of approximately $0.3 million, share based compensation of approximately $0.8 million, depreciation of approximately $0.1 million, advertising and marketing costs of approximately $0.1 million, legal and professional costs of approximately $0.1 million, consulting costs of approximately $0.1 million, and other costs of approximately $0.2 million.

 

General and administrative expenses for the three months ended March 31, 2022 were comprised primarily of approximately $0.9 million in payroll and related costs, $0.3 million in legal and professional fees, $0.2 million in facilities costs, $0.2 million of depreciation expense, $0.1 million of IR and marketing costs, $0.1 million of insurance costs, $0.1 million of computer support and internet costs, and $0.1 million in consulting fees.

 

Other Income and Expenses

 

Interest expense was approximately $1.4 million for the three months ended March 31, 2023, compared to approximately $0.8 million for the three months ended March 31, 2022. The increase was due to an increase in principal balances and to increased interest rates due to default on the notes.

 

Interest expense – related parties was approximately $0.1 million for the three months ended March 31, 2023, compared to $0 in the prior period.

 

During the three months ended March 31, 2022, we recorded a gain on waiver fee shares of approximately $0.2 million.

 

During the three months ended March 31, 2022, we recorded a gain on settlement of accrued salary of approximately $15,000.

 

During the three months ended March 31, 2023. We recorded a gain on termination of operating lease in the amount of approximately $0.3.

 

During the three months ended March 31, 2022, we recorded a loss on settlement of accounts payable of approximately $78,000.

 

During the three months ended March 31, 2023, we recorded a loss on the revaluation of derivative liabilities of approximately $0.1 million compared to a gain in the amount of approximately $80,000 during the three months ended March 31, 2022.

 

The Company accrued Preferred Stock dividends of approximately $79,000 compared to approximately $80,000 for the three months ended March 31, 2022.

 

For the three months ended March 31, 2023, we had a net loss available to common shareholders of approximately $5.7 million, or a net loss per share, basic and diluted of ($1.18) compared to a net loss available to common shareholders of approximately $3.8 million, or a net loss per share, basic and diluted of ($0.87), for the three months ended March 31, 2022.

 

Liquidity and Capital Resources

 

To date, we have not generated sufficient revenue from operations or raised capital to support our operations. We have financed a portion of our operations through the sale of equity securities and short-term borrowings. As of March 31, 2023, we had cash of approximately $300 compared to cash of approximately $36,000 as of December 31, 2022.

 

Net cash used in operating activities was approximately $35,000 for the three months ended March 31, 2023. This is the result of the halting of the Company’s clinic operations. Cash used in operations for the three months ended March 31, 2022, was approximately $1.9 million.

 

Net cash used in investing activities was $0 for the three months ended March 31, 2023 compared to $20,000 for the three months ended March 31, 2022.

 

 

Net cash provided by financing activities for the three months ended March 31, 2023, was $0, compared to $0.9 million for the three months ended March 31, 2022.

 

At March 31, 2023, we have the following cash based current liabilities: Accounts payable and accrued liabilities of $8.3 million; notes payable of $6.2 million; notes payable to related parties of $2.8 million; SBA Loan Payable of $0.5 million; lease liabilities of $0.5 million; accrued interest payable of $0.5 million; accrued interest payable to related parties of $0.4 million; and other current liabilities of $0.1 million.  We also have the following liabilities which are payable in stock: derivative liabilities of $0.6 million, preferred stock dividends of $0.4, and preferred stock dividends payable to related parties of $30,000.

 

We have undertaken the following action plan to improve our liquidity:  (i) We have raised approximately $94,000 from the sale of office equipment, supplies, and other assets; (ii) several institutional investors have invested in our Seres F Preferred Stock; (iii) we have restructured our SBA Loan; (iv) we are negotiating with vendors to convert our accounts payable into common stock or Series F Preferred stock, (iv) We are negotiating with lenders to convert our notes payable into Series F Preferred Stock, or revise the terms of the notes; (v) We are negotiating with landlords to resolve the amounts due under the leases by offering to convert these amounts to equity or promissory notes.  See below for details regarding the progress we have made in the implementation of this plan.

 

Initial funds raised via the above efforts will be used primarily to complete the Company’s SEC filings.

 

SBA Loan

 

On July 12, 2023, the Company entered into a payment plan arrangement with the U.S. Small Business Administration regarding PPP Loan. The terms of the payment plan call for monthly payments of approximately $2,595 for 180 months beginning July 1, 2023 resulting in total payments in the amount of $467,116.

 

Sale of Series F Preferred Stock Sold for Cash

 

On April 11, 2023, the Company entered into securities purchase agreements (each a “Purchase Agreement”) with investors providing for the sale and issuance of (i) Series F 12% PIK Convertible Perpetual Preferred Stock, par value $0.01 per share (the “Series F Shares”) and (ii) warrants to purchase shares of Common Stock (the “Warrants,” and together with the Series F Shares, the “Securities”). The Warrants have an initial exercise price of $2.50 per share and the final number of shares of Common Stock the warrant is exercisable for will equal the number of shares of Common Stock into which the Series F Shares convert divided by 2. The Series F can be converted, at the option of the Series F shareholder into shares of the Company’s common stock at a price equal to 65% of the Volume Weighted Average Price ("VWAP”) on the conversion date. No conversions can occur until the Company has successfully completed an uplist to NASDAQ.

 

From April 11 through June 30, 2023, we have raised a total of $900,000 through the sale of Series F Securities as follows:

 

On April 11, 2023, the Company entered into a Purchase Agreement for the sale of 863 Securities at a price of $1,000 per Security for cash in the amount of $375,000 plus incentives in the amount of $487,500.

 

On April 11, 2023, the Company entered into a Purchase Agreement for the sale of 288 Securities at a price of $1,000 per Security for cash in the amount of $125,000 plus incentives in the amount of $162,500.

 

On April 11, 2023, the Company entered into a Purchase Agreement for the sale of 345 Securities at a price of $1,000 per Security for cash in the amount of $150,000 plus incentives in the amount of $195,000.

 

On June 30, 2023, the Company entered into a Purchase Agreement for the sale of 250 Securities at a price of $1,000 per Security for cash in the amount of $250,000.

 

Also in connection with the Purchase Agreements, the Company entered into separate exchange agreements pursuant to which the investors in the Series F Preferred Stock exchanged certain securities, as defined in each individual Exchange Agreement, for a number Series F Shares (based on their liquidation preference of $1,000) equal to 120%, 165% or 230%, depending on whether the investor is investing additional funds into the bridge financing, of the “Principal Amount,” “Stated Value” and/or liquidation preference of the Exchange Securities (including any payoff bonus, accrued dividends or interest).

 

Series F Preferred Stock Issued for Conversion of notes payable and accrued interest

 

Through June 30, 2023, we have converted a total of $3,947,071 in debt and accrued interest to Series F Preferred Stock as follows:

 

 

On April 11, 2023, in transactions with nine investors, the Company issued an aggregate 8,023 shares of Series F Preferred Stock at a price of $1,000 per share in exchange for debt and accrued interest in the amount of $3,947,071, default fees of $912,500, and payoff incentives of 3,158,722.

 

Series F Preferred Stock Issued for Conversion of Series C and Series D Preferred Stock

 

Through June 30, 2023, we have converted a total Series C and D Preferred Stock and accrued interest with a total stated value in the amount of $3,954,068 to Series F Preferred Stock as follows:

 

On April 11, 2023, in transactions with two investors, the Company issued an aggregate 2,051 shares of Series F Preferred Stock at a price of $1,000 per share in exchange for Series C Preferred Stock and accrued dividends with a stated value of $1,271,109 and incentives in the aggregate amount of $779,056.

 

On April 11, 2023, in transactions with five investors, the Company issued an aggregate 3,884 shares of Series F Preferred Stock at a price of $1,000 per share in exchange for Series D Preferred Stock and accrued dividends with a stated value of $2,683,159 and incentives in the aggregate amount of $1,200,365.

 

Series F Preferred Stock Issued for Conversion of Accounts Payable

Through June 30, 2023, we have converted a total of $146,204 of accounts payable to Series F Preferred Stock as follows:

 

On June 29, 2023, the Company issued an aggregate 147 shares of Series F Preferred Stock to two creditors in satisfaction of accounts payable in the aggregate amount of $146,214.

 

Common Stock issued for conversion of Accounts payable

 

Through June 30, 2023, we have converted a total of $105,089 of accounts payable to common stock as follows:

 

On June 29, 2023, the Company issued 131,362 shares of common stock at a price of $0.80 per share to a vendor in satisfaction of accounts payable in the amount of $105,089.

 

We expect to continue to convert existing liabilities to our Series F Preferred Stock or to common stock and to raise additional funds via the sale of our Series F Preferred Stock, though there can be no assurance that we will be successful in doing so.

 

Critical Accounting Estimates

 

Management uses various estimates and assumptions in preparing our financial statements in accordance with generally accepted accounting principles. These estimates and assumptions affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities, and the reported revenues and expenses. Accounting estimates that are the most important to the presentation of our results of operations and financial condition, and which require the greatest use of judgment by management, are designated as our critical accounting estimates. We have the following critical accounting estimates:

 

 

Estimates and assumptions used in the valuation of derivative liabilities: Management utilizes a lattice model to estimate the fair value of derivative liabilities. The model includes subjective assumptions that can materially affect the fair value estimates.

 

 

ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK.

 

Because we are allowed to comply with the disclosure obligations applicable to a “smaller reporting company,” as defined by Rule 12b-2 of the Exchange Act, with respect to this Quarterly Report on Form 10-Q, we are not required to provide the information required by this Item.

 

ITEM 4. CONTROLS AND PROCEDURES.

 

(a) Evaluation of Disclosure Controls and Procedures

 

Our management, with the participation of our Chief Executive Officer and our Chief Financial Officer, has evaluated the effectiveness of our disclosure controls and procedures (as such term is defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act) as of the end of the period covered by this report. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed in the reports we file or submit under the Exchange Act is accumulated and communicated to management, including our Chief Executive Officer and Chief Financial Officer, as appropriate, to allow timely decisions regarding required disclosure. Based on such evaluations, the Company’s management has identified what it believes are material weaknesses in the Company’s disclosure controls and procedures and concluded that we did not have effective disclosure controls and procedures.

 

The deficiencies in our disclosure controls and procedures included (i) lack of segregation of duties and (ii) lack of sufficient resources to ensure that information required to be disclosed by the Company in the reports that the Company files or submits to the SEC are recorded, processed, summarized, and reported, within the time periods specified in the SEC’s rules and forms.

 

The Company intends to take corrective action to ensure that information required to be disclosed by the Company pursuant to the reports that the Company files or submits to the SEC is accumulated and communicated to the Company’s management, including its principal executive and principal financial officers, or persons performing similar functions, as appropriate to allow timely decisions regarding required disclosure.

 

(b) Changes in Internal Control Over Financial Reporting

 

There have been no changes in our internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) of the Exchange Act) that occurred during our first quarter ended March 31, 2023, that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

 

 

PART II. OTHER INFORMATION

 

ITEM 1. LEGAL PROCEEDINGS

 

From time to time, we may become involved in legal proceedings or be subject to claims arising in the ordinary course of our business.

 

On June 23, 2022, The Good Clinic LLC was notified that a former employee had filed a lawsuit for wrongful termination. The Good Clinic believes the lawsuit is without merit. The Company was not named in the suit. The Company expects to resolve it for nominal consideration. No change has been noted related to this lawsuit.

 

On October 25, 2022, the Company was notified that a vendor filed suit related to a contract dispute naming both The Good Clinic and The CEO of the Good Clinic. This suit was settled on May 5, 2023, and dismissed with prejudice on May 12, 2023. The settlement included the issuance of the Company’s restricted common stock. As a part of the settlement the Company issued 2,552 shares of its restricted common stock to the plaintiff and it issued to the CEO of The Good Clinic 19,622 of its restricted common stock, plus $3,000 in cash for reimbursement of expenses related to settling the suit with the vendor.

 

The Company has a number of legal situations involved with the winding down of its clinic business activities including claims regarding certain construction contracts and as a part of the process of cancellation of leases. The following is a summary as of the date of this filing:

 

 

The Wayzata, MN clinic leases was terminated for a commitment to pay $25,000.

 

Possession of two Denver, Colorado clinic leases, known as Quincy and Radiant, has been relinquished to the landlords. The lease obligations remain in negotiations as does the handling of the mechanics liens placed on the properties.

 

The Eagan clinic, aka Vikings clinic, gave up possession in January of 2023. The mechanics lien has been placed on the property and was settled by the landlord in a confidential settlement with the lien holder. The Landlord terminated the lease as of March 3, 2023. Mitesco is now in settlement negotiations with the landlord for the handling of lease obligations. The Landlord filed suit against the Company on July 21, 2023 for unpaid rent, expenses related unpaid lease obligations and the settled construction lien.

 

The St. Paul clinic possession was relinquished in March 2023. The handling of lease obligations remain in negotiations, as does the handling of the mechanics liens placed on the properties.

 

The St. Louis Park clinic possession was relinquished in April 2023. The handling of lease obligations remain in negotiations, as does the handling of the mechanics liens placed on the properties.

 

The Maple Grove clinic eviction occurred in April 2023. The handling of lease obligations remain in negotiations as does the handling of the mechanics liens placed on the properties. On August 22, 2023 the landlord filed a lawsuit related to alleged unmet lease obligations and related to a construction lien on the property by the general contractor related to alleged non-payment of construction expenses.

 

The Northeast Minneapolis clinic, aka Nordhaus clinic, possession was relinquished in May 2023. There is no lien on the property. The handling of lease obligations remains in negotiations with the landlord.

 

ITEM 1A. RISK FACTORS

 

Our business is subject to risks and events that, if they occur, could adversely affect our financial condition and results of operations and the trading price of our securities. In addition to the other information set forth in this quarterly report on Form 10-Q, you should carefully consider the factors described in Part I, Item 1A. “Risk Factors” of our Annual Report on Form 10-K for the fiscal year ended December 31, 2022, filed with the Securities and Exchange Commission on July 14, 2023. There have been no material changes to the risk factors described in that report.

 

ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES, USE OF PROCEEDS, AND ISSUER PURCHASES OF EQUITY SECURITIES

 

The following securities were issued pursuant to an exemption contained in section 4(a)(2) of the Securities Act of 1933.

 

Common Stock

 

On January 23, 2023, the Company issued 150,000 shares of common stock at the market price of $3.19 per share to a service provider.

 

On February 21, 2023, the Company issued 150,000 shares of common stock at the market price of $2.27 per share to a service provider.

 

 

During the three months ended March 31, 2023, GS Capital converted principal and accrued interest in a convertible note payable into shares of common stock as follows: On February 14, 2023, 9,846 shares were issued at a price of $1.74 per share; on February 28, 2023, 13,555 shares were issued at a price of $1.50 per share; on March 9, 2023, 15,265 shares were issued at a price of $1.50 per share; and on March 28, 2023, 18,472 shares were issued at a price of $1.25 per share.

 

On March 31, 2023, the Company issued a total of 8,063 shares of common stock for accrued dividends on its Series X Preferred Stock.

 

Of this amount, a total of 1,066 shares were issued to officers and directors, 4,160 were issued to a related party shareholder, and 2,837 were issued to non-related parties.

 

ITEM 3. DEFAULTS UPON SENIOR SECURITIES

 

Not Applicable.

 

ITEM 4. MINE SAFETY DISCLOSURES

 

Not Applicable.

 

ITEM 5. OTHER INFORMATION

 

Not Applicable.

 

ITEM 6. EXHIBITS

 

The following exhibits are included with this Quarterly Report on Form 10Q

 

 

 

 

 

Form

Type

 

Exhibit

Number

 

Date

Filed

 

Filed

Herewith

 

 

 

 

 

 

 

 

 

 

 

3.1

 

Certificate of Incorporation of Trunity Holdings, Inc., dated January 18, 2012.

 

8-K

 

10.1

 

1/31/2012

 

 

 

 

 

 

 

 

 

 

 

 

 

3.2

 

Bylaws of Trunity Holdings, Inc., dated January 18, 2012.

 

8-K

 

10.2

 

1/31/2012

 

 

 

 

 

 

 

 

 

 

 

 

 

3.3

 

Certificate of Ownership Merging between Trunity Holdings, Inc. and Brain Tree International, Inc. dated January 24, 2012.

 

10-K

 

3.3

 

4/16/2013

 

 

 

 

 

 

 

 

 

 

 

 

 

3.4

 

Certificate of Amendment to the Certificate of Incorporation of Trunity Holdings, Inc., dated December 24, 2015.

 

8-K

 

3.1(i)

 

1/06/2016

 

 

 

 

 

 

 

 

 

 

 

 

 

3.5

 

Certificate of Designations of Series X Preferred Stock of True Nature Holding, Inc.

 

8-K

 

3.6

 

1/06/2020

 

 

 

 

 

 

 

 

 

 

 

 

 

3.6

 

Form of Amended and Restated Certificate of Designations of Series A Preferred Stock of True Nature Holding, Inc.

 

8-K

 

3.07

 

3/13/2020

 

 

 

 

 

 

 

 

 

 

 

 

 

3.7

 

Certificate of Amendment of the Certificate of Incorporation of True Nature Holding, Inc. dated April 21, 2020.

 

10-Q

 

3.7

 

8/14/2020

 

 

 

 

 

 

 

 

 

 

 

 

 

3.8

 

Certificate of Amendment of Certificate of Incorporation, dated as of November 5, 2020, correcting December 24, 2015, Certificate of Amendment.

 

10-Q

 

3.8

 

11/13/2020

 

 

 

 

 

 

 

 

 

 

 

 

 

3.9

 

Bylaws of Mitesco, Inc., as amended, dated November 10, 2020

 

10-Q

 

3.9

 

11/13/2020

 

 

 

 

 

 

 

 

Form

Type

 

Exhibit

Number

 

Date

Filed

 

Filed

Herewith

 

 

 

 

 

 

 

 

 

 

 

3.10

 

Certificate of Designations, Preferences and Rights of the Series C Convertible Preferred Stock of Mitesco, Inc.

 

8-K

 

3.1

 

03/26/2021

   
                     

3.11

 

Certificate of Correction to the Certificate of Designations, Preferences and Rights of the Series C Convertible Preferred Stock of Mitesco, Inc.

 

8-K

 

3.2

 

03/26/2021

   
                     
3.12   Certificate of Designations, Preferences and Rights of Series E Convertible Perpetual Preferred Stock of Mitesco   8-K   3.1   11/14/2022    
                     
3.13   Certificate of Designations, Preferences and Rights of Series F 12% PIK Convertible Perpetual Preferred Stock of Mitesco, Inc.   8-K   3.1   04/18/2023    
                     

31.1

 

Certification by the Principal Executive Officer of the Registrant pursuant to Rule 13a-14(a) or Rule 15d-14(a) of the Securities Exchange Act of 1934, as amended, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002

 

 

 

 

 

 

 

X

 

 

 

 

 

 

 

 

 

 

 

31.2

 

Certification by the Principal Financial Officer of the Registrant pursuant to Rule 13a-14(a) or Rule 15d-14(a) of the Securities Exchange Act of 1934, as amended, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of

 

 

 

 

 

 

 

X

 

 

 

 

 

 

 

 

 

 

 

32.1

 

Certification by the Principal Executive Officer and Principal Financial Officer of the Registrant pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

 

 

 

 

 

 

 

X

 

 

 

 

 

 

 

 

 

 

 

32.2

 

Certification by the Principal Financial Officer of the Registrant pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

 

 

 

 

 

 

 

X

 

 

 

 

 

 

 

 

 

 

 

101.INS

 

XBRL INSTANCE DOCUMENT

 

 

 

 

 

 

 

X

 

 

 

 

 

 

 

 

 

 

 

101.SCH

 

XBRL TAXONOMY EXTENSION SCHEMA

 

 

 

 

 

 

 

X

 

 

 

 

 

 

 

 

 

 

 

101.CAL

 

XBRL TAXONOMY EXTENSION CALCULATION LINKBASE

 

 

 

 

 

 

 

X

 

 

 

 

 

 

 

 

 

 

 

101.DEF

 

XBRL TAXONOMY EXTENSION DEFINITION LINKBASE

 

 

 

 

 

 

 

X

 

 

 

 

 

 

 

 

 

 

 

101.LAB

 

XBRL TAXONOMY EXTENSION LABEL LINKBASE

 

 

 

 

 

 

 

X

 

 

 

 

 

 

 

 

 

 

 

101.PRE

 

XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE

 

 

 

 

 

 

 

X

 

 

 

 

 

 

 

 

 

 

 

104

 

Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101)

 

 

 

 

 

 

 

X

 

 

SIGNATURE

 

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the Registrant has duly caused this Quarterly Report on Form 10-Q for the three months ended March 31, 2023, to be signed on its behalf by the undersigned, thereunto duly authorized.

 

 

 

 

 

 

MITESCO, INC.

 

 

 

 

Dated: October 4, 2023

By:

/s/ Tom Brodmerkel

 

 

 

Tom Brodmerkel

Chief Financial Officer and Principal Financial Officer

 

 

47
NONE Yes false --12-31 Q1 0000802257 0000802257 2023-01-01 2023-03-31 0000802257 2023-09-25 0000802257 2023-03-31 0000802257 2022-12-31 0000802257 us-gaap:RelatedPartyMember 2023-03-31 0000802257 us-gaap:RelatedPartyMember 2022-12-31 0000802257 us-gaap:SeriesAPreferredStockMember 2023-03-31 0000802257 us-gaap:SeriesAPreferredStockMember 2022-12-31 0000802257 us-gaap:SeriesCPreferredStockMember 2023-03-31 0000802257 us-gaap:SeriesCPreferredStockMember 2022-12-31 0000802257 us-gaap:SeriesDPreferredStockMember 2023-03-31 0000802257 us-gaap:SeriesDPreferredStockMember 2022-12-31 0000802257 miti:SeriesXPreferredStockMember 2023-03-31 0000802257 miti:SeriesXPreferredStockMember 2022-12-31 0000802257 us-gaap:ServiceMember 2023-01-01 2023-03-31 0000802257 us-gaap:ServiceMember 2022-01-01 2022-03-31 0000802257 us-gaap:ProductMember 2023-01-01 2023-03-31 0000802257 us-gaap:ProductMember 2022-01-01 2022-03-31 0000802257 2022-01-01 2022-03-31 0000802257 us-gaap:RelatedPartyMember 2023-01-01 2023-03-31 0000802257 us-gaap:RelatedPartyMember 2022-01-01 2022-03-31 0000802257 us-gaap:NonrelatedPartyMember 2023-01-01 2023-03-31 0000802257 us-gaap:NonrelatedPartyMember 2022-01-01 2022-03-31 0000802257 us-gaap:SeriesCPreferredStockMember us-gaap:PreferredStockMember 2021-12-31 0000802257 us-gaap:SeriesDPreferredStockMember us-gaap:PreferredStockMember 2021-12-31 0000802257 miti:SeriesXPreferredStockMember us-gaap:PreferredStockMember 2021-12-31 0000802257 us-gaap:CommonStockMember 2021-12-31 0000802257 us-gaap:AdditionalPaidInCapitalMember 2021-12-31 0000802257 miti:StockSubscribedMember 2021-12-31 0000802257 us-gaap:RetainedEarningsMember 2021-12-31 0000802257 2021-12-31 0000802257 us-gaap:AdditionalPaidInCapitalMember 2022-01-01 2022-03-31 0000802257 us-gaap:AccountsPayableMember us-gaap:CommonStockMember 2022-01-01 2022-03-31 0000802257 us-gaap:AccountsPayableMember us-gaap:AdditionalPaidInCapitalMember 2022-01-01 2022-03-31 0000802257 us-gaap:AccountsPayableMember 2022-01-01 2022-03-31 0000802257 us-gaap:CommitmentsMember us-gaap:CommonStockMember 2022-01-01 2022-03-31 0000802257 us-gaap:CommitmentsMember us-gaap:AdditionalPaidInCapitalMember 2022-01-01 2022-03-31 0000802257 us-gaap:CommitmentsMember 2022-01-01 2022-03-31 0000802257 miti:WaiverFeeMember us-gaap:CommonStockMember 2022-01-01 2022-03-31 0000802257 miti:WaiverFeeMember us-gaap:AdditionalPaidInCapitalMember 2022-01-01 2022-03-31 0000802257 miti:WaiverFeeMember miti:StockSubscribedMember 2022-01-01 2022-03-31 0000802257 miti:WaiverFeeMember 2022-01-01 2022-03-31 0000802257 miti:DiamondNote1Member us-gaap:AdditionalPaidInCapitalMember 2022-01-01 2022-03-31 0000802257 miti:DiamondNote1Member 2022-01-01 2022-03-31 0000802257 miti:DiscountOnNotePayableDueToWarrantsMember us-gaap:AdditionalPaidInCapitalMember 2022-01-01 2022-03-31 0000802257 miti:DiscountOnNotePayableDueToWarrantsMember 2022-01-01 2022-03-31 0000802257 us-gaap:CommonStockMember 2022-01-01 2022-03-31 0000802257 miti:SharesPreviouslySubscribedMember us-gaap:CommonStockMember 2022-01-01 2022-03-31 0000802257 miti:SharesPreviouslySubscribedMember us-gaap:AdditionalPaidInCapitalMember 2022-01-01 2022-03-31 0000802257 miti:SharesPreviouslySubscribedMember miti:StockSubscribedMember 2022-01-01 2022-03-31 0000802257 us-gaap:RetainedEarningsMember 2022-01-01 2022-03-31 0000802257 us-gaap:SeriesCPreferredStockMember us-gaap:PreferredStockMember 2022-03-31 0000802257 us-gaap:SeriesDPreferredStockMember us-gaap:PreferredStockMember 2022-03-31 0000802257 miti:SeriesXPreferredStockMember us-gaap:PreferredStockMember 2022-03-31 0000802257 us-gaap:CommonStockMember 2022-03-31 0000802257 us-gaap:AdditionalPaidInCapitalMember 2022-03-31 0000802257 miti:StockSubscribedMember 2022-03-31 0000802257 us-gaap:RetainedEarningsMember 2022-03-31 0000802257 2022-03-31 0000802257 us-gaap:SeriesCPreferredStockMember us-gaap:PreferredStockMember 2022-12-31 0000802257 us-gaap:SeriesDPreferredStockMember us-gaap:PreferredStockMember 2022-12-31 0000802257 miti:SeriesXPreferredStockMember us-gaap:PreferredStockMember 2022-12-31 0000802257 us-gaap:CommonStockMember 2022-12-31 0000802257 us-gaap:AdditionalPaidInCapitalMember 2022-12-31 0000802257 miti:StockSubscribedMember 2022-12-31 0000802257 us-gaap:RetainedEarningsMember 2022-12-31 0000802257 us-gaap:ConvertibleDebtMember us-gaap:CommonStockMember 2023-01-01 2023-03-31 0000802257 us-gaap:ConvertibleDebtMember us-gaap:AdditionalPaidInCapitalMember 2023-01-01 2023-03-31 0000802257 us-gaap:ConvertibleDebtMember 2023-01-01 2023-03-31 0000802257 us-gaap:AdditionalPaidInCapitalMember 2023-01-01 2023-03-31 0000802257 us-gaap:CommonStockMember 2023-01-01 2023-03-31 0000802257 miti:StockIssuedForDividendsPayableMember miti:SeriesXPreferredStockMember us-gaap:CommonStockMember 2023-01-01 2023-03-31 0000802257 miti:StockIssuedForDividendsPayableMember miti:SeriesXPreferredStockMember us-gaap:AdditionalPaidInCapitalMember 2023-01-01 2023-03-31 0000802257 miti:StockIssuedForDividendsPayableMember miti:SeriesXPreferredStockMember 2023-01-01 2023-03-31 0000802257 us-gaap:RetainedEarningsMember 2023-01-01 2023-03-31 0000802257 us-gaap:SeriesCPreferredStockMember us-gaap:PreferredStockMember 2023-03-31 0000802257 us-gaap:SeriesDPreferredStockMember us-gaap:PreferredStockMember 2023-03-31 0000802257 miti:SeriesXPreferredStockMember us-gaap:PreferredStockMember 2023-03-31 0000802257 us-gaap:CommonStockMember 2023-03-31 0000802257 us-gaap:AdditionalPaidInCapitalMember 2023-03-31 0000802257 miti:StockSubscribedMember 2023-03-31 0000802257 us-gaap:RetainedEarningsMember 2023-03-31 0000802257 miti:StockSubscribedMember 2023-01-01 2023-03-31 0000802257 miti:StockSubscribedMember 2022-01-01 2022-03-31 0000802257 us-gaap:AccountsPayableMember 2023-01-01 2023-03-31 0000802257 us-gaap:AccountsPayableMember 2022-01-01 2022-03-31 0000802257 2022-12-12 2022-12-12 0000802257 us-gaap:EmployeeStockOptionMember 2023-01-01 2023-03-31 0000802257 us-gaap:EmployeeStockOptionMember 2022-01-01 2022-03-31 0000802257 us-gaap:WarrantMember 2023-01-01 2023-03-31 0000802257 us-gaap:WarrantMember 2022-01-01 2022-03-31 0000802257 us-gaap:ConvertibleDebtSecuritiesMember us-gaap:PreferredStockMember 2023-01-01 2023-03-31 0000802257 us-gaap:ConvertibleDebtSecuritiesMember us-gaap:PreferredStockMember 2022-01-01 2022-03-31 0000802257 us-gaap:ConvertibleDebtSecuritiesMember miti:AccruedInterestMember 2023-01-01 2023-03-31 0000802257 us-gaap:ConvertibleDebtSecuritiesMember miti:AccruedInterestMember 2022-01-01 2022-03-31 0000802257 miti:SeriesXPreferredStockMember 2023-01-01 2023-03-31 0000802257 srt:OfficerMember miti:SeriesXPreferredStockMember 2023-01-01 2023-03-31 0000802257 us-gaap:MajorityShareholderMember miti:SeriesXPreferredStockMember 2023-01-01 2023-03-31 0000802257 us-gaap:NonrelatedPartyMember miti:SeriesXPreferredStockMember 2023-01-01 2023-03-31 0000802257 miti:DiamondNote1Member 2022-02-14 0000802257 miti:DiamondNote1Member 2022-02-14 2022-02-14 0000802257 miti:DiamondNote1Member us-gaap:MeasurementInputDefaultRateMember 2022-02-14 0000802257 miti:WarrantsAt2500Member miti:DiamondNote1Member 2022-02-14 2022-02-14 0000802257 miti:WarrantsAt2500Member miti:DiamondNote1Member 2022-02-14 0000802257 miti:WarrantsAt3750Member miti:DiamondNote1Member 2022-02-14 2022-02-14 0000802257 miti:WarrantsAt3750Member miti:DiamondNote1Member 2022-02-14 0000802257 miti:SeriesXPreferredStockMember 2022-01-01 2022-03-31 0000802257 srt:OfficerMember miti:SeriesXPreferredStockMember 2022-01-01 2022-03-31 0000802257 us-gaap:MajorityShareholderMember miti:SeriesXPreferredStockMember 2022-01-01 2022-03-31 0000802257 us-gaap:NonrelatedPartyMember miti:SeriesXPreferredStockMember 2022-01-01 2022-03-31 0000802257 2022-01-01 2022-12-31 0000802257 miti:WayzataMinnesotaMember 2023-02-03 2023-02-03 0000802257 miti:WayzataMinnesotaMember 2023-02-03 0000802257 miti:LeaseSettlementMember miti:WayzataMinnesotaMember 2023-02-03 0000802257 miti:WayzataMinnesotaMember 2023-01-01 2023-03-31 0000802257 miti:EagenMinnesotaMember 2023-03-31 0000802257 miti:PPPLoanMember 2020-05-04 0000802257 miti:PPPLoanMember 2022-01-01 2022-12-31 0000802257 miti:PPPLoanMember 2023-01-01 2023-03-31 0000802257 miti:PPPLoanMember 2023-03-31 0000802257 miti:AJBCapitalNoteMember us-gaap:CommitmentsMember 2022-03-18 2022-03-18 0000802257 miti:AJBCapitalNoteMember 2022-03-18 0000802257 miti:AJBCapitalNoteMember 2022-11-18 0000802257 miti:AJBCapitalNoteMember 2022-03-18 2022-03-18 0000802257 miti:AJBCapitalNoteMember miti:OriginalIssueDiscountMember 2022-03-18 0000802257 srt:MinimumMember miti:AJBCapitalNoteMember 2022-03-18 0000802257 miti:AJBCapitalNoteMember us-gaap:MeasurementInputDefaultRateMember 2022-03-18 0000802257 miti:AJBCapitalNoteMember 2022-01-01 2022-12-31 0000802257 miti:AJBCapitalNoteMember 2022-12-31 0000802257 miti:AJBCapitalNoteMember miti:DefaultPenaltyMember 2023-03-31 0000802257 miti:AJBCapitalNoteMember 2023-03-31 0000802257 miti:AJBCapitalNoteMember 2023-01-01 2023-03-31 0000802257 miti:AnsonInvestmentsNoteMember 2022-04-06 2022-04-06 0000802257 miti:AnsonInvestmentsNoteMember 2022-04-06 0000802257 miti:AnsonInvestmentsNoteMember miti:OriginalIssueDiscountMember 2022-04-06 0000802257 srt:MinimumMember miti:AnsonInvestmentsNoteMember 2022-04-06 0000802257 miti:AnsonInvestmentsNoteMember us-gaap:MeasurementInputDefaultRateMember 2022-04-06 0000802257 miti:AnsonInvestmentsNoteMember 2022-01-01 2022-12-31 0000802257 miti:AnsonInvestmentsNoteMember 2022-12-31 0000802257 miti:AnsonInvestmentsNoteMember miti:DefaultPenaltyMember 2023-03-31 0000802257 miti:AnsonInvestmentsNoteMember 2023-03-31 0000802257 miti:AnsonInvestmentsNoteMember 2023-01-01 2023-03-31 0000802257 miti:AnsonEastNoteMember 2022-04-06 2022-04-06 0000802257 miti:AnsonEastNoteMember 2022-04-06 0000802257 miti:AnsonEastNoteMember miti:OriginalIssueDiscountMember 2022-04-06 0000802257 srt:MinimumMember miti:AnsonEastNoteMember 2022-04-06 0000802257 miti:AnsonEastNoteMember us-gaap:MeasurementInputDefaultRateMember 2022-04-06 0000802257 miti:AnsonEastNoteMember 2022-01-01 2022-12-31 0000802257 miti:AnsonEastNoteMember 2022-12-31 0000802257 miti:AnsonEastNoteMember miti:DefaultPenaltyMember 2023-03-31 0000802257 miti:AnsonEastNoteMember 2023-03-31 0000802257 miti:AnsonEastNoteMember 2023-01-01 2023-03-31 0000802257 miti:GSCapitalNoteMember 2022-04-18 2022-04-18 0000802257 miti:GSCapitalNoteMember 2022-04-18 0000802257 srt:MinimumMember miti:GSCapitalNoteMember 2022-04-18 0000802257 miti:GSCapitalNoteMember us-gaap:MeasurementInputDefaultRateMember 2022-04-18 0000802257 miti:GSCapitalNoteMember 2022-01-01 2022-12-31 0000802257 miti:GSCapitalNoteMember 2022-12-31 0000802257 miti:GSCapitalNoteMember 2023-01-01 2023-03-31 0000802257 miti:AccruedInterestMember miti:GSCapitalNoteMember 2023-01-01 2023-03-31 0000802257 miti:FeesMember miti:GSCapitalNoteMember 2023-01-01 2023-03-31 0000802257 miti:GSCapitalNoteMember 2023-03-31 0000802257 miti:GSCapitalNoteMember miti:DefaultPenaltyMember 2023-03-31 0000802257 miti:KishonNoteMember 2022-05-10 2022-05-10 0000802257 miti:KishonNoteMember 2022-05-10 0000802257 miti:KishonNoteMember miti:OriginalIssueDiscountMember 2022-05-10 0000802257 srt:MinimumMember miti:KishonNoteMember 2022-05-10 0000802257 miti:KishonNoteMember us-gaap:MeasurementInputDefaultRateMember 2022-05-10 0000802257 miti:KishonNoteMember 2022-01-01 2022-12-31 0000802257 miti:KishonNoteMember 2022-12-31 0000802257 miti:KishonNoteMember miti:DefaultPenaltyMember 2023-03-31 0000802257 miti:KishonNoteMember 2023-03-31 0000802257 miti:KishonNoteMember 2023-01-01 2023-03-31 0000802257 miti:FinneganNote1Member 2022-05-23 0000802257 miti:FinneganNote1Member 2022-05-23 2022-05-23 0000802257 miti:FinneganNote1Member us-gaap:MeasurementInputDefaultRateMember 2022-05-23 0000802257 miti:FinneganNote1Member 2022-01-01 2022-12-31 0000802257 miti:FinneganNote1Member 2022-12-31 0000802257 miti:FinneganNote1Member 2023-01-01 2023-03-31 0000802257 miti:FinneganNote1Member 2023-03-31 0000802257 miti:MDiamondNoteMember 2022-04-26 0000802257 miti:MDiamondNoteMember 2022-04-26 2022-04-26 0000802257 miti:MDiamondNoteMember us-gaap:MeasurementInputDefaultRateMember 2022-04-26 0000802257 miti:MDiamondNoteMember 2022-01-01 2022-12-31 0000802257 miti:MDiamondNoteMember 2022-12-31 0000802257 miti:MDiamondNoteMember 2023-01-01 2023-03-31 0000802257 miti:MDiamondNoteMember 2023-03-31 0000802257 miti:FinneganNote2Member 2022-05-26 0000802257 miti:FinneganNote2Member 2022-05-26 2022-05-26 0000802257 miti:FinneganNote2Member us-gaap:MeasurementInputDefaultRateMember 2022-05-26 0000802257 miti:FinneganNote2Member 2022-01-01 2022-12-31 0000802257 miti:FinneganNote2Member 2022-12-31 0000802257 miti:FinneganNote2Member 2023-01-01 2023-03-31 0000802257 miti:FinneganNote2Member 2023-03-31 0000802257 miti:DragonNoteMember 2022-06-09 0000802257 miti:DragonNoteMember 2022-06-09 2022-06-09 0000802257 miti:DragonNoteMember us-gaap:MeasurementInputDefaultRateMember 2022-06-09 0000802257 miti:DragonNoteMember 2022-01-01 2022-12-31 0000802257 miti:DragonNoteMember 2022-12-31 0000802257 miti:DragonNoteMember 2023-01-01 2023-03-31 0000802257 miti:DragonNoteMember 2023-03-31 0000802257 miti:MackayNoteMember 2022-07-07 0000802257 miti:MackayNoteMember 2022-07-07 2022-07-07 0000802257 miti:MackayNoteMember us-gaap:MeasurementInputDefaultRateMember 2022-07-07 0000802257 miti:MackayNoteMember 2022-01-01 2022-12-31 0000802257 miti:MackayNoteMember 2022-12-31 0000802257 miti:MackayNoteMember 2023-01-01 2023-03-31 0000802257 miti:MackayNoteMember 2023-03-31 0000802257 miti:SchrierNoteMember 2022-07-07 0000802257 miti:SchrierNoteMember 2022-07-07 2022-07-07 0000802257 miti:SchrierNoteMember us-gaap:MeasurementInputDefaultRateMember 2022-07-07 0000802257 miti:SchrierNoteMember 2022-01-01 2022-12-31 0000802257 miti:SchrierNoteMember 2022-12-31 0000802257 miti:SchrierNoteMember 2023-01-01 2023-03-31 0000802257 miti:SchrierNoteMember 2023-03-31 0000802257 miti:NommsenNoteMember 2022-07-26 0000802257 miti:NommsenNoteMember 2022-07-26 2022-07-26 0000802257 miti:NommsenNoteMember us-gaap:MeasurementInputDefaultRateMember 2022-07-26 0000802257 miti:NommsenNoteMember 2022-01-01 2022-12-31 0000802257 miti:NommsenNoteMember 2022-12-31 0000802257 miti:NommsenNoteMember 2023-01-01 2023-03-31 0000802257 miti:NommsenNoteMember 2023-03-31 0000802257 miti:CaplanNoteMember 2022-07-27 0000802257 miti:CaplanNoteMember 2022-07-27 2022-07-27 0000802257 miti:CaplanNoteMember us-gaap:MeasurementInputDefaultRateMember 2022-07-27 0000802257 miti:CaplanNoteMember 2022-01-01 2022-12-31 0000802257 miti:CaplanNoteMember 2022-12-31 0000802257 miti:CaplanNoteMember 2023-01-01 2023-03-31 0000802257 miti:CaplanNoteMember 2023-03-31 0000802257 miti:FinneganNote3Member 2022-08-04 0000802257 miti:FinneganNote3Member 2022-08-04 2022-08-04 0000802257 miti:FinneganNote3Member us-gaap:MeasurementInputDefaultRateMember 2022-08-04 0000802257 miti:FinneganNote3Member 2022-01-01 2022-12-31 0000802257 miti:FinneganNote3Member 2022-12-31 0000802257 miti:FinneganNote3Member 2023-01-01 2023-03-31 0000802257 miti:FinneganNote3Member 2023-03-31 0000802257 miti:EnrightNoteMember 2022-08-04 0000802257 miti:EnrightNoteMember 2022-08-04 2022-08-04 0000802257 miti:EnrightNoteMember us-gaap:MeasurementInputDefaultRateMember 2022-08-04 0000802257 miti:EnrightNoteMember 2022-01-01 2022-12-31 0000802257 miti:EnrightNoteMember 2022-12-31 0000802257 miti:EnrightNoteMember 2023-01-01 2023-03-31 0000802257 miti:EnrightNoteMember 2023-03-31 0000802257 miti:MitchellNoteMember 2022-09-02 0000802257 miti:MitchellNoteMember 2022-09-02 2022-09-02 0000802257 miti:MitchellNoteMember us-gaap:MeasurementInputDefaultRateMember 2022-09-02 0000802257 miti:MitchellNoteMember 2022-01-01 2022-12-31 0000802257 miti:MitchellNoteMember 2022-12-31 0000802257 miti:MitchellNoteMember 2023-01-01 2023-03-31 0000802257 miti:MitchellNoteMember 2023-03-31 0000802257 miti:LightmasNoteMember 2022-09-02 0000802257 miti:LightmasNoteMember 2022-09-02 2022-09-02 0000802257 miti:LightmasNoteMember us-gaap:MeasurementInputDefaultRateMember 2022-09-02 0000802257 miti:LightmasNoteMember 2022-01-01 2022-12-31 0000802257 miti:LightmasNoteMember 2022-12-31 0000802257 miti:LightmasNoteMember 2023-01-01 2023-03-31 0000802257 miti:LightmasNoteMember 2023-03-31 0000802257 miti:LewisNoteMember 2022-09-02 0000802257 miti:LewisNoteMember 2022-09-02 2022-09-02 0000802257 miti:LewisNoteMember us-gaap:MeasurementInputDefaultRateMember 2022-09-02 0000802257 miti:LewisNoteMember 2022-01-01 2022-12-31 0000802257 miti:LewisNoteMember 2022-12-31 0000802257 miti:LewisNoteMember 2023-01-01 2023-03-31 0000802257 miti:LewisNoteMember 2023-03-31 0000802257 miti:GoffNoteMember 2022-09-02 0000802257 miti:GoffNoteMember 2022-09-02 2022-09-02 0000802257 miti:GoffNoteMember us-gaap:MeasurementInputDefaultRateMember 2022-09-02 0000802257 miti:GoffNoteMember 2022-01-01 2022-12-31 0000802257 miti:GoffNoteMember 2022-12-31 0000802257 miti:GoffNoteMember 2023-01-01 2023-03-31 0000802257 miti:GoffNoteMember 2023-03-31 0000802257 miti:HaganNoteMember 2022-09-02 0000802257 miti:HaganNoteMember 2022-09-02 2022-09-02 0000802257 miti:HaganNoteMember us-gaap:MeasurementInputDefaultRateMember 2022-09-02 0000802257 miti:HaganNoteMember 2022-01-01 2022-12-31 0000802257 miti:HaganNoteMember 2022-12-31 0000802257 miti:HaganNoteMember 2023-01-01 2023-03-31 0000802257 miti:HaganNoteMember 2023-03-31 0000802257 miti:DarlingNoteMember 2022-09-14 0000802257 miti:DarlingNoteMember 2022-09-14 2022-09-14 0000802257 miti:DarlingNoteMember us-gaap:MeasurementInputDefaultRateMember 2022-09-14 0000802257 miti:DarlingNoteMember 2022-01-01 2022-12-31 0000802257 miti:DarlingNoteMember 2022-12-31 0000802257 miti:DarlingNoteMember 2023-01-01 2023-03-31 0000802257 miti:DarlingNoteMember 2023-03-31 0000802257 miti:LeathNoteMember 2022-09-15 0000802257 miti:LeathNoteMember 2022-09-15 2022-09-15 0000802257 miti:LeathNoteMember us-gaap:MeasurementInputDefaultRateMember 2022-09-15 0000802257 miti:LeathNoteMember 2022-01-01 2022-12-31 0000802257 miti:LeathNoteMember 2022-12-31 0000802257 miti:LeathNoteMember 2023-01-01 2023-03-31 0000802257 miti:LeathNoteMember 2023-03-31 0000802257 miti:CavalryNoteMember 2022-10-05 0000802257 miti:CavalryNoteMember us-gaap:SeriesCPreferredStockMember 2022-10-05 0000802257 miti:CavalryNoteMember us-gaap:SeriesDPreferredStockMember 2022-10-05 0000802257 miti:CavalryNoteMember us-gaap:MeasurementInputDefaultRateMember 2022-10-05 0000802257 miti:CavalryNoteMember 2022-01-01 2022-12-31 0000802257 miti:CavalryNoteMember 2022-12-31 0000802257 miti:CavalryExchangeAgreementMember us-gaap:SeriesCPreferredStockMember 2022-12-31 0000802257 miti:CavalryExchangeAgreementMember us-gaap:SeriesDPreferredStockMember 2022-12-31 0000802257 miti:CavalryNoteMember 2023-01-01 2023-03-31 0000802257 miti:CavalryNoteMember 2023-03-31 0000802257 miti:MercerNote1Member 2022-10-07 0000802257 miti:MercerNote1Member 2022-10-07 2022-10-07 0000802257 miti:MercerNote1Member us-gaap:SeriesCPreferredStockMember 2022-10-07 0000802257 miti:MercerNote1Member us-gaap:SeriesDPreferredStockMember 2022-10-07 0000802257 miti:MercerNote1Member us-gaap:MeasurementInputDefaultRateMember 2022-10-07 0000802257 miti:MercerNote1Member 2022-01-01 2022-12-31 0000802257 miti:MercerNote1Member 2022-12-31 0000802257 miti:MercerExchangeAgreementMember us-gaap:SeriesCPreferredStockMember 2022-12-31 0000802257 miti:MercerExchangeAgreementMember us-gaap:SeriesDPreferredStockMember 2022-12-31 0000802257 miti:MercerNote1Member 2023-01-01 2023-03-31 0000802257 miti:MercerNote1Member 2023-03-31 0000802257 miti:PinzNoteMember 2022-10-10 0000802257 miti:PinzNoteMember 2022-10-10 2022-10-10 0000802257 miti:PinzNoteMember us-gaap:SeriesDPreferredStockMember 2022-10-10 0000802257 miti:PinzNoteMember us-gaap:MeasurementInputDefaultRateMember 2022-10-10 0000802257 miti:PinzNoteMember 2022-01-01 2022-12-31 0000802257 miti:PinzNoteMember 2022-12-31 0000802257 miti:PinzExchangeAgreementMember 2022-12-31 0000802257 miti:PinzNoteMember 2023-01-01 2023-03-31 0000802257 miti:PinzNoteMember 2023-03-31 0000802257 miti:MercerNote2Member 2022-10-24 0000802257 miti:MercerNote2Member 2022-10-24 2022-10-24 0000802257 miti:MercerNote2Member us-gaap:MeasurementInputDefaultRateMember 2022-10-24 0000802257 miti:MercerNote2Member 2022-12-02 0000802257 miti:MercerNote2Member 2022-01-01 2022-12-31 0000802257 miti:MercerNote2Member 2022-12-31 0000802257 miti:MercerNote2Member 2023-01-01 2023-03-31 0000802257 miti:MercerNote2Member 2023-03-31 0000802257 miti:MercerNote3Member 2022-12-02 0000802257 miti:MercerNote3Member 2022-12-02 2022-12-02 0000802257 miti:MercerNote3Member us-gaap:MeasurementInputDefaultRateMember 2022-12-02 0000802257 miti:MercerNote3Member 2022-10-24 0000802257 miti:MercerNote3Member 2022-01-01 2022-12-31 0000802257 miti:MercerNote3Member 2022-12-31 0000802257 miti:MercerNote3Member 2023-01-01 2023-03-31 0000802257 miti:MercerNote3Member 2023-03-31 0000802257 us-gaap:NotesPayableOtherPayablesMember 2023-03-31 0000802257 us-gaap:NotesPayableOtherPayablesMember 2022-12-31 0000802257 miti:HoweNoteMember 2021-12-30 0000802257 miti:HoweNoteMember 2021-12-30 2021-12-30 0000802257 miti:HoweNoteMember us-gaap:MeasurementInputDefaultRateMember 2021-12-30 0000802257 miti:HoweNoteMember 2022-01-01 2022-12-31 0000802257 miti:HoweNoteMember 2022-12-31 0000802257 miti:HoweNoteMember 2023-01-01 2023-03-31 0000802257 miti:HoweNoteMember 2023-03-31 0000802257 miti:DiamondNote1Member 2022-02-24 0000802257 miti:DiamondNote1Member 2022-02-24 2022-02-24 0000802257 miti:DiamondNote1Member us-gaap:MeasurementInputDefaultRateMember 2022-02-24 0000802257 miti:DiamondNote1Member 2022-01-01 2022-12-31 0000802257 miti:DiamondNote1Member 2022-12-31 0000802257 miti:DiamondNote1Member 2023-01-01 2023-03-31 0000802257 miti:DiamondNote1Member 2023-03-31 0000802257 miti:DiamondNote2Member 2022-03-18 0000802257 miti:DiamondNote2Member 2022-03-18 2022-03-18 0000802257 miti:DiamondNote2Member us-gaap:MeasurementInputDefaultRateMember 2022-03-18 0000802257 miti:DiamondNote2Member 2022-01-01 2022-12-31 0000802257 miti:DiamondNote2Member 2022-12-31 0000802257 miti:DiamondNote2Member 2023-01-01 2023-03-31 0000802257 miti:DiamondNote2Member 2023-03-31 0000802257 miti:DiamondNote3Member 2022-04-27 0000802257 miti:DiamondNote3Member 2022-04-27 2022-04-27 0000802257 miti:DiamondNote3Member us-gaap:MeasurementInputDefaultRateMember 2022-04-27 0000802257 miti:DiamondNote3Member 2022-01-01 2022-12-31 0000802257 miti:DiamondNote3Member 2022-12-31 0000802257 miti:DiamondNote3Member 2023-01-01 2023-03-31 0000802257 miti:DiamondNote3Member 2023-03-31 0000802257 miti:DiamondNote4Member 2022-05-18 0000802257 miti:DiamondNote4Member 2022-05-18 2022-05-18 0000802257 miti:DiamondNote4Member us-gaap:MeasurementInputDefaultRateMember 2022-05-18 0000802257 miti:DiamondNote4Member 2022-01-01 2022-12-31 0000802257 miti:DiamondNote4Member 2022-12-31 0000802257 miti:DiamondNote4Member 2023-01-01 2023-03-31 0000802257 miti:DiamondNote4Member 2023-03-31 0000802257 miti:DiamondNote5Member 2022-05-26 0000802257 miti:DiamondNote5Member 2022-05-26 2022-05-26 0000802257 miti:DiamondNote5Member us-gaap:MeasurementInputDefaultRateMember 2022-05-26 0000802257 miti:DiamondNote5Member 2022-01-01 2022-12-31 0000802257 miti:DiamondNote5Member 2022-12-31 0000802257 miti:DiamondNote5Member 2023-01-01 2023-03-31 0000802257 miti:DiamondNote5Member 2023-03-31 0000802257 miti:LindstromNote1Member 2022-05-26 0000802257 miti:LindstromNote1Member 2022-05-26 2022-05-26 0000802257 miti:LindstromNote1Member us-gaap:MeasurementInputDefaultRateMember 2022-05-26 0000802257 miti:LindstromNote1Member 2022-01-01 2022-12-31 0000802257 miti:LindstromNote1Member 2022-12-31 0000802257 miti:LindstromNote1Member 2023-01-01 2023-03-31 0000802257 miti:LindstromNote1Member 2023-03-31 0000802257 miti:DobbertinNote1Member 2022-05-26 0000802257 miti:DobbertinNote1Member 2022-05-26 2022-05-26 0000802257 miti:DobbertinNote1Member us-gaap:MeasurementInputDefaultRateMember 2022-05-26 0000802257 miti:DobbertinNote1Member 2022-01-01 2022-12-31 0000802257 miti:DobbertinNote1Member 2022-12-31 0000802257 miti:DobbertinNote1Member 2023-01-01 2023-03-31 0000802257 miti:DobbertinNote1Member 2023-03-31 0000802257 miti:HoweNote2Member 2022-06-09 0000802257 miti:HoweNote2Member 2022-06-09 2022-06-09 0000802257 miti:HoweNote2Member us-gaap:MeasurementInputDefaultRateMember 2022-06-09 0000802257 miti:HoweNote2Member 2022-01-01 2022-12-31 0000802257 miti:HoweNote2Member 2022-12-31 0000802257 miti:HoweNote2Member 2023-01-01 2023-03-31 0000802257 miti:HoweNote2Member 2023-03-31 0000802257 miti:HoweNote3Member 2022-07-21 0000802257 miti:HoweNote3Member 2022-07-21 2022-07-21 0000802257 miti:HoweNote3Member us-gaap:MeasurementInputDefaultRateMember 2022-07-21 0000802257 miti:HoweNote3Member 2022-01-01 2022-12-31 0000802257 miti:HoweNote3Member 2022-12-31 0000802257 miti:HoweNote3Member 2023-01-01 2023-03-31 0000802257 miti:HoweNote3Member 2023-03-31 0000802257 miti:IturreguiNoteMember 2022-07-21 0000802257 miti:IturreguiNoteMember 2022-07-21 2022-07-21 0000802257 miti:IturreguiNoteMember us-gaap:MeasurementInputDefaultRateMember 2022-07-21 0000802257 miti:IturreguiNoteMember 2022-01-01 2022-12-31 0000802257 miti:IturreguiNoteMember 2022-12-31 0000802257 miti:IturreguiNoteMember 2023-01-01 2023-03-31 0000802257 miti:IturreguiNoteMember 2023-03-31 0000802257 miti:HoweNote4Member 2022-08-18 0000802257 miti:HoweNote4Member 2022-08-18 2022-08-18 0000802257 miti:HoweNote4Member us-gaap:MeasurementInputDefaultRateMember 2022-08-18 0000802257 miti:HoweNote4Member 2022-01-01 2022-12-31 0000802257 miti:HoweNote4Member 2022-12-31 0000802257 miti:HoweNote4Member 2023-01-01 2023-03-31 0000802257 miti:HoweNote4Member 2023-03-31 0000802257 miti:November292022NotesMember 2022-11-29 2022-11-29 0000802257 miti:November292022NotesMember us-gaap:MeasurementInputDefaultRateMember 2022-11-29 0000802257 miti:November292022NotesMember 2022-11-29 0000802257 miti:November292022NotesMember 2022-01-01 2022-12-31 0000802257 miti:November292022NotesMember 2022-12-31 0000802257 miti:November292022NotesMember 2023-01-01 2023-03-31 0000802257 miti:November292022NotesMember 2023-03-31 0000802257 srt:MinimumMember 2022-01-01 2022-12-31 0000802257 srt:MaximumMember 2022-01-01 2022-12-31 0000802257 srt:MinimumMember 2022-12-31 0000802257 srt:MaximumMember 2022-12-31 0000802257 srt:MinimumMember 2023-01-01 2023-03-31 0000802257 srt:MaximumMember 2023-01-01 2023-03-31 0000802257 2023-01-23 2023-01-23 0000802257 2023-01-23 0000802257 2023-02-21 2023-02-21 0000802257 2023-02-21 0000802257 miti:PrincipalMember miti:GSCapitalNoteMember 2023-02-14 2023-02-14 0000802257 miti:AccruedInterestMember miti:GSCapitalNoteMember 2023-02-14 2023-02-14 0000802257 miti:FeesMember miti:GSCapitalNoteMember 2023-02-14 2023-02-14 0000802257 miti:GSCapitalNoteMember 2023-02-14 0000802257 miti:GSCapitalNoteMember 2023-02-14 2023-02-14 0000802257 miti:PrincipalMember miti:GSCapitalNoteMember 2023-02-28 2023-02-28 0000802257 miti:AccruedInterestMember miti:GSCapitalNoteMember 2023-02-28 2023-02-28 0000802257 miti:FeesMember miti:GSCapitalNoteMember 2023-02-28 2023-02-28 0000802257 miti:GSCapitalNoteMember 2023-02-28 0000802257 2023-02-28 2023-02-28 0000802257 miti:PrincipalMember miti:GSCapitalNoteMember 2023-03-09 2023-03-09 0000802257 miti:AccruedInterestMember miti:GSCapitalNoteMember 2023-03-09 2023-03-09 0000802257 miti:FeesMember miti:GSCapitalNoteMember 2023-03-09 2023-03-09 0000802257 miti:GSCapitalNoteMember 2023-03-09 0000802257 miti:GSCapitalNoteMember 2023-03-09 2023-03-09 0000802257 miti:PrincipalMember miti:GSCapitalNoteMember 2023-03-28 2023-03-28 0000802257 miti:AccruedInterestMember miti:GSCapitalNoteMember 2023-03-28 2023-03-28 0000802257 miti:FeesMember miti:GSCapitalNoteMember 2023-03-28 2023-03-28 0000802257 miti:GSCapitalNoteMember 2023-03-28 0000802257 miti:GSCapitalNoteMember 2023-03-28 2023-03-28 0000802257 miti:SeriesXPreferredStockMember 2023-01-01 2023-03-31 0000802257 miti:SeriesXPreferredStockMember srt:OfficerMember 2023-01-01 2023-03-31 0000802257 miti:SeriesXPreferredStockMember us-gaap:MajorityShareholderMember 2023-01-01 2023-03-31 0000802257 miti:SeriesXPreferredStockMember us-gaap:NonrelatedPartyMember 2023-01-01 2023-03-31 0000802257 2022-01-12 0000802257 2022-01-12 2022-01-12 0000802257 miti:GardnerAgreementMember 2022-01-05 2022-01-05 0000802257 miti:GardnerAgreementMember 2022-01-05 0000802257 miti:GardnerAgreementMember us-gaap:RestrictedStockMember 2022-01-05 2022-01-05 0000802257 miti:WaiverFeeMember 2022-03-22 2022-03-31 0000802257 miti:WaiverFeeMember 2022-01-01 2022-09-30 0000802257 miti:AJBCapitalInvestorsMember 2022-03-31 2022-03-31 0000802257 miti:AJBCapitalInvestorsMember us-gaap:MarketApproachValuationTechniqueMember 2022-03-31 0000802257 miti:AJBCapitalNoteMember 2022-03-31 0000802257 miti:AJBCapitalNoteMember miti:WarrantAndCommitmentFeesMember miti:AJBCapitalInvestorsMember 2022-03-31 0000802257 miti:StockSubscribedMember 2022-03-31 2022-03-31 0000802257 us-gaap:AccountsPayableMember miti:StockSubscribedMember 2022-03-31 2022-03-31 0000802257 us-gaap:SeriesEPreferredStockMember 2023-03-31 0000802257 us-gaap:SeriesFPreferredStockMember 2023-03-31 0000802257 us-gaap:SeriesCPreferredStockMember 2023-01-01 2023-03-31 0000802257 us-gaap:SeriesCPreferredStockMember 2022-01-01 2022-03-31 0000802257 us-gaap:SeriesDPreferredStockMember 2023-01-01 2023-03-31 0000802257 us-gaap:SeriesDPreferredStockMember 2022-01-01 2022-03-31 0000802257 us-gaap:SeriesEPreferredStockMember 2022-11-07 0000802257 2022-11-07 2022-11-07 0000802257 2022-11-07 0000802257 us-gaap:SeriesFPreferredStockMember 2023-03-23 0000802257 us-gaap:SeriesFPreferredStockMember 2023-03-23 2023-03-23 0000802257 miti:TheGoodClinicMember us-gaap:SeriesAPreferredStockMember 2023-01-01 2023-03-31 0000802257 us-gaap:EmployeeStockOptionMember 2023-03-31 0000802257 us-gaap:FairValueInputsLevel1Member 2023-03-31 0000802257 us-gaap:FairValueInputsLevel2Member 2023-03-31 0000802257 us-gaap:FairValueInputsLevel3Member 2023-03-31 0000802257 us-gaap:FairValueInputsLevel1Member 2022-03-31 0000802257 us-gaap:FairValueInputsLevel2Member 2022-03-31 0000802257 us-gaap:FairValueInputsLevel3Member 2022-03-31 0000802257 miti:PaidToPlaintiffMember 2022-10-25 0000802257 miti:PaidToCEOMember 2022-10-25 0000802257 miti:PaidToCEOMember 2022-10-25 2022-10-25 0000802257 us-gaap:SubsequentEventMember 2023-04-04 2023-04-04 0000802257 us-gaap:SubsequentEventMember 2023-04-04 0000802257 us-gaap:SubsequentEventMember 2023-04-05 2023-04-05 0000802257 us-gaap:SubsequentEventMember 2023-04-05 0000802257 us-gaap:SubsequentEventMember 2023-05-05 2023-05-05 0000802257 us-gaap:SubsequentEventMember 2023-05-05 0000802257 us-gaap:RelatedPartyMember us-gaap:SubsequentEventMember 2023-05-09 2023-05-09 0000802257 us-gaap:SubsequentEventMember 2023-05-09 0000802257 us-gaap:SubsequentEventMember 2023-06-09 2023-06-09 0000802257 us-gaap:SubsequentEventMember 2023-06-09 0000802257 srt:OfficerMember us-gaap:SubsequentEventMember 2023-06-09 2023-06-09 0000802257 miti:FormerDirectorMember us-gaap:SubsequentEventMember 2023-06-09 2023-06-09 0000802257 us-gaap:RelatedPartyMember us-gaap:SubsequentEventMember 2023-06-09 2023-06-09 0000802257 us-gaap:SubsequentEventMember 2023-06-29 2023-06-29 0000802257 us-gaap:SubsequentEventMember 2023-06-29 0000802257 us-gaap:AccountsPayableMember us-gaap:SubsequentEventMember 2023-06-29 2023-06-29 0000802257 us-gaap:SubsequentEventMember 2023-08-29 2023-08-29 0000802257 us-gaap:SubsequentEventMember 2023-08-29 0000802257 miti:PPPLoanMember us-gaap:SubsequentEventMember 2023-07-12 2023-07-12 0000802257 miti:PPPLoanMember us-gaap:SubsequentEventMember 2023-07-12 0000802257 us-gaap:SeriesFPreferredStockMember us-gaap:SubsequentEventMember 2023-04-11 0000802257 us-gaap:SubsequentEventMember 2023-04-11 0000802257 miti:SPA1Member us-gaap:SeriesFPreferredStockMember us-gaap:SubsequentEventMember 2023-04-11 2023-04-11 0000802257 miti:SPA1Member us-gaap:SeriesFPreferredStockMember us-gaap:SubsequentEventMember 2023-04-11 0000802257 miti:SPA2Member us-gaap:SeriesFPreferredStockMember us-gaap:SubsequentEventMember 2023-04-11 2023-04-11 0000802257 miti:SPA2Member us-gaap:SeriesFPreferredStockMember us-gaap:SubsequentEventMember 2023-04-11 0000802257 miti:SPA3Member us-gaap:SeriesFPreferredStockMember us-gaap:SubsequentEventMember 2023-04-11 2023-04-11 0000802257 miti:SPA3Member us-gaap:SeriesFPreferredStockMember us-gaap:SubsequentEventMember 2023-04-11 0000802257 us-gaap:SeriesFPreferredStockMember us-gaap:SubsequentEventMember 2023-06-30 2023-06-30 0000802257 us-gaap:SeriesFPreferredStockMember us-gaap:SubsequentEventMember 2023-06-30 0000802257 us-gaap:SeriesFPreferredStockMember 2023-04-11 0000802257 us-gaap:SeriesFPreferredStockMember us-gaap:SubsequentEventMember 2023-04-11 2023-04-11 0000802257 us-gaap:SubsequentEventMember 2023-04-11 2023-04-11 0000802257 us-gaap:SeriesCPreferredStockMember us-gaap:SubsequentEventMember 2023-04-11 2023-04-11 0000802257 us-gaap:SeriesDPreferredStockMember us-gaap:SubsequentEventMember 2023-04-11 2023-04-11 0000802257 us-gaap:AccountsPayableMember us-gaap:SubsequentEventMember 2023-04-11 2023-04-11 0000802257 miti:SheilaSchweitzerMember us-gaap:SubsequentEventMember 2023-06-01 2023-06-01 xbrli:shares iso4217:USD iso4217:USD xbrli:shares xbrli:pure

EXHIBIT 31.1

 

CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER

AND PRINCIPAL FINANCIAL OFFICER

PURSUANT TO RULE 13a-14 OR RULE 15d-14 OF THE SECURITIES EXCHANGE ACT OF 1934,

AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

 

 

I, Lawrence Diamond, certify that:

 

1.

I have reviewed this quarterly report on Form 10-Q of Mitesco, Inc.;

 

2.

Based on my knowledge, this annual report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this annual report;

 

3.

Based on my knowledge, the financial statements, and other financial information included in this annual report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this annual report;

 

4.

I am responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

 

a)

Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this annual report is being prepared;

 

b)

Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

 

c)

Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this annual report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this annual report based on such evaluation; and

 

d)

Disclosed in this annual report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

 

5.

I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s Board of Directors (or persons performing the equivalent functions):

 

a)

All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

 

b)

Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

 

 

Date: October 4, 2023

 

 

 

/s/ Lawrence Diamond

Lawrence Diamond

Chief Executive Officer and Principal Executive Officer


 

 

EXHIBIT 31.2

 

CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER

AND PRINCIPAL FINANCIAL OFFICER

PURSUANT TO RULE 13a-14 OR RULE 15d-14 OF THE SECURITIES EXCHANGE ACT OF 1934,

AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

 

 

I, Thomas Brodmerkel, certify that:

 

1.

I have reviewed this quarterly report on Form 10-Q of Mitesco, Inc.;

 

2.

Based on my knowledge, this annual report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this annual report;

 

3.

Based on my knowledge, the financial statements, and other financial information included in this annual report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this annual report;

 

4.

I am responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

 

a)

Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this annual report is being prepared;

 

b)

Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

 

c)

Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this annual report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this annual report based on such evaluation; and

 

d)

Disclosed in this annual report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

 

5.

I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s Board of Directors (or persons performing the equivalent functions):

 

a)

All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

 

b)

Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

 

 

Date: October 4, 2023

 

 

 

/s/ Thomas Brodmerkel                                                            

Thomas Brodmerkel

Chief Financial Officer and Principal Financial Officer

 

 

EXHIBIT 32.1

 

CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

 

 

In connection with the quarterly report of Mitesco, Inc. (the “Company”) on Form 10-Q for the three months ended March 31, 2023, as filed with the Securities and Exchange Commission on the date hereof, I, Lawrence Diamond, Chief Executive Officer and Director of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to my knowledge:

 

1.

The quarterly report on Form 10-Q fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

 

2.

The information contained in the report fairly presents, in all material respects, the financial condition and results of operations of the Company.

 

 

Date: October 4, 2023

 

 

/s/ Lawrence Diamond

Lawrence Diamond

Chief Executive Officer and Principal Executive Officer

 

 

 

 

EXHIBIT 32.2

 

CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

 

 

In connection with the quarterly report of Mitesco, Inc. (the “Company”) on Form 10-Q for the three months ended March 31, 2023, as filed with the Securities and Exchange Commission on the date hereof, I, Thomas Brodmerkel, Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to my knowledge:

 

1.

The quarterly report on Form 10-Q fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

 

2.

The information contained in the report fairly presents, in all material respects, the financial condition and results of operations of the Company.

 

 

Date: October 4, 2023

 

 

/s/ Thomas Brodmerkel

Thomas Brodmerkel

Chief Financial Officer and Principal Financial Officer

 

 

 
v3.23.3
Document And Entity Information - shares
3 Months Ended
Mar. 31, 2023
Sep. 25, 2023
Document Information Line Items    
Entity Registrant Name MITESCO, INC.  
Trading Symbol N/A  
Document Type 10-Q  
Current Fiscal Year End Date --12-31  
Entity Common Stock, Shares Outstanding   5,310,761
Amendment Flag false  
Entity Central Index Key 0000802257  
Entity Current Reporting Status No  
Entity Filer Category Non-accelerated Filer  
Document Period End Date Mar. 31, 2023  
Document Fiscal Year Focus 2023  
Document Fiscal Period Focus Q1  
Entity Small Business true  
Entity Emerging Growth Company false  
Entity Shell Company false  
Document Quarterly Report true  
Document Transition Report false  
Entity File Number 000-53601  
Entity Incorporation, State or Country Code DE  
Entity Tax Identification Number 87-0496850  
Entity Address, Address Line One 18202 Minnetonka Blvd., Suite 100  
Entity Address, City or Town Deephaven  
Entity Address, State or Province MN  
Entity Address, Postal Zip Code 55391  
City Area Code 844  
Local Phone Number 844-383-8689  
Title of 12(b) Security N/A  
Security Exchange Name NONE  
Entity Interactive Data Current Yes  
v3.23.3
CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($)
Mar. 31, 2023
Dec. 31, 2022
Current assets    
Cash and cash equivalents $ 299 $ 35,623
Accounts Receivable 6,602 30,943
Inventory 90 0
Prepaid expenses 59,830 113,722
Total current assets 66,821 180,288
Right to use assets, net 0 544,063
Fixed assets, net of accumulated depreciation of $45,000 and $.06 million 47,016 1,877,629
Total Assets 113,837 2,601,980
Current liabilities    
Accounts payable and accrued liabilities 8,340,773 7,353,215
Accrued interest 513,256 362,094
Derivative liabilities 679,690 568,912
Lease liability - operating leases, current 512,895 442,866
Notes payable, net of discounts 6,166,240 5,112,701
SBA Loan Payable 460,406 460,406
Other current liabilities 121,136 96,136
Preferred stock dividends payable 444,864 395,407
Total current liabilities 20,374,179 17,802,471
Lease Liability- operating leases, non-current 3,553,932 3,936,858
Total Liabilities 23,928,111 21,739,329
Commitments and contingencies
Stockholders' deficit    
Common stock subscribed 36,575 36,575
Common stock, $0.01 par value, 500,000,000 shares authorized, 4,995,573 and 4,630,372 shares issued and outstanding as of March 31, 2023 and December 31 2022, respectively 49,957 46,305
Additional paid-in capital 30,385,762 29,452,514
Accumulated deficit (54,328,286) (48,714,461)
Total stockholders' deficit (23,814,274) (19,137,349)
Total liabilities and stockholders' deficit 113,837 2,601,980
Series A Preferred Stock [Member]    
Stockholders' deficit    
Preferred stock, Value 0 0
Series C Preferred Stock [Member]    
Stockholders' deficit    
Preferred stock, Value 10,476 10,476
Series D Preferred Stock [Member]    
Stockholders' deficit    
Preferred stock, Value 31,000 31,000
Series X Preferred Stock [Member]    
Stockholders' deficit    
Preferred stock, Value 242 242
Related Party [Member]    
Current liabilities    
Accrued interest 313,691 198,753
Notes payable, net of discounts 2,791,176 2,776,962
Preferred stock dividends payable $ 30,052 $ 35,019
v3.23.3
CONDENSED CONSOLIDATED BALANCE SHEETS (Parentheticals) - USD ($)
Mar. 31, 2023
Dec. 31, 2022
Fixed assets, accumulated depreciation (in Dollars) $ 45,000 $ 0.06
Notes payable, discounts (in Dollars) $ 0 $ 0.4
Common stock, par value (in Dollars per share) $ 0.01 $ 0.01
Common stock, shares authorized 500,000,000 500,000,000
Common stock, shares issued 4,995,573 4,630,372
Common stock, shares outstanding 4,995,573 4,630,372
Series A Preferred Stock [Member]    
Preferred stock, par value (in Dollars per share) $ 0.01 $ 0.01
Preferred stock, shares issued 0 0
Preferred stock, shares outstanding 0 0
Series C Preferred Stock [Member]    
Preferred stock, par value (in Dollars per share) $ 0.01 $ 0.01
Preferred stock, shares issued 1,047,619 1,047,619
Preferred stock, shares outstanding 1,047,619 1,047,619
Series D Preferred Stock [Member]    
Preferred stock, par value (in Dollars per share) $ 0.01 $ 0.01
Preferred stock, shares issued 3,100,000 3,100,000
Preferred stock, shares outstanding 3,100,000 3,100,000
Series X Preferred Stock [Member]    
Preferred stock, par value (in Dollars per share) $ 0.01 $ 0.01
Preferred stock, shares issued 24,227 24,227
Preferred stock, shares outstanding 24,227 24,227
Related Party [Member]    
Notes payable, discounts (in Dollars) $ 8,000 $ 0.3
v3.23.3
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)
3 Months Ended
Mar. 31, 2023
Mar. 31, 2022
Revenue $ 0 $ 120,376
Cost of goods sold 2,419 588,323
Gross (loss) profit (2,419) (467,947)
Operating expenses:    
General and administrative 2,011,404 2,563,829
Impairment of fixed assets 2,271,893 0
Total operating expenses 4,283,297 2,563,829
Net Operating Loss (4,285,716) (3,031,776)
Other income (expense):    
Interest expense (1,376,066) (828,325)
Gain on termination of operating lease 287,897 0
Gain on waiver and commitment fee shares 0 198,273
Gain on settlement of accrued salary 0 15,032
(Loss) Gain on settlement of accounts payable 0 (78,235)
Loss on revaluation of derivative liabilities (110,778) 79,837
Total other expense (1,328,109) (613,418)
Loss before provision for income taxes (5,613,825) (3,645,194)
Provision for income taxes 0 0
Net loss (5,613,825) (3,645,194)
Preferred stock dividends (79,818) (79,692)
Net loss available to common shareholders $ (5,693,644) $ (3,724,886)
Net loss per share - basic and diluted (in Dollars per share) $ (1.18) $ (0.87)
Weighted average shares outstanding - basic and diluted (in Shares) 4,825,054 4,274,064
Service [Member]    
Revenue $ 0 $ 92,461
Cost of goods sold 2,419 577,556
Product [Member]    
Revenue 0 27,915
Cost of goods sold 0 10,767
Related Party [Member]    
Other income (expense):    
Interest expense (129,162) 0
Preferred stock dividends (17,996) (17,997)
Nonrelated Party [Member]    
Other income (expense):    
Preferred stock dividends $ (61,823) $ (61,695)
v3.23.3
CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS’ EQUITY (DEFICIT) - USD ($)
Diamond Note 1 [Member]
Additional Paid-in Capital [Member]
Diamond Note 1 [Member]
Discount on Note Payable Due to Warrants [Member]
Additional Paid-in Capital [Member]
Discount on Note Payable Due to Warrants [Member]
Accounts Payable [Member]
Common Stock [Member]
Accounts Payable [Member]
Additional Paid-in Capital [Member]
Accounts Payable [Member]
Convertible Debt [Member]
Common Stock [Member]
Convertible Debt [Member]
Additional Paid-in Capital [Member]
Convertible Debt [Member]
Series C Preferred Stock [Member]
Preferred Stock [Member]
Series C Preferred Stock [Member]
Series D Preferred Stock [Member]
Preferred Stock [Member]
Series D Preferred Stock [Member]
Series X Preferred Stock [Member]
Stock Issued for Dividends Payable [Member]
Common Stock [Member]
Series X Preferred Stock [Member]
Stock Issued for Dividends Payable [Member]
Additional Paid-in Capital [Member]
Series X Preferred Stock [Member]
Stock Issued for Dividends Payable [Member]
Series X Preferred Stock [Member]
Preferred Stock [Member]
Series X Preferred Stock [Member]
Commitments [Member]
Common Stock [Member]
Commitments [Member]
Additional Paid-in Capital [Member]
Commitments [Member]
Waiver Fee [Member]
Common Stock [Member]
Waiver Fee [Member]
Additional Paid-in Capital [Member]
Waiver Fee [Member]
Stock Subscribed [Member]
Waiver Fee [Member]
Shares Previously Subscribed [Member]
Common Stock [Member]
Shares Previously Subscribed [Member]
Additional Paid-in Capital [Member]
Shares Previously Subscribed [Member]
Stock Subscribed [Member]
Common Stock [Member]
Additional Paid-in Capital [Member]
Stock Subscribed [Member]
Retained Earnings [Member]
Total
Balance at Dec. 31, 2021                     $ 9,406   $ 31,000         $ 242                       $ 42,667 $ 26,385,728 $ 132,163 $ (25,478,332) $ 1,122,874
Balance (in Shares) at Dec. 31, 2021                     940,644   3,100,000         24,227                       4,266,669        
Vesting of shares issued to employees                                                             1,512     1,512
Vesting of stock options issued to employees                                                             167,015     167,015
Stock issued for conversion         $ 636 $ 577,599 $ 578,235                                       $ 76 $ 95,512 $ (95,588)          
Stock issued for conversion (in Shares)         63,593                                           7,648              
Preferred stock dividends                       $ (16,395)   $ (48,156)         $ (15,141)                       (79,692)     (79,692)
Net loss for the period                                                                 (3,645,194) (3,645,194)
Fee shares                                       $ 344 $ 242,962 $ 243,306 $ 308 $ 275,410 $ 91,440 $ 367,158                
Fee shares (in Shares)                                       34,400     30,835                      
Warrants issued (in Shares) 2,914 2,914 2,213 2,213                                                            
Gain on settlement of accrued payroll                                                           $ (80) 80     (78,235)
Gain on settlement of accrued payroll (in Shares)                                                           (8,000)        
Balance at Mar. 31, 2022                     $ 9,406   $ 31,000         $ 242                       $ 43,951 27,671,253 128,015 (29,123,526) (1,239,659)
Balance (in Shares) at Mar. 31, 2022                     940,644   3,100,000         24,227                       4,395,145        
Balance at Dec. 31, 2022                     $ 10,476   $ 31,000         $ 242                       $ 46,305 29,452,514 36,575 (48,714,461) $ (19,137,349)
Balance (in Shares) at Dec. 31, 2022                     1,047,619   3,100,000         24,227                       4,630,372       4,630,372
Vesting of stock options issued to employees                                                             933     $ 933
Issuance of common stock to service providers                                                           $ 3,000 894,000     897,000
Issuance of common stock to service providers (in Shares)                                                           300,000        
Stock issued for conversion               $ 571 $ 82,885 $ 83,456         $ 81 $ 35,248 $ 35,329                                  
Stock issued for conversion (in Shares)               57,138             8,063                                      
Preferred stock dividends                       $ (16,521)   $ (48,156)         $ (15,141)                       (79,818)     (79,818)
Net loss for the period                                                                 (5,613,825) (5,613,825)
Gain on settlement of accrued payroll                                                                   0
Balance at Mar. 31, 2023                     $ 10,476   $ 31,000         $ 242                       $ 49,957 $ 30,385,762 $ 36,575 $ (54,328,286) $ (23,814,274)
Balance (in Shares) at Mar. 31, 2023                     1,047,619   3,100,000         24,227                       4,995,573       4,995,573
v3.23.3
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)
3 Months Ended 12 Months Ended
Mar. 31, 2023
Mar. 31, 2022
Dec. 31, 2022
CASH FLOWS FROM OPERATING ACTIVITIES      
Net loss $ (5,613,825) $ (3,645,194)  
Adjustments to reconcile net loss to net cash used in operating activities:      
Impairment of assets 2,271,893 0  
Gain on lease termination (287,897) 0  
Depreciation 102,783 179,886  
Penalties on notes payable 1,102,778 0  
Amortization of right-to-use asset 0 267,463  
Financing cost - waiver fee shares 0 565,431  
Gain on waiver fee shares 0 (198,273)  
Gain on conversion of accrued salary 0 (15,032)  
(Gain) loss on revaluation of derivative liabilities 110,778 (79,837)  
Loss on settlement of accounts payable 0 78,235  
Amortization of discount on notes payable 23,538 231,180  
Share-based compensation 897,933 168,527  
Changes in assets and liabilities:      
Accounts receivables 24,341 (11,274)  
Prepaid expenses 53,892 (19,699)  
Inventory (90) (5,279)  
Accounts payable and accrued liabilities 989,559 534,132  
Operating lease liability, net 0 12,158  
Net cash used in operating activities (35,324) (1,905,862)  
CASH FLOWS FROM INVESTING ACTIVITIES      
Cash paid for acquisition of fixed assets and construction in progress 0 (19,223)  
Net cash used in investing activities 0 (19,223)  
CASH FLOWS FROM FINANCING ACTIVITIES      
Proceeds from notes payable, net of discounts 0 675,000  
Net cash provided by financing activities 0 1,023,750  
Net decrease in cash and cash equivalents (35,324) (901,335)  
Cash and cash equivalents at beginning of period 35,623 1,164,483 $ 1,164,483
Cash and cash equivalents at end of period 299 263,148 $ 35,623
SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION:      
Interest paid 0 2,680  
NON-CASH INVESTING AND FINANCING ACTIVITIES:      
Preferred stock dividend 79,818 79,692  
Increase in capital expenditures included in accounts payable 109,383 1,009,471  
Stock Subscribed [Member]      
NON-CASH INVESTING AND FINANCING ACTIVITIES:      
Stock issued for common stock subscribed 83,456 0  
Conversion of accounts payable to common stock 83,456 0  
Accounts Payable [Member]      
NON-CASH INVESTING AND FINANCING ACTIVITIES:      
Stock issued for common stock subscribed 0 500,000  
Conversion of accounts payable to common stock 0 500,000  
Related Party [Member]      
Adjustments to reconcile net loss to net cash used in operating activities:      
Amortization of discount on notes payable 14,214 0  
Changes in assets and liabilities:      
Accrued interest 114,938 0  
CASH FLOWS FROM FINANCING ACTIVITIES      
Proceeds from notes payable, net of discounts 0 348,750  
NON-CASH INVESTING AND FINANCING ACTIVITIES:      
Preferred stock dividend 17,996 17,997  
Nonrelated Party [Member]      
Changes in assets and liabilities:      
Accrued interest 159,841 31,714  
NON-CASH INVESTING AND FINANCING ACTIVITIES:      
Preferred stock dividend $ 61,823 $ 61,695  
v3.23.3
Description of Business
3 Months Ended
Mar. 31, 2023
Accounting Policies [Abstract]  
Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]

Note 1: Description of Business

 

Company Overview

 

Mitesco, Inc. (the “Company,” “we,” “us,” or “our”) was formed in the state of Delaware on January 18, 2012. On December 9, 2015, we restructured our operations and acquired Newco4pharmacy, LLC, a development stage company which sought to acquire compounding pharmacy businesses. As a part of the restructuring, we completed a “spin out” of our former business line. On April 24, 2020, we changed our name to Mitesco, Inc.

 

We are a holding company with current operating plans to participate in the healthcare industry through the development of healthcare services, and with a view toward additional services and technology that may find a ready market in the healthcare industry. During early 2022 we continued on our plan to open primary care clinics around the United States in select markets, utilizing the experience, expertise, and training of licensed, advanced degreed nurse practitioners (“Nurse Practitioners”). During 2022 our clinics provided complete primary care, as well as a limited set of offerings addressing more specific needs for the general public. The medical practice focuses on whole person health and prevention. During late 2022 we decided to close our clinics due to a lack of funding for their operations and growth plans.

 

We have always had a view toward additional healthcare technology and services offerings and are committing more time to that effort going forward. We have a number of near-term opportunities that we hope to pursue, assuming the capital markets make sufficient funding available at reasonable rates.

 

Our operations are subject to comprehensive federal, state, and local laws and regulations in the jurisdictions in which it does business. There also continues to be a heightened level of review and/or audit by federal and state regulators of the health and related benefits industry’s business and reporting practices. As of the date of this filing, we are not subject to any actual or anticipated regulatory reviews or audits relating to our operations.

 

The laws and rules governing our businesses and interpretations of those laws and rules continue to evolve each year and are subject to frequent change. The application of these complex legal and regulatory requirements to the detailed operation of our businesses creates areas of uncertainty. Further, there are numerous proposed health care, financial services and other laws and regulations at the federal and state level some of which could adversely affect our businesses if they are enacted. We cannot predict whether pending or future federal or state legislation will have an adverse effect on our business.

 

We can give no assurance that the businesses, financial condition, operating results and/or cash flows will not be materially adversely affected, or that we will not be required to materially change its business practices, based on: (i) future enactment of new health care or other laws or regulations; (ii) the interpretation or application of existing laws or regulations, including the laws and regulations described in this Government Regulation section, as they may relate to one or more of our businesses, one or more of the industries in which we compete and/or the health care industry generally; (iii) our pending or future federal or state governmental investigations.

 

Reverse Stock Split

 

On December 12, 2022, our board of directors approved the filing of a certificate of amendment to our amended and restated certificate of incorporation (the “Amendment”) with the Secretary of State of the State of Delaware to affect the one-for-fifty. The Amendment became effective at 5:00 p.m. Eastern Time on December 12, 2022.

 

Pursuant to the Amendment, at the effective time of the Amendment, every fifty (50) shares of our issued and outstanding common stock was automatically combined into one (1) issued and outstanding share of common stock The Reverse Stock Split affected all shares of our common stock outstanding immediately prior to the effective time of the Amendment. No fractional shares were issued as a result of the Reverse Stock Split. Stockholders of record who would otherwise be entitled to receive a fractional share received a full share thereof. As a result of the Reverse Stock Split, proportionate adjustments were made to the per share exercise price and/or the number of shares issuable upon the exercise or vesting of all stock options and warrants issued by us and outstanding immediately prior to the effective time of the Amendment, which resulted in a proportionate decrease in the number of shares of our common stock reserved for issuance upon exercise or vesting of such stock options and warrants and a proportionate increase in the exercise price of all such stock options and warrants. In addition, the number of shares reserved for issuance under our equity compensation plans immediately prior to the effective time of the Amendment were reduced proportionately. All share and per share amounts of common stock presented in this Quarterly Report on Form 10-Q have been retroactively adjusted to reflect the Reverse Stock Split.

v3.23.3
Financial Condition, Going Concern and Management Plans
3 Months Ended
Mar. 31, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Substantial Doubt about Going Concern [Text Block]

Note 2: Financial Condition, Going Concern and Management Plans

 

As of March 31, 2023, the Company had cash and cash equivalents of approximately $300, current liabilities of $20.4 million, and has incurred significant losses from the previous clinic operations. Our strategy is to acquire healthcare technology and service businesses that have a unique positioning that gives them a differentiated competitive advantage in the market that  improves patients’ experience and outcomes and reduces healthcare costs as compared to other available treatments and solution. As previously noted, we made a strategic decision to reduce our capital needs by closing our clinic operations in the fourth quarter of 2022 and releasing a significant portion of our staff. As we redevelop our new strategy for lower cost operations, we expect to focus on acquisition of existing healthcare technology and services businesses. The Company’s activities are subject to significant risks and uncertainties, including failing to secure additional funding to execute its business plan.

 

Effective December 8, 2022, we closed all of our clinic locations due to a lack of funding. Subsequent to that date we have lost possession of all clinic locations. Due to difficulty in securing financing, we are uncertain of when or even if we will be able to resume operations at any clinic location.

 

As a result of these factors, there is substantial doubt about the ability of the Company to continue as a going concern for one year from the date the financial statements are issued. The Company’s continuance is dependent on raising capital and generating revenues sufficient to sustain operations. However, as of the date of these consolidated financial statements, no formal agreement exists.

 

The accompanying unaudited condensed consolidated financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts or amounts classified as liabilities that might be necessary should the Company be forced to take any such actions.

 

The COVID-19 pandemic, decades-high inflation and concerns about an economic recession in the United States or other major markets has resulted in, among other things, volatility in the capital markets that may have the effect of reducing the Company’s ability to access capital, which could in the future negatively affect the Company’s liquidity. In addition, a recession or market correction due to these factors could materially affect the Company’s business and the value of its common stock.

v3.23.3
Summary of Significant Accounting Policies
3 Months Ended
Mar. 31, 2023
Accounting Policies [Abstract]  
Significant Accounting Policies [Text Block]

Note 3: Summary of Significant Accounting Policies

 

Principles of Consolidation The accompanying condensed consolidated financial statements include the accounts of Mitesco, Inc., and its wholly owned subsidiaries Mitesco NA, LLC and The Good Clinic, LLC. In addition, we anticipate that we will rely on the operating activities of certain legal entities in which we will not maintain a controlling ownership interest but over which we will have indirect influence and of which we will be considered the primary beneficiary. We expect that these entities will typically be subject to nominee ownership and transfer restriction agreements that effectively transfer the majority of the economic risks and rewards of their ownership to the Company. The Company’s management, restriction and other agreements concerning such nominee-owned entities typically includes both financial terms and protective and participating rights to the entities’ operating, strategic and non-clinical governance decisions which transfer substantial powers over and economic responsibility for these entities to the Company. As such, the Company applies the guidance of the Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) 810 – Consolidation (“ASC 810”), to determine when an entity that is insufficiently capitalized or not controlled through its voting interests, referred to as a variable interest entity should be consolidated. All intercompany balances and transactions have been eliminated.

 

Use of Estimates - The preparation of these financial statements requires our management to make estimates and assumptions about future events that affect the amounts reported in the financial statements and related notes. Future events and their effects cannot be determined with absolute certainty. Therefore, the determination of estimates requires the exercise of judgment.

 

Significant Accounting Policies

 

There have been no material changes in the Company’s significant accounting policies from those previously disclosed in the 2022 Annual Report.

 

New Accounting Standards

 

From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board (“FASB”) or other standard setting bodies that the Company adopts as of the specified effective date. Unless otherwise discussed, the Company does not believe that the impact of recently issued standards that are not yet effective will have a material impact on its financial position or results of operations upon adoption.

v3.23.3
Net Loss Per Share Applicable to Common Shareholders
3 Months Ended
Mar. 31, 2023
Earnings Per Share [Abstract]  
Earnings Per Share [Text Block]

Note 4: Net Loss Per Share Applicable to Common Shareholders

 

Net Loss per Share Applicable to Common Stockholders

 

Basic loss per common share is computed by dividing net loss by the weighted average number of common shares outstanding during the reporting period. Diluted loss per common share is computed similarly to basic loss per common share except that it reflects the potential dilution that could occur if dilutive securities or other obligations to issue common stock were exercised or converted into common stock.

 

The following table sets forth the computation of loss per share for the three months ended March 31, 2023, and 2022, respectively:

 

   

For the Three Months Ended

 
   

March 31,

 
   

2023

   

2022

 

Numerator:

               

Net loss applicable to common shareholders

  $ (5,693,644

)

  $ (3,724,886

)

                 

Denominator:

               

Weighted average common shares outstanding

    4,825,054       4,274,064  
                 

Net loss per share:

               

Basic and diluted

  $ (1.18

)

  $ (0.87

)

 

The Company excluded all common equivalent shares outstanding for warrants, options, and convertible instruments to purchase common stock from the calculation of diluted net loss per share because all such securities are antidilutive for the periods presented. As of March 31, 2023, and 2022, the following shares were issuable and excluded from the calculation of diluted loss:

 

   

For the Years Ended

 
   

March 31,

 
   

2023

   

2022

 

Common stock options

    215,881       373,425  

Common stock purchase warrants

    672,334       628,100  

Convertible Preferred Stock

    347,652       347,652  

Accrued interest on Preferred Stock

    47,767       24,618  

Potentially dilutive securities

    1,283,634       1,373,795  
v3.23.3
Related Party Transactions
3 Months Ended
Mar. 31, 2023
Related Party Transactions [Abstract]  
Related Party Transactions Disclosure [Text Block]

Note 5: Related Party Transactions

 

For the three months ended March 31, 2023:

 

During the three months ended March 31, 2023, the Company accrued dividends on its Series X Preferred Stock in the total amount of $15,141. Of this amount, a total of $2,000 was payable to officers and directors, $7,814 was payable to a related party shareholder, and $5,327 was payable to non-related parties.

 

On March 31, 2023, the Company issued a total of 8,063 shares of common stock for accrued dividends on its Series X Preferred Stock. Of this amount, a total of 1,066 shares were issued to officers and directors, 4,160 were issued to a related party shareholder, and 2,837 were issued to no-related parties.

 

For the three months ended March 31, 2022:

 

The Company issued a 10% Promissory Note due August 14, 2022 (the “Note”), dated February 14, 2022, to Lawrence Diamond (the “Lender”). Mr. Diamond is the Chief Executive Officer of the Company and a member of its Board of Directors. The principal amount of the Note is $175,000, carries a 10% interest rate per annum, payable in monthly installments, and has a maturity date that is the earlier of (i) six (6) months from the date of execution, or (ii) the date on which the Company successfully lists its shares of common stock on Nasdaq or NYSE. The purchase price of the Note payable to the Company for the Note was $148,750 and was funded on February 14, 2022. The amount payable at maturity will be $175,000 plus 10% of that amount plus accrued and unpaid interest. Following an event of default, as defined in the Note, the principal amount shall bear interest for each day until paid, at a rate per annum equal to the lesser of the maximum interest permitted by applicable law and 18%. The Note contains a “most favored nations” clause that provides that, so long as the Note is outstanding, if the Company issues any new security, which the Lender reasonably believes contains a term that is more favorable than those in the Note, the Company shall notify the Lender of such term, and such term, at the option of the Lender, shall become a part of the Note. In addition to the Note and Lender will be issued 7,350 5-year warrants that may be exercised at $25.00 per share and 7,350 5-year warrants that may be exercised at $37.50 per share. These warrants have all of the same terms as those previously issued in conjunction with the Company’s Series C Preferred shares and its Series D Preferred shares.

 

During the three months ended March 31, 2022, the Company accrued dividends on its Series X Preferred Stock in the total amount of approximately $15,000. Of this amount, a total of $2,000 was payable to officers and directors, $8,000 was payable to a related party shareholder, and $6,000 was payable to non-related parties.

v3.23.3
Accounts Payable and Accrued Liabilities
3 Months Ended
Mar. 31, 2023
Payables and Accruals [Abstract]  
Accounts Payable and Accrued Liabilities Disclosure [Text Block]

Note 6: Accounts Payable and Accrued Liabilities

 

Accounts payable and accrued liabilities consisted of the following at March 31, 2023 and December 31, 2022:

 

   

March 31,

   

December 31,

 
   

2023

   

2022

 

Trade accounts payable

  $ 7,482,128     $ 6,761,793  

Accrued payroll and payroll taxes

    858,645       590,915  

Other

    -       507  

Total accounts payable and accrued liabilities

  $ 8,340,773     $ 7,353,215  
v3.23.3
Right to Use Assets and Lease Liabilities - Operating Leases
3 Months Ended
Mar. 31, 2023
Disclosure Text Block [Abstract]  
Lessee, Operating Leases [Text Block]

Note 7: Right to Use Assets and Lease Liabilities Operating Leases

 

During the year ended December 31, 2022, the Company recognized an impairment of Right-to-Use (RTU) assets in the amount of $3.2 million in connection with the closing of its clinics during the period. During the three months ended March 31, 2023, the Company recognized an additional impairment in the amount of $0.5 million in connection with its remaining leased properties.

 

As of March 31, 2023, the Company had total operating lease liabilities of approximately $4.1 million and right to use assets of $0, which were included in the condensed consolidated balance sheet.

 

Right to use assets – operating leases are summarized below:

 

   

March 31,

2023

   

December 31,

2022

 

Right to use assets, net

  $ -     $ 544,063  

 

Operating lease liabilities are summarized below:

   

March 31,

2023

   

December 31,

2022

 

Lease liability

  $ 4,066,827     $ 4,379,724  

Less: current portion

    (512,895

)

    (442,866

)

Lease liability, non-current

  $ 3,553,932     $ 3,936,858  

 

Maturity analysis under these lease agreements are as follows:

 

For the twelve months ended March 31, 2024

  $ 1,087,018  

For the twelve months ended March 31, 2025

    824,520  

For the twelve months ended March 31, 2026

    843,270  

For the twelve months ended March 31, 2027

    862,264  

For the twelve months ended March 31, 2028

    880,268  

Thereafter

    1,586,661  

Total

  $ 6,084,001  

Less: Present value discount

    (2,017,174

)

Lease liability

  $ 4,066,827  

 

Effective February 3, 2023, the Company entered into a termination agreement for the lease of its clinic located in Wayzata, Minnesota. The terms of the agreement call for a payment by the Company in the amount of $25,000 in full settlement of all amounts payable by the Company under this lease. The amount of operating lease liability recorded by the Company at the time of the settlement was $312,897. The Company accrued a liability in the amount of $25,000 and recorded a gain on settlement of lease liability in the amount of $287,897 during the three months ended March 31, 2023.

 

Effective March 3, 2023, the Company entered into a termination agreement for the lease of its clinic located in Eagen, Minnesota. The Company is currently involved in legal proceedings with the landlord of this clinic, and no gain or loss was recorded on this lease termination. An estimate of the potential liability resulting from these legal proceedings cannot be made at this time. At March 31, 2023, an operating lease liability in the amount of $474,074 is recorded on the Company’s balance sheet in connection with this lease.

v3.23.3
SBA Loan Payable
3 Months Ended
Mar. 31, 2023
Small Business Administration Loan Payable Abstract  
Small Business Administration Loan Payable [Text Block]

Note 8: SBA Loan Payable

 

PPP Loan

 

During March 2020, in response to the COVID-19 crisis, the federal government announced plans to offer loans to small businesses in various forms, including the Payroll Protection Program, or “PPP”, established as part of the Corona Virus Aid, Relief and Economic Security Act (“CARES Act”) and administered by the U.S. Small Business Administration. On April 25, 2020, the Company entered an unsecured Promissory Note with Bank of America for a loan in the original principal amount of $460,400, and the Company received the full amount of the loan proceeds on May 4, 2020 (the “PPP Loan”). The PPP Loan bears interest at the rate of 1% per year. During the year ended December 31, 2022, the Company accrued interest in the amount of $4,632

 

During the three months ended March 31, 2023, the Company accrued interest in the amount of $1,135 on the PPP Loan; at March 31, 2023, the balance due on this loan was principal in the amount of $460,400 and accrued interest in the amount of $12,424. This loan is in default at March 31, 2023.

v3.23.3
Notes Payable
3 Months Ended
Mar. 31, 2023
Notes Payable [Line Items]  
Debt Disclosure [Text Block]

Note 9: Notes Payable

 

AJB Note

 

On March 18, 2022, the Company entered into a Securities Purchase Agreement (the “AJB Agreement”) with AJB Capital Investments, LLC (“AJB”) with respect to the sale and issuance to AJB of: (i) an initial commitment fee in the amount of $430,000 in the form of 34,400 shares (the “AJB Commitment Fee Shares”) of the Company’s Common Stock, (ii) a promissory note in the aggregate principal amount of $750,000 (the “AJB Note”), and (iii) Common Stock Purchase Warrants to purchase 15,000 shares of the Company’s Common Stock (the “AJB Warrants”). The AJB Note and AJB Warrants were issued on March 17, 2022 and were held in escrow pending effectiveness of the AJB Agreement. Should AJB receive net proceeds of less than $430,000 from the sale of the AJB Commitment Fee Shares, the Company will issue additional shares to AJB or pay the shortfall amount to AJB in cash (the “AJB True-up Obligation”. The terms of the AJB Agreement resulted in the Company recording a derivative liability in the initial amount of $106,608. On November 18, 2022, the Company issued 91,328 shares of common stock to AJB and recorded a loss in the amount of $9,007 in connection with the settlement of the AJB True-up Obligation. See notes 11 and 12.

 

The AJB Note was issued in the principal amount of $750,000 for a purchase price of $675,000, resulting in an original issue discount of $75,000, and has a due date, as extended, of March 17, 2023. The AJB Note bears interest at the rate of 10% per year for the first six months and 12% thereafter. In the event of default as defined in the AJB Note this rate will increase to 18% and the AJB Note will become convertible at a price per share equal to the lowest trading price during the previous twenty trading days prior to the conversion date. The AJB Note entered default status on October 6, 2022. The AJB Commitment Fee Shares and AJB Warrants resulted in a discount to the AJB Note in the amount of $349,914. The Company charged the amount of $62,000 to interest on the AJB Note during the year ended December 31, 2022. Discounts in the amount of $424,914 were amortized to interest expense during the year ended December 31, 2022, and total discounts in the amount of $0 remained outstanding at December 31, 2022. Principal and accrued interest in the amounts $750,000 and $22,833, respectively, were due on the AJB Note at December 31, 2022.

 

During the three months ended March 31, 2023, a default penalty in the amount of $375,000 and an additional fee in the amount of $15,000 were added to the principal amount of the AJB note, and interest in the amount of $62,897 was accrued. At March 31, 2023, principal and interest in the amount of $1,140,000 and $85,730, respectively, were due on the AJB Note. This note was in default at March 31, 2023.

 

Anson Investments Note

 

On April 6, 2022, the Company entered into a Securities Purchase Agreement (the “Anson Investments Agreement”) with Anson Investments Master Fund LP (“Anson Investments”) with respect to the sale and issuance to Anson Investments of: (i) an initial commitment fee in the amount of $322,500 in the form of 25,800 shares (the “Anson Investments Commitment Fee Shares”) of the Company’s Common Stock, (ii) a promissory note in the aggregate principal amount of $562,500 (the “Anson Investments Note”), and (iii) Common Stock Purchase Warrants to purchase 11,250 shares of the Common Stock (the “Anson Investments Warrants”). Should Anson Investments receive net proceeds of less than $322,500 from the sale of the Anson Investments Commitment Fee Shares, the Company will issue additional shares to Anson Investments or pay the shortfall amount to Anson Investments in cash. The terms of the Anson Investments Agreement resulted in the Company recording a derivative liability in the initial amount of $27,040.

 

The Anson Investments Note was issued in the principal amount of $562,500 for a purchase price of $506,250 resulting in an original issue discount of $56,250. The Anson Investments Note has a due date of October 6, 2022 and bears interest at the rate of 10% per year for the first six months and 12% thereafter. In the event of default as defined in the Anson Investments Note this rate will increase to 18% and the Anson Investment Note will become convertible at a price per share equal to the lowest trading price during the previous twenty trading days prior to the conversion date. The Anson Investments Note entered default status on October 6, 2022. The Anson Investments Commitment Fee Shares and Anson Investments Warrants resulted in a discount to the Anson Investments Note in the amount of $416,375. The Company charged the amount of $68,844 to interest on the Anson Investments note during the year ended December 31, 2022. Discounts in the amount of $472,625 were amortized to interest expense during the year ended December 31, 2022, and total discounts in the amount of $0 remained outstanding at December 31, 2022. Principal and accrued interest in the amounts $562,500 and $41,500, respectively, were due on the AJB Note at December 31, 2022.

 

During the three months ended March 31, 2023, a default penalty in the amount of $281,250 and an additional fee in the amount of $15,000 were added to the principal amount of the Anson Investments Note, and interest in the amount of $22,433 was accrued. At March 31, 2023, principal and interest in the amount of $858,750 and $63,933, respectively, were due on the Anson Investments Note. This note was in default at March 31, 2023.

 

Anson East Note

 

On April 6, 2022, the Company entered into a Securities Purchase Agreement (the “Anson East Agreement”) with Anson East Master Fund LP (“Anson East”) with respect to the sale and issuance to Anson East of: (i) an initial commitment fee in the amount of $107,500 in the form of 8,600 shares (the “Anson East Commitment Fee Shares”) of the Company’s Common Stock, (ii) a promissory note in the aggregate principal amount of $187,500 (the “Anson East Note”), and (iii) Common Stock Purchase Warrants to purchase 3,750 shares of the Company’s common stock (the “Anson East Warrants”). Should Anson East receive net proceeds of less than $107,500 from the sale of the Anson East Commitment Fee Shares, the Company will issue additional shares to Anson East or pay the shortfall amount to Anson East in cash. The terms of the Anson East Agreement resulted in the Company recording a derivative liability in the initial amount of $9,014.

 

The Anson East Note was issued in the principal amount of $187,500 for a purchase price of $168,750 resulting in an original issue discount of $18,750. The Anson East Note has a due date of October 6, 2022 and bears interest at the rate of 10% per year for the first six months and 12% thereafter. In the event of default as defined in the Anson East Note this rate will increase to 18%, and the Anson East Note will become convertible at a price per share equal to the lowest trading price during the previous twenty trading days prior to the conversion date. The Anson East Note entered default status on October 6, 2022. The Anson East Commitment Fee Shares and Anson East Warrants resulted in a discount to the Anson East Note in the amount of $147,290. The Company charged the amount of $22,948 to interest on the Anson Investments note during the year ended December 31, 2022. Discounts in the amount of $166,040 were amortized to interest expense during the year ended December 31, 2022, and total discounts in the amount of $0 remained outstanding at December 31, 2022. Principal and accrued interest in the amounts $187,500 and $13,833, respectively, were due on the Anson East Note at December 31, 2022.

 

During the three months ended March 31, 2023, a default penalty in the amount of $93,750 and an additional fee in the amount of $15,000 were added to the principal amount of the Anson East Note, and interest in the amount of $7,922 was accrued. At March 31, 2023, principal and interest in the amount of $296,250 and $21,755, respectively, were due on the Anson East Note. This note was in default at March 31, 2023.

 

GS Capital Note

 

On April 18, 2022, the Company entered into a Securities Purchase Agreement (the “GS Capital Agreement”) with GS Capital Investments, LLC (“GS Capital”) with respect to the sale and issuance to GS Capital of: (i) an initial commitment fee in the amount of $159,259 in the form of 12,741 shares (the “GS Capital Commitment Fee Shares”) of the Company’s Common Stock, (ii) a promissory note in the aggregate principal amount of $277,777 (the “GS Capital Note”), and (iii) Common Stock Purchase Warrants to purchase 5,556 shares of the Company’s common stock (the “GS Capital Warrants”). Should GS Capital receive net proceeds of less than $159,259 from the sale of the GS Capital Commitment Fee Shares, the Company will issue additional shares to GS Capital or pay the shortfall amount to GS Capital in cash. The terms of the GS Capital Agreement resulted in the Company recording a derivative liability in the initial amount of $21,920.

 

The GS Capital Note was issued in the principal amount of $277,777 for a purchase price of $250,000 resulting in an original issue discount of $27,777. The GS Capital Note has a due date of November 10, 2022 and bears interest at the rate of 10% per year for the first six months and 12% thereafter. In the event of default as defined in the GS Capital Note this rate will increase to 18%, and the GS Capital Note will become convertible at a price per share equal to the lowest trading price during the previous twenty trading days prior to the conversion date. The GS Capital Note entered default status on October 19, 2022. The GS Capital Commitment Fee Shares and GS Capital Warrants resulted in a discount to the GS Capital Note in the amount of $162,158. The Company charged the amount of $32,155 to interest on the GS Capital Note during the year ended December 31, 2022. Discounts in the amount of $212,435 were amortized to interest expense during the year ended December 31, 2022, and total discounts in the amount of $0 remained outstanding at December 31, 2022. Principal and accrued interest in the amounts $277,777 and $19,578, respectively, were due on the GS Capital Note at December 31, 2022.

 

During the three months ended March 31, 2023, GS Capital converted an aggregate amount of $72,777 of principal, $8,679 of accrued interest, and $2,000 of fees in the GL Capital Note into an aggregate of 57,138 shares of the Company’s common stock at an average price of $1.46 per share. These conversions were made pursuant to the terms of the GS Capital Note, and no gain or loss was recorded on these transactions. During the three months ended March 31, 2023, a default penalty in the amount of $138,889 and an additional fee in the amount of $15,000 were added to the principal amount of the GS Capital Note, and interest in the amount of $11,591 was accrued. At March 31, 2023, principal and interest in the amount of $358,889 and $22,490, respectively, were due on the GS Capital Note. This note was in default at March 31, 2023.

 

Kishon Note

 

On May 10, 2022, the Company entered into a Securities Purchase Agreement (the “Kishon Agreement”) with Kishon Investments, LLC (“Kishon”) with respect to the sale and issuance to Kishon of: (i) an initial commitment fee in the amount of $159,259 in the form of 12,741 shares (the “Kishon Commitment Fee Shares”) of the Company’s Common Stock, (ii) a promissory note in the aggregate principal amount of $277,777 (the “Kishon Note”), and (iii) Common Stock Purchase Warrants to purchase 5,556 shares of the Company’s common stock (the “Kishon Warrants”). Should Kishon receive net proceeds of less than $159,259 from the sale of the Kishon Commitment Fee Shares, the Company will issue additional shares to Kishon or pay the shortfall amount to Kishon in cash. The terms of the Kishon Agreement resulted in the Company recording a derivative liability in the initial amount of $27,793.

 

The Kishon Note was issued in the principal amount of $277,777 for a purchase price of $250,000 resulting in an original issue discount of $27,777. The Kishon Note has a due date of November 10, 2022 and bears interest at the rate of 10% per year for the first six months and 12% thereafter. In the event of default as defined in the Kishon Note this rate will increase to 18%, and the Kishon Note will become convertible at a price per share equal to the lowest trading price during the previous twenty trading days prior to the conversion date. The Kishon Note entered default status on November 11, 2022. The Kishon Commitment Fee Shares and Kishon Warrants resulted in a discount to the Kishon Note in the amount of $138,492. The Company charged the amount of $28,624 to interest on the Kishon Note during the year ended December 31, 2022. Discounts in the amount of $181,269 were amortized to interest expense during the year ended December 31, 2022, and total discounts in the amount of $0 remained outstanding at December 31, 2022. Principal and accrued interest in the amounts $277,777 and $17,822, respectively, were due on the Kishon Note at December 31, 2022. The Kishon Note was in default at December 31, 2022.

 

During the three months ended March 31, 2023, a default penalty in the amount of $138,889 and an additional fee in the amount of $15,000 were added to the principal amount of the Kishon Note, and interest in the amount of $12,004 was accrued. At March 31, 2023, principal and interest in the amount of $431,666 and $29,826, respectively, were due on the GS Capital Note. This note was in default at March 31, 2023.

 

Finnegan Note 1

 

On May 23, 2022, the Company issued a 10% Promissory Note in the principal amount of $47,059 to Jessica Finnegan (the “Finnegan Note 1”). The Finnegan Note 1 bears interest at the rate of 10% per annum accrued monthly and has a maturity date that is the earlier of (i) November 20, 2022, as extended, or (ii) five (5) business days after the date on which the Company successfully lists its shares of common stock on Nasdaq or NYSE. The purchase price of the Finnegan Note 1 was $40,000; the amount payable at maturity will be $47,059 plus 10% of that amount plus any accrued and unpaid interest. Following an event of default as defined in the Finnegan Note 1, the principal amount shall bear interest for each day until paid at a rate per annum equal to the lesser of the maximum interest permitted by applicable law and 18%. The Finnegan Note 1 entered default status on November 21, 2022, and the interest rate increased to 18%. The Finnegan Note 1 contains a “most favored nations” clause that provides that, so long as the note is outstanding, if the Company issues any new security which Ms. Finnegan reasonably believes contains a term that is more favorable than those in the Finnegan Note 1, the Company shall notify Ms. Finnegan of such term, and such term, at the option of Ms. Finnegan, shall become a part of the Finnegan Note 1. In addition, Ms. Finnegan received five-year warrants to purchase 386 shares of common stock at a price of $25.00 per share with a fair value of $2,000 at the date of issuance, and 1,930 shares of common stock with a value of $3,240; these amounts were recorded as discounts to the Finnegan Note 1. Interest in the amount of $3,285 was accrued on the Finnegan Note 1 during the year ended December 31, 2022. Discounts in the amount of $17,005 were amortized to interest expense during the year ended December 31, 2022, and total discounts in the amount of $0 remained outstanding at December 31, 2022. Principal and accrued interest in the amounts $51,765 and $3,285, respectively, were due on the Finnegan Note 1 at December 31, 2022.

 

During the three months ended March 31, 2023, interest in the amount of $2,163 was accrued on the Finnegan Note 1; principal and accrued interest in the amount of $51,765 and $5,448, respectively, were due on this note at March 31, 2023. This note was in default at March 31, 2023.

 

M Diamond Note

 

On May 26, 2022, the Company issued a 10% Promissory Note in the principal amount of $58,823 to Melissa Diamond (the “M Diamond Note”). The M Diamond Note bears interest at the rate of 10% per annum accrued monthly and has a maturity date that is the earlier of (i) November 30, 2022, or (ii) five business days after the date on which the Company successfully lists its shares of common stock on Nasdaq or NYSE. The purchase price of the M Diamond Note was $50,000; the amount payable at maturity will be $58,823 plus 10% of that amount plus any accrued and unpaid interest. Following an event of default as defined in the M Diamond Note, the principal amount shall bear interest for each day until paid at a rate per annum equal to the lesser of the maximum interest permitted by applicable law and 18%. The M Diamond Note entered default status on December 1, 2022, and the interest rate increased to 18%. The M Diamond Note contains a “most favored nations” clause that provides that, so long as the note is outstanding, if the Company issues any new security which Ms. Diamond reasonably believes contains a term that is more favorable than those in the M Diamond Note, the Company shall notify Ms. Diamond of such term, and such term, at the option of Ms. Diamond, shall become a part of the M Diamond Note. In addition, Ms. Diamond received five-year warrants to purchase 483 shares of common stock at a price of $25.00 per share with a fair value of $2,500 at the date of issuance, and 483 shares of common stock with a value of $4,050; these amounts were recorded as discounts to the M Diamond Note. Interest in the amount of $3,929 was accrued on the M Diamond Note during the year ended December 31, 2022. Discounts in the amount of $21,256 were amortized to interest expense during the year ended December 31, 2022, and total discounts in the amount of $0 remained outstanding at December 31, 2022. Principal and accrued interest in the amounts $64,705 and $3,929, respectively, were due on the M Diamond Note at December 31, 2022. During the three months ended March 31, 2023, interest in the amount of $2,702 was accrued on the M Diamond Note; principal and accrued interest in the amount of $64,705 and $6,631, respectively, were due on this note at March 31, 2023. This note was in default at March 31, 2023.

 

Finnegan Note 2

 

On May 26, 2022, the Company issued a 10% Promissory Note in the principal amount of $29,412 to Jessica Finnegan (the “Finnegan Note 2”). The Finnegan Note 2 bears interest at the rate of 10% per annum accrued monthly and has a maturity date that is the earlier of (i) November 30, 2022, or (ii) five business days after the date on which the Company successfully lists its shares of common stock on Nasdaq or NYSE. The purchase price of the Finnegan Note 2 was $25,000; the amount payable at maturity will be $29,412 plus 10% of that amount plus any accrued and unpaid interest. Following an event of default as defined in the Finnegan Note 2, the principal amount shall bear interest for each day until paid at a rate per annum equal to the lesser of the maximum interest permitted by applicable law and 18%. The Finnegan Note 2 entered default status on December 1, 2022, and the interest rate increased to 18%. The Finnegan Note 2 contains a “most favored nations” clause that provides that, so long as the note is outstanding, if the Company issues any new security which Ms. Finnegan reasonably believes contains a term that is more favorable than those in the Finnegan Note 2, the Company shall notify Ms. Finnegan of such term, and such term, at the option of Ms. Finnegan, shall become a part of the Finnegan Note 2. In addition, Ms. Finnegan received five-year warrants to purchase 242 shares of common stock at a price of $25.00 per share with a fair value of $1,250 at the date of issuance, and 242 shares of common stock with a value of $2,025; these amounts were recorded as discounts to the Finnegan Note 2. Interest in the amount of $1,965 was accrued on the Finnegan Note 2 during the year ended December 31, 2022. Discounts in the amount of $10,625 were amortized to interest expense during the year ended December 31, 2022, and total discounts in the amount of $0 remained outstanding at December 31, 2022. Principal and accrued interest in the amounts $32,353 and $1,965, respectively, were due on the Finnegan Note 2 at December 31, 2022. During the three months ended March 31, 2023, interest in the amount of $1,350 was accrued on the Finnegan Note 2; principal and accrued interest in the amount of $32,353 and $3,315, respectively, were due on this note at March 31, 2023. This note was in default at March 31, 2023.

 

Dragon Note

 

On June 9, 2022, the Company issued a 10% Promissory Note in the principal amount of $588,235 (the “Dragon Note”) to Dragon Dynamic Funds Platform Ltd (“Dragon Dynamic”). The Dragon Note bears interest at the rate of 10% per annum accrued monthly and has a maturity date that is the earlier of (i) December 9, 2022, or (ii) five business days after the date on which the Company successfully lists its shares of common stock on Nasdaq or NYSE. The purchase price of the Dragon Note was $500,000; the amount payable at maturity will be $588,235 plus 10% of that amount plus any accrued and unpaid interest. Costs in the amount of $47,500 were charged to discount on the Dragon Note. Following an event of default as defined in the Dragon Note, the principal amount shall bear interest for each day until paid at a rate per annum equal to the lesser of the maximum interest permitted by applicable law and 18%. The Dragon Note entered default status on December 10, 2022, and the interest rate increased to 18%. The Dragon Note contains a “most favored nations” clause that provides that, so long as the note is outstanding, if the Company issues any new security which Dragon Dynamic reasonably believes contains a term that is more favorable than those in the Dragon Note, the Company shall notify Dragon Dynamic of such term, and such term, at the option of Dragon Dynamic, shall become a part of the Dragon Note. In addition, Dragon Dynamic received five-year warrants to purchase 4,824 shares of common stock at a price of $25.00 per share with a fair value of $21,500 at the date of issuance, and 4,824 shares of common stock with a value of $44,000; these amounts were recorded as discounts to the Dragon Note. Interest in the amount of $35,874 was accrued on the Dragon Note during the year ended December 31, 2022. Discounts in the amount of $260,059 were amortized to interest expense during the year ended December 31, 2022, and total discounts in the amount of $0 remained outstanding at December 31, 2022. Principal and accrued interest in the amounts $647,059 and $35,874, respectively, were due on the Dragon Note at December 31, 2022. During the three months ended March 31, 2023, interest in the amount of $26,969 was accrued on the Dragon Note; principal and accrued interest in the amount of $647,059 and $62,843, respectively, were due on this note at March 31, 2023. This note was in default at March 31, 2023.

 

Mackay Note

 

On July 7, 2022, the Company issued a 10% Promissory Note in the principal amount of $294,118 to Mackay Investments, LLC (the “Mackay Note”). The Mackay Note bears interest at the rate of 10% per annum accrued monthly and has a maturity date that is the earlier of (i) August 10, 2022, or (ii) five business days after the date on which the Company successfully lists its shares of common stock on Nasdaq or NYSE. The purchase price of the Mackay Note was $250,000; the amount payable at maturity will be $294,118 plus 10% of that amount plus any accrued and unpaid interest. Following an event of default as defined in the Mackay Note, the principal amount shall bear interest for each day until paid at a rate per annum equal to the lesser of the maximum interest permitted by applicable law and 18%. The Mackay Note entered default status on August 11, 2022, and the interest rate increased to 18%. The Mackay Note contains a “most favored nations” clause that provides that, so long as the note is outstanding, if the Company issues any new security which Mackay Investments, LLC reasonably believes contains a term that is more favorable than those in the Mackay Note, the Company shall notify Mackay Investments, LLC of such term, and such term, at the option of Mackay Investments, LLC , shall become a part of the Mackay Note. In addition, Mackay Investments, LLC received five-year warrants to purchase 2,412 shares of common stock at a price of $25.00 per share with a fair value of $10,250 at the date of issuance, and 2,412 shares of common stock with a value of $44,118; these amounts were recorded as discounts to the Mackay Note. Interest in the amount of $20,193 was accrued on the Mackay Note during the year ended December 31, 2022. Discounts in the amount of $96,280 were amortized to interest expense during the year ended December 31, 2022, and total discounts in the amount of $0 remained outstanding at December 31, 2022. Principal and accrued interest in the amounts $323,530 and $20,193, respectively, were due on the Mackay Note at December 31, 2022.During the three months ended March 31, 2023, interest in the amount of $16,850 was accrued on the Mackay Note; principal and accrued interest in the amount of $323,530 and $37,043 respectively, were due on this note at March 31, 2023. This note was in default at March 31, 2023.

 

Schrier Note

 

On July 7, 2022, the Company issued a 10% Promissory Note in the principal amount of $23,259 to Charles Schrier (the “Schrier Note”). The Schrier Note bears interest at the rate of 10% per annum accrued monthly and has a maturity date that is the earlier of (i) January 8, 2023, or (ii) five business days after the date on which the Company successfully lists its shares of common stock on Nasdaq or NYSE. The purchase price of the Schrier Note was $20,000; the amount payable at maturity will be $23,529 plus 10% of that amount plus any accrued and unpaid interest. Following an event of default as defined in the Schrier Note, the principal amount shall bear interest for each day until paid at a rate per annum equal to the lesser of the maximum interest permitted by applicable law and 18%. The Schrier Note contains a “most favored nations” clause that provides that, so long as the note is outstanding, if the Company issues any new security which Mr. Schrier reasonably believes contains a term that is more favorable than those in the Schrier Note, the Company shall notify Mr. Schrier of such term, and such term, at the option of Mr. Schrier, shall become a part of the Schrier Note. In addition, Mr. Schrier received five-year warrants to purchase 193 shares of common stock at a price of $25.00 per share with a fair value of $820 at the date of issuance, and 193 shares of common stock with a value of $1,000; these amounts were recorded as discounts to the Schrier Note. Interest in the amount of $1,141 was accrued on the Schrier Note during the year ended December 31, 2022. Discounts in the amount of $7,367 were amortized to interest expense during the year ended December 31, 2022, and total discounts in the amount of $335 remained outstanding at December 31, 2022. Principal and accrued interest in the amounts $25,882 and $1,141, respectively, were due on the Schrier Note at December 31, 2022. During the three months ended March 31, 2023, interest in the amount of $1,033 was accrued on the Schrier Note; principal and accrued interest in the amount of $25,882 and $2,174, respectively, were due on this note at March 31, 2023. This note was in default at March 31, 2023.

 

Nommsen Note

 

On July 26, 2022, the Company issued a 10% Promissory Note in the principal amount of $58,823 to Eric S. Nommsen (the “Nommsen Note”). The Nommsen Note bears interest at the rate of 10% per annum accrued monthly and has a maturity date that is the earlier of (i) November 30, 2022, as extended, or (ii) five business days after the date on which the Company successfully lists its shares of common stock on Nasdaq or NYSE. The purchase price of the Nommsen Note was $50,000; the amount payable at maturity will be $58,823 plus 10% of that amount plus any accrued and unpaid interest. Following an event of default as defined in the Nommsen Note, the principal amount shall bear interest for each day until paid at a rate per annum equal to the lesser of the maximum interest permitted by applicable law and 18%. The Nommsen Note entered default status on December 1, 2022, and the interest rate increased to 18%. The Nommsen Note contains a “most favored nations” clause that provides that, so long as the note is outstanding, if the Company issues any new security which Mr. Nommsen reasonably believes contains a term that is more favorable than those in the Nommsen Note, the Company shall notify Mr. Nommsen of such term, and such term, at the option of Mr. Nommsen, shall become a part of the Nommsen Note. In addition, Mr. Nommsen received five-year warrants to purchase 483 shares of common stock at a price of $25.00 per share with a fair value of $1,850 at the date of issuance, and 483 shares of common stock with a value of $2,350; these amounts were recorded as discounts to the Nommsen Note. Interest in the amount of $2,946 was accrued on the Nommsen Note during the year ended December 31, 2022. Discounts in the amount of $18,905 were amortized to interest expense during the year ended December 31, 2022, and total discounts in the amount of $0 remained outstanding at December 31, 2022. Principal and accrued interest in the amounts $64,705 and $2,946, respectively, were due on the Nommsen Note at December 31, 2022. During the three months ended March 31, 2023, interest in the amount of $2,688 was accrued on the Nommsen Note; principal and accrued interest in the amount of $64,705 and $5,634, respectively, were due on this note at March 31, 2023. This note was in default at March 31, 2023.

 

Caplan Note

 

On July 27, 2022, the Company issued a 10% Promissory Note in the principal amount of $58,823 to James H. Caplan (the “Caplan Note”). The Caplan Note bears interest at the rate of 10% per annum accrued monthly and has a maturity date that is the earlier of (i) January 21, 2023, or (ii) five business days after the date on which the Company successfully lists its shares of common stock on Nasdaq or NYSE. The purchase price of the Caplan Note was $50,000; the amount payable at maturity will be $58,823 plus 10% of that amount plus any accrued and unpaid interest. Following an event of default as defined in the Caplan Note, the principal amount shall bear interest for each day until paid at a rate per annum equal to the lesser of the maximum interest permitted by applicable law and 18%. The Caplan Note contains a “most favored nations” clause that provides that, so long as the note is outstanding, if the Company issues any new security which Mr. Caplan reasonably believes contains a term that is more favorable than those in the Caplan Note, the Company shall notify Mr. Caplan of such term, and such term, at the option of Mr. Caplan, shall become a part of the Caplan Note. In addition, Mr. Caplan received five-year warrants to purchase 483 shares of common stock at a price of $25.00 per share with a fair value of $1,850 at the date of issuance, and 483 shares of common stock with a value of $2,350; these amounts were recorded as discounts to the Caplan Note. Interest in the amount of $2,531 was accrued on the Caplan Note during the year ended December 31, 2022. Discounts in the amount of $16,675 were amortized to interest expense during the year ended December 31, 2022, and total discounts in the amount of $2,230 remained outstanding at December 31, 2022. Principal and accrued interest in the amounts $64,705 and $2,531, respectively, were due on the Caplan Note at December 31, 2022. During the three months ended March 31, 2023, interest in the amount of $2,406 was accrued on the Caplan Note; principal and accrued interest in the amount of $64,705 and $4,937, respectively, were due on this note at March 31, 2023. This note was in default at March 31, 2023.

 

Finnegan Note 3

 

On August 4, 2022, the Company issued a 10% Promissory Note in the principal amount of $29,412 (the “Finnegan Note 3”) to Jessica, Kevin C., Brody, Isabella and Jack Finnegan (collectively, the “Finnegans”). The Finnegan Note 3 bears interest at the rate of 10% per annum accrued monthly and has a maturity date that is the earlier of (i) February 3, 2023, or (ii) five business days after the date on which the Company successfully lists its shares of common stock on Nasdaq or NYSE. The purchase price of the Finnegan Note 3 was $25,000; the amount payable at maturity will be $29,412 plus 10% of that amount plus any accrued and unpaid interest. Following an event of default as defined in the Finnegan Note 3, the principal amount shall bear interest for each day until paid at a rate per annum equal to the lesser of the maximum interest permitted by applicable law and 18%. The Finnegan Note 3 contains a “most favored nations” clause that provides that, so long as the note is outstanding, if the Company issues any new security which The Finnegans reasonably believes contains a term that is more favorable than those in the Finnegan Note 3, the Company shall notify The Finnegans of such term, and such term, at the option of The Finnegans, shall become a part of the Finnegan Note 3. In addition, The Finnegans received five-year warrants to purchase 242 shares of common stock at a price of $25.00 per share with a fair value of $850 at the date of issuance, and 242 shares of common stock with a value of $1,100; these amounts were recorded as discounts to the Finnegan Note 3. Interest in the amount of $1,200 was accrued on the Finnegan Note 3 during the year ended December 31, 2022. Discounts in the amount of $7,575 were amortized to interest expense during the year ended December 31, 2022, and total discounts in the amount of $1,728 remained outstanding at December 31, 2022. Principal and accrued interest in the amounts $32,353 and $1,200, respectively, were due on the Finnegan Note 3 at December 31, 2022. During the three months ended March 31, 2023, interest in the amount of $1,125 was accrued on the Finnegan Note 3; principal and accrued interest in the amount of $32,353 and $2,325, respectively, were due on this note at March 31, 2023. This note was in default at March 31, 2023.

 

Enright Note

 

On August 4, 2022, the Company issued a 10% Promissory Note in the principal amount of $120,000 to Jack Enright (the “Enright Note”). The Enright Note bears interest at the rate of 10% per annum accrued monthly and has a maturity date that is the earlier of (i) February 3, 2023, or (ii) five business days after the date on which the Company successfully lists its shares of common stock on Nasdaq or NYSE. The purchase price of the Enright Note was $102,000; the amount payable at maturity will be $120,000 plus 10% of that amount plus any accrued and unpaid interest. Following an event of default as defined in the Enright Note, the principal amount shall bear interest for each day until paid at a rate per annum equal to the lesser of the maximum interest permitted by applicable law and 18%. The Enright Note contains a “most favored nations” clause that provides that, so long as the note is outstanding, if the Company issues any new security which Mr. Enright reasonably believes contains a term that is more favorable than those in the Enright Note, the Company shall notify Mr. Enright of such term, and such term, at the option of Mr. Enright, shall become a part of the Enright Note. In addition, Mr. Enright received 984 shares of common stock with a value of $6,317; this amount was recorded as a discount to the Enright Note. Interest in the amount of $4,899 was accrued on the Enright Note during the year ended December 31, 2022. Discounts in the amount of $29,571 were amortized to interest expense during the year ended December 31, 2022, and total discounts in the amount of $6,746 remained outstanding at December 31, 2022. Principal and accrued interest in the amounts $132,000 and $4,899, respectively, were due on the Enright Note at December 31, 2022. During the three months ended March 31, 2023, interest in the amount of $4,561 was accrued on the Enright Note; principal and accrued interest in the amount of $132,000 and $9,460, respectively, were due on this note at March 31, 2023. This note was in default at March 31, 2023.

 

Mitchell Note

 

On September 2, 2022, the Company issued a 10% Promissory Note in the principal amount of $71,000 to John Mitchell (the “Mitchell Note”). The Mitchell Note bears interest at the rate of 10% per annum accrued monthly and has a maturity date that is the earlier of (i) November 30, 2022, or (ii) five business days after the date on which the Company successfully lists its shares of common stock on Nasdaq or NYSE. The purchase price of the Mitchell Note was $60,350; the amount payable at maturity will be $71,000 plus 10% of that amount plus any accrued and unpaid interest. Following an event of default as defined in the Mitchell Note, the principal amount shall bear interest for each day until paid at a rate per annum equal to the lesser of the maximum interest permitted by applicable law and 18%. The Mitchell Note entered default status on December 1, 2022, and the interest rate increased to 18%. The Mitchell Note contains a “most favored nations” clause that provides that, so long as the note is outstanding, if the Company issues any new security which Mr. Mitchell reasonably believes contains a term that is more favorable than those in the Mitchell Note, the Company shall notify Mr. Mitchell of such term, and such term, at the option of Mr. Mitchell, shall become a part of the Mitchell Note. In addition, Mr. Mitchell received 582 shares of common stock with a value of $3,124; this amount was recorded as a discount to the Mitchell Note. Interest in the amount of $2,817 was accrued on the Mitchell Note during the year ended December 31, 2022. Discounts in the amount of $20,874 were amortized to interest expense during the year ended December 31, 2022, and total discounts in the amount of $0 remained outstanding at December 31, 2022. Principal and accrued interest in the amounts $78,100 and $2,817, respectively, were due on the Mitchell Note at December 31, 2022. The Mitchell Note was in default at December 31, 2022. During the three months ended March 31, 2023, interest in the amount of $3,234 was accrued on the Mitchell Note; principal and accrued interest in the amount of $78,100 and $6,051, respectively, were due on this note at March 31, 2023. This note was in default at March 31, 2023.

 

Lightmas Note

 

On September 2, 2022, the Company issued a 10% Promissory Note in the principal amount of $60,000 to Frank Lightmas (the “Lightmas Note”). The Lightmas Note bears interest at the rate of 10% per annum accrued monthly and has a maturity date that is the earlier of (i) November 30, 2022, or (ii) five business days after the date on which the Company successfully lists its shares of common stock on Nasdaq or NYSE. The purchase price of the Lightmas Note was $51,000; the amount payable at maturity will be $60,000 plus 10% of that amount plus any accrued and unpaid interest. Following an event of default as defined in the Lightmas Note, the principal amount shall bear interest for each day until paid at a rate per annum equal to the lesser of the maximum interest permitted by applicable law and 18%. The Lightmas Note entered default status on December 1, 2022, and the interest rate increased to 18%. The Lightmas Note contains a “most favored nations” clause that provides that, so long as the note is outstanding, if the Company issues any new security which Mr. Lightmas reasonably believes contains a term that is more favorable than those in the Lightmas Note, the Company shall notify Mr. Lightmas of such term, and such term, at the option of Mr. Lightmas, shall become a part of the Lightmas Note. In addition, Mr. Lightmas received 492 shares of common stock with a value of $2,640; this amount was recorded as a discount to the Lightmas Note. Interest in the amount of $2,380 was accrued on the Lightmas Note during the year ended December 31, 2022. Discounts in the amount of $17,640 were amortized to interest expense during the year ended December 31, 2022, and total discounts in the amount of $0 remained outstanding at December 31, 2022. Principal and accrued interest in the amounts $66,000 and $2,380, respectively, were due on the Lightmas Note at December 31, 2022. The Lightmas Note was in default at December 31, 2022. During the three months ended March 31, 2023, interest in the amount of $2,733 was accrued on the Lightmas Note; principal and accrued interest in the amount of $66,000 and $5,113, respectively, were due on this note at March 31, 2023. This note was in default at March 31, 2023.

 

Lewis Note

 

On September 2, 2022, the Company issued a 10% Promissory Note in the principal amount of $30,000 to Lisa Lewis (the “Lewis Note”). The Lewis Note bears interest at the rate of 10% per annum accrued monthly and has a maturity date that is the earlier of (i) November 30, 2022, or (ii) five business days after the date on which the Company successfully lists its shares of common stock on Nasdaq or NYSE. The purchase price of the Lewis Note was $25,500; the amount payable at maturity will be $30,000 plus 10% of that amount plus any accrued and unpaid interest. Following an event of default as defined in the Lewis Note, the principal amount shall bear interest for each day until paid at a rate per annum equal to the lesser of the maximum interest permitted by applicable law and 18%. The Lewis Note entered default status on December 1, 2022, and the interest rate increased to 18%. The Lewis Note contains a “most favored nations” clause that provides that, so long as the note is outstanding, if the Company issues any new security which Ms. Lewis reasonably believes contains a term that is more favorable than those in the Lewis Note, the Company shall notify Ms. Lewis of such term, and such term, at the option of Ms. Lewis, shall become a part of the Lewis Note. In addition, Ms. Lewis received 246 shares of common stock with a value of $1,320; this amount was recorded as a discount to the Lewis Note. Interest in the amount of $1,190 was accrued on the Lewis Note during the year ended December 31, 2022. Discounts in the amount of $8,820 were amortized to interest expense during the year ended December 31, 2022, and total discounts in the amount of $0 remained outstanding at December 31, 2022. Principal and accrued interest in the amounts $33,000 and $1,190, respectively, were due on the Lewis Note at December 31, 2022. The Lewis Note was in default at December 31, 2022. During the three months ended March 31, 2023, interest in the amount of $1,367 was accrued on the Lewis Note; principal and accrued interest in the amount of $33,000 and $2,557, respectively, were due on this note at March 31, 2023. This note was in default at March 31, 2023.

 

Goff Note

 

On September 2, 2022, the Company issued a 10% Promissory Note in the principal amount of $30,000 to Sharon Goff (the “Goff Note”). The Goff Note bears interest at the rate of 10% per annum accrued monthly and has a maturity date that is the earlier of (i) November 30, 2022, or (ii) five business days after the date on which the Company successfully lists its shares of common stock on Nasdaq or NYSE. The purchase price of the Goff Note was $25,500; the amount payable at maturity will be $30,000 plus 10% of that amount plus any accrued and unpaid interest. Following an event of default as defined in the Goff Note, the principal amount shall bear interest for each day until paid at a rate per annum equal to the lesser of the maximum interest permitted by applicable law and 18%. The Goff Note entered default status on December 1, 2022, and the interest rate increased to 18%. The Goff Note contains a “most favored nations” clause that provides that, so long as the note is outstanding, if the Company issues any new security which Ms. Goff reasonably believes contains a term that is more favorable than those in the Goff Note, the Company shall notify Ms. Goff of such term, and such term, at the option of Ms. Goff, shall become a part of the Goff Note. In addition, Ms. Goff received 246 shares of common stock with a value of $1,320; this amount was recorded as a discount to the Goff Note. Interest in the amount of $1,190 was accrued on the Goff Note during the year ended December 31, 2022. Discounts in the amount of $8,820 were amortized to interest expense during the year ended December 31, 2022, and total discounts in the amount of $0 remained outstanding at December 31, 2022. Principal and accrued interest in the amounts $33,000 and $1,190, respectively, were due on the Goff Note at December 31, 2022. The Goff Note was in default at December 31, 2022. During the three months ended March 31, 2023, interest in the amount of $1,367 was accrued on the Goff Note; principal and accrued interest in the amount of $33,000 and $2,557, respectively, were due on this note at March 31, 2023. This note was in default at March 31, 2023.

 

Hagan Note

 

On September 2, 2022, the Company issued a 10% Promissory Note in the principal amount of $100,000 to Cliff Hagan (the “Hagan Note”). The Hagan Note bears interest at the rate of 10% per annum accrued monthly and has a maturity date that is the earlier of (i) December 10, 2022, or (ii) five business days after the date on which the Company successfully lists its shares of common stock on Nasdaq or NYSE. The purchase price of the Hagan Note was $85,000; the amount payable at maturity will be $100,000 plus 10% of that amount plus any accrued and unpaid interest. Following an event of default as defined in the Hagan Note, the principal amount shall bear interest for each day until paid at a rate per annum equal to the lesser of the maximum interest permitted by applicable law and 18%. The Hagan Note entered default status on December 11, 2022, and the interest rate increased to 18%. The Hagan Note contains a “most favored nations” clause that provides that, so long as the note is outstanding, if the Company issues any new security which Mr. Hagan reasonably believes contains a term that is more favorable than those in the Hagan Note, the Company shall notify Mr. Hagan of such term, and such term, at the option of Mr. Hagan, shall become a part of the Hagan Note. In addition, Mr. Hagan received 820 shares of common stock with a value of $4,715; this amount was recorded as a discount to the Hagan Note. Interest in the amount of $3,556 was accrued on the Hagan Note during the year ended December 31, 2022. Discounts in the amount of $29,715 were amortized to interest expense during the year ended December 31, 2022, and total discounts in the amount of $0 remained outstanding at December 31, 2022. Principal and accrued interest in the amounts $110,000 and $3,556, respectively, were due on the Hagan Note at December 31, 2022. During the three months ended March 31, 2023, interest in the amount of $4,550 was accrued on the Hagan Note; principal and accrued interest in the amount of $110,000 and $8,106, respectively, were due on this note at March 31, 2023. This note was in default at March 31, 2023.

 

Darling Note

 

On September 14, 2022, the Company issued a 10% Promissory Note in the principal amount of $200,000 to Darling Capital, LLC (“Darling”), (the “Darling Note”). The Darling Note bears interest at the rate of 10% per annum accrued monthly and has a maturity date that is the earlier of (i) December 15, 2022, or (ii) five business days after the date on which the Company successfully lists its shares of common stock on Nasdaq or NYSE. The purchase price of the Darling Note was $170,000; the amount payable at maturity will be $200,000 plus 10% of that amount plus any accrued and unpaid interest. Following an event of default as defined in the Darling Note, the principal amount shall bear interest for each day until paid at a rate per annum equal to the lesser of the maximum interest permitted by applicable law and 18%. The Darling Note entered default status on December 15, 2022, and the interest rate increased to 18%. The Darling Note contains a “most favored nations” clause that provides that, so long as the note is outstanding, if the Company issues any new security which Darling reasonably believes contains a term that is more favorable than those in the Darling Note, the Company shall notify Darling of such term, and such term, at the option of Darling shall become a part of the Darling Note. In addition, Darling received 1,640 shares of common stock with a value of $10,824; this amount was recorded as a discount to the Darling Note. Interest in the amount of $6,619 was accrued on the Darling Note during the year ended December 31, 2022. Discounts in the amount of $60,824 were amortized to interest expense during the year ended December 31, 2022, and total discounts in the amount of $0 remained outstanding at December 31, 2022. Principal and accrued interest in the amounts $220,000 and $6,619, respectively, were due on the Darling Note at December 31, 2022. During the three months ended March 31, 2023, interest in the amount of $9,092 was accrued on the Darling Note; principal and accrued interest in the amount of $220,000 and $15,711, respectively, were due on this note at March 31, 2023. This note was in default at March 31, 2023.

 

Leath Note

 

On September 15, 2022, the Company issued a 10% Promissory Note in the principal amount of $50,000 to Mack Leath (the “Leath Note”). The Leath Note bears interest at the rate of 10% per annum accrued monthly and has a maturity date that is the earlier of (i) December 15, 2022, or (ii) five business days after the date on which the Company successfully lists its shares of common stock on Nasdaq or NYSE. The purchase price of the Leath Note was $42,500; the amount payable at maturity will be $55,000 plus 10% of that amount plus any accrued and unpaid interest. Following an event of default as defined in the Leath Note, the principal amount shall bear interest for each day until paid at a rate per annum equal to the lesser of the maximum interest permitted by applicable law and 18%. The Leath Note entered default status on December 16, 2022, and the interest rate increased to 18%. The Leath Note contains a “most favored nations” clause that provides that, so long as the note is outstanding, if the Company issues any new security which Mr. Leath reasonably believes contains a term that is more favorable than those in the Leath Note, the Company shall notify Mr. Leath of such term, and such term, at the option of Mr. Leath, shall become a part of the Leath Note. In addition, Mr. Leath received 410 shares of common stock with a value of $2,868; this amount was recorded as a discount to the Leath Note. Interest in the amount of $1,641 was accrued on the Leath Note during the year ended December 31, 2022. Discounts in the amount of $15,368 were amortized to interest expense during the year ended December 31, 2022, and total discounts in the amount of $0 remained outstanding at December 31, 2022. Principal and accrued interest in the amounts $55,000 and $1,641, respectively, were due on the Leath Note at December 31, 2022. During the three months ended March 31, 2023, interest in the amount of $2,273 was accrued on the Leath Note; principal and accrued interest in the amount of $55,000 and $3,914, respectively, were due on this note at March 31, 2023. This note was in default at March 31, 2023.

 

Cavalry Note

 

On October 5, 2022, the Company issued a 10% Promissory Note in the principal amount of $500,000 to the Cavalry Fund LLP (“Cavalry”), (the “Cavalry Note”) with a due date of December 31, 2022. The Cavalry Note is subject to an exchange agreement (the “Series E Exchange Agreement”) whereby Cavalry will exchange (a) amounts due under the Cavalry Note, (b) 1,000,000 shares of the Company’s Series C Convertible Preferred Stock, and (c) 750,000 shares of the Company’s Series D Convertible Preferred Stock for a number of shares of the Company’s Series E Convertible Preferred Stock equal to 150% of the principal amount of the Cavalry Note plus 150% of the stated value of the Series C and Series D convertible Preferred Stock. See note 12. The Cavalry Note bears interest at the rate of 10% per annum which will accrue from the date of the note only if the Cavalry Note is not converted pursuant to the Series E Exchange Agreement by December 10, 2022. Following an event of default as defined in the Cavalry Note, the principal amount shall bear interest for each day until paid at a rate per annum equal to the lesser of the maximum interest permitted by applicable law and 18%. The Cavalry Note contains a “most favored nations” clause that provides that, so long as the note is outstanding, if the Company issues any new security which Cavalry reasonably believes contains a term that is more favorable than those in the Cavalry Note, the Company shall notify the Cavalry of such term, and such term, at the option of Cavalry, shall become a part of the Cavalry Note. In addition, Cavalry received five-year warrants to purchase 750 shares of common stock at a price equal to the price of any warrant included in an offering in connection with listing at the Nasdaq Global Market. These warrants are not deemed issued at December 31, 2022 because the exercise price was not yet determined. Costs in the amount of $7,500 were also charged to discount on the Cavalry Note. Discounts in the amount of $10,500 were amortized to interest expense during the year ended December 31, 2022, and total discounts in the amount of $0 remained outstanding at December 31, 2022. Principal and accrued interest in the amounts $500,000 and $11,918, respectively, were due on the Cavalry Note at December 31, 2022.

 

Concurrent with the Cavalry Note, the Company entered into an exchange agreement (the “Cavalry Exchange Agreement”). Pursuant to the Calvary Exchange Agreement, Cavalry shall exchange (a) 1,000,000 shares of the Company’s Series C Convertible Preferred Stock (b) 750,000 shares of the Company’s Series D Convertible Preferred Stock and (c) amounts owing under the Cavalry Note, for a number of Series E Convertible Preferred Stock (the “Series E Shares”) equal to 150% of the principal amount of the Cavalry Note, plus 150% of the stated value of the Series C Shares and Series D Shares (the “Series E Exchange Value”). No transactions occurred pursuant to the Cavalry Exchange Agreement during the year ended December 31, 2022. See notes 12 and 16.

 

During the three months ended March 31, 2023, interest in the amount of $22,655 was accrued on the Cavalry Note; principal and accrued interest in the amount of $500,000 and $34,583, respectively, were due on this note at March 31, 2023. This note was in default at March 31, 2023.

 

Mercer Note 1

 

On October 7, 2022, the Company issued a 10% Promissory Note in the principal amount of $300,000 to the Mercer Street Global Opportunity Fund (“Mercer”), (the “Mercer Note 1”) with a due date of December 31, 2022. The Mercer Note 1 is subject to the Series E Exchange Agreement whereby Mercer will exchange (a) amounts due under the Mercer Note 1, (b) 47,619 shares of the Company’s Series C Convertible Preferred Stock, and (c) 750,000 shares of the Company’s Series D Convertible Preferred Stock for a number of shares of the Company’s Series E Convertible Preferred Stock equal to 150% of the principal amount of the Mercer Note 1 plus 150% of the stated value of the Series C and Series D convertible Preferred Stock. See note 12. The Mercer Note 1 bears interest at the rate of 10% per annum which will accrue from the date of the note only if the Mercer Note 1 is not converted pursuant to the Series E Exchange Agreement by December 10, 2022. Following an event of default as defined in the Mercer Note 1, the principal amount shall bear interest for each day until paid at a rate per annum equal to the lesser of the maximum interest permitted by applicable law and 18%. The Mercer Note 1 contains a “most favored nations” clause that provides that, so long as the note is outstanding, if the Company issues any new security which Mercer reasonably believes contains a term that is more favorable than those in the Mercer Note 1, the Company shall notify Mercer of such term, and such term, at the option of Mercer, shall become a part of the Mercer Note 1. In addition, Mercer received five-year warrants to purchase 750 shares of common stock at a price equal to the price of any warrant included in an offering in connection with listing at the Nasdaq Global Market. These warrants are not deemed issued at December 31, 2022 because the exercise price was not yet determined. Interest in the amount of $6,986 was accrued on the Mercer Note 1 during the year ended December 31, 2022. Discounts in the amount of $10,500 were amortized to interest expense during the year ended December 31, 2022, and total discounts in the amount of $0 remained outstanding at December 31, 2022. Principal and accrued interest in the amounts $300,000 and $6,986, respectively, were due on the Mercer Note 1 at December 31, 2022.

 

Concurrent with the Mercer Note 1, the Company entered into an exchange agreement (the “Mercer Exchange Agreement”). Pursuant to the Mercer Exchange Agreement, Mercer shall exchange (a) 47,619 shares of the Company’s Series C Convertible Preferred Stock, (b) 750,000 shares of the Company’s Series D Convertible Preferred Stock, and (c) amounts owing under the Mercer Note, for a number of Series E Convertible Preferred Stock (the “Series E Shares”) equal to 150% of the principal amount of the Mercer Note, plus 150% of the stated value of the Series C Shares and Series D Shares (the “Series E Exchange Value”). No transactions occurred pursuant to the Cavalry Exchange Agreement during the year ended December 31, 2022. See note 12 and 16.

 

During the three months ended March 31, 2023, interest in the amount of $13,597 was accrued on the Mercer Note 1; principal and accrued interest in the amount of $300,000 and $20,583, respectively, were due on this note at March 31, 2023. This note was in default at March 31, 2023.

 

Pinz Note

 

On October 10, 2022, the Company issued a 10% Promissory Note in the principal amount of $30,000 to the Pinz Capital Special Opportunities Fund (“Pinz”), (the “Pinz Note”) with a due date of December 31, 2022. The Pinz Note is subject to the Series E Exchange Agreement whereby Pinz will exchange (a) amounts due under the Pinz Note, (b) 100,000 shares of the Company’s Series D Convertible Preferred Stock for a number of shares of the Company’s Series E Convertible Preferred Stock equal to 150% of the principal amount of the Pinz Note plus 150% of the stated value of the Series D convertible Preferred Stock. See note 12. The Pinz Note bears interest at the rate of 10% per annum which will accrue from the date of the note only if the Pinz Note is not converted pursuant to the Series E Exchange Agreement by December 10, 2022. Following an event of default as defined in the Pinz Note, the principal amount shall bear interest for each day until paid at a rate per annum equal to the lesser of the maximum interest permitted by applicable law and 18%. The Pinz Note contains a “most favored nations” clause that provides that, so long as the note is outstanding, if the Company issues any new security which the Pinz Fund LLP reasonably believes contains a term that is more favorable than those in the Pinz Note, the Company shall notify the Pinz Fund LLP of such term, and such term, at the option of the Pinz Fund, LLP, shall become a part of the Pinz Note. In Interest in the amount of $6,986 was accrued on the Pinz Note during the year ended December 31, 2022. Discounts in the amount of $2,100 were amortized to interest expense during the year ended December 31, 2022, and total discounts in the amount of $0 remained outstanding at December 31, 2022. Principal and accrued interest in the amounts $30,000 and $674, respectively, were due on the Pinz Note at December 31, 2022.

 

Concurrent with the Pinz Note, the Company entered into an exchange agreement (the “Pinz Exchange Agreement”). Pursuant to the Pinz Exchange Agreement, Pinz shall exchange (a) 100,000 shares of the Company’s Series D Convertible Preferred Stock, and (b) amounts owing under the Pinz Note, for a number of Series E Convertible Preferred Stock equal to 150% of the principal amount of the Pinz Note, plus 150% of the stated value of the Series D Shares. No transactions occurred pursuant to the Pinz Exchange Agreement during the year ended December 31, 2022. See note 12 and 16.

 

During the three months ended March 31, 2023, interest in the amount of $1,359 was accrued on the Pinz Note; principal and accrued interest in the amount of $30,000 and $2,033, respectively, were due on this note at March 31, 2023. This note was in default at March 31, 2023.

 

Mercer Note 2

 

On October 24, 2022, the Company issued a 10% Promissory Note in the principal amount of $100,000 to Mercer (the “Mercer Note 2”) with a due date of December 31, 2022. The Mercer Note 2 is subject to the Series E Exchange Agreement whereby Mercer will exchange (a) amounts due under the Mercer Note 2 for a number of shares of the Company’s Series E Convertible Preferred Stock equal to 150% of the principal amount of the Mercer Note 2. See note 122. The Mercer Note 2 bears interest at the rate of 10% per annum which will accrue from the date of the note only if the Mercer Note 2 is not converted pursuant to the Series E Exchange Agreement by December 10, 2022. Following an event of default as defined in the Mercer Note 2, the principal amount shall bear interest for each day until paid at a rate per annum equal to the lesser of the maximum interest permitted by applicable law and 18%. The Mercer Note 2 contains a “most favored nations” clause that provides that, so long as the note is outstanding, if the Company issues any new security which Mercer reasonably believes contains a term that is more favorable than those in the Mercer Note 2, the Company shall notify Mercer of such term, and such term, at the option of Mercer, shall become a part of the Mercer Note 2. In addition, Mercer received five-year warrants to purchase 750 shares of common stock at a price equal to the price of any warrant included in an offering in connection with listing at the Nasdaq Global Market. These warrants are not deemed issued at December 31, 2022 because the exercise price was not yet determined. Interest in the amount of $1,863 was accrued on the Mercer Note 2 during the year ended December 31, 2022. Discounts in the amount of $1,900 were amortized to interest expense during the year ended December 31, 2022, and total discounts in the amount of $0 remained outstanding at December 31, 2022. Principal and accrued interest in the amounts $100,000 and $1,863, respectively, were due on the Mercer Note 2 at December 31, 2022.

 

Amounts due under the Mercer Note 2 will convert pursuant to the terms of the Mercer Exchange Agreement into shares of the Company’s series E Preferred Stock. See note 12 and 16.

 

During the three months ended March 31, 2023, interest in the amount of $4,526 was accrued on the Mercer Note 2; principal and accrued interest in the amount of $100,000 and $6,389, respectively, were due on this note at March 31, 2023. This note was in default at March 31, 2023.

 

Mercer Note 3

 

On December 2, 2022, the Company issued a 10% Promissory Note in the principal amount of $125,000 to Mercer (the “Mercer Note 3”) with a due date of May 21, 2023. The Mercer Note 3 is subject to the Series E Exchange Agreement whereby Mercer will exchange amounts due under the Mercer Note 3 for a number of shares of the Company’s Series E Convertible Preferred Stock equal to 150% of the principal amount of the Mercer Note 3. See note 12. The Mercer Note 3 bears interest at the rate of 10% per annum which will accrue from the date of the note only if the Mercer Note 3 is not converted pursuant to the Series E Exchange Agreement by May 10, 2023. Following an event of default as defined in the Mercer Note 3, the principal amount shall bear interest for each day until paid at a rate per annum equal to the lesser of the maximum interest permitted by applicable law and 18%. The Mercer Note 3 contains a “most favored nations” clause that provides that, so long as the note is outstanding, if the Company issues any new security which Mercer reasonably believes contains a term that is more favorable than those in the Mercer Note 3, the Company shall notify Mercer of such term, and such term, at the option of Mercer, shall become a part of the Mercer Note 3. In addition, Mercer received five-year warrants to purchase 750 shares of common stock at a price equal to the price of any warrant included in an offering in connection with listing at the Nasdaq Global Market. These warrants are not deemed issued at December 31, 2022 because the exercise price was not yet. determined. Discounts in the amount of $4,028 were amortized to interest expense during the year ended December 31, 2022, and total discounts in the amount of $20,972 remained outstanding at December 31, 2022. Principal and accrued interest in the amounts $125,000 and $993, respectively, were due on the Mercer Note 3 at December 31, 2022.

 

During the three months ended March 31, 2023, interest in the amount of $3,139 was accrued on the Mercer Note 3; principal and accrued interest in the amount of $125,000 and $4,132, respectively, were due on this note at March 31, 2023. This note was in default at March 31, 2023.

 

These amounts are reflected in the table below:

 

   

March 31,

2023

   

December 31,

2022

 

Notes Payable

  $ 6,174,712     $ 5,144,742  

Less: Discount

    (8,472

)

    (32,041

)

Notes payable - net of discount

  $ 6,166,240     $ 5,112,701  
                 

Current Portion, net of discount

  $ 6,166,240     $ 5,112,701  

Long-term portion, net of discount

  $ -     $ -  

 

Interest expense on notes payable was $248,596 and $0 for the three months ended March 31, 2023 and 2022, respectively. Accrued interest on notes payable was $475,276 and $362,094 at March 31, 2023 and December 31, 2022, respectively.

Related Party [Member]  
Notes Payable [Line Items]  
Debt Disclosure [Text Block]

Note 10: Notes Payable Related Parties

 

Howe Note 1

 

On December 30, 2021, we issued a 10% Promissory Note in the principal amount of $1,000,000 in a related party transaction to the Michael C. Howe Living Trust (the “Howe Note 1”). Michael C. Howe is the Chief Executive Officer of the Good Clinic LLC, one of our subsidiaries. The Howe Note 1 bears interest at the rate of 10% interest rate per annum and has a maturity date that is the earlier of (i) November 30, 2022, as extended, or (ii) five (5) business days after the date on which the Company successfully lists its shares of common stock on Nasdaq or NYSE. The purchase price of the Howe Note 1 was $850,000; the amount payable at maturity will be $1,000,000 plus 10% of that amount plus any accrued and unpaid interest. Following an event of default, as defined in the Howe Note 1, the principal amount shall bear interest for each day until paid at a rate per annum equal to the lesser of the maximum interest permitted by applicable law and 18%. The Howe Note 1 entered delinquent status on December 1, 2022, and the interest rate increased to 18%. The Howe Note 1 contains a “most favored nations” clause that provides that, so long as the note is outstanding, if the Company issues any new security, which Mr. Howe reasonably believes contains a term that is more favorable than those in the Howe Note 1, we shall notify Mr. Howe of such term, and such term, at the option of Mr. Howe, shall become a part of the Howe Note 1. In addition, Mr. Howe five-year warrants to purchase 42,000 shares of common stock at a price of $25.00 per share, and five-year warrants to purchase 42,000 shares of common stock at $37.50 per share with an aggregate fair value of $261,568 at the date of issuance, which was recorded as a discount to this note. Interest in the amount of $106,795 was accrued on the Howe Note 1 during the year ended December 31, 2022. Discounts in the amount of $511,568 were amortized to interest expense during the year ended December 31, 2022, and total discounts in the amount of $0 remained outstanding at December 31, 2022. Principal and accrued interest in the amounts $1,100,000 and $106,795, respectively, were due on the Howe Note 1 at December 31, 2022.

 

During the three months ended March 31, 2023, interest in the amount of $46,761 was accrued on the Howe Note 1; principal and accrued interest in the amount of $1,100,000 and $153,556, respectively, were due on this note at March 31, 2023. This note was in default at March 31, 2023.

 

Diamond Note 1

 

On February 24, 2022, the Company issued a 10% Promissory Note in the principal amount of $175,000 in a related party transaction to Lawrence Diamond, our Chief Executive Officer and a member of our Board of Directors (the “Diamond Note 1”). The Diamond Note 1 bears interest at the rate of 10% per annum accrued monthly and has a maturity date that is the earlier of (i) November 30, 2022, as extended, or (ii) five business days after the date on which the Company successfully lists its shares of common stock on Nasdaq or NYSE. The purchase price of the Diamond Note 1 was $148,750; the amount payable at maturity will be $175,000 plus 10% of that amount plus any accrued and unpaid interest. Following an event of default as defined in the Diamond Note 1, the principal amount shall bear interest for each day until paid at a rate per annum equal to the lesser of the maximum interest permitted by applicable law and 18%. The Diamond Note 1 entered default status on December 1, 2022, and the interest rate increased to 18%. The Diamond Note 1 contains a “most favored nations” clause that provides that, so long as the note is outstanding, if the Company issues any new security which Mr. Diamond reasonably believes contains a term that is more favorable than those in the Diamond Note 1, the Company shall notify Mr. Diamond of such term, and such term, at the option of Mr. Diamond, shall become a part of the Diamond Note 2. In addition, Mr. Diamond received five-year warrants to purchase 7,350 shares of common stock at a price of $25.00 per share, and five-year warrants to purchase 7,350 shares of common stock at $37.50 per share with an aggregate fair value of $2,914 at the date of issuance, which was recorded as a discount to this note. Interest in the amount of $16,052 was accrued on the Diamond Note 1 during the year ended December 31, 2022. Discounts in the amount of $46,664 were amortized to interest expense during the year ended December 31, 2022, and total discounts in the amount of $0 remained outstanding at December 31, 2022. Principal and accrued interest in the amounts $192,500 and $16,052, respectively, were due on the Diamond Note 1 at December 31, 2022.

 

During the three months ended March 31, 2023, interest in the amount of $8,099 was accrued on the Diamond Note 1; principal and accrued interest in the amount of $192,500 and $24,151, respectively, were due on this note at March 31, 2023. This note was in default at March 31, 2023.

 

Diamond Note 2

 

On March 18, 2022, the Company issued a 10% Promissory Note in the principal amount of $235,294 in a related party transaction to Lawrence Diamond, our Chief Executive Officer and a member of our Board of Directors (the “Diamond Note 2). The Diamond Note 2 bears interest at the rate of 10% per annum accrued monthly and has a maturity date that is the earlier of (i) November 30, 2022, as extended, or (ii) five business days after the date on which the Company successfully lists its shares of common stock on Nasdaq or NYSE. The purchase price of the Diamond Note 2 was $200,000; the amount payable at maturity will be $235,294 plus 10% of that amount plus any accrued and unpaid interest. Following an event of default as defined in the Diamond Note 2, the principal amount shall bear interest for each day until paid at a rate per annum equal to the lesser of the maximum interest permitted by applicable law and 18%. The Diamond Note 2 entered default status on December 1, 2022, and the interest rate increased to 18%. The Diamond Note 2 contains a “most favored nations” clause that provides that, so long as the note is outstanding, if the Company issues any new security which Mr. Diamond reasonably believes contains a term that is more favorable than those in the Diamond Note 2, the Company shall notify Mr. Diamond of such term, and such term, at the option of Mr. Diamond, shall become a part of the Diamond Note 2. In addition, Mr. Diamond received five-year warrants to purchase 1,930 shares of common stock at a price of $25.00 per share a fair value of $2,213 at the date of issuance, which was recorded as a discount to this note. Interest in the amount of $1,676 was accrued on the Diamond Note 2 during the year ended December 31, 2022. Principal in the amount of $235,294 was paid on the Diamond Note 2 during the year ended December 31, 2022. Discounts in the amount of $61,036 were amortized to interest expense during the year ended December 31, 2022, and total discounts in the amount of $0 remained outstanding at December 31, 2022. Principal and accrued interest in the amounts $23,529 and $1,699, respectively, were due on the Diamond Note 2 at December 31, 2022.

 

During the three months ended March 31, 2023, interest in the amount of $0 was accrued on the Diamond Note 2; principal and accrued interest in the amount of $23,529 and $1,676, respectively, were due on this note at March 31, 2023. This note was in default at March 31, 2023.

 

Diamond Note 3

 

On April 27, 2022, the Company issued a 10% Promissory Note in the principal amount of $235,294 in a related party transaction to Lawrence Diamond, our Chief Executive Officer and a member of our Board of Directors (the “Diamond Note 3”). The Diamond Note 3 bears interest at the rate of 10% per annum accrued monthly and has a maturity date that is the earlier of (i) November 30, 2022, as extended, or (ii) five business days after the date on which the Company successfully lists its shares of common stock on Nasdaq or NYSE. The purchase price of the Diamond Note 3 was $200,000; the amount payable at maturity will be $235,294 plus 10% of that amount plus any accrued and unpaid interest. Following an event of default as defined in the Diamond Note 3, the principal amount shall bear interest for each day until paid at a rate per annum equal to the lesser of the maximum interest permitted by applicable law and 18%. The Diamond Note 3 entered default status on December 1, 2022, and the interest rate increased to 18%. The Diamond Note 3 contains a “most favored nations” clause that provides that, so long as the note is outstanding, if the Company issues any new security which Mr. Diamond reasonably believes contains a term that is more favorable than those in the Diamond Note 3, the Company shall notify Mr. Diamond of such term, and such term, at the option of Mr. Diamond, shall become a part of the Diamond Note 3. In addition, Mr. Diamond received five-year warrants to purchase 1,930 shares of common stock at a price of $25.00 per share with a fair value of $8,800 at the date of issuance, and 1,930 shares of common stock with a value of $16,200; these amounts were recorded as discounts on the Diamond Note 3. Interest in the amount of $17,586 was accrued on the Diamond Note 3 during the year ended December 31, 2022. Discounts in the amount of $83,823 were amortized to interest expense during the year ended December 31, 2022, and total discounts in the amount of $0 remained outstanding at December 31, 2022. Principal and accrued interest in the amounts $258,823 and $17,586, respectively, were due on the Diamond Note 3 at December 31, 2022.

 

During the three months ended March 31, 2023, interest in the amount of $10,832 was accrued on the Diamond Note 3; principal and accrued interest in the amount of $258,823 and $28,418, respectively, were due on this note at March 31, 2023. This note was in default at March 31, 2023.

 

Diamond Note 4

 

On May 18, 2022, the Company issued a 10% Promissory Note in the principal amount of $47,059 in a related party transaction to Lawrence Diamond, our Chief Executive Officer and a member of our Board of Directors (the “Diamond Note 4”). The Diamond Note 4 bears interest at the rate of 10% per annum accrued monthly and has a maturity date that is the earlier of (i) November 30, 2022, as extended, or (ii) five business days after the date on which the Company successfully lists its shares of common stock on Nasdaq or NYSE. The purchase price of the Diamond Note 4 was $40,000; the amount payable at maturity will be $47,059 plus 10% of that amount plus any accrued and unpaid interest. Following an event of default as defined in the Diamond Note 4, the principal amount shall bear interest for each day until paid at a rate per annum equal to the lesser of the maximum interest permitted by applicable law and 18%. The Diamond Note 4 entered default status on December 1, 2022, and the interest rate increased to 18%. The Diamond Note 4 contains a “most favored nations” clause that provides that, so long as the note is outstanding, if the Company issues any new security which Mr. Diamond reasonably believes contains a term that is more favorable than those in the Diamond Note 4, the Company shall notify Mr. Diamond of such term, and such term, at the option of Mr. Diamond, shall become a part of the Diamond Note 4. In addition, Mr. Diamond received five-year warrants to purchase 386 shares of common stock at a price of $25.00 per share with a fair value of $2,960 at the date of issuance, and 1,930 shares of common stock with a value of $3,160; these amounts were recorded as discounts on the Diamond Note 4. Interest in the amount of $3,245 was accrued on the Diamond Note 4 during the year ended December 31, 2022. Discounts in the amount of $17,885 were amortized to interest expense during the year ended December 31, 2022, and total discounts in the amount of $0 remained outstanding at December 31, 2022. Principal and accrued interest in the amounts $51,765 and $3,245, respectively, were due on the Diamond Note 4 at December 31, 2022.

 

During the three months ended March 31, 2023, interest in the amount of $2,164 was accrued on the Diamond Note 4; principal and accrued interest in the amount of $51,765 and $5,409, respectively, were due on this note at March 31, 2023. This note was in default at March 31, 2023.

 

Diamond Note 5

 

On May 26, 2022, the Company issued a 10% Promissory Note in the principal amount of $58,823 in a related party transaction to Lawrence Diamond, our Chief Executive Officer and a member of our Board of Directors (the “Diamond Note 5”). The Diamond Note 5 bears interest at the rate of 10% per annum accrued monthly and has a maturity date that is the earlier of (i) November 30, 2022, or (ii) five business days after the date on which the Company successfully lists its shares of common stock on Nasdaq or NYSE. The purchase price of the Diamond Note 5 was $50,000; the amount payable at maturity will be $58,823 plus 10% of that amount plus any accrued and unpaid interest. Following an event of default as defined in the Diamond Note 5, the principal amount shall bear interest for each day until paid at a rate per annum equal to the lesser of the maximum interest permitted by applicable law and 18%. The Diamond Note 5 entered default status on December 1, 2022, and the interest rate increased to 18%. The Diamond Note 5 contains a “most favored nations” clause that provides that, so long as the note is outstanding, if the Company issues any new security which Mr. Diamond reasonably believes contains a term that is more favorable than those in the Diamond Note 5, the Company shall notify Mr. Diamond of such term, and such term, at the option of Mr. Diamond, shall become a part of the Diamond Note 5. In addition, Mr. Diamond received five-year warrants to purchase 483 shares of common stock at a price of $25.00 per share with a fair value of $2,500 at the date of issuance, and 483 shares of common stock with a value of $4,050; these amounts were recorded as discounts to the Diamond Note 5. Interest in the amount of $3,929 was accrued on the Diamond Note 5 during the year ended December 31, 2022. Discounts in the amount of $21,256 were amortized to interest expense during the year ended December 31, 2022, and total discounts in the amount of $0 remained outstanding at December 31, 2022. Principal and accrued interest in the amounts $64,705 and $3,929, respectively, were due on the Diamond Note 5 at December 31, 2022.

 

During the three months ended March 31, 2023, interest in the amount of $2,702 was accrued on the Diamond Note 5; principal and accrued interest in the amount of $64,705 and $6,631, respectively, were due on this note at March 31, 2023. This note was in default at March 31, 2023.

 

Lindstrom Note 1

 

On May 26, 2022, the Company issued a 10% Promissory Note in the principal amount of $41,176 in a related party transaction to Jenny Lindstrom, the Company’s Chief Legal Officer (the “Lindstrom Note 1”). The Lindstrom Note 1 bears interest at the rate of 10% per annum accrued monthly and has a maturity date that is the earlier of (i) November 30, 2022, or (ii) five business days after the date on which the Company successfully lists its shares of common stock on Nasdaq or NYSE. The purchase price of the Lindstrom Note 1 was $35,000; the amount payable at maturity will be $41,176 plus 10% of that amount plus any accrued and unpaid interest. Following an event of default as defined in the Lindstrom Note 1, the principal amount shall bear interest for each day until paid at a rate per annum equal to the lesser of the maximum interest permitted by applicable law and 18%. The Lindstrom Note 1 entered default status on December 1, 2022, and the interest rate increased to 18%. The Lindstrom Note 1 contains a “most favored nations” clause that provides that, so long as the note is outstanding, if the Company issues any new security which Ms. Lindstrom reasonably believes contains a term that is more favorable than those in the Lindstrom Note 1, the Company shall notify Ms. Lindstrom of such term, and such term, at the option of Ms. Lindstrom, shall become a part of the Lindstrom Note 1. In addition, Ms. Lindstrom received five-year warrants to purchase 338 shares of common stock at a price of $25.00 per share with a fair value of $1,750 at the date of issuance, and 338 shares of common stock with a value of $2,835; these amounts were recorded as discounts to the Lindstrom Note 1. Interest in the amount of $2,750 was accrued on the Lindstrom Note 1 during the year ended December 31, 2022. Discounts in the amount of $14,879 were amortized to interest expense during the year ended December 31, 2022, and total discounts in the amount of $0 remained outstanding at December 31, 2022. Principal and accrued interest in the amounts $45,294 and $2,750, respectively, were due on the Lindstrom Note 1 at December 31, 2022.

 

During the three months ended March 31, 2023, interest in the amount of $1,891 was accrued on the Lindstrom Note; principal and accrued interest in the amount of $45,294 and $4,641, respectively, were due on this note at March 31, 2023. This note was in default at March 31, 2023.

 

Dobbertin Note

 

On May 26, 2022, the Company issued a 10% Promissory Note in the principal amount of $17,647 in a related party transaction to Alexander Dobbertin (the “Dobbertin Note”). Mr. Dobbertin is the spouse of Jenny Lindstrom, the Company’s Chief Legal Officer. The Dobbertin Note bears interest at the rate of 10% per annum accrued monthly and has a maturity date that is the earlier of (i) November 30, 2022, or (ii) five business days after the date on which the Company successfully lists its shares of common stock on Nasdaq or NYSE. The purchase price of the Dobbertin Note was $15,000; the amount payable at maturity will be $17,647 plus 10% of that amount plus any accrued and unpaid interest. Following an event of default as defined in the Dobbertin Note, the principal amount shall bear interest for each day until paid at a rate per annum equal to the lesser of the maximum interest permitted by applicable law and 18%. The Dobbertin Note entered default status on December 1, 2022, and the interest rate increased to 18%. The Dobbertin Note contains a “most favored nations” clause that provides that, so long as the note is outstanding, if the Company issues any new security which Mr. Dobbertin reasonably believes contains a term that is more favorable than those in the Dobbertin Note, the Company shall notify Mr. Dobbertin of such term, and such term, at the option of Mr. Dobbertin, shall become a part of the Dobbertin Note. In addition, Mr. Dobbertin received five-year warrants to purchase 145 shares of common stock at a price of $25.00 per share with a fair value of $750 at the date of issuance, and 145 shares of common stock with a value of $1,215; these amounts were recorded as discounts to the Dobbertin Note. Interest in the amount of $1,179 was accrued on the Dobbertin Note during the year ended December 31, 2022. Discounts in the amount of $6,377 were amortized to interest expense during the year ended December 31, 2022, and total discounts in the amount of $0 remained outstanding at December 31, 2022. Principal and accrued interest in the amounts $19,412 and $1,179, respectively, were due on the Dobbertin Note at December 31, 2022.

 

During the three months ended March 31, 2023, interest in the amount of $811 was accrued on the Dobbertin Note; principal and accrued interest in the amount of $19,412 and $1,990, respectively, were due on this note at March 31, 2023. This note was in default at March 31, 2023.

 

Howe Note 2

 

On June 9, 2022, the Company issued a 10% Promissory Note in the principal amount of $300,000 in a related party transaction to the Michael C. Howe Living Trust (the “Howe Note 2”). Michael C. Howe is the Chief Executive Officer of the Good Clinic LLC, one of our subsidiaries. The Howe Note 2 bears interest at the rate of 10% per annum accrued monthly and has a maturity date that is the earlier of (i) November 30, 2022, or (ii) five business days after the date on which the Company successfully lists its shares of common stock on Nasdaq or NYSE. The purchase price of the Howe Note 2 was $255,000; the amount payable at maturity will be $300,000 plus 10% of that amount plus any accrued and unpaid interest. Following an event of default as defined in the Howe Note 2, the principal amount shall bear interest for each day until paid at a rate per annum equal to the lesser of the maximum interest permitted by applicable law and 18%. The Howe Note 2 entered default status on December 1, 2022, and the interest rate increased to 18%. The Howe Note 2 contains a “most favored nations” clause that provides that, so long as the note is outstanding, if the Company issues any new security which Mr. Howe reasonably believes contains a term that is more favorable than those in the Howe Note 2, the Company shall notify Mr. Howe of such term, and such term, at the option of Mr. Howe, shall become a part of the Howe Note 2. In addition, Mr. Howe received five-year warrants to purchase 2,460 shares of common stock at a price of $25.00 per share with a fair value of $10,965 at the date of issuance, and 2,460 shares of common stock with a value of $22,440; these amounts were recorded as discounts to the Howe Note 2. Interest in the amount of $18,888 was accrued on the Howe Note 2 during the year ended December 31, 2022. Discounts in the amount of $108,405 were amortized to interest expense during the year ended December 31, 2022, and total discounts in the amount of $0 remained outstanding at December 31, 2022. Principal and accrued interest in the amounts $330,000 and $18,888, respectively, were due on the Howe Note 2 at December 31, 2022.

 

During the three months ended March 31, 2023, interest in the amount of $8,099 was accrued on the Howe Note 2; principal and accrued interest in the amount of $330,000 and $32,650, respectively, were due on this note at March 31, 2023. This note was in default at March 31, 2023.

 

Howe Note 3

 

On July 21, 2022, the Company issued a 10% Promissory Note in the principal amount of $300,000 in a related party transaction to the Michael C. Howe Living Trust (the “Howe Note 3”). Michael C. Howe is the Chief Executive Officer of the Good Clinic LLC, one of our subsidiaries. The Howe Note 3 bears interest at the rate of 10% per annum accrued monthly and has a maturity date that is the earlier of (i) November 30, 2022, as extended, or (ii) five business days after the date on which the Company successfully lists its shares of common stock on Nasdaq or NYSE. The purchase price of the Howe Note 3 was $255,000; the amount payable at maturity will be $300,000 plus 10% of that amount plus any accrued and unpaid interest. Following an event of default as defined in the Howe Note 3, the principal amount shall bear interest for each day until paid at a rate per annum equal to the lesser of the maximum interest permitted by applicable law and 18%. The Howe Note 3 entered default status on December 1, 2022, and the interest rate increased to 18%. The Howe Note 3 contains a “most favored nations” clause that provides that, so long as the note is outstanding, if the Company issues any new security which Mr. Howe reasonably believes contains a term that is more favorable than those in the Howe Note 3, the Company shall notify Mr. Howe of such term, and such term, at the option of Mr. Howe, shall become a part of the Howe Note 3. In addition, Mr. Howe received five-year warrants to purchase 2,460 shares of common stock at a price of $25.00 per share with a fair value of $9,945 at the date of issuance, and 2,460 shares of common stock with a value of $12,495; these amounts were recorded as discounts to the Howe Note 3. Interest in the amount of $15,436 was accrued on the Howe Note 3 during the year ended December 31, 2022. Discounts in the amount of $97,440 were amortized to interest expense during the year ended December 31, 2022, and total discounts in the amount of $0 remained outstanding at December 31, 2022. Principal and accrued interest in the amounts $330,000 and $15,436, respectively, were due on the Howe Note 3 at December 31, 2022.

 

During the three months ended March 31, 2023, interest in the amount of $13,714 was accrued on the Howe Note 3; principal and accrued interest in the amount of $330,000 and $29,150, respectively, were due on this note at March 31, 2023. This note was in default at March 31, 2023.

 

Iturregui Note 1

 

On July 21, 2022, the Company issued a 10% Promissory Note in the principal amount of $29,412 in a related party transaction to Juan Carlos Iturregui, a member of the Company’s Board of Directors (the “Iturregui Note 1”). The Iturregui Note 1 bears interest at the rate of 10% per annum accrued monthly and has a maturity date that is the earlier of (i) January 21, 2023, or (ii) five business days after the date on which the Company successfully lists its shares of common stock on Nasdaq or NYSE. The purchase price of the Iturregui Note 1 was $25,000; the amount payable at maturity will be $29,412 plus 10% of that amount plus any accrued and unpaid interest. Following an event of default as defined in the Iturregui Note 1, the principal amount shall bear interest for each day until paid at a rate per annum equal to the lesser of the maximum interest permitted by applicable law and 18%. The Iturregui Note 1 contains a “most favored nations” clause that provides that, so long as the note is outstanding, if the Company issues any new security which Mr. Iturregui reasonably believes contains a term that is more favorable than those in the Iturregui Note 1, the Company shall notify Mr. Iturregui of such term, and such term, at the option of Mr. Iturregui, shall become a part of the Iturregui Note 1. In addition, Mr. Iturregui received five-year warrants to purchase 242 shares of common stock at a price of $25.00 per share with a fair value of $975 at the date of issuance, and 242 shares of common stock with a value of $1,225; these amounts were recorded as discounts to the Iturregui Note 1. Interest in the amount of $1,313 was accrued on the Iturregui Note 1 during the year ended December 31, 2022. Discounts in the amount of $8,464 were amortized to interest expense during the year ended December 31, 2022, and total discounts in the amount of $1,089 remained outstanding at December 31, 2022. Principal and accrued interest in the amounts $32,353 and $1,313, respectively, were due on the Iturregui Note 1 at December 31, 2022.

 

During the three months ended March 31, 2023, interest in the amount of $1,205 was accrued on the Iturregui Note 1; principal and accrued interest in the amount of $32,353 and $2,518, respectively, were due on this note at March 31, 2023. This note was in default at March 31, 2023.

 

Howe Note 4

 

On August 18, 2022, the Company issued a 10% Promissory Note in the principal amount of $200,000 in a related party transaction to the Michael C. Howe Living Trust (the “Howe Note 4”). Michael C. Howe is the Chief Executive Officer of the Good Clinic LLC, one of our subsidiaries. The Howe Note 4 bears interest at the rate of 10% per annum accrued monthly and has a maturity date that is the earlier of (i) November 30, 2022, or (ii) five business days after the date on which the Company successfully lists its shares of common stock on Nasdaq or NYSE. The purchase price of the Howe Note 4 was $170,000; the amount payable at maturity will be $200,000 plus 10% of that amount plus any accrued and unpaid interest. Following an event of default as defined in the Howe Note 4, the principal amount shall bear interest for each day until paid at a rate per annum equal to the lesser of the maximum interest permitted by applicable law and 18%. The Howe Note 4 entered default status on December 1, 2022, and the interest rate increased to 18%. The Howe Note 4 contains a “most favored nations” clause that provides that, so long as the note is outstanding, if the Company issues any new security which Mr. Howe reasonably believes contains a term that is more favorable than those in the Howe Note 4, the Company shall notify Mr. Howe of such term, and such term, at the option of Mr. Howe, shall become a part of the Howe Note 4. In addition, Mr. Howe received 1,640 shares of common stock with a value of $10,775; this amount was recorded as a discount to the Howe Note 4. Interest in the amount of $8,756 was accrued on the Howe Note 4 during the year ended December 31, 2022. Discounts in the amount of $60,775 were amortized to interest expense during the year ended December 31, 2022, and total discounts in the amount of $0 remained outstanding at December 31, 2022. Principal and accrued interest in the amounts $220,000 and $8,756, respectively, were due on the Howe Note 4 at December 31, 2022.

 

During the three months ended March 31, 2023, interest in the amount of $9,677 was accrued on the Howe Note 4; principal and accrued interest in the amount of $220,000 and $18,433, respectively, were due on this note at March 31, 2023. This note was in default at March 31, 2023.

 

November 29, 2022 Notes

 

On November 29, 2022, the Company issued seven identical promissory notes (the “November 29 Notes”) in related party transactions to the following individuals: (1) Thomas Brodmerkel, the Company’s CFO and Board Member; (2) Lawrence Diamond, the Company’s Chief Executive Officer and Board Member; (3) Sheila Schweitzer, Board Member; (4) Faraz Naqvi, a former Board Member; (5) Juan Carlos Iturregui, Board Member; (6) Jenny Lindstrom, the Company’s former Vice President and Chief Legal Officer; and (7) Michael C. Howe, Chief Executive Officer of The Good Clinic, one of our subsidiaries (collectively, the “November 29 Lenders”).

 

The November 29 notes have due dates of May 28, 2023. The November 29 Notes are subject to the Series E Exchange Agreement whereby each of the November 29 Lenders will exchange (a) amounts due under the November 29 Notes for a number of shares of the Company’s Series E Convertible Preferred Stock equal to 150% of the principal amount of each November 29 Note. See note 12. The November 29 Notes bear interest at the rate of 10% per annum which will accrue from the date of the note only if the November 29 Notes are not converted pursuant to the Series E Exchange Agreement by May 10, 2023. Following an event of default as defined in the November 29 Notes, the principal amount shall bear interest for each day until paid at a rate per annum equal to the lesser of the maximum interest permitted by applicable law and 18%. The November 29 Notes contain a “most favored nations” clause that provides that, so long as the note is outstanding, if the Company issues any new security which November 29 Lender reasonably believes contains a term that is more favorable than those in the November 29 Note, the Company shall notify the November 29 Lenders of such term, and such term, at the option of the November 29 Lenders, shall become a part of the November 29 Note. In addition, each of the November 29 Lenders will receive five-year warrants to purchase 750 shares of the Company’s common stock at a price equal to the price of any warrant included in an offering in connection with listing at the Nasdaq Global Market. These warrants are not deemed issued at December 31, 2022 because the exercise price was not yet determined. Discounts in the amount of $667 were amortized to interest expense for each of the November 29 Notes during the year ended December 31, 2022, and discounts in the amount of $3,083 remained outstanding for each of the November 29 Notes at December 31, 2022. Principal and accrued interest in the amounts $18,750 and $164, respectively, were due on each of the seven November 29 Note at December 31, 2022.

 

Concurrent with the November 29 Notes, the Company entered into separate exchange agreements (the “November 29 Notes Exchange Agreements”). Pursuant to the November 29 Notes Exchange Agreements, amounts due under the November 29 Notes will be exchanged for a number Series E Convertible Preferred Stock equal to 150% of the principal amount of the Notes. No transactions occurred pursuant to the November 29 Notes Exchange Agreements during the year ended December 31, 2022.

 

During the three months ended March 31, 2023, interest in the amount of $471 was accrued on each of the November 29 Notes; principal and accrued interest in the amount of $18,750 and $635, respectively, were due on each of these notes at March 31, 2023. These notes were in default at March 31, 2023.

 

These amounts are reflected in the table below:

 

   

March 31,

2023

   

December 31,

2022

 

Notes Payable

  $ 2,799,632     $ 2,799,632  

Less: Discount

  $ (8,456

)

  $ (22,670

)

Notes payable – net of discounts

  $ 2,791,176     $ 2,776,962  
                 

Current Portion, net of discount

  $ 2,791,176     $ 2,776,962  

Long-term portion, net of discount

  $ -     $ -  

 

Interest expense on notes payable – related parties was $114,938 and $27,174 for the three months ended March 31, 2023 and 2022, respectively Accrued interest on notes payable – related parties was $313,691 and $198,753 at March 31, 2023 and December 31, 2022, respectively.

v3.23.3
Derivative Liabilities
3 Months Ended
Mar. 31, 2023
Disclosure Text Block [Abstract]  
Derivatives and Fair Value [Text Block]

Note 11: Derivative Liabilities

 

Certain of the Company’s convertible notes and warrants contain features that create derivative liabilities. The pricing model the Company uses for determining fair value of its derivatives is the Lattice Model. Valuations derived from this model are subject to ongoing internal and external verification and review. The model uses market-sourced inputs such as interest rates and stock price volatilities. Selection of these inputs involves management’s judgment and may impact net income. The derivative components of these notes are valued at issuance, at conversion, at restructuring, and at each period end.

 

Derivative liability activity for the for the period ended March 31, 2023 is summarized in the table below:

 

December 31, 2022

  $ 568,912  

Loss on revaluation

    110,778  

March 31, 2023

  $ 679,690  

 

The Company uses a Monte Carlo model to value certain features of its notes payable that create derivative liabilities. The following table summarizes the assumptions for the valuations:

 

   

December 31,

 
   

2022

 

Volatility

    95.1% to 123.2

%

Stock Price

  $ 1.06 to 3.50  

Risk-free interest rates

    4.35% to 4.37

%

Term (years)

    0.73 to 0.86  

 

   

March 31,

 
   

2023

 

Volatility

    159.6% to 169.9

%

Stock Price

  $ 1.24  

Risk-free interest rates

    4.40

%

Term (years)

    0.52 to 0.61  

 

Certain of our notes payable contain a commitment fee obligation with a true-up feature. The following assumptions were used for the valuation of the derivative liability associated with this obligation:

 

 

The stock price would fluctuate with the Company projected volatility.

 

The projected volatility curve from an annualized analysis for each valuation date was based on the historical volatility of the Company and the term remaining for the True-Up obligation.

 

The Company expected the note would be repaid 90% of the time by the maturity date, at which point the Company would redeem the 1,000,000 redeemable commitment fee shares for $1.

 

In the event the Company did not repay the note in time, the shareholders would sell their shares subject to volume restrictions.

 

Discount rates were based on risk-free rates in effect based on the remaining term. 50,000 simulations were run for each Monte Carlo simulation.

v3.23.3
Stockholders’ Equity (Deficit)
3 Months Ended
Mar. 31, 2023
Stockholders' Equity Note [Abstract]  
Equity [Text Block]

Note 12: Stockholders Equity (Deficit)

 

Common Stock

 

The Company has authorized 500,000,000 shares of common stock, par value $0.01; 4,995,573 shares were issued and outstanding on March 31, 2023.

 

Common Stock Transactions During the Three Months Ended March 31, 2023

 

On January 23, 2023, the Company issued 150,000 shares of common stock at the market price of $3.45 per share to a service provider. The aggregate value of $517,500 was charged to non-cash compensation during the three months ended March 31, 2023.

 

On February 21, 2023, the Company issued 150,000 shares of common stock at the market price of $2.53 per share to a service provider. The aggregate value of $379,500 was charged to non-cash compensation during the three months ended March 31, 2023.

 

During the three months ended March 31, 2023, GS Capital converted principal and accrued interest in a convertible note payable into shares of common stock as follows: On February 14, 2023, principal of $15,000, accrued interest of $1,632, and fees of $500 were converted at a price of $1.74 per share into 9,846 shares of common stock; on February 28, 2023, principal of $17,777, accrued interest of $2,057, and fees of $500 were converted at a price of $1.50 per share into 13,555 shares of common stock; on March 9, 2023, principal of $20,000, accrued interest of $2,399, and fees of $500 were converted at a price of $1.50 per share into 15,265 shares of common stock; and on March 28, 2023, principal of $20,000, accrued interest of $2,581, and fees of $500 were converted at a price of $1.25 per share into 18,472 shares of common stock. These conversions were made pursuant to the terms of the convertible note agreement and no gain or loss was recognized on these transactions.

 

On March 31, 2023, the Company issued a total of 8,063 shares of common stock for accrued dividends on its Series X Preferred Stock. Of this amount, a total of 1,066 shares were issued to officers and directors, 4,160 were issued to a related party shareholder, and 2,837 were issued to no-related parties.

 

Common Stock Transactions During the Three Months Ended March 31, 2022

 

On January 12, 2022, the Company entered into a settlement agreement with an ex-employee. Pursuant to the terms of this agreement, the Company agreed to pay the amount of $19,032 for accrued salary, and the employee returned to the Company for cancellation 8,000 shares of common stock previously issued as compensation. These shares were valued at par value of $0.01 or a total value of $4,000; the Company recorded a gain on cancellation of these shares in the amount of $15,032.

 

The Company entered into a debt-for-equity exchange agreement with Gardner Builders Holdings, LLC (“Gardner”) on January 7, 2022 (the “Debt for Equity Agreement”). Pursuant to the Debt for Equity Agreement, the Company issued shares of restricted common stock to Gardner in exchange for the Company Debt Obligations, as defined below.

 

The Agreement settled for certain accounts payable amounts owed by the Company to the Creditor (the “Accounts Payable Amount”) as well as upcoming amounts that will become due between the date of the Agreement and April 1, 2022. The Agreement also settled accrued interest and penalties on the amounts due through January 5, 2022, as well as future interest payments on amounts to be accrued in the first quarter of 2022 (collectively, the “Additional Costs”, and combined with the Accounts Payable Amount, the “Company Debt Obligations”). The Accounts Payable Amount was $500,000, the Additional Costs were $294,912 and the conversion price was $12.50. As a result, 63,593 Restricted Shares were authorized to be issued. The Company’s Board of Directors approved the Agreement on January 5, 2022.

 

On March 22, 2022 and March 31, 2022, the Company issued an aggregate 30,834 shares of common stock as waiver fees to holders of the Series C and Series D Preferred Stock for their waivers of certain covenants as set forth and defined in the Series C and Series C Certificates of Designations. The Company valued these shares at their contractual price of $12.50 per share and recorded the amount of $385,431 as waiver fees during the three months ended March 31, 2022. The Company recorded an aggregate gain upon issuance of these shares in the amount of $198,273 based on the market price of the Company’s common stock on the date of issuance.

 

On March 31, 2022, the Company issued 34,400 Commitment Fee Shares to AJB Capital Investors, LLC; see note 8. The Company utilized an outside valuation consultant to value the commitment fee shares, the True-Up Provision, and warrants. A Monte Carlo model was used to value the warrants and call features, and a probability weighted expected return model was used to value the True-Up Provision. The contractual price of the common stock $12.50 per share; valuation purposes, the common stock was valued at the market price on the date of the transaction of $6.14 per share. The derivative liability was valued at $106,608 on the date of the transaction. The discount on the notes due to the Commitment Fee Shares and warrants was valued at $349,914. The Company recorded the amount of $226,106 to additional paid-in capital pursuant to this transaction.

 

On March 31, 2022, the Company issued 7,647 shares of common stock at a price of $12.50 per share which were previously subscribed for the conversion of accounts payable in the amount of $95,558.

 

Preferred Stock

 

We have authorized to issue 100,000,000 shares of Preferred Stock with such rights designations and preferences as determined by our Board of Directors. We have designated 500,000 shares of Series A Preferred, 3,000,000 shares of Series C Preferred, 10,000,000 shares of Series D Preferred, 10,000 shares of Series E Preferred,  140,000 shares of Series F Preferred, and  27,324 shares of Series X Preferred.

 

Series A Preferred Stock Transactions During the Three Months Ended March 31, 2023

 

None.

 

Series A Preferred Stock Transactions During the Three Months Ended March 31, 2022

 

None.

 

Series C Preferred Stock

 

Series C Preferred Stock Transactions During the Three Months Ended March 31, 2023

 

The Company accrued dividends in the amount of $16,521 on the Series C Preferred Stock.

 

Series C Preferred Stock Transactions During the Three Months Ended March 31, 2022

 

The Company accrued dividends in the amount of $16,395 on the Series C Preferred Stock.

 

Series D Preferred Stock

 

Series D Preferred Stock Transactions During the Three Months Ended March 31, 2023

 

The Company accrued dividends in the amount of $48,156 on the Series D Preferred Stock.

 

Series D Preferred Stock Transactions During the Three Months Ended March 31, 2022

 

The Company accrued dividends in the amount of $48,156 on the Series D Preferred Stock.

 

Series E Preferred Stock

 

On November 7, 2022, the Company filed a Certificate of Designations, Preferences and Rights of Series E Convertible Perpetual Preferred Stock (the “Series E”) with the Delaware Secretary of State. The number of shares of Series E designated is 10,000 and each share of Series E has a stated value equal to $1,000. Each share of Series E Preferred Stock shall have a par value of $0.01.

 

Each share of Series E shall become convertible, at the option of the holder, commencing on the date of issuance, into such number of fully paid and non-assessable shares of Common Stock. The conversion price shall be, as of the conversion date, (a) prior to the date of the qualified offering the average VWAP per share of the Common Stock for the five (5) trading days prior to the date of conversion and (b) on or following the date of the qualified offering, the qualified offering price (the “Conversion Price”). Immediately following the 120th day following the qualified offering, the Conversion Price shall be adjusted to the lesser of (a) the average VWAP per share of the Common Stock for the five (5) trading days immediately following the 120th day following the qualified offering and (b) the Conversion Price on such date, which shall in no event be less than $0.05.

 

Series E Preferred Stock Transactions During the Three Months Ended March 31, 2023

 

None.

 

Series F Preferred Stock

 

On March 23, 2023, the Company filed a Certificate of Designation, Preferences and Rights of Series F 12% PIK Convertible Perpetual Preferred Stock (the "Series F”) with the Delaware Secretary of State. The number of shares of Series F designated is 140,000 and each share of Series F has a stated value equal to $1,000. Each share of Series F Preferred Stock shall have a par value of $0.01. Holders of the Series F are entitled to receive payment in kind dividends ("PIK Dividends”) at the quarterly rate of three-hundredths of one share outstanding per Series F Share. The Series F can be converted, at the option of the Series F shareholder into shares of the Company’s common stock at a price equal to 65% of the Volume Weighted Average Price ("VWAP”) on the conversion date. No conversions can occur until the Company has successfully completed an uplist to NASDAQ.

 

Series F Preferred Stock Transactions During the Three Months Ended March 31, 2023

 

None.

 

Series X Preferred Stock

 

The Company has 24,227 shares of its 10% Series X Cumulative Redeemable Perpetual Preferred Stock (the “Series X Preferred Stock”) outstanding as of March 31, 2023 and December 31, 2022. The Series X Preferred Stock has a par value of $0.01 per share, no stated maturity, a liquidation preference of $25.00 per share, and will not be subject to any sinking fund or mandatory redemption and will remain outstanding indefinitely unless the Company decides to redeem or otherwise repurchase the Series X Preferred Stock; the Series X Preferred Stock is not redeemable prior to November 4, 2020. The Series X Preferred Stock will rank senior to all classes of the Company’s common and preferred stock and accrues dividends at the rate of 10% on $25.00 per share. The Company reserves the right to pay the dividends in shares of the Company’s common stock at a price equal to the average closing price over the five days prior to the date of the dividend declaration. Each one share of the Series X Preferred Stock is entitled to 20,000 votes on all matters submitted to a vote of our shareholders.

 

Series X Preferred Stock Transactions During the Three Month Ended March 31, 2023

 

The Company accrued dividends in the amount of $15,141 on the Series X Preferred Stock.

 

On March 31, 2023, the Company issued 8,063 shares of common stock at an average price of $4.38 per share for accrued dividends on the Series X Preferred Stock.

 

Series X Preferred Stock Transactions During the Three Months Ended March 31, 2022

 

The Company accrued dividends in the amount of $15,141 on the Series X Preferred Stock.

 

Stock Options

 

The following table summarizes the options outstanding at March 31, 2023 and the related prices for the options to purchase shares of the Company’s common stock:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Weighted

 

 

 

 

 

 

Weighted

 

 

 

 

 

 

 

 

 

 

Weighted

 

 

average

 

 

 

 

 

 

average

 

 

 

 

 

 

 

 

 

 

average

 

 

exercise

 

 

 

 

 

 

exercise

 

 

Range of

 

 

Number of

 

 

remaining

 

 

price of

 

 

Number of

 

 

price of

 

 

exercise

 

 

options

 

 

contractual

 

 

outstanding

 

 

options

 

 

exercisable

 

 

prices

 

 

outstanding

 

 

life (years)

 

 

options

 

 

exercisable

 

 

options

 

 

$

1.50- 16.00

     

215,881

     

7.94

   

$

9.39

     

129,148

   

$

7.73

 
           

215,881

     

7.94

   

$

9.39

     

129,148

   

$

7.73

 

 

Transactions involving stock options are summarized as follows:

 

   

Shares

   

Weighted- Average

Exercise Price ($) (A)

 

Outstanding at December 31, 2022

    310,692     $ 10.01  

Granted

    -     $ -  

Expired

    (94,811

)

  $ 11.44  

Outstanding at March 31, 2023

    215,881     $ 9.39  

Options vested and exercisable

    129,148     $ 7.73  

 

At March 31, 2023, the total stock-based compensation cost related to unvested awards not yet recognized was $2.1 million.

 

Warrants

 

The following table summarizes the warrants outstanding on March 31, 2023, and the related prices for the warrants to purchase shares of the Company’s common stock:

 

   

Shares

   

Weighted- Average

Exercise Price ($)

 
                 

Outstanding on December 31, 2022

    672,334     $ 30.68  

Granted

    -     $ -  

Exercised

    -     $ -  

Outstanding on March 31, 2023

    672,334     $ 30.68  
v3.23.3
Fair Value of Financial Instruments
3 Months Ended
Mar. 31, 2023
Fair Value Disclosures [Abstract]  
Fair Value Disclosures [Text Block]

Note 13: Fair Value Measurements

 

The following summarizes the Company’s derivative financial liabilities that are recorded at fair value on a recurring basis at March 31, 2023 and 2022.

 

   

March 31, 2023

 
   

Level 1

   

Level 2

   

Level 3

   

Total

 

Liabilities

                               

Derivative liabilities

  $ -     $ -     $ 679,690     $ 679,690  

 

   

March 31, 2022

 
   

Level 1

   

Level 2

   

Level 3

   

Total

 

Liabilities

                               

Derivative liabilities

  $ -     $ -     $ 568,912     $ 568,912  
v3.23.3
Commitments and Contingencies
3 Months Ended
Mar. 31, 2023
Commitments and Contingencies Disclosure [Abstract]  
Commitments and Contingencies Disclosure [Text Block]

Note 14: Commitments and Contingencies

 

Legal

 

From time to time, we may become involved in legal proceedings or be subject to claims arising in the ordinary course of our business.

 

On June 23, 2022, The Good Clinic LLC was notified that a former employee had filed a lawsuit for wrongful termination. The Good Clinic believes the lawsuit is without merit. The Company was not named in the suit. The Company expects to resolve it for nominal consideration. No change has been noted related to this lawsuit.

 

On October 25, 2022, the Company was notified that a vendor filed suit related to a contract dispute naming both The Good Clinic and The CEO of the Good Clinic. This suit was settled on May 5, 2023, and dismissed with prejudice on May 12, 2023. The settlement included the issuance of the Company’s restricted common stock. As a part of the settlement the Company issued 2,552 shares of its restricted common stock to the plaintiff and it issued to the CEO of The Good Clinic 19,622 of its restricted common stock, plus $3,000 in cash for reimbursement of expenses related to settling the suit with the vendor.

 

The Company has a number of legal situations involved with the winding down of its clinic business activities including claims regarding certain construction contracts and as a part of the process of cancellation of leases. The following is a summary as of the date of this filing:

 

 

The Wayzata, MN clinic leases was terminated for a commitment to pay $25,000.

 

Possession of the two Denver, Colorado clinic leases, known as Quincy and Radiant, has been relinquished to the landlords. The lease obligations remain in negotiations as does the handling of the mechanics liens placed on the properties.

 

The Eagan clinic, aka Vikings clinic, gave up possession in January of 2023. The mechanics lien has been placed on the property and was settled by the landlord in a confidential settlement with the lien holder. The Landlord terminated the lease as of March 3, 2023. Mitesco is now in settlement negotiations with the landlord for the handling of lease obligations. The Landlord filed suit against the Company on July 21, 2023 for unpaid rent, expenses related unpaid lease obligations and the settled construction lien.

 

The St. Paul clinic possession was relinquished in March 2023. The handling of lease obligations remain in negotiations, as does the handling of the mechanics liens placed on the properties.

 

The St. Louis Park clinic possession was relinquished in April 2023. The handling of lease obligations remain in negotiations as does the handling of the mechanics liens placed on the properties.

 

The Maple Grove clinic eviction occurred in April 2023. The handling of lease obligations remain in negotiations, as does the handling of the mechanics liens placed on the properties. On August 22, 2023 the landlord filed a lawsuit related to alleged unmet lease obligations and related to a construction lien on the property by the general contractor related to alleged non-payment of construction expenses.

 

The Northeast Minneapolis clinic, aka Nordhaus clinic, possession was relinquished in May 2023. There is no lien on the property. The handling of lease obligations remains in negotiations with the landlord.

v3.23.3
Subsequent Events
3 Months Ended
Mar. 31, 2023
Subsequent Events [Abstract]  
Subsequent Events [Text Block]

Note 15: Subsequent Events

 

Issuance of Common Stock

 

On April 4, 2023, the Company issued 2,952 shares of common stock at a price of $1.05 per share to a service provider.

 

On April 5, 2023, the Company issued 94,738 shares of common stock to an investor at a price of $1.32 per share pursuant to a true-up agreement.

 

On May 5, 2023, the Company issued 2,552 shares of common stock to an investor at a price of $1.05 per share for satisfaction of accounts payable.

 

On May 9, 2023, the Company issued 19,622 shares of common stock to Michael C. Howe, a related party, at a price of $0.94 per share to reimburse Mr. Howe for costs incurred in connection with a settlement agreement with a vendor.

 

On June 9, 2023, the Company issued 20,212 shares of common stock as dividends on its Series X Preferred Stock at a price of $1.25 per share, including 1,670 to an officer, 1,003 to an ex-director, and 10,426 to a related party shareholder.

 

On June 29, 2023, the Company issued 131,362 shares of common stock at a price of $0.80 per share to a vendor in satisfaction of accounts payable in the amount of $105,089.

 

On August 29, 2023, the Company issued 43,750 shares of common stock at a price of $0.80 per share to a vendor in satisfaction of accounts payable in the amount of $35,000.

 

PPP Loan Payment Plan

 

On July 12, 2023, the Company entered into a payment plan arrangement with the U.S. Small Business Administration regarding PPP Loan. The terms of the payment plan call for monthly payments of approximately $2,595 for 180 months beginning July 1, 2023 resulting in total payments in the amount of $467,116.

 

Issuance of Series F Preferred Stock

 

Sale of Series F Preferred Stock Sold for Cash

 

On April 11, 2023, the Company entered into securities purchase agreements (each a “Purchase Agreement”) with investors providing for the sale and issuance of (i) Series F 12% PIK Convertible Perpetual Preferred Stock, par value $0.01 per share (the “Series F Shares”) and (ii) warrants to purchase shares of Common Stock (the “Warrants,” and together with the Series F Shares, the “Securities”). The Warrants have an initial exercise price of $2.50 per share and the final number of shares of Common Stock the warrant is exercisable for will equal the number of shares of Common Stock into which the Series F Shares convert divided by 2.

 

On April 11, 2023, the Company entered into a Purchase Agreement for the sale of 863 Securities at a price of $1,000 per Security for cash in the amount of $375,000 plus incentives in the amount of $487,500.

 

On April 11, 2023, the Company entered into a Purchase Agreement for the sale of 288 Securities at a price of $1,000 per Security for cash in the amount of $125,000 plus incentives in the amount of $162,500.

 

On April 11, 2023, the Company entered into a Purchase Agreement for the sale of 345 Securities at a price of $1,000 per Security for cash in the amount of $150,000 plus incentives in the amount of $195,000.

 

On June 30, 2023, the Company entered into a Purchase Agreement for the sale of 250 Securities at a price of $1,000 per Security for cash in the amount of $250,000.

 

Series F Preferred Stock Issued for Conversion of Debt

 

Also in connection with the Purchase Agreements, the Company entered into separate exchange agreements pursuant to which the investors in the Series F Preferred Stock exchanged certain securities, as defined in each individual Exchange Agreement, for a number Series F Shares (based on their liquidation preference of $1,000) equal to 120%, 165% or 230%, depending on whether the investor invested additional funds into the bridge financing, of the “Principal Amount,” “Stated Value” and/or liquidation preference of the Exchange Securities (including any payoff bonus, accrued dividends or interest).

 

On April 11, 2023, in transactions with nine investors, the Company issued an aggregate 8,023 shares of Series F Preferred Stock at a price of $1,000 per share in exchange for debt and accrued interest, including payoff bonuses, in the aggregate amount of $8,018,293.

 

Series F Preferred Stock Issued for Conversion of Series C and Series D Preferred Stock

 

On April 11, 2023, in transactions with two investors, the Company issued an aggregate 2,051 shares of Series F Preferred Stock at a price of $1,000 per share in exchange for Series C Preferred Stock and accrued dividends and payoff bonuses in the aggregate amount of $2,050,165.

 

On April 11, 2023, in transactions with five investors, the Company issued an aggregate 3,884 shares of Series F Preferred Stock at a price of $1,000 per share in exchange for Series D Preferred Stock and accrued dividends and payoff bonuses in the aggregate amount of $3,883,524.

 

Series F Preferred Stock Issued for Conversion of Accounts Payable

 

On June 29, 2023, the Company issued an aggregate 147 shares of Series F Preferred Stock to two creditors in satisfaction of accounts payable in the aggregate amount of $146,214.

 

Appointment of Ms. Sheila Schweitzer as Chairperson of the Board of Directors and President, Chief Operating Officer

 

Effective June 1, 2023, the Board of Directors appointed Ms. Sheila Schweitzer to the position of Chief Operating Officer. Ms. Schweitzer will receive a salary in the amount of $200,000 per year. Her employment agreement is for a period of one year.

 

Effective June 6, 2023, the Board of Directors of the Company appointed Ms. Schweitzer, who has been a member of the Board of Directors since 2021, to the position of Chairperson, replacing Mr. Tom Brodmerkel, who has completed his term as Chair. Mr. Brodmerkel will remain as Chief Financial Officer and continue to serve as a member of the Company’s Board of Directors.

 

Appointment of Mr. Allen Plunk to the Board of Directors

 

On July 18, 2023 the Company appointed Mr. Allen Plunk to its Board of Directors. This follows a recent assessment of its healthcare operations and coincides with its decision to place new emphasis on building out its acquisition of healthcare technology and services entities. Mr. Plunk will receive compensation commensurate with that of all other members of the Board of Directors.

v3.23.3
Accounting Policies, by Policy (Policies)
3 Months Ended
Mar. 31, 2023
Accounting Policies [Abstract]  
Consolidation, Policy [Policy Text Block]

Principles of Consolidation The accompanying condensed consolidated financial statements include the accounts of Mitesco, Inc., and its wholly owned subsidiaries Mitesco NA, LLC and The Good Clinic, LLC. In addition, we anticipate that we will rely on the operating activities of certain legal entities in which we will not maintain a controlling ownership interest but over which we will have indirect influence and of which we will be considered the primary beneficiary. We expect that these entities will typically be subject to nominee ownership and transfer restriction agreements that effectively transfer the majority of the economic risks and rewards of their ownership to the Company. The Company’s management, restriction and other agreements concerning such nominee-owned entities typically includes both financial terms and protective and participating rights to the entities’ operating, strategic and non-clinical governance decisions which transfer substantial powers over and economic responsibility for these entities to the Company. As such, the Company applies the guidance of the Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) 810 – Consolidation (“ASC 810”), to determine when an entity that is insufficiently capitalized or not controlled through its voting interests, referred to as a variable interest entity should be consolidated. All intercompany balances and transactions have been eliminated.

Use of Estimates, Policy [Policy Text Block]

Use of Estimates - The preparation of these financial statements requires our management to make estimates and assumptions about future events that affect the amounts reported in the financial statements and related notes. Future events and their effects cannot be determined with absolute certainty. Therefore, the determination of estimates requires the exercise of judgment.

New Accounting Pronouncements, Policy [Policy Text Block]

New Accounting Standards

From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board (“FASB”) or other standard setting bodies that the Company adopts as of the specified effective date. Unless otherwise discussed, the Company does not believe that the impact of recently issued standards that are not yet effective will have a material impact on its financial position or results of operations upon adoption.

v3.23.3
Net Loss Per Share Applicable to Common Shareholders (Tables)
3 Months Ended
Mar. 31, 2023
Earnings Per Share [Abstract]  
Schedule of Earnings Per Share, Basic and Diluted [Table Text Block] The following table sets forth the computation of loss per share for the three months ended March 31, 2023, and 2022, respectively:
   

For the Three Months Ended

 
   

March 31,

 
   

2023

   

2022

 

Numerator:

               

Net loss applicable to common shareholders

  $ (5,693,644

)

  $ (3,724,886

)

                 

Denominator:

               

Weighted average common shares outstanding

    4,825,054       4,274,064  
                 

Net loss per share:

               

Basic and diluted

  $ (1.18

)

  $ (0.87

)

Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block] The Company excluded all common equivalent shares outstanding for warrants, options, and convertible instruments to purchase common stock from the calculation of diluted net loss per share because all such securities are antidilutive for the periods presented. As of March 31, 2023, and 2022, the following shares were issuable and excluded from the calculation of diluted loss:
   

For the Years Ended

 
   

March 31,

 
   

2023

   

2022

 

Common stock options

    215,881       373,425  

Common stock purchase warrants

    672,334       628,100  

Convertible Preferred Stock

    347,652       347,652  

Accrued interest on Preferred Stock

    47,767       24,618  

Potentially dilutive securities

    1,283,634       1,373,795  
v3.23.3
Accounts Payable and Accrued Liabilities (Tables)
3 Months Ended
Mar. 31, 2023
Payables and Accruals [Abstract]  
Schedule of Accounts Payable and Accrued Liabilities [Table Text Block] Accounts payable and accrued liabilities consisted of the following at March 31, 2023 and December 31, 2022:
   

March 31,

   

December 31,

 
   

2023

   

2022

 

Trade accounts payable

  $ 7,482,128     $ 6,761,793  

Accrued payroll and payroll taxes

    858,645       590,915  

Other

    -       507  

Total accounts payable and accrued liabilities

  $ 8,340,773     $ 7,353,215  
v3.23.3
Right to Use Assets and Lease Liabilities - Operating Leases (Tables)
3 Months Ended
Mar. 31, 2023
Disclosure Text Block [Abstract]  
Lease, Cost [Table Text Block] Right to use assets – operating leases are summarized below:
   

March 31,

2023

   

December 31,

2022

 

Right to use assets, net

  $ -     $ 544,063  
Operating lease liabilities are summarized below:
   

March 31,

2023

   

December 31,

2022

 

Lease liability

  $ 4,066,827     $ 4,379,724  

Less: current portion

    (512,895

)

    (442,866

)

Lease liability, non-current

  $ 3,553,932     $ 3,936,858  

 

Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block] Maturity analysis under these lease agreements are as follows:

For the twelve months ended March 31, 2024

  $ 1,087,018  

For the twelve months ended March 31, 2025

    824,520  

For the twelve months ended March 31, 2026

    843,270  

For the twelve months ended March 31, 2027

    862,264  

For the twelve months ended March 31, 2028

    880,268  

Thereafter

    1,586,661  

Total

  $ 6,084,001  

Less: Present value discount

    (2,017,174

)

Lease liability

  $ 4,066,827  
v3.23.3
Notes Payable (Tables)
3 Months Ended
Mar. 31, 2023
Notes Payable (Tables) [Line Items]  
Schedule of Debt [Table Text Block] These amounts are reflected in the table below:
   

March 31,

2023

   

December 31,

2022

 

Notes Payable

  $ 6,174,712     $ 5,144,742  

Less: Discount

    (8,472

)

    (32,041

)

Notes payable - net of discount

  $ 6,166,240     $ 5,112,701  
                 

Current Portion, net of discount

  $ 6,166,240     $ 5,112,701  

Long-term portion, net of discount

  $ -     $ -  
Related Party [Member]  
Notes Payable (Tables) [Line Items]  
Schedule of Debt [Table Text Block] These amounts are reflected in the table below:
   

March 31,

2023

   

December 31,

2022

 

Notes Payable

  $ 2,799,632     $ 2,799,632  

Less: Discount

  $ (8,456

)

  $ (22,670

)

Notes payable – net of discounts

  $ 2,791,176     $ 2,776,962  
                 

Current Portion, net of discount

  $ 2,791,176     $ 2,776,962  

Long-term portion, net of discount

  $ -     $ -  
v3.23.3
Derivative Liabilities (Tables)
3 Months Ended
Mar. 31, 2023
Disclosure Text Block [Abstract]  
Schedule of Derivative Instruments [Table Text Block] Derivative liability activity for the for the period ended March 31, 2023 is summarized in the table below:

December 31, 2022

  $ 568,912  

Loss on revaluation

    110,778  

March 31, 2023

  $ 679,690  

 

Fair Value, Assets and Liabilities Measured on Nonrecurring Basis, Valuation Techniques [Table Text Block] The Company uses a Monte Carlo model to value certain features of its notes payable that create derivative liabilities. The following table summarizes the assumptions for the valuations:
   

December 31,

 
   

2022

 

Volatility

    95.1% to 123.2

%

Stock Price

  $ 1.06 to 3.50  

Risk-free interest rates

    4.35% to 4.37

%

Term (years)

    0.73 to 0.86  
   

March 31,

 
   

2023

 

Volatility

    159.6% to 169.9

%

Stock Price

  $ 1.24  

Risk-free interest rates

    4.40

%

Term (years)

    0.52 to 0.61  
v3.23.3
Stockholders’ Equity (Deficit) (Tables)
3 Months Ended
Mar. 31, 2023
Stockholders' Equity Note [Abstract]  
Share-Based Payment Arrangement, Option, Exercise Price Range [Table Text Block] The following table summarizes the options outstanding at March 31, 2023 and the related prices for the options to purchase shares of the Company’s common stock:

 

 

 

 

 

 

 

 

 

 

 

 

 

Weighted

 

 

 

 

 

 

Weighted

 

 

 

 

 

 

 

 

 

 

Weighted

 

 

average

 

 

 

 

 

 

average

 

 

 

 

 

 

 

 

 

 

average

 

 

exercise

 

 

 

 

 

 

exercise

 

 

Range of

 

 

Number of

 

 

remaining

 

 

price of

 

 

Number of

 

 

price of

 

 

exercise

 

 

options

 

 

contractual

 

 

outstanding

 

 

options

 

 

exercisable

 

 

prices

 

 

outstanding

 

 

life (years)

 

 

options

 

 

exercisable

 

 

options

 

 

$

1.50- 16.00

     

215,881

     

7.94

   

$

9.39

     

129,148

   

$

7.73

 
           

215,881

     

7.94

   

$

9.39

     

129,148

   

$

7.73

 
Share-Based Payment Arrangement, Option, Activity [Table Text Block] Transactions involving stock options are summarized as follows:
   

Shares

   

Weighted- Average

Exercise Price ($) (A)

 

Outstanding at December 31, 2022

    310,692     $ 10.01  

Granted

    -     $ -  

Expired

    (94,811

)

  $ 11.44  

Outstanding at March 31, 2023

    215,881     $ 9.39  

Options vested and exercisable

    129,148     $ 7.73  
Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block] The following table summarizes the warrants outstanding on March 31, 2023, and the related prices for the warrants to purchase shares of the Company’s common stock:
   

Shares

   

Weighted- Average

Exercise Price ($)

 
                 

Outstanding on December 31, 2022

    672,334     $ 30.68  

Granted

    -     $ -  

Exercised

    -     $ -  

Outstanding on March 31, 2023

    672,334     $ 30.68  
v3.23.3
Fair Value of Financial Instruments (Tables)
3 Months Ended
Mar. 31, 2023
Fair Value Disclosures [Abstract]  
Schedule of Derivative Liabilities at Fair Value [Table Text Block] The following summarizes the Company’s derivative financial liabilities that are recorded at fair value on a recurring basis at March 31, 2023 and 2022.
   

March 31, 2023

 
   

Level 1

   

Level 2

   

Level 3

   

Total

 

Liabilities

                               

Derivative liabilities

  $ -     $ -     $ 679,690     $ 679,690  
   

March 31, 2022

 
   

Level 1

   

Level 2

   

Level 3

   

Total

 

Liabilities

                               

Derivative liabilities

  $ -     $ -     $ 568,912     $ 568,912  
v3.23.3
Description of Business (Details)
Dec. 12, 2022
Accounting Policies [Abstract]  
Stockholders' Equity, Reverse Stock Split every fifty (50) shares of our issued and outstanding common stock was automatically combined into one (1) issued and outstanding share of common stock
v3.23.3
Financial Condition, Going Concern and Management Plans (Details) - USD ($)
Mar. 31, 2023
Dec. 31, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]    
Cash Equivalents, at Carrying Value $ 300  
Liabilities, Current $ 20,374,179 $ 17,802,471
v3.23.3
Net Loss Per Share Applicable to Common Shareholders (Details) - Schedule of Earnings Per Share, Basic and Diluted - USD ($)
3 Months Ended
Mar. 31, 2023
Mar. 31, 2022
Numerator:    
Net loss applicable to common shareholders $ (5,693,644) $ (3,724,886)
Denominator:    
Weighted average common shares outstanding 4,825,054 4,274,064
Net loss per share:    
Basic and diluted $ (1.18) $ (0.87)
v3.23.3
Net Loss Per Share Applicable to Common Shareholders (Details) - Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share - shares
3 Months Ended
Mar. 31, 2023
Mar. 31, 2022
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]    
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 1,283,634 1,373,795
Share-Based Payment Arrangement, Option [Member]    
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]    
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 215,881 373,425
Warrant [Member]    
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]    
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 672,334 628,100
Preferred Stock [Member] | Convertible Debt Securities [Member]    
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]    
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 347,652 347,652
Accrued Interest [Member] | Convertible Debt Securities [Member]    
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]    
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 47,767 24,618
v3.23.3
Related Party Transactions (Details) - USD ($)
3 Months Ended
Feb. 24, 2022
Feb. 14, 2022
Mar. 31, 2023
Mar. 31, 2022
Related Party Transactions (Details) [Line Items]        
Dividends, Preferred Stock     $ 79,818 $ 79,692
Proceeds from Issuance of Debt     $ 0 675,000
Class of Warrant or Rights, Granted (in Shares)     0  
Series X Preferred Stock [Member]        
Related Party Transactions (Details) [Line Items]        
Dividends, Preferred Stock     $ 15,141 15,141
Preferred Stock Dividends, Shares (in Shares)     8,063  
Diamond Note 1 [Member]        
Related Party Transactions (Details) [Line Items]        
Debt Instrument, Face Amount $ 175,000 $ 175,000    
Debt Instrument, Interest Rate, Stated Percentage 10.00% 10.00%    
Debt Instrument, Term   6 months    
Proceeds from Issuance of Debt $ 148,750 $ 148,750    
Diamond Note 1 [Member] | Measurement Input, Default Rate [Member]        
Related Party Transactions (Details) [Line Items]        
Debt Instrument, Interest Rate, Stated Percentage 18.00% 18.00%    
Diamond Note 1 [Member] | Warrants at $25.00 [Member]        
Related Party Transactions (Details) [Line Items]        
Class of Warrant or Rights, Granted (in Shares)   7,350    
Warrants and Rights Outstanding, Term   5 years    
Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per share)   $ 25    
Diamond Note 1 [Member] | Warrants at $37.50 [Member]        
Related Party Transactions (Details) [Line Items]        
Class of Warrant or Rights, Granted (in Shares)   7,350    
Warrants and Rights Outstanding, Term   5 years    
Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per share)   $ 37.5    
Officer [Member] | Series X Preferred Stock [Member]        
Related Party Transactions (Details) [Line Items]        
Dividends, Preferred Stock     $ 2,000 2,000
Preferred Stock Dividends, Shares (in Shares)     1,066  
Majority Shareholder [Member] | Series X Preferred Stock [Member]        
Related Party Transactions (Details) [Line Items]        
Dividends, Preferred Stock     $ 7,814 8,000
Preferred Stock Dividends, Shares (in Shares)     4,160  
Nonrelated Party [Member]        
Related Party Transactions (Details) [Line Items]        
Dividends, Preferred Stock     $ 61,823 61,695
Nonrelated Party [Member] | Series X Preferred Stock [Member]        
Related Party Transactions (Details) [Line Items]        
Dividends, Preferred Stock     $ 5,327 $ 6,000
Preferred Stock Dividends, Shares (in Shares)     2,837  
v3.23.3
Accounts Payable and Accrued Liabilities (Details) - Schedule of Accounts Payable and Accrued Liabilities - USD ($)
Mar. 31, 2023
Dec. 31, 2022
Schedule Of Accounts Payable And Accrued Liabilities Abstract    
Trade accounts payable $ 7,482,128 $ 6,761,793
Accrued payroll and payroll taxes 858,645 590,915
Other 0 507
Total $ 8,340,773 $ 7,353,215
v3.23.3
Right to Use Assets and Lease Liabilities - Operating Leases (Details) - USD ($)
3 Months Ended 12 Months Ended
Feb. 03, 2023
Mar. 31, 2023
Mar. 31, 2022
Dec. 31, 2022
Right to Use Assets and Lease Liabilities - Operating Leases (Details) [Line Items]        
Impairment, Lessor Asset under Operating Lease   $ 500,000   $ 3,200,000
Operating Lease, Liability   4,066,827   4,379,724
Operating Lease, Right-of-Use Asset   0   $ 544,063
Gain (Loss) on Termination of Lease   287,897 $ 0  
Wayzata, Minnesota [Member]        
Right to Use Assets and Lease Liabilities - Operating Leases (Details) [Line Items]        
Operating Lease, Liability $ 312,897      
Operating Lease, Payments 25,000      
Gain (Loss) on Termination of Lease   287,897    
Wayzata, Minnesota [Member] | Lease Settlement [Member]        
Right to Use Assets and Lease Liabilities - Operating Leases (Details) [Line Items]        
Other Liabilities $ 25,000      
Eagen, Minnesota [Member]        
Right to Use Assets and Lease Liabilities - Operating Leases (Details) [Line Items]        
Operating Lease, Liability   $ 474,074    
v3.23.3
Right to Use Assets and Lease Liabilities - Operating Leases (Details) - Lease, Cost - USD ($)
Mar. 31, 2023
Dec. 31, 2022
Lease, Cost [Abstract]    
Right to use assets, net $ 0 $ 544,063
Lease liability 4,066,827 4,379,724
Less: current portion (512,895) (442,866)
Lease liability, non-current $ 3,553,932 $ 3,936,858
v3.23.3
Right to Use Assets and Lease Liabilities - Operating Leases (Details) - Lessee, Operating Lease, Liability, Maturity - USD ($)
Mar. 31, 2023
Dec. 31, 2022
Lessee Operating Lease Liability Maturity Abstract    
For the twelve months ended March 31, 2024 $ 1,087,018  
For the twelve months ended March 31, 2025 824,520  
For the twelve months ended March 31, 2026 843,270  
For the twelve months ended March 31, 2027 862,264  
For the twelve months ended March 31, 2028 880,268  
Thereafter 1,586,661  
Total 6,084,001  
Less: Present value discount (2,017,174)  
Lease liability $ 4,066,827 $ 4,379,724
v3.23.3
SBA Loan Payable (Details) - PPP Loan [Member] - USD ($)
3 Months Ended 12 Months Ended
Mar. 31, 2023
Dec. 31, 2022
May 04, 2020
SBA Loan Payable (Details) [Line Items]      
Debt Instrument, Face Amount     $ 460,400
Debt Instrument, Interest Rate, Effective Percentage     1.00%
Debt Instrument, Increase, Accrued Interest $ 1,135 $ 4,632  
Debt Instrument, Debt Default, Amount 460,400    
Interest Payable $ 12,424    
v3.23.3
Notes Payable (Details) - USD ($)
3 Months Ended 12 Months Ended
Mar. 28, 2023
Mar. 09, 2023
Feb. 28, 2023
Feb. 14, 2023
Dec. 02, 2022
Nov. 29, 2022
Oct. 24, 2022
Oct. 10, 2022
Oct. 07, 2022
Sep. 15, 2022
Sep. 14, 2022
Sep. 02, 2022
Aug. 18, 2022
Aug. 04, 2022
Jul. 27, 2022
Jul. 26, 2022
Jul. 21, 2022
Jul. 07, 2022
Jun. 09, 2022
May 26, 2022
May 23, 2022
May 18, 2022
May 10, 2022
Apr. 27, 2022
Apr. 26, 2022
Apr. 18, 2022
Apr. 06, 2022
Mar. 18, 2022
Feb. 24, 2022
Feb. 14, 2022
Dec. 30, 2021
Mar. 31, 2023
Mar. 31, 2022
Dec. 31, 2022
Nov. 18, 2022
Oct. 05, 2022
Jan. 12, 2022
Notes Payable (Details) [Line Items]                                                                          
Class of Warrant or Right, Outstanding (in Shares)                                                               672,334   672,334      
Common Stock, Shares, Issued (in Shares)                                                               4,995,573   4,630,372      
Common Stock, Value, Issued                                                               $ 49,957   $ 46,305      
Debt Instrument, Unamortized Discount                                                               8,472   32,041      
Amortization of Debt Discount (Premium)                                                               23,538 $ 231,180        
Debt Instrument, Unamortized Discount, Current                                                               $ 0   0.4      
Debt Conversion, Converted Instrument, Shares Issued (in Shares)     13,555                                                         57,138          
Debt, Current                                                               $ 6,166,240   5,112,701      
Proceeds from Issuance of Debt                                                               0 675,000        
Interest Expense, Debt                                                               248,596 0        
Interest Payable, Current                                                               $ 513,256   $ 362,094      
Common Stock, Par or Stated Value Per Share (in Dollars per share)                                                               $ 0.01   $ 0.01     $ 0.01
AJB Capital Note [Member]                                                                          
Notes Payable (Details) [Line Items]                                                                          
Debt Instrument, Face Amount                                                       $ 750,000                  
Class of Warrant or Right, Outstanding (in Shares)                                                       15,000                  
Derivative Liability                                                       $ 106,608         106,608        
Common Stock, Shares, Issued (in Shares)                                                                     91,328    
Common Stock, Value, Issued                                                                     $ 9,007    
Payments to Acquire Debt Securities, Available-for-Sale                                                       675,000                  
Debt Instrument, Unamortized Discount                                                       $ 349,914                  
Debt Conversion, Converted Instrument, Expiration or Due Date                                                       Mar. 17, 2023                  
Debt Instrument, Interest Rate, Stated Percentage                                                       12.00%                  
Interest Expense, Long-Term Debt                                                                   $ 62,000      
Amortization of Debt Discount (Premium)                                                                   424,914      
Debt Instrument, Discount Outstanding                                                                   0      
Debt Instrument, Debt Default, Amount                                                               $ 1,140,000   750,000      
Interest Payable                                                               85,730   22,833      
Debt Instrument, Fee Amount                                                               15,000          
Debt Instrument, Increase, Accrued Interest                                                               62,897          
AJB Capital Note [Member] | Measurement Input, Default Rate [Member]                                                                          
Notes Payable (Details) [Line Items]                                                                          
Debt Instrument, Interest Rate, Stated Percentage                                                       18.00%                  
AJB Capital Note [Member] | Minimum [Member]                                                                          
Notes Payable (Details) [Line Items]                                                                          
Debt Instrument, Interest Rate, Stated Percentage                                                       10.00%                  
Anson Investments Note [Member]                                                                          
Notes Payable (Details) [Line Items]                                                                          
Stock Issued During Period, Value, Other                                                     $ 322,500                    
Stock Issued During Period, Shares, Other (in Shares)                                                     25,800                    
Debt Instrument, Face Amount                                                     $ 562,500                    
Class of Warrant or Right, Outstanding (in Shares)                                                     11,250                    
Derivative Liability                                                     $ 27,040                    
Payments to Acquire Debt Securities, Available-for-Sale                                                     506,250                    
Debt Instrument, Unamortized Discount                                                     $ 416,375                    
Debt Conversion, Converted Instrument, Expiration or Due Date                                                     Oct. 06, 2022                    
Debt Instrument, Interest Rate, Stated Percentage                                                     12.00%                    
Interest Expense, Long-Term Debt                                                                   68,844      
Amortization of Debt Discount (Premium)                                                                   472,625      
Debt Instrument, Discount Outstanding                                                                   0      
Debt Instrument, Debt Default, Amount                                                               858,750   562,500      
Interest Payable                                                               63,933   41,500      
Debt Instrument, Fee Amount                                                               15,000          
Debt Instrument, Increase, Accrued Interest                                                               22,433          
Anson Investments Note [Member] | Measurement Input, Default Rate [Member]                                                                          
Notes Payable (Details) [Line Items]                                                                          
Debt Instrument, Interest Rate, Stated Percentage                                                     18.00%                    
Anson Investments Note [Member] | Minimum [Member]                                                                          
Notes Payable (Details) [Line Items]                                                                          
Debt Instrument, Interest Rate, Stated Percentage                                                     10.00%                    
Anson East Note [Member]                                                                          
Notes Payable (Details) [Line Items]                                                                          
Stock Issued During Period, Value, Other                                                     $ 107,500                    
Stock Issued During Period, Shares, Other (in Shares)                                                     8,600                    
Debt Instrument, Face Amount                                                     $ 187,500                    
Class of Warrant or Right, Outstanding (in Shares)                                                     3,750                    
Derivative Liability                                                     $ 9,014                    
Payments to Acquire Debt Securities, Available-for-Sale                                                     168,750                    
Debt Instrument, Unamortized Discount                                                     $ 147,290                    
Debt Conversion, Converted Instrument, Expiration or Due Date                                                     Oct. 06, 2022                    
Debt Instrument, Interest Rate, Stated Percentage                                                     12.00%                    
Interest Expense, Long-Term Debt                                                                   22,948      
Amortization of Debt Discount (Premium)                                                                   166,040      
Debt Instrument, Discount Outstanding                                                                   0      
Debt Instrument, Debt Default, Amount                                                               296,250   187,500      
Interest Payable                                                               21,755   13,833      
Debt Instrument, Fee Amount                                                               15,000          
Debt Instrument, Increase, Accrued Interest                                                               7,922          
Anson East Note [Member] | Measurement Input, Default Rate [Member]                                                                          
Notes Payable (Details) [Line Items]                                                                          
Debt Instrument, Interest Rate, Stated Percentage                                                     18.00%                    
Anson East Note [Member] | Minimum [Member]                                                                          
Notes Payable (Details) [Line Items]                                                                          
Debt Instrument, Interest Rate, Stated Percentage                                                     10.00%                    
GS Capital Note [Member]                                                                          
Notes Payable (Details) [Line Items]                                                                          
Stock Issued During Period, Value, Other                                                   $ 159,259                      
Stock Issued During Period, Shares, Other (in Shares)                                                   12,741                      
Debt Instrument, Face Amount                                                   $ 277,777                      
Class of Warrant or Right, Outstanding (in Shares)                                                   5,556                      
Derivative Liability                                                   $ 21,920                      
Payments to Acquire Debt Securities, Available-for-Sale                                                   250,000                      
Debt Instrument, Unamortized Discount                                                   $ 162,158                      
Debt Conversion, Converted Instrument, Expiration or Due Date                                                   Nov. 10, 2022                      
Debt Instrument, Interest Rate, Stated Percentage                                                   12.00%                      
Interest Expense, Long-Term Debt                                                                   32,155      
Amortization of Debt Discount (Premium)                                                                   212,435      
Debt Instrument, Discount Outstanding                                                                   0      
Debt Instrument, Debt Default, Amount                                                               358,889   277,777      
Interest Payable                                                               22,490   19,578      
Debt Instrument, Fee Amount                                                               15,000          
Debt Instrument, Increase, Accrued Interest                                                               11,591          
Debt Instrument, Unamortized Discount, Current                                                   $ 27,777                      
Debt Conversion, Original Debt, Amount                                                               $ 72,777          
Debt Conversion, Converted Instrument, Shares Issued (in Shares) 18,472 15,265   9,846                                                                  
Debt Instrument, Convertible, Conversion Price (in Dollars per share) $ 1.25 $ 1.5 $ 1.5 $ 1.74                                                       $ 1.46          
GS Capital Note [Member] | Measurement Input, Default Rate [Member]                                                                          
Notes Payable (Details) [Line Items]                                                                          
Debt Instrument, Interest Rate, Stated Percentage                                                   18.00%                      
GS Capital Note [Member] | Minimum [Member]                                                                          
Notes Payable (Details) [Line Items]                                                                          
Debt Instrument, Interest Rate, Stated Percentage                                                   10.00%                      
GS Capital Note [Member] | Accrued Interest [Member]                                                                          
Notes Payable (Details) [Line Items]                                                                          
Debt Conversion, Original Debt, Amount $ 2,581 $ 2,399 $ 2,057 $ 1,632                                                       $ 8,679          
GS Capital Note [Member] | Fees [Member]                                                                          
Notes Payable (Details) [Line Items]                                                                          
Debt Conversion, Original Debt, Amount $ 500 $ 500 $ 500 $ 500                                                       2,000          
Kishon Note [Member]                                                                          
Notes Payable (Details) [Line Items]                                                                          
Stock Issued During Period, Value, Other                                             $ 159,259                            
Stock Issued During Period, Shares, Other (in Shares)                                             12,741                            
Debt Instrument, Face Amount                                             $ 277,777                            
Class of Warrant or Right, Outstanding (in Shares)                                             5,556                            
Derivative Liability                                             $ 27,793                            
Debt Instrument, Unamortized Discount                                             $ 138,492                            
Debt Conversion, Converted Instrument, Expiration or Due Date                                             Nov. 10, 2022                            
Debt Instrument, Interest Rate, Stated Percentage                                             12.00%                            
Interest Expense, Long-Term Debt                                                                   28,624      
Amortization of Debt Discount (Premium)                                                                   181,269      
Debt Instrument, Discount Outstanding                                                                   0      
Debt Instrument, Debt Default, Amount                                                               431,666   277,777      
Interest Payable                                                               29,826   17,822      
Debt Instrument, Fee Amount                                                               15,000          
Debt Instrument, Increase, Accrued Interest                                                               12,004          
Debt, Current                                             $ 277,777                            
Proceeds from Issuance of Debt                                             $ 250,000                            
Kishon Note [Member] | Measurement Input, Default Rate [Member]                                                                          
Notes Payable (Details) [Line Items]                                                                          
Debt Instrument, Interest Rate, Stated Percentage                                             18.00%                            
Kishon Note [Member] | Minimum [Member]                                                                          
Notes Payable (Details) [Line Items]                                                                          
Debt Instrument, Interest Rate, Stated Percentage                                             10.00%                            
Finnegan Note 1 [Member]                                                                          
Notes Payable (Details) [Line Items]                                                                          
Debt Instrument, Face Amount                                         $ 47,059                                
Class of Warrant or Right, Outstanding (in Shares)                                         386                                
Common Stock, Shares, Issued (in Shares)                                         1,930                                
Common Stock, Value, Issued                                         $ 3,240                                
Debt Instrument, Interest Rate, Stated Percentage                                         10.00%                                
Interest Expense, Long-Term Debt                                                                   3,285      
Amortization of Debt Discount (Premium)                                                                   17,005      
Debt Instrument, Discount Outstanding                                                                   0      
Debt Instrument, Debt Default, Amount                                                               51,765   51,765      
Interest Payable                                                               5,448   3,285      
Debt Instrument, Increase, Accrued Interest                                                               2,163          
Proceeds from Issuance of Debt                                         $ 40,000                                
Debt Instrument, Maturity Date                                         Nov. 20, 2022                                
Share Price (in Dollars per share)                                         $ 25                                
Warrants and Rights Outstanding                                         $ 2,000                                
Finnegan Note 1 [Member] | Measurement Input, Default Rate [Member]                                                                          
Notes Payable (Details) [Line Items]                                                                          
Debt Instrument, Interest Rate, Stated Percentage                                         18.00%                                
M Diamond Note [Member]                                                                          
Notes Payable (Details) [Line Items]                                                                          
Debt Instrument, Face Amount                                                 $ 58,823                        
Class of Warrant or Right, Outstanding (in Shares)                                                 483                        
Common Stock, Shares, Issued (in Shares)                                                 483                        
Common Stock, Value, Issued                                                 $ 4,050                        
Debt Instrument, Interest Rate, Stated Percentage                                                 10.00%                        
Interest Expense, Long-Term Debt                                                                   3,929      
Amortization of Debt Discount (Premium)                                                                   21,256      
Debt Instrument, Discount Outstanding                                                                   0      
Debt Instrument, Debt Default, Amount                                                               64,705   64,705      
Interest Payable                                                               6,631   3,929      
Debt Instrument, Increase, Accrued Interest                                                               2,702          
Proceeds from Issuance of Debt                                                 $ 50,000                        
Debt Instrument, Maturity Date                                                 Nov. 30, 2022                        
Warrants and Rights Outstanding                                                 $ 2,500                        
Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per share)                                                 $ 25                        
M Diamond Note [Member] | Measurement Input, Default Rate [Member]                                                                          
Notes Payable (Details) [Line Items]                                                                          
Debt Instrument, Interest Rate, Stated Percentage                                                 18.00%                        
Finnegan Note 2 [Member]                                                                          
Notes Payable (Details) [Line Items]                                                                          
Debt Instrument, Face Amount                                       $ 29,412                                  
Class of Warrant or Right, Outstanding (in Shares)                                       242                                  
Common Stock, Shares, Issued (in Shares)                                       242                                  
Common Stock, Value, Issued                                       $ 2,025                                  
Interest Expense, Long-Term Debt                                                                   1,965      
Amortization of Debt Discount (Premium)                                                                   10,625      
Debt Instrument, Discount Outstanding                                                                   0      
Debt Instrument, Debt Default, Amount                                                               32,353   32,353      
Interest Payable                                                               3,315   1,965      
Debt Instrument, Increase, Accrued Interest                                                               1,350          
Proceeds from Issuance of Debt                                       $ 25,000                                  
Debt Instrument, Maturity Date                                       Nov. 30, 2022                                  
Share Price (in Dollars per share)                                       $ 25                                  
Warrants and Rights Outstanding                                       $ 1,250                                  
Finnegan Note 2 [Member] | Measurement Input, Default Rate [Member]                                                                          
Notes Payable (Details) [Line Items]                                                                          
Debt Instrument, Interest Rate, Stated Percentage                                       18.00%                                  
Dragon Note [Member]                                                                          
Notes Payable (Details) [Line Items]                                                                          
Debt Instrument, Face Amount                                     $ 588,235                                    
Class of Warrant or Right, Outstanding (in Shares)                                     4,824                                    
Common Stock, Shares, Issued (in Shares)                                     4,824                                    
Common Stock, Value, Issued                                     $ 44,000                                    
Debt Instrument, Interest Rate, Stated Percentage                                     10.00%                                    
Interest Expense, Long-Term Debt                                                                   35,874      
Amortization of Debt Discount (Premium)                                                                   260,059      
Debt Instrument, Discount Outstanding                                                                   0      
Debt Instrument, Debt Default, Amount                                                               647,059   647,059      
Interest Payable                                                               62,843   35,874      
Debt Instrument, Increase, Accrued Interest                                                               26,969          
Proceeds from Issuance of Debt                                     $ 500,000                                    
Debt Instrument, Maturity Date                                     Dec. 09, 2022                                    
Warrants and Rights Outstanding                                     $ 21,500                                    
Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per share)                                     $ 25                                    
Debt Issuance Costs, Gross                                     $ 47,500                                    
Dragon Note [Member] | Measurement Input, Default Rate [Member]                                                                          
Notes Payable (Details) [Line Items]                                                                          
Debt Instrument, Interest Rate, Stated Percentage                                     18.00%                                    
Mackay Note [Member]                                                                          
Notes Payable (Details) [Line Items]                                                                          
Debt Instrument, Face Amount                                   $ 294,118                                      
Class of Warrant or Right, Outstanding (in Shares)                                   2,412                                      
Common Stock, Shares, Issued (in Shares)                                   2,412                                      
Common Stock, Value, Issued                                   $ 44,118                                      
Debt Instrument, Interest Rate, Stated Percentage                                   10.00%                                      
Interest Expense, Long-Term Debt                                                                   20,193      
Amortization of Debt Discount (Premium)                                                                   96,280      
Debt Instrument, Discount Outstanding                                                                   0      
Debt Instrument, Debt Default, Amount                                                               323,530   323,530      
Interest Payable                                                               37,043   20,193      
Debt Instrument, Increase, Accrued Interest                                                               16,850          
Proceeds from Issuance of Debt                                   $ 250,000                                      
Debt Instrument, Maturity Date                                   Aug. 10, 2022                                      
Share Price (in Dollars per share)                                   $ 25                                      
Warrants and Rights Outstanding                                   $ 10,250                                      
Mackay Note [Member] | Measurement Input, Default Rate [Member]                                                                          
Notes Payable (Details) [Line Items]                                                                          
Debt Instrument, Interest Rate, Stated Percentage                                   18.00%                                      
Schrier Note [Member]                                                                          
Notes Payable (Details) [Line Items]                                                                          
Debt Instrument, Face Amount                                   $ 23,259                                      
Class of Warrant or Right, Outstanding (in Shares)                                   193                                      
Common Stock, Shares, Issued (in Shares)                                   193                                      
Common Stock, Value, Issued                                   $ 1,000                                      
Debt Instrument, Interest Rate, Stated Percentage                                   10.00%                                      
Interest Expense, Long-Term Debt                                                                   1,141      
Amortization of Debt Discount (Premium)                                                                   7,367      
Debt Instrument, Discount Outstanding                                                                   335      
Debt Instrument, Debt Default, Amount                                                               25,882   25,882      
Interest Payable                                                               2,174   1,141      
Debt Instrument, Increase, Accrued Interest                                                               1,033          
Proceeds from Issuance of Debt                                   $ 20,000                                      
Debt Instrument, Maturity Date                                   Jan. 08, 2023                                      
Warrants and Rights Outstanding                                   $ 820                                      
Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per share)                                   $ 25                                      
Schrier Note [Member] | Measurement Input, Default Rate [Member]                                                                          
Notes Payable (Details) [Line Items]                                                                          
Debt Instrument, Interest Rate, Stated Percentage                                   18.00%                                      
Nommsen Note [Member]                                                                          
Notes Payable (Details) [Line Items]                                                                          
Debt Instrument, Face Amount                               $ 58,823                                          
Class of Warrant or Right, Outstanding (in Shares)                               483                                          
Common Stock, Shares, Issued (in Shares)                               483                                          
Common Stock, Value, Issued                               $ 2,350                                          
Debt Instrument, Interest Rate, Stated Percentage                               10.00%                                          
Interest Expense, Long-Term Debt                                                                   2,946      
Amortization of Debt Discount (Premium)                                                                   18,905      
Debt Instrument, Discount Outstanding                                                                   0      
Debt Instrument, Debt Default, Amount                                                               64,705   64,705      
Interest Payable                                                               5,634   2,946      
Debt Instrument, Increase, Accrued Interest                                                               2,688          
Proceeds from Issuance of Debt                               $ 50,000                                          
Debt Instrument, Maturity Date                               Nov. 30, 2022                                          
Warrants and Rights Outstanding                               $ 1,850                                          
Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per share)                               $ 25                                          
Nommsen Note [Member] | Measurement Input, Default Rate [Member]                                                                          
Notes Payable (Details) [Line Items]                                                                          
Debt Instrument, Interest Rate, Stated Percentage                               18.00%                                          
Caplan Note [Member]                                                                          
Notes Payable (Details) [Line Items]                                                                          
Debt Instrument, Face Amount                             $ 58,823                                            
Class of Warrant or Right, Outstanding (in Shares)                             483                                            
Common Stock, Shares, Issued (in Shares)                             483                                            
Common Stock, Value, Issued                             $ 2,350                                            
Debt Instrument, Interest Rate, Stated Percentage                             10.00%                                            
Interest Expense, Long-Term Debt                                                                   2,531      
Amortization of Debt Discount (Premium)                                                                   16,675      
Debt Instrument, Discount Outstanding                                                                   2,230      
Debt Instrument, Debt Default, Amount                                                               64,705   64,705      
Interest Payable                                                               4,937   2,531      
Debt Instrument, Increase, Accrued Interest                                                               2,406          
Proceeds from Issuance of Debt                             $ 50,000                                            
Debt Instrument, Maturity Date                             Jan. 21, 2023                                            
Warrants and Rights Outstanding                             $ 1,850                                            
Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per share)                             $ 25                                            
Caplan Note [Member] | Measurement Input, Default Rate [Member]                                                                          
Notes Payable (Details) [Line Items]                                                                          
Debt Instrument, Interest Rate, Stated Percentage                             18.00%                                            
Finnegan Note 3 [Member]                                                                          
Notes Payable (Details) [Line Items]                                                                          
Debt Instrument, Face Amount                           $ 29,412                                              
Class of Warrant or Right, Outstanding (in Shares)                           242                                              
Common Stock, Shares, Issued (in Shares)                           242                                              
Common Stock, Value, Issued                           $ 1,100                                              
Debt Instrument, Interest Rate, Stated Percentage                           10.00%                                              
Interest Expense, Long-Term Debt                                                                   1,200      
Amortization of Debt Discount (Premium)                                                                   7,575      
Debt Instrument, Discount Outstanding                                                                   1,728      
Debt Instrument, Debt Default, Amount                                                               32,353   32,353      
Interest Payable                                                               2,325   1,200      
Debt Instrument, Increase, Accrued Interest                                                               1,125          
Proceeds from Issuance of Debt                           $ 25,000                                              
Debt Instrument, Maturity Date                           Feb. 03, 2023                                              
Warrants and Rights Outstanding                           $ 850                                              
Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per share)                           $ 25                                              
Finnegan Note 3 [Member] | Measurement Input, Default Rate [Member]                                                                          
Notes Payable (Details) [Line Items]                                                                          
Debt Instrument, Interest Rate, Stated Percentage                           18.00%                                              
Enright Note [Member]                                                                          
Notes Payable (Details) [Line Items]                                                                          
Debt Instrument, Face Amount                           $ 120,000                                              
Common Stock, Shares, Issued (in Shares)                           984                                              
Common Stock, Value, Issued                           $ 6,317                                              
Debt Instrument, Interest Rate, Stated Percentage                           10.00%                                              
Interest Expense, Long-Term Debt                                                                   4,899      
Amortization of Debt Discount (Premium)                                                                   29,571      
Debt Instrument, Discount Outstanding                                                                   6,746      
Debt Instrument, Debt Default, Amount                                                               132,000   132,000      
Interest Payable                                                               9,460   4,899      
Debt Instrument, Increase, Accrued Interest                                                               4,561          
Proceeds from Issuance of Debt                           $ 102,000                                              
Debt Instrument, Maturity Date                           Feb. 03, 2023                                              
Enright Note [Member] | Measurement Input, Default Rate [Member]                                                                          
Notes Payable (Details) [Line Items]                                                                          
Debt Instrument, Interest Rate, Stated Percentage                           18.00%                                              
Mitchell Note [Member]                                                                          
Notes Payable (Details) [Line Items]                                                                          
Debt Instrument, Face Amount                       $ 71,000                                                  
Common Stock, Shares, Issued (in Shares)                       582                                                  
Common Stock, Value, Issued                       $ 3,124                                                  
Debt Instrument, Interest Rate, Stated Percentage                       10.00%                                                  
Interest Expense, Long-Term Debt                                                                   2,817      
Amortization of Debt Discount (Premium)                                                                   20,874      
Debt Instrument, Discount Outstanding                                                                   0      
Debt Instrument, Debt Default, Amount                                                               78,100   78,100      
Interest Payable                                                               6,051   2,817      
Debt Instrument, Increase, Accrued Interest                                                               3,234          
Proceeds from Issuance of Debt                       $ 60,350                                                  
Debt Instrument, Maturity Date                       Nov. 30, 2022                                                  
Mitchell Note [Member] | Measurement Input, Default Rate [Member]                                                                          
Notes Payable (Details) [Line Items]                                                                          
Debt Instrument, Interest Rate, Stated Percentage                       18.00%                                                  
Lightmas Note [Member]                                                                          
Notes Payable (Details) [Line Items]                                                                          
Debt Instrument, Face Amount                       $ 60,000                                                  
Common Stock, Shares, Issued (in Shares)                       492                                                  
Common Stock, Value, Issued                       $ 2,640                                                  
Debt Instrument, Interest Rate, Stated Percentage                       10.00%                                                  
Interest Expense, Long-Term Debt                                                                   2,380      
Amortization of Debt Discount (Premium)                                                                   17,640      
Debt Instrument, Discount Outstanding                                                                   0      
Debt Instrument, Debt Default, Amount                                                               66,000   66,000      
Interest Payable                                                               5,113   2,380      
Debt Instrument, Increase, Accrued Interest                                                               2,733          
Proceeds from Issuance of Debt                       $ 51,000                                                  
Debt Instrument, Maturity Date                       Nov. 30, 2022                                                  
Lightmas Note [Member] | Measurement Input, Default Rate [Member]                                                                          
Notes Payable (Details) [Line Items]                                                                          
Debt Instrument, Interest Rate, Stated Percentage                       18.00%                                                  
Lewis Note [Member]                                                                          
Notes Payable (Details) [Line Items]                                                                          
Debt Instrument, Face Amount                       $ 30,000                                                  
Common Stock, Shares, Issued (in Shares)                       246                                                  
Common Stock, Value, Issued                       $ 1,320                                                  
Debt Instrument, Interest Rate, Stated Percentage                       10.00%                                                  
Interest Expense, Long-Term Debt                                                                   1,190      
Amortization of Debt Discount (Premium)                                                                   8,820      
Debt Instrument, Discount Outstanding                                                                   0      
Debt Instrument, Debt Default, Amount                                                               33,000   33,000      
Interest Payable                                                               2,557   1,190      
Debt Instrument, Increase, Accrued Interest                                                               1,367          
Proceeds from Issuance of Debt                       $ 25,500                                                  
Debt Instrument, Maturity Date                       Nov. 30, 2022                                                  
Lewis Note [Member] | Measurement Input, Default Rate [Member]                                                                          
Notes Payable (Details) [Line Items]                                                                          
Debt Instrument, Interest Rate, Stated Percentage                       18.00%                                                  
Goff Note [Member]                                                                          
Notes Payable (Details) [Line Items]                                                                          
Debt Instrument, Face Amount                       $ 30,000                                                  
Common Stock, Shares, Issued (in Shares)                       246                                                  
Common Stock, Value, Issued                       $ 1,320                                                  
Debt Instrument, Interest Rate, Stated Percentage                       10.00%                                                  
Interest Expense, Long-Term Debt                                                                   1,190      
Amortization of Debt Discount (Premium)                                                                   8,820      
Debt Instrument, Discount Outstanding                                                                   0      
Debt Instrument, Debt Default, Amount                                                               33,000   33,000      
Interest Payable                                                               2,557   1,190      
Debt Instrument, Increase, Accrued Interest                                                               1,367          
Proceeds from Issuance of Debt                       $ 25,500                                                  
Debt Instrument, Maturity Date                       Nov. 30, 2022                                                  
Goff Note [Member] | Measurement Input, Default Rate [Member]                                                                          
Notes Payable (Details) [Line Items]                                                                          
Debt Instrument, Interest Rate, Stated Percentage                       18.00%                                                  
Hagan Note [Member]                                                                          
Notes Payable (Details) [Line Items]                                                                          
Debt Instrument, Face Amount                       $ 100,000                                                  
Common Stock, Shares, Issued (in Shares)                       820                                                  
Common Stock, Value, Issued                       $ 4,715                                                  
Debt Instrument, Interest Rate, Stated Percentage                       10.00%                                                  
Interest Expense, Long-Term Debt                                                                   3,556      
Amortization of Debt Discount (Premium)                                                                   29,715      
Debt Instrument, Discount Outstanding                                                                   0      
Debt Instrument, Debt Default, Amount                                                               110,000   110,000      
Interest Payable                                                               8,106   3,556      
Debt Instrument, Increase, Accrued Interest                                                               4,550          
Proceeds from Issuance of Debt                       $ 85,000                                                  
Debt Instrument, Maturity Date                       Dec. 10, 2022                                                  
Hagan Note [Member] | Measurement Input, Default Rate [Member]                                                                          
Notes Payable (Details) [Line Items]                                                                          
Debt Instrument, Interest Rate, Stated Percentage                       18.00%                                                  
Darling Note [Member]                                                                          
Notes Payable (Details) [Line Items]                                                                          
Debt Instrument, Face Amount                     $ 200,000                                                    
Common Stock, Shares, Issued (in Shares)                     1,640                                                    
Common Stock, Value, Issued                     $ 10,824                                                    
Debt Instrument, Interest Rate, Stated Percentage                     10.00%                                                    
Interest Expense, Long-Term Debt                                                                   6,619      
Amortization of Debt Discount (Premium)                                                                   60,824      
Debt Instrument, Discount Outstanding                                                                   0      
Debt Instrument, Debt Default, Amount                                                               220,000   220,000      
Interest Payable                                                               15,711   6,619      
Debt Instrument, Increase, Accrued Interest                                                               9,092          
Proceeds from Issuance of Debt                     $ 170,000                                                    
Debt Instrument, Maturity Date                     Dec. 15, 2022                                                    
Darling Note [Member] | Measurement Input, Default Rate [Member]                                                                          
Notes Payable (Details) [Line Items]                                                                          
Debt Instrument, Interest Rate, Stated Percentage                     18.00%                                                    
Leath Note [Member]                                                                          
Notes Payable (Details) [Line Items]                                                                          
Debt Instrument, Face Amount                   $ 50,000                                                      
Common Stock, Shares, Issued (in Shares)                   410                                                      
Common Stock, Value, Issued                   $ 2,868                                                      
Debt Instrument, Interest Rate, Stated Percentage                   10.00%                                                      
Interest Expense, Long-Term Debt                                                                   1,641      
Amortization of Debt Discount (Premium)                                                                   15,368      
Debt Instrument, Discount Outstanding                                                                   0      
Debt Instrument, Debt Default, Amount                                                               55,000   55,000      
Interest Payable                                                               3,914   1,641      
Debt Instrument, Increase, Accrued Interest                                                               2,273          
Proceeds from Issuance of Debt                   $ 42,500                                                      
Debt Instrument, Maturity Date                   Dec. 15, 2022                                                      
Debt Securities, Held-to-Maturity, Fair Value                   $ 55,000                                                      
Leath Note [Member] | Measurement Input, Default Rate [Member]                                                                          
Notes Payable (Details) [Line Items]                                                                          
Debt Instrument, Interest Rate, Stated Percentage                   18.00%                                                      
Cavalry Note [Member]                                                                          
Notes Payable (Details) [Line Items]                                                                          
Debt Instrument, Face Amount                                                                       $ 500,000  
Class of Warrant or Right, Outstanding (in Shares)                                                                       750  
Debt Instrument, Unamortized Discount                                                                       $ 7,500  
Debt Instrument, Interest Rate, Stated Percentage                                                                       10.00%  
Amortization of Debt Discount (Premium)                                                                   10,500      
Debt Instrument, Discount Outstanding                                                                   0      
Debt Instrument, Debt Default, Amount                                                               500,000   500,000      
Interest Payable                                                               34,583   11,918      
Debt Instrument, Increase, Accrued Interest                                                               22,655          
Cavalry Note [Member] | Measurement Input, Default Rate [Member]                                                                          
Notes Payable (Details) [Line Items]                                                                          
Debt Instrument, Interest Rate, Stated Percentage                                                                       18.00%  
Mercer Note 1 [Member]                                                                          
Notes Payable (Details) [Line Items]                                                                          
Debt Instrument, Face Amount                 $ 300,000                                                        
Class of Warrant or Right, Outstanding (in Shares)                 750                                                        
Debt Instrument, Interest Rate, Stated Percentage                 10.00%                                                        
Interest Expense, Long-Term Debt                                                                   6,986      
Amortization of Debt Discount (Premium)                                                                   10,500      
Debt Instrument, Discount Outstanding                                                                   0      
Debt Instrument, Debt Default, Amount                                                               300,000   300,000      
Interest Payable                                                               20,583   6,986      
Debt Instrument, Increase, Accrued Interest                                                               13,597          
Debt Instrument, Maturity Date                 Dec. 31, 2022                                                        
Mercer Note 1 [Member] | Measurement Input, Default Rate [Member]                                                                          
Notes Payable (Details) [Line Items]                                                                          
Debt Instrument, Interest Rate, Stated Percentage                 18.00%                                                        
Pinz Note [Member]                                                                          
Notes Payable (Details) [Line Items]                                                                          
Debt Instrument, Face Amount               $ 30,000                                                          
Debt Instrument, Interest Rate, Stated Percentage               10.00%                                                          
Interest Expense, Long-Term Debt                                                                   6,986      
Amortization of Debt Discount (Premium)                                                                   2,100      
Debt Instrument, Discount Outstanding                                                                   0      
Debt Instrument, Debt Default, Amount                                                               30,000   30,000      
Interest Payable                                                               2,033          
Debt Instrument, Increase, Accrued Interest                                                               1,359   $ 674      
Debt Instrument, Maturity Date               Dec. 31, 2022                                                          
Pinz Note [Member] | Measurement Input, Default Rate [Member]                                                                          
Notes Payable (Details) [Line Items]                                                                          
Debt Instrument, Interest Rate, Stated Percentage               18.00%                                                          
Pinz Exchange Agreement [Member]                                                                          
Notes Payable (Details) [Line Items]                                                                          
Preferred Stock, Convertible, Shares Issuable (in Shares)                                                                   100,000      
Mercer Note 2 [Member]                                                                          
Notes Payable (Details) [Line Items]                                                                          
Debt Instrument, Face Amount             $ 100,000                                                            
Class of Warrant or Right, Outstanding (in Shares)         750                                                                
Interest Expense, Long-Term Debt                                                                   $ 1,863      
Amortization of Debt Discount (Premium)                                                                   1,900      
Debt Instrument, Discount Outstanding                                                                   0      
Debt Instrument, Debt Default, Amount                                                               100,000   100,000      
Interest Payable                                                               6,389          
Debt Instrument, Increase, Accrued Interest                                                               4,526   1,863      
Debt Instrument, Maturity Date             Dec. 31, 2022                                                            
Mercer Note 2 [Member] | Measurement Input, Default Rate [Member]                                                                          
Notes Payable (Details) [Line Items]                                                                          
Debt Instrument, Interest Rate, Stated Percentage             18.00%                                                            
Mercer Note 3 [Member]                                                                          
Notes Payable (Details) [Line Items]                                                                          
Debt Instrument, Face Amount         $ 125,000                                                                
Class of Warrant or Right, Outstanding (in Shares)             750                                                            
Debt Instrument, Interest Rate, Stated Percentage         10.00%                                                                
Amortization of Debt Discount (Premium)                                                                   4,028      
Debt Instrument, Discount Outstanding                                                                   20,972      
Debt Instrument, Debt Default, Amount                                                               125,000   125,000      
Interest Payable                                                               4,132          
Debt Instrument, Increase, Accrued Interest                                                               3,139   993      
Debt Instrument, Maturity Date         May 21, 2023                                                                
Mercer Note 3 [Member] | Measurement Input, Default Rate [Member]                                                                          
Notes Payable (Details) [Line Items]                                                                          
Debt Instrument, Interest Rate, Stated Percentage         18.00%                                                                
Notes Payable, Other Payables [Member]                                                                          
Notes Payable (Details) [Line Items]                                                                          
Interest Payable, Current                                                               475,276   362,094      
Howe Note [Member]                                                                          
Notes Payable (Details) [Line Items]                                                                          
Debt Instrument, Face Amount                                                             $ 1,000,000            
Class of Warrant or Right, Outstanding (in Shares)                                                             42,000            
Common Stock, Shares, Issued (in Shares)                                                             42,000            
Common Stock, Value, Issued                                                             $ 261,568            
Debt Instrument, Interest Rate, Stated Percentage                                                             10.00%            
Interest Expense, Long-Term Debt                                                                   106,795      
Amortization of Debt Discount (Premium)                                                                   511,568      
Debt Instrument, Discount Outstanding                                                                   0      
Debt Instrument, Debt Default, Amount                                                               1,100,000   1,100,000      
Interest Payable                                                               153,556   106,795      
Debt Instrument, Increase, Accrued Interest                                                               46,761          
Proceeds from Issuance of Debt                                                             $ 850,000            
Debt Instrument, Maturity Date                                                             Nov. 30, 2022            
Share Price (in Dollars per share)                                                             $ 25            
Common Stock, Par or Stated Value Per Share (in Dollars per share)                                                             $ 37.5            
Howe Note [Member] | Measurement Input, Default Rate [Member]                                                                          
Notes Payable (Details) [Line Items]                                                                          
Debt Instrument, Interest Rate, Stated Percentage                                                             18.00%            
Diamond Note 1 [Member]                                                                          
Notes Payable (Details) [Line Items]                                                                          
Debt Instrument, Face Amount                                                         $ 175,000 $ 175,000              
Class of Warrant or Right, Outstanding (in Shares)                                                         7,350                
Common Stock, Shares, Issued (in Shares)                                                         7,350                
Common Stock, Value, Issued                                                         $ 2,914                
Debt Instrument, Interest Rate, Stated Percentage                                                         10.00% 10.00%              
Interest Expense, Long-Term Debt                                                                   16,052      
Amortization of Debt Discount (Premium)                                                                   46,664      
Debt Instrument, Discount Outstanding                                                                   0      
Debt Instrument, Debt Default, Amount                                                               192,500   192,500      
Interest Payable                                                               24,151   16,052      
Debt Instrument, Increase, Accrued Interest                                                               8,099          
Proceeds from Issuance of Debt                                                         $ 148,750 $ 148,750              
Debt Instrument, Maturity Date                                                         Nov. 30, 2022                
Share Price (in Dollars per share)                                                         $ 25                
Common Stock, Par or Stated Value Per Share (in Dollars per share)                                                         $ 37.5                
Diamond Note 1 [Member] | Measurement Input, Default Rate [Member]                                                                          
Notes Payable (Details) [Line Items]                                                                          
Debt Instrument, Interest Rate, Stated Percentage                                                         18.00% 18.00%              
Diamond Note 2 [Member]                                                                          
Notes Payable (Details) [Line Items]                                                                          
Debt Instrument, Face Amount                                                       $ 235,294                  
Class of Warrant or Right, Outstanding (in Shares)                                                       1,930                  
Debt Instrument, Interest Rate, Stated Percentage                                                       10.00%                  
Interest Expense, Long-Term Debt                                                                   1,676      
Amortization of Debt Discount (Premium)                                                                   61,036      
Debt Instrument, Discount Outstanding                                                                   0      
Debt Instrument, Debt Default, Amount                                                               23,529   23,529      
Interest Payable                                                               1,676   1,699      
Debt Instrument, Increase, Accrued Interest                                                               0          
Proceeds from Issuance of Debt                                                       $ 200,000                  
Debt Instrument, Maturity Date                                                       Nov. 30, 2022                  
Share Price (in Dollars per share)                                                       $ 25                  
Warrants and Rights Outstanding                                                       $ 2,213                  
Debt Instrument, Repaid, Principal                                                                   235,294      
Diamond Note 2 [Member] | Measurement Input, Default Rate [Member]                                                                          
Notes Payable (Details) [Line Items]                                                                          
Debt Instrument, Interest Rate, Stated Percentage                                                       18.00%                  
Diamond Note 3 [Member]                                                                          
Notes Payable (Details) [Line Items]                                                                          
Debt Instrument, Face Amount                                               $ 235,294                          
Class of Warrant or Right, Outstanding (in Shares)                                               1,930                          
Common Stock, Shares, Issued (in Shares)                                               1,930                          
Common Stock, Value, Issued                                               $ 16,200                          
Debt Instrument, Interest Rate, Stated Percentage                                               10.00%                          
Interest Expense, Long-Term Debt                                                                   17,586      
Amortization of Debt Discount (Premium)                                                                   83,823      
Debt Instrument, Discount Outstanding                                                                   0      
Debt Instrument, Debt Default, Amount                                                               258,823   258,823      
Interest Payable                                                               28,418   17,586      
Debt Instrument, Increase, Accrued Interest                                                               10,832          
Proceeds from Issuance of Debt                                               $ 200,000                          
Debt Instrument, Maturity Date                                               Nov. 30, 2022                          
Share Price (in Dollars per share)                                               $ 25                          
Warrants and Rights Outstanding                                               $ 8,800                          
Diamond Note 3 [Member] | Measurement Input, Default Rate [Member]                                                                          
Notes Payable (Details) [Line Items]                                                                          
Debt Instrument, Interest Rate, Stated Percentage                                               18.00%                          
Diamond Note 4 [Member]                                                                          
Notes Payable (Details) [Line Items]                                                                          
Debt Instrument, Face Amount                                           $ 47,059                              
Class of Warrant or Right, Outstanding (in Shares)                                           386                              
Common Stock, Shares, Issued (in Shares)                                           1,930                              
Common Stock, Value, Issued                                           $ 3,160                              
Interest Expense, Long-Term Debt                                                                   3,245      
Amortization of Debt Discount (Premium)                                                                   17,885      
Debt Instrument, Discount Outstanding                                                                   0      
Debt Instrument, Debt Default, Amount                                                               51,765   51,765      
Interest Payable                                                               5,409   3,245      
Debt Instrument, Increase, Accrued Interest                                                               2,164          
Proceeds from Issuance of Debt                                           $ 40,000                              
Debt Instrument, Maturity Date                                           Nov. 30, 2022                              
Share Price (in Dollars per share)                                           $ 25                              
Warrants and Rights Outstanding                                           $ 2,960                              
Diamond Note 4 [Member] | Measurement Input, Default Rate [Member]                                                                          
Notes Payable (Details) [Line Items]                                                                          
Debt Instrument, Interest Rate, Stated Percentage                                           18.00%                              
Diamond Note 5 [Member]                                                                          
Notes Payable (Details) [Line Items]                                                                          
Debt Instrument, Face Amount                                       $ 58,823                                  
Class of Warrant or Right, Outstanding (in Shares)                                       483                                  
Common Stock, Shares, Issued (in Shares)                                       483                                  
Common Stock, Value, Issued                                       $ 4,050                                  
Debt Instrument, Interest Rate, Stated Percentage                                       10.00%                                  
Interest Expense, Long-Term Debt                                                                   3,929      
Amortization of Debt Discount (Premium)                                                                   21,256      
Debt Instrument, Discount Outstanding                                                                   0      
Debt Instrument, Debt Default, Amount                                                               64,705   64,705      
Interest Payable                                                               6,631   3,929      
Debt Instrument, Increase, Accrued Interest                                                               2,702          
Proceeds from Issuance of Debt                                       $ 50,000                                  
Debt Instrument, Maturity Date                                       Nov. 30, 2022                                  
Share Price (in Dollars per share)                                       $ 25                                  
Warrants and Rights Outstanding                                       $ 2,500                                  
Diamond Note 5 [Member] | Measurement Input, Default Rate [Member]                                                                          
Notes Payable (Details) [Line Items]                                                                          
Debt Instrument, Interest Rate, Stated Percentage                                       18.00%                                  
Lindstrom Note 1 [Member]                                                                          
Notes Payable (Details) [Line Items]                                                                          
Debt Instrument, Face Amount                                       $ 41,176                                  
Class of Warrant or Right, Outstanding (in Shares)                                       338                                  
Common Stock, Shares, Issued (in Shares)                                       338                                  
Common Stock, Value, Issued                                       $ 2,835                                  
Debt Instrument, Interest Rate, Stated Percentage                                       10.00%                                  
Interest Expense, Long-Term Debt                                                                   2,750      
Amortization of Debt Discount (Premium)                                                                   14,879      
Debt Instrument, Discount Outstanding                                                                   0      
Debt Instrument, Debt Default, Amount                                                               45,294   45,294      
Interest Payable                                                               4,641   2,750      
Debt Instrument, Increase, Accrued Interest                                                               1,891          
Proceeds from Issuance of Debt                                       $ 35,000                                  
Debt Instrument, Maturity Date                                       Nov. 30, 2022                                  
Share Price (in Dollars per share)                                       $ 25                                  
Warrants and Rights Outstanding                                       $ 1,750                                  
Lindstrom Note 1 [Member] | Measurement Input, Default Rate [Member]                                                                          
Notes Payable (Details) [Line Items]                                                                          
Debt Instrument, Interest Rate, Stated Percentage                                       18.00%                                  
Dobbertin Note 1 [Member]                                                                          
Notes Payable (Details) [Line Items]                                                                          
Debt Instrument, Face Amount                                       $ 17,647                                  
Class of Warrant or Right, Outstanding (in Shares)                                       145                                  
Common Stock, Shares, Issued (in Shares)                                       145                                  
Common Stock, Value, Issued                                       $ 1,215                                  
Interest Expense, Long-Term Debt                                                                   1,179      
Amortization of Debt Discount (Premium)                                                                   6,377      
Debt Instrument, Discount Outstanding                                                                   0      
Debt Instrument, Debt Default, Amount                                                               19,412   19,412      
Interest Payable                                                               1,990   1,179      
Debt Instrument, Increase, Accrued Interest                                                               811          
Proceeds from Issuance of Debt                                       $ 15,000                                  
Debt Instrument, Maturity Date                                       Nov. 30, 2022                                  
Share Price (in Dollars per share)                                       $ 25                                  
Warrants and Rights Outstanding                                       $ 750                                  
Dobbertin Note 1 [Member] | Measurement Input, Default Rate [Member]                                                                          
Notes Payable (Details) [Line Items]                                                                          
Debt Instrument, Interest Rate, Stated Percentage                                       18.00%                                  
Howe Note 2 [Member]                                                                          
Notes Payable (Details) [Line Items]                                                                          
Debt Instrument, Face Amount                                     $ 300,000                                    
Class of Warrant or Right, Outstanding (in Shares)                                     2,460                                    
Common Stock, Shares, Issued (in Shares)                                     2,460                                    
Common Stock, Value, Issued                                     $ 22,440                                    
Debt Instrument, Interest Rate, Stated Percentage                                     10.00%                                    
Interest Expense, Long-Term Debt                                                                   18,888      
Amortization of Debt Discount (Premium)                                                                   108,405      
Debt Instrument, Discount Outstanding                                                                   0      
Debt Instrument, Debt Default, Amount                                                               330,000   330,000      
Interest Payable                                                               32,650   18,888      
Debt Instrument, Increase, Accrued Interest                                                               8,099          
Proceeds from Issuance of Debt                                     $ 255,000                                    
Debt Instrument, Maturity Date                                     Nov. 30, 2022                                    
Share Price (in Dollars per share)                                     $ 25                                    
Warrants and Rights Outstanding                                     $ 10,965                                    
Howe Note 2 [Member] | Measurement Input, Default Rate [Member]                                                                          
Notes Payable (Details) [Line Items]                                                                          
Debt Instrument, Interest Rate, Stated Percentage                                     18.00%                                    
Howe Note 3 [Member]                                                                          
Notes Payable (Details) [Line Items]                                                                          
Debt Instrument, Face Amount                                 $ 300,000                                        
Class of Warrant or Right, Outstanding (in Shares)                                 2,460                                        
Common Stock, Shares, Issued (in Shares)                                 2,460                                        
Common Stock, Value, Issued                                 $ 12,495                                        
Debt Instrument, Interest Rate, Stated Percentage                                 10.00%                                        
Interest Expense, Long-Term Debt                                                                   15,436      
Amortization of Debt Discount (Premium)                                                                   97,440      
Debt Instrument, Discount Outstanding                                                                   0      
Debt Instrument, Debt Default, Amount                                                               330,000   330,000      
Interest Payable                                                               29,150   15,436      
Debt Instrument, Increase, Accrued Interest                                                               13,714          
Proceeds from Issuance of Debt                                 $ 255,000                                        
Debt Instrument, Maturity Date                                 Nov. 30, 2022                                        
Share Price (in Dollars per share)                                 $ 25                                        
Warrants and Rights Outstanding                                 $ 9,945                                        
Howe Note 3 [Member] | Measurement Input, Default Rate [Member]                                                                          
Notes Payable (Details) [Line Items]                                                                          
Debt Instrument, Interest Rate, Stated Percentage                                 18.00%                                        
Iturregui Note [Member]                                                                          
Notes Payable (Details) [Line Items]                                                                          
Debt Instrument, Face Amount                                 $ 29,412                                        
Class of Warrant or Right, Outstanding (in Shares)                                 242                                        
Common Stock, Shares, Issued (in Shares)                                 242                                        
Common Stock, Value, Issued                                 $ 1,225                                        
Debt Instrument, Interest Rate, Stated Percentage                                 10.00%                                        
Interest Expense, Long-Term Debt                                                                   1,313      
Amortization of Debt Discount (Premium)                                                                   8,464      
Debt Instrument, Discount Outstanding                                                                   1,089      
Debt Instrument, Debt Default, Amount                                                               32,353   32,353      
Interest Payable                                                               2,518   1,313      
Debt Instrument, Increase, Accrued Interest                                                               1,205          
Proceeds from Issuance of Debt                                 $ 25,000                                        
Debt Instrument, Maturity Date                                 Jan. 21, 2023                                        
Share Price (in Dollars per share)                                 $ 25                                        
Warrants and Rights Outstanding                                 $ 975                                        
Iturregui Note [Member] | Measurement Input, Default Rate [Member]                                                                          
Notes Payable (Details) [Line Items]                                                                          
Debt Instrument, Interest Rate, Stated Percentage                                 18.00%                                        
Howe Note 4 [Member]                                                                          
Notes Payable (Details) [Line Items]                                                                          
Debt Instrument, Face Amount                         $ 200,000                                                
Common Stock, Shares, Issued (in Shares)                         1,640                                                
Common Stock, Value, Issued                         $ 10,775                                                
Debt Instrument, Interest Rate, Stated Percentage                         10.00%                                                
Interest Expense, Long-Term Debt                                                                   8,756      
Amortization of Debt Discount (Premium)                                                                   60,775      
Debt Instrument, Discount Outstanding                                                                   0      
Debt Instrument, Debt Default, Amount                                                               220,000   220,000      
Interest Payable                                                               18,433   8,756      
Debt Instrument, Increase, Accrued Interest                                                               9,677          
Proceeds from Issuance of Debt                         $ 170,000                                                
Debt Instrument, Maturity Date                         Nov. 30, 2022                                                
Howe Note 4 [Member] | Measurement Input, Default Rate [Member]                                                                          
Notes Payable (Details) [Line Items]                                                                          
Debt Instrument, Interest Rate, Stated Percentage                         18.00%                                                
November 29, 2022 Notes [Member]                                                                          
Notes Payable (Details) [Line Items]                                                                          
Class of Warrant or Right, Outstanding (in Shares)           750                                                              
Amortization of Debt Discount (Premium)                                                                   667      
Debt Instrument, Discount Outstanding                                                                   3,083      
Debt Instrument, Debt Default, Amount                                                               18,750   18,750      
Interest Payable                                                               635   $ 164      
Debt Instrument, Increase, Accrued Interest                                                               471          
Debt Instrument, Maturity Date           May 28, 2023                                                              
November 29, 2022 Notes [Member] | Measurement Input, Default Rate [Member]                                                                          
Notes Payable (Details) [Line Items]                                                                          
Debt Instrument, Interest Rate, Stated Percentage           18.00%                                                              
Series C Preferred Stock [Member] | Cavalry Note [Member]                                                                          
Notes Payable (Details) [Line Items]                                                                          
Preferred Stock, Convertible, Shares Issuable (in Shares)                                                                       1,000,000  
Series C Preferred Stock [Member] | Cavalry Exchange Agreement [Member]                                                                          
Notes Payable (Details) [Line Items]                                                                          
Preferred Stock, Convertible, Shares Issuable (in Shares)                                                                   1,000,000      
Series C Preferred Stock [Member] | Mercer Note 1 [Member]                                                                          
Notes Payable (Details) [Line Items]                                                                          
Preferred Stock, Convertible, Shares Issuable (in Shares)                 47,619                                                        
Series C Preferred Stock [Member] | Mercer Exchange Agreement [Member]                                                                          
Notes Payable (Details) [Line Items]                                                                          
Preferred Stock, Convertible, Shares Issuable (in Shares)                                                                   47,619      
Series D Preferred Stock [Member] | Cavalry Note [Member]                                                                          
Notes Payable (Details) [Line Items]                                                                          
Preferred Stock, Convertible, Shares Issuable (in Shares)                                                                       750,000  
Series D Preferred Stock [Member] | Cavalry Exchange Agreement [Member]                                                                          
Notes Payable (Details) [Line Items]                                                                          
Preferred Stock, Convertible, Shares Issuable (in Shares)                                                                   750,000      
Series D Preferred Stock [Member] | Mercer Note 1 [Member]                                                                          
Notes Payable (Details) [Line Items]                                                                          
Preferred Stock, Convertible, Shares Issuable (in Shares)                 750,000                                                        
Series D Preferred Stock [Member] | Mercer Exchange Agreement [Member]                                                                          
Notes Payable (Details) [Line Items]                                                                          
Preferred Stock, Convertible, Shares Issuable (in Shares)                                                                   750,000      
Series D Preferred Stock [Member] | Pinz Note [Member]                                                                          
Notes Payable (Details) [Line Items]                                                                          
Preferred Stock, Convertible, Shares Issuable (in Shares)               100,000                                                          
Commitments [Member] | AJB Capital Note [Member]                                                                          
Notes Payable (Details) [Line Items]                                                                          
Stock Issued During Period, Value, Other                                                       $ 430,000                  
Stock Issued During Period, Shares, Other (in Shares)                                                       34,400                  
Original Issue Discount [Member] | AJB Capital Note [Member]                                                                          
Notes Payable (Details) [Line Items]                                                                          
Debt Instrument, Unamortized Discount                                                       $ 75,000                  
Original Issue Discount [Member] | Anson Investments Note [Member]                                                                          
Notes Payable (Details) [Line Items]                                                                          
Debt Instrument, Unamortized Discount                                                     $ 56,250                    
Original Issue Discount [Member] | Anson East Note [Member]                                                                          
Notes Payable (Details) [Line Items]                                                                          
Debt Instrument, Unamortized Discount                                                     $ 18,750                    
Original Issue Discount [Member] | Kishon Note [Member]                                                                          
Notes Payable (Details) [Line Items]                                                                          
Debt Instrument, Unamortized Discount                                             $ 27,777                            
Default Penalty [Member] | AJB Capital Note [Member]                                                                          
Notes Payable (Details) [Line Items]                                                                          
Debt Instrument, Fee Amount                                                               375,000          
Default Penalty [Member] | Anson Investments Note [Member]                                                                          
Notes Payable (Details) [Line Items]                                                                          
Debt Instrument, Fee Amount                                                               281,250          
Default Penalty [Member] | Anson East Note [Member]                                                                          
Notes Payable (Details) [Line Items]                                                                          
Debt Instrument, Fee Amount                                                               93,750          
Default Penalty [Member] | GS Capital Note [Member]                                                                          
Notes Payable (Details) [Line Items]                                                                          
Debt Instrument, Fee Amount                                                               138,889          
Default Penalty [Member] | Kishon Note [Member]                                                                          
Notes Payable (Details) [Line Items]                                                                          
Debt Instrument, Fee Amount                                                               138,889          
Related Party [Member]                                                                          
Notes Payable (Details) [Line Items]                                                                          
Debt Instrument, Unamortized Discount                                                               8,456   $ 22,670      
Amortization of Debt Discount (Premium)                                                               14,214 0        
Interest Payable                                                               313,691   198,753      
Debt Instrument, Unamortized Discount, Current                                                               8,000   0.3      
Debt, Current                                                               2,791,176   2,776,962      
Proceeds from Issuance of Debt                                                               0 348,750        
Interest Expense, Debt                                                               114,938 $ 27,174        
Interest Payable, Current                                                               $ 313,691   $ 198,753      
v3.23.3
Notes Payable (Details) - Schedule of Debt - USD ($)
Mar. 31, 2023
Dec. 31, 2022
Schedule Of Debt Abstract    
Notes Payable $ 6,174,712 $ 5,144,742
Less: Discount (8,472) (32,041)
Notes payable - net of discount 6,166,240 5,112,701
Current Portion, net of discount 6,166,240 5,112,701
Long-term portion, net of discount $ 0 $ 0
v3.23.3
Notes Payable - Related Parties (Details) - Schedule of Debt, Related Parties - Related Party [Member] - USD ($)
Mar. 31, 2023
Dec. 31, 2022
Notes Payable - Related Parties (Details) - Schedule of Debt, Related Parties [Line Items]    
Notes Payable $ 2,799,632 $ 2,799,632
Less: Discount (8,456) (22,670)
Notes payable – net of discounts 2,791,176 2,776,962
Current Portion, net of discount 2,791,176 2,776,962
Long-term portion, net of discount $ 0 $ 0
v3.23.3
Derivative Liabilities (Details) - Schedule of Derivative Liability Acitivity
3 Months Ended
Mar. 31, 2023
USD ($)
Schedule Of Derivative Liability Acitivity Abstract  
Balance $ 568,912
Loss on revaluation 110,778
Balance $ 679,690
v3.23.3
Derivative Liabilities (Details) - Schedule of Valuation Assumptions - $ / shares
3 Months Ended 12 Months Ended
Mar. 31, 2023
Dec. 31, 2022
Derivative Liabilities (Details) - Schedule of Valuation Assumptions [Line Items]    
Stock Price (in Dollars per share) $ 1.24  
Risk-free interest rates 4.40%  
Minimum [Member]    
Derivative Liabilities (Details) - Schedule of Valuation Assumptions [Line Items]    
Volatility 159.60% 95.10%
Stock Price (in Dollars per share)   $ 1.06
Risk-free interest rates   4.35%
Term (years) 6 months 7 days 8 months 23 days
Maximum [Member]    
Derivative Liabilities (Details) - Schedule of Valuation Assumptions [Line Items]    
Volatility 169.90% 123.20%
Stock Price (in Dollars per share)   $ 3.5
Risk-free interest rates   4.37%
Term (years) 7 months 9 days 10 months 9 days
v3.23.3
Stockholders’ Equity (Deficit) (Details) - USD ($)
3 Months Ended 9 Months Ended
Mar. 28, 2023
Mar. 23, 2023
Mar. 09, 2023
Feb. 28, 2023
Feb. 21, 2023
Feb. 14, 2023
Jan. 23, 2023
Nov. 07, 2022
Apr. 18, 2022
Mar. 31, 2022
Mar. 31, 2022
Jan. 12, 2022
Jan. 05, 2022
Mar. 31, 2023
Mar. 31, 2022
Sep. 30, 2022
Dec. 31, 2022
Nov. 18, 2022
Mar. 18, 2022
Stockholders’ Equity (Deficit) (Details) [Line Items]                                      
Common Stock, Shares Authorized (in Shares)                           500,000,000     500,000,000    
Common Stock, Par or Stated Value Per Share (in Dollars per share)                       $ 0.01   $ 0.01     $ 0.01    
Common Stock, Shares, Issued (in Shares)                           4,995,573     4,630,372    
Common Stock, Shares, Outstanding (in Shares)                           4,995,573     4,630,372    
Stock Issued During Period, Shares, Issued for Services (in Shares)         150,000   150,000                        
Shares Issued, Price Per Share (in Dollars per share)         $ 2.53   $ 3.45             $ 4.38          
Share-Based Payment Arrangement, Expense         $ 379,500   $ 517,500                        
Debt Conversion, Converted Instrument, Shares Issued (in Shares)       13,555                   57,138          
Accrued Salaries, Current                       $ 19,032              
Shares Issued, Shares, Share-Based Payment Arrangement, Forfeited (in Shares)                       8,000              
Shares Issued, Value, Share-Based Payment Arrangement, Forfeited                       $ 4,000              
Gains (Losses) on Restructuring of Debt                       $ 15,032   $ 0 $ 15,032        
Other Accrued Liabilities, Current                           0     $ 507    
Other Noncash Expense                           1,102,778 0        
                          0 198,273        
Debt Instrument, Unamortized Discount                           $ 8,472     $ 32,041    
Preferred Stock, Shares Authorized (in Shares)                           100,000,000          
Dividends, Preferred Stock                           $ 79,818 $ 79,692        
Preferred Stock, Convertible, Terms               Each share of Series E shall become convertible, at the option of the holder, commencing on the date of issuance, into such number of fully paid and non-assessable shares of Common Stock. The conversion price shall be, as of the conversion date, (a) prior to the date of the qualified offering the average VWAP per share of the Common Stock for the five (5) trading days prior to the date of conversion and (b) on or following the date of the qualified offering, the qualified offering price (the “Conversion Price”). Immediately following the 120th day following the qualified offering, the Conversion Price shall be adjusted to the lesser of (a) the average VWAP per share of the Common Stock for the five (5) trading days immediately following the 120th day following the qualified offering and (b) the Conversion Price on such date, which shall in no event be less than $0.05.                      
Preferred Stock, Convertible, Conversion Price (in Dollars per share)               $ 0.05                      
Stock Subscribed [Member]                                      
Stockholders’ Equity (Deficit) (Details) [Line Items]                                      
Shares Issued, Price Per Share (in Dollars per share)                   $ 12.5 $ 12.5       $ 12.5        
Stock Issued During Period, Shares, Other (in Shares)                     7,647                
GS Capital Note [Member]                                      
Stockholders’ Equity (Deficit) (Details) [Line Items]                                      
Debt Conversion, Original Debt, Amount                           $ 72,777          
Debt Instrument, Convertible, Conversion Price (in Dollars per share) $ 1.25   $ 1.5 $ 1.5   $ 1.74               $ 1.46          
Debt Conversion, Converted Instrument, Shares Issued (in Shares) 18,472   15,265     9,846                          
Stock Issued During Period, Shares, Other (in Shares)                 12,741                    
Derivative Liability                 $ 21,920                    
Debt Instrument, Unamortized Discount                 $ 162,158                    
GS Capital Note [Member] | Principal [Member]                                      
Stockholders’ Equity (Deficit) (Details) [Line Items]                                      
Debt Conversion, Original Debt, Amount $ 20,000   $ 20,000 $ 17,777   $ 15,000                          
GS Capital Note [Member] | Accrued Interest [Member]                                      
Stockholders’ Equity (Deficit) (Details) [Line Items]                                      
Debt Conversion, Original Debt, Amount 2,581   2,399 2,057   1,632               $ 8,679          
GS Capital Note [Member] | Fees [Member]                                      
Stockholders’ Equity (Deficit) (Details) [Line Items]                                      
Debt Conversion, Original Debt, Amount $ 500   $ 500 $ 500   $ 500               $ 2,000          
Series X Preferred Stock [Member]                                      
Stockholders’ Equity (Deficit) (Details) [Line Items]                                      
Stock Issued During Period, Shares, New Issues (in Shares)                           8,063          
AJB Capital Note [Member]                                      
Stockholders’ Equity (Deficit) (Details) [Line Items]                                      
Common Stock, Shares, Issued (in Shares)                                   91,328  
Derivative Liability                   $ 106,608 $ 106,608       $ 106,608       $ 106,608
Debt Instrument, Unamortized Discount                                     $ 349,914
Accounts Payable [Member] | Stock Subscribed [Member]                                      
Stockholders’ Equity (Deficit) (Details) [Line Items]                                      
Debt Conversion, Original Debt, Amount                     $ 95,558                
Series A Preferred Stock [Member]                                      
Stockholders’ Equity (Deficit) (Details) [Line Items]                                      
Preferred Stock, Shares Authorized (in Shares)                           500,000          
Preferred Stock, Par or Stated Value Per Share (in Dollars per share)                           $ 0.01     $ 0.01    
Preferred Stock, Shares Outstanding (in Shares)                           0     0    
Series A Preferred Stock [Member] | The Good Clinic [Member]                                      
Stockholders’ Equity (Deficit) (Details) [Line Items]                                      
Preferred Stock, Dividend Rate, Percentage                           10.00%          
Series C Preferred Stock [Member]                                      
Stockholders’ Equity (Deficit) (Details) [Line Items]                                      
Preferred Stock, Shares Authorized (in Shares)                           3,000,000          
Dividends, Preferred Stock                           $ 16,521 16,395        
Preferred Stock, Par or Stated Value Per Share (in Dollars per share)                           $ 0.01     $ 0.01    
Preferred Stock, Shares Outstanding (in Shares)                           1,047,619     1,047,619    
Series D Preferred Stock [Member]                                      
Stockholders’ Equity (Deficit) (Details) [Line Items]                                      
Preferred Stock, Shares Authorized (in Shares)                           10,000,000          
Dividends, Preferred Stock                           $ 48,156 48,156        
Preferred Stock, Par or Stated Value Per Share (in Dollars per share)                           $ 0.01     $ 0.01    
Preferred Stock, Shares Outstanding (in Shares)                           3,100,000     3,100,000    
Series E Preferred Stock [Member]                                      
Stockholders’ Equity (Deficit) (Details) [Line Items]                                      
Preferred Stock, Shares Authorized (in Shares)               10,000           10,000          
Preferred Stock, Liquidation Preference Per Share (in Dollars per share)               $ 1,000                      
Preferred Stock, Par or Stated Value Per Share (in Dollars per share)               $ 0.01                      
Series F Preferred Stock [Member]                                      
Stockholders’ Equity (Deficit) (Details) [Line Items]                                      
Preferred Stock, Shares Authorized (in Shares)   140,000                       140,000          
Preferred Stock, Liquidation Preference Per Share (in Dollars per share)   $ 1,000                                  
Preferred Stock, Par or Stated Value Per Share (in Dollars per share)   $ 0.01                                  
Preferred Stock, Convertible, Terms   The Series F can be converted, at the option of the Series F shareholder into shares of the Company’s common stock at a price equal to 65% of the Volume Weighted Average Price ("VWAP”) on the conversion date. No conversions can occur until the Company has successfully completed an uplist to NASDAQ.                                  
Series X Preferred Stock [Member]                                      
Stockholders’ Equity (Deficit) (Details) [Line Items]                                      
Preferred Stock, Shares Authorized (in Shares)                           27,324          
Dividends, Preferred Stock                           $ 15,141 15,141        
Preferred Stock, Liquidation Preference Per Share (in Dollars per share)                           $ 25          
Preferred Stock, Par or Stated Value Per Share (in Dollars per share)                           $ 0.01     $ 0.01    
Preferred Stock, Shares Outstanding (in Shares)                           24,227     24,227    
Preferred Stock, Dividend Payment Terms                           The Company reserves the right to pay the dividends in shares of the Company’s common stock at a price equal to the average closing price over the five days prior to the date of the dividend declaration.          
Preferred Stock, Voting Rights                           Each one share of the Series X Preferred Stock is entitled to 20,000 votes on all matters submitted to a vote of our shareholders.          
Waiver Fee [Member]                                      
Stockholders’ Equity (Deficit) (Details) [Line Items]                                      
Stock Issued During Period, Shares, Other (in Shares)                   30,834                  
Other Noncash Expense                               $ 385,431      
                              $ 198,273      
Share-Based Payment Arrangement, Option [Member]                                      
Stockholders’ Equity (Deficit) (Details) [Line Items]                                      
Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount                           $ 2.1          
Officer [Member] | Series X Preferred Stock [Member]                                      
Stockholders’ Equity (Deficit) (Details) [Line Items]                                      
Stock Issued During Period, Shares, New Issues (in Shares)                           1,066          
Officer [Member] | Series X Preferred Stock [Member]                                      
Stockholders’ Equity (Deficit) (Details) [Line Items]                                      
Dividends, Preferred Stock                           $ 2,000 2,000        
Majority Shareholder [Member] | Series X Preferred Stock [Member]                                      
Stockholders’ Equity (Deficit) (Details) [Line Items]                                      
Stock Issued During Period, Shares, New Issues (in Shares)                           4,160          
Majority Shareholder [Member] | Series X Preferred Stock [Member]                                      
Stockholders’ Equity (Deficit) (Details) [Line Items]                                      
Dividends, Preferred Stock                           $ 7,814 8,000        
Nonrelated Party [Member]                                      
Stockholders’ Equity (Deficit) (Details) [Line Items]                                      
Dividends, Preferred Stock                           $ 61,823 61,695        
Nonrelated Party [Member] | Series X Preferred Stock [Member]                                      
Stockholders’ Equity (Deficit) (Details) [Line Items]                                      
Stock Issued During Period, Shares, New Issues (in Shares)                           2,837          
Nonrelated Party [Member] | Series X Preferred Stock [Member]                                      
Stockholders’ Equity (Deficit) (Details) [Line Items]                                      
Dividends, Preferred Stock                           $ 5,327 $ 6,000        
Gardner Agreement [Member]                                      
Stockholders’ Equity (Deficit) (Details) [Line Items]                                      
Debt Instrument, Convertible, Conversion Price (in Dollars per share)                         $ 12.5            
Debt Conversion, Converted Instrument, Amount                         $ 500,000            
Other Accrued Liabilities, Current                         $ 294,912            
Gardner Agreement [Member] | Restricted Stock [Member]                                      
Stockholders’ Equity (Deficit) (Details) [Line Items]                                      
Debt Conversion, Converted Instrument, Shares Issued (in Shares)                         63,593            
AJB Capital Investors [Member]                                      
Stockholders’ Equity (Deficit) (Details) [Line Items]                                      
Stock Issued During Period, Shares, Other (in Shares)                     34,400                
Contract, Price per share (in Dollars per share)                     $ 12.5                
Adjustments to Additional Paid in Capital, Other                     $ 226,106                
AJB Capital Investors [Member] | Valuation, Market Approach [Member]                                      
Stockholders’ Equity (Deficit) (Details) [Line Items]                                      
Shares Issued, Price Per Share (in Dollars per share)                   $ 6.14 $ 6.14       $ 6.14        
AJB Capital Investors [Member] | Warrant and Commitment Fees [Member] | AJB Capital Note [Member]                                      
Stockholders’ Equity (Deficit) (Details) [Line Items]                                      
Debt Instrument, Unamortized Discount                   $ 349,914 $ 349,914       $ 349,914        
v3.23.3
Stockholders’ Equity (Deficit) (Details) - Share-based Payment Arrangement, Option, Exercise Price Range - $ / shares
3 Months Ended
Mar. 31, 2023
Dec. 31, 2022
Share Based Payment Arrangement Option Exercise Price Range Abstract    
Range of exercise prices $ 1.5  
Range of exercise prices $ 16  
Number of options outstanding (in Shares) 215,881 310,692
Weighted average remaining contractual life (years) 7 years 11 months 8 days  
Weighted average exercise price of outstanding options $ 9.39 $ 10.01
Number of options exercisable (in Shares) 129,148  
Weighted average exercise price of exercisable options $ 7.73  
v3.23.3
Stockholders’ Equity (Deficit) (Details) - Share-based Payment Arrangement, Option, Activity
3 Months Ended
Mar. 31, 2023
$ / shares
shares
Share Based Payment Arrangement Option Activity Abstract  
Outstanding, Number of Shares | shares 310,692
Outstanding, Weighted-Average Exercise Price | $ / shares $ 10.01
Options Vested and Exercisable, Number of Shares | shares 129,148
Options Vested and Exercisable, Weighted-Average Exercise Price | $ / shares $ 7.73
Granted, Number of Shares | shares 0
Granted, Weighted-Average Exercise Price | $ / shares $ 0
Cancelled/Expired, Number of Shares | shares (94,811)
Cancelled/Expired, Weighted-Average Exercise Price | $ / shares $ 11.44
Outstanding, Number of Shares | shares 215,881
Outstanding, Weighted-Average Exercise Price | $ / shares $ 9.39
v3.23.3
Stockholders’ Equity (Deficit) (Details) - Schedule of Stockholders' Equity Note, Warrants or Rights
3 Months Ended
Mar. 31, 2023
$ / shares
shares
Schedule Of Stockholders Equity Note Warrants Or Rights Abstract  
Outstanding, Number of Shares | shares 672,334
Outstanding, Weighted Average Exercise Price | $ / shares $ 30.68
Granted, Number of Shares | shares 0
Granted, Weighted Average Exercise Price | $ / shares $ 0
Exercised, Number of Shares | shares 0
Exercised, Weighted Average Exercise Price | $ / shares $ 0
Outstanding, Number of Shares | shares 672,334
Outstanding, Weighted Average Exercise Price | $ / shares $ 30.68
v3.23.3
Fair Value of Financial Instruments (Details) - Schedule of Derivative Financial Liabilities at Fair Value - USD ($)
Mar. 31, 2023
Dec. 31, 2022
Mar. 31, 2022
Fair Value of Financial Instruments (Details) - Schedule of Derivative Financial Liabilities at Fair Value [Line Items]      
Derivative liabilities $ 679,690 $ 568,912 $ 568,912
Fair Value, Inputs, Level 1 [Member]      
Fair Value of Financial Instruments (Details) - Schedule of Derivative Financial Liabilities at Fair Value [Line Items]      
Derivative liabilities 0   0
Fair Value, Inputs, Level 2 [Member]      
Fair Value of Financial Instruments (Details) - Schedule of Derivative Financial Liabilities at Fair Value [Line Items]      
Derivative liabilities 0   0
Fair Value, Inputs, Level 3 [Member]      
Fair Value of Financial Instruments (Details) - Schedule of Derivative Financial Liabilities at Fair Value [Line Items]      
Derivative liabilities $ 679,690   $ 568,912
v3.23.3
Commitments and Contingencies (Details) - USD ($)
Oct. 25, 2022
Mar. 31, 2023
Commitments and Contingencies (Details) [Line Items]    
Lease Termination Commitment Due   $ 25,000
Paid to Plaintiff [Member]    
Commitments and Contingencies (Details) [Line Items]    
Financial Instruments Subject to Mandatory Redemption, Settlement Terms, Number of Shares 2,552  
Paid to CEO [Member]    
Commitments and Contingencies (Details) [Line Items]    
Financial Instruments Subject to Mandatory Redemption, Settlement Terms, Number of Shares 19,622  
Payments for Legal Settlements $ 3,000  
v3.23.3
Subsequent Events (Details) - USD ($)
3 Months Ended
Aug. 29, 2023
Jul. 12, 2023
Jun. 30, 2023
Jun. 29, 2023
Jun. 09, 2023
Jun. 01, 2023
May 09, 2023
May 05, 2023
Apr. 11, 2023
Apr. 05, 2023
Apr. 04, 2023
Feb. 28, 2023
Feb. 21, 2023
Jan. 23, 2023
Mar. 31, 2023
Mar. 23, 2023
Dec. 31, 2022
Subsequent Events (Details) [Line Items]                                  
Stock Issued During Period, Shares, Issued for Services                         150,000 150,000      
Shares Issued, Price Per Share (in Dollars per share)                         $ 2.53 $ 3.45 $ 4.38    
Long-Term Debt (in Dollars)                             $ 0   $ 0
Debt Conversion, Converted Instrument, Shares Issued                       13,555     57,138    
Series F Preferred Stock [Member]                                  
Subsequent Events (Details) [Line Items]                                  
Preferred Stock, Par or Stated Value Per Share (in Dollars per share)                               $ 0.01  
Preferred Stock, Liquidation Preference, Value (in Dollars)                 $ 1,000                
Subsequent Event [Member]                                  
Subsequent Events (Details) [Line Items]                                  
Stock Issued During Period, Shares, Issued for Services                     2,952            
Shares Issued, Price Per Share (in Dollars per share) $ 0.8     $ 0.8 $ 1.25   $ 0.94 $ 1.05   $ 1.32 $ 1.05            
Stock Issued During Period, Shares, New Issues 43,750     131,362 20,212     2,552   94,738              
Debt Conversion, Original Debt, Amount (in Dollars)                 $ 8,018,293                
Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per share)                 $ 2.5                
Subsequent Event [Member] | Accounts Payable [Member]                                  
Subsequent Events (Details) [Line Items]                                  
Debt Conversion, Original Debt, Amount (in Dollars)       $ 105,089         $ 146,214                
Debt Conversion, Converted Instrument, Shares Issued                 147                
Subsequent Event [Member] | PPP Loan [Member]                                  
Subsequent Events (Details) [Line Items]                                  
Debt Instrument, Periodic Payment (in Dollars)   $ 2,595                              
Debt Instrument, Frequency of Periodic Payment   180 months                              
Debt Instrument, Date of First Required Payment   Jul. 01, 2023                              
Long-Term Debt (in Dollars)   $ 467,116                              
Subsequent Event [Member] | Series C Preferred Stock [Member]                                  
Subsequent Events (Details) [Line Items]                                  
Debt Conversion, Original Debt, Amount (in Dollars)                 $ 2,050,165                
Debt Conversion, Converted Instrument, Shares Issued                 2,051                
Subsequent Event [Member] | Series D Preferred Stock [Member]                                  
Subsequent Events (Details) [Line Items]                                  
Debt Conversion, Original Debt, Amount (in Dollars)                 $ 3,883,524                
Debt Conversion, Converted Instrument, Shares Issued                 3,884                
Subsequent Event [Member] | Sheila Schweitzer [Member]                                  
Subsequent Events (Details) [Line Items]                                  
Salary and Wage, Officer, Excluding Cost of Good and Service Sold (in Dollars)           $ 200,000                      
Subsequent Event [Member] | Series F Preferred Stock [Member]                                  
Subsequent Events (Details) [Line Items]                                  
Shares Issued, Price Per Share (in Dollars per share)     $ 1,000           $ 1,000                
Stock Issued During Period, Shares, New Issues     250                            
Preferred Stock, Par or Stated Value Per Share (in Dollars per share)                 $ 0.01                
Proceeds from Issuance of Preferred Stock and Preference Stock (in Dollars)     $ 250,000                            
Debt Conversion, Converted Instrument, Shares Issued                 8,023                
Subsequent Event [Member] | Series F Preferred Stock [Member] | SPA 1 [Member]                                  
Subsequent Events (Details) [Line Items]                                  
Shares Issued, Price Per Share (in Dollars per share)                 $ 1,000                
Stock Issued During Period, Shares, New Issues                 863                
Proceeds from Issuance of Preferred Stock and Preference Stock (in Dollars)                 $ 375,000                
Proceeds from Issuance of Preferred Stock, Preference Stock, and Warrants (in Dollars)                 $ 487,500                
Subsequent Event [Member] | Series F Preferred Stock [Member] | SPA 2 [Member]                                  
Subsequent Events (Details) [Line Items]                                  
Shares Issued, Price Per Share (in Dollars per share)                 $ 1,000                
Stock Issued During Period, Shares, New Issues                 288                
Proceeds from Issuance of Preferred Stock and Preference Stock (in Dollars)                 $ 125,000                
Proceeds from Issuance of Preferred Stock, Preference Stock, and Warrants (in Dollars)                 $ 162,500                
Subsequent Event [Member] | Series F Preferred Stock [Member] | SPA 3 [Member]                                  
Subsequent Events (Details) [Line Items]                                  
Shares Issued, Price Per Share (in Dollars per share)                 $ 1,000                
Stock Issued During Period, Shares, New Issues                 345                
Proceeds from Issuance of Preferred Stock and Preference Stock (in Dollars)                 $ 150,000                
Proceeds from Issuance of Preferred Stock, Preference Stock, and Warrants (in Dollars)                 $ 195,000                
Related Party [Member]                                  
Subsequent Events (Details) [Line Items]                                  
Long-Term Debt (in Dollars)                             $ 0   $ 0
Related Party [Member] | Subsequent Event [Member]                                  
Subsequent Events (Details) [Line Items]                                  
Stock Issued During Period, Shares, New Issues         10,426   19,622                    
Officer [Member] | Subsequent Event [Member]                                  
Subsequent Events (Details) [Line Items]                                  
Stock Issued During Period, Shares, New Issues         1,670                        
Former Director [Member] | Subsequent Event [Member]                                  
Subsequent Events (Details) [Line Items]                                  
Stock Issued During Period, Shares, New Issues         1,003                        

Mitesco (PK) (USOTC:MITI)
Historical Stock Chart
From Mar 2024 to Apr 2024 Click Here for more Mitesco (PK) Charts.
Mitesco (PK) (USOTC:MITI)
Historical Stock Chart
From Apr 2023 to Apr 2024 Click Here for more Mitesco (PK) Charts.